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ABSTRACT 
Osteoarthritis affects 8.75 million people in the United Kingdom. Acute episodes of 
pain (“acute flares”) may be an important, although poorly understood, part of its 
natural history. This thesis is a mixed methods study of acute flares in knee 
osteoarthritis, exploring how to define them for the purposes of research, their 
frequency, nature, impact, and possible causes. 
 
My systematic review of 69 studies found a variety of ad hoc definitions and 
concluded that key domains used to define acute events in other chronic conditions - 
worsening signs/symptoms, minimum duration, speed of onset, impact - could 
provide the basis for future consensus. Based on worsening symptoms alone, a 
secondary analysis of existing cohort data estimated that 23-32% of symptomatic 
adults over 50 years report significant variability in their knee symptoms. A 
prospectively designed cross-sectional survey and nested pen-and-paper daily diary 
study, designed with lay member input, found that flares were often disruptive and 
associated with changes in pain quality, nature of knee symptoms and increased 
health care utilisation, and self-care activity. Findings from the analysis of 15 patient 
semi-structured interviews supported these associations with flares, but also 
highlighted the  variable nature of the pain experience and the impact ‘major’ flares 
had on their daily functioning.  The participants described the differences between 
daily variability in pain and flares, and this highlighted the importance of using a 
minimum duration in flare definitions to differentiate between them. 
 
Findings from the secondary analysis of the Knee Clinical Assessment Study 
(CAS(K)) data and diary study suggest that nearly a half of adults aged over 50 years 
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with knee OA may experience an acute flare. Flares impact on daily activities and 
social participation, and may take a median of 8 days to settle although this appears 
highly variable. While not consistently demonstrated, susceptibility (for example 
previous knee surgery and higher body mass index) and extrinsic mechanical 
exposures (such as squatting and heavy lifting) are implicated as causes of acute 
flares in knee OA although larger-scale studies to confirm and extend these findings 
are needed. 
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1. Background 
This thesis is concerned with the occurrence of acute episodes or flare-ups in knee 
osteoarthritis. The central contention is that acute flares are a feature of the natural 
history of osteoarthritis, at least for some individuals, and that the observation of 
these might ultimately give useful insights into the pathogenesis of osteoarthritis, 
earlier identification and have practical application for improved episode 
management, and intervention studies. 
 
1.1 Diagnosis of osteoarthritis 
Osteoarthritis is primarily diagnosed and managed in primary care (1). There are no 
single accepted set of diagnostic criteria for osteoarthritis. The National Institute for 
Health and Care Excellence (NICE), which provides evidence based guidelines for 
healthcare in England,  offers the most user friendly recommendation where OA is 
diagnosed based on clinical symptoms alone: 
“Adults aged 45 or over are diagnosed with osteoarthritis clinically without 
investigations if they have activity-related joint pain and any morning joint 
stiffness lasts no longer than 30 minutes.” (2) 
European League Against Rheumatism (EULAR) recommendations include the 
addition of reduced function and clinical examination findings such as crepitus, 
reduced range of movement, and bony enlargement (3). The American College of 
Rheumatology (ACR) goes one step further offering alongside clinical diagnosis 
radiographic and laboratory diagnostic criteria (4). These added items lead to 
improved diagnostic accuracy but may not be practical in primary care. 
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Radiographic findings, although not required to make a diagnosis of OA, when 
present include joint space narrowing, osteophytes, subchondral bone sclerosis, and 
subchondral ‘cysts’ (3). Radiographic findings often conflict with clinical status and 
are usually reserved for research studies or where there is diagnostic uncertainty (5). 
 
1.2 Management 
The mainstay of management in OA takes place in the community (1).  There are a 
number of international guidelines on the management of osteoarthritis that reflect 
the need to take a community based approach, these include the European League 
Against Rheumatism (EULAR) (6, 7), Osteoarthritis Research Society International 
(OARSI) (8), and ACR (9). In English primary care, management of OA is generally 
guided by NICE (2). The guidelines, however, predominantly focus on the 
management of chronic OA, with little reference to acute events. 
In knee osteoarthritis (and osteoarthritis in general) international and national 
guidelines place a firm emphasis on the importance of education, exercise, weight 
loss, and self-management (2, 6-9). Non-pharmacological treatments for knee OA 
that are mentioned but recommended inconsistently across guidelines include: 
appliances, walking aids, footwear including insoles, femoral taping, acupuncture, 
and electrotherapy (2, 6-9).  
The most commonly recommended analgesics include paracetamol and nonsteroidal 
anti-inflammatory drugs (NSAIDs). Paracetamol has come under recent scrutiny due 
to lack of efficacy shown in a recent meta-analysis (10) and safety concerns. In future 
guidelines, it may therefore only be recommended as an adjunct to other therapies. 
Topical NSAIDs are known to be effective and have a low side effect profile (11), and 
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are advised first line on their own or in combination with paracetamol (2, 6, 8, 9). Oral 
NSAIDs are generally effective against pain but concerns about side effects 
(gastrointestinal and cardiovascular) means they are only recommended second line 
if paracetamol and topical NSAIDs are ineffective. Opioids are generally advised to 
be used with caution due to adverse events; notably dependence (2, 6, 8, 9). 
Intraarticular corticosteroids are recommended for flares of knee pain due to their 
short-lived duration of action and when oral medication is contraindicated or has 
failed. There is conflicting advice on the recommendation of glucosamine and 
chondroitin, and intraarticular injection of hyaluronic acid. ACR draws attention to the 
use of duloxetine for severe symptoms but has little mention in other guidelines (9). 
The role of arthroscopy in the management of knee osteoarthritis is now reserved for 
cases of knee locking and referral for knee arthroplasty is advised where there is 
severe pain and functional limitation (2, 6, 8, 9). 
NICE is the only guideline to offer recommendation on review and follow up of 
patients with OA which includes reviewing symptoms, progression, continued 
education and supporting self-management, and reviewing therapy. 
Despite a number of guidelines, primary care clinicians find optimising management 
of osteoarthritis challenging (12). In the context of multimorbidity, (the presence of 
two or more chronic conditions (13)) other conditions are usually prioritised over OA, 
for example angina. This may be due to patient safety concerns (e.g. focussing on 
the condition which has the greater threat to the patient’s health), financial incentives 
attached to other conditions, the limited availability of resources to manage OA, for 
example physical therapy and lack of treatment options (14). When consulting about 
OA, patients feel that OA is normalised, that the information given is vague and that 
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education on disease course is lacking (14, 15). General Practitioners (GPs) find 
managing OA challenging due to the limited management options and resources 
available, and a perception that patients are unwilling to change their lifestyle leading 
to avoidance of conversations on weight management which can lead to suboptimal 
care (15). Successful pilots of physiotherapists as the first point of contact for 
musculoskeletal problems has been trialled which reduced demand on GPs, 
optimised management and reduced referrals to secondary care (16). A greater 
range of healthcare practitioners are now providing care to primary care patients,, 
notably: physician associates, paramedics, pharmacists and advanced nurse 
practitioners (17). It is important that all of those delivering care have an 
understanding of different presentations of osteoarthritis and its management in order 
to improve patient experience outcomes.   
 
1.3 Aetiopathogenesis of osteoarthritis 
Osteoarthritis is defined as both a clinical syndrome of use-related joint pain, stiffness 
and reduced function, and a pathological process affecting synovial joints or an 
‘illness’ and a ‘disease’ (18).  It has been argued that the aetiopathogenesis of OA is 
best understood as a process of repeated failure of the repair mechanisms of the 
joint in response to abnormal biomechanical and biochemical forces acting on the 
joint (19). While the relative contributions of mechanical factors and inflammation to 
osteoarthritis pathogenesis remain the subject of considerable debate (20), there is 
general acceptance, particularly with the advent of MRI-based studies, that 
osteoarthritis involves all joint tissues in the synovial joint including articular cartilage, 
subchondral bone, synovium, ligaments, and muscles (3, 21). Bone remodelling, 
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leading to the development of outgrowths, osteophytes, and sclerotic lesions (22) are 
well known features of OA. 
Articular cartilage has been the focus for much previous research on osteoarthritis 
and it has been argued that since it is not innervated clinical features may only 
become apparent later on in the degradation process (19).  
Pathological changes in all of these tissues may contribute to osteoarthritis pain. The 
role of inflammation in osteoarthritis has been the subject of considerable recent 
interest, having traditionally been viewed as relatively minor. Studies have 
demonstrated synovial inflammation in patients with OA using MRI, Ultrasound and 
histological specimens (23).  It is hypothesised that resultant inflammation in the 
synovial fluid, possibly from ‘cartilage debris and catabolic mediators’ leads to an 
imbalance in degradation and repair mechanisms (19). Increased amounts of 
inflammatory mediators have been demonstrated in patients with early knee OA 
compared to late OA (24). Furthermore, some studies suggest that even before OA 
develops, inflammation is present within the joint, for example, either from increased 
adipose tissue in obese patients which activates mechanoreceptors on chondrocytes, 
from products produced through the ageing process (advanced glycation end 
products) or increased proinflammatory cytokines as a result of decreased ovarian 
function in post-menopausal females (25).  
In reality, it is likely that both inflammation and mechanical factors work together 
resulting in joint failure, however it is difficult to disentangle this complex process 
particularly due to the complex inter-play of contributing factors. 
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1.4 Risk factors for onset and progression of OA 
Risk factors have been identified for the development of OA, the progression of OA, 
and for OA-related disability and this topic has been discussed in several reviews 
(22, 26-28). Age is probably the most notable risk factor and this is likely due to 
factors relating to the ageing process and a cumulative effect of certain exposures 
(27, 29). Other factors that were associated with risk of knee OA in a recent 
systematic review and meta-analysis included: being overweight or obese, having 
previous knee injury, and being a female gender (30). The increased incidence of OA 
and the presence of more severe radiographic changes in menopausal women has 
led to a hypothesis on the protective impact of oestrogen although this is poorly 
understood (26). Obesity increases the risk of development of OA and risk of 
radiographic progression (26). This is likely due to a number of factors, both 
mechanical resulting from increased loading on knee joints and metabolic from 
mechanisms related to increased adipose tissue (31). 
Activity that puts repeated strains or stressors on the knee, for example, high levels 
of physical activity and repeated occupational exposures such as heavy lifting and 
knee bending have also been associated with increased risk of OA (30, 32). Of note 
not all types of physical activity lead to knee OA and evidence is conflicting as to 
whether it is the activity itself, injury or both that leads to OA (22). 
Knee injury, particularly trauma to the anterior cruciate ligament, meniscal tears, and 
articular cartilage damage can lead to damage to surrounding structures and 
subsequent development of osteoarthritis (26). Where injury occurs at an early age, 
this may contribute to a considerable number of years lived with pain and potential 
disability.   
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1.5 Epidemiology of OA 
1.5.1 Prevalence 
Prevalence estimates for osteoarthritis are highly sensitive to case definition, data 
source and target population (33). Prevalence estimates from four (34) primary care 
databases ranged from 164 to 426 per 10,000 people aged 15 years and over for 
osteoarthritis. In the United Kingdom, data from general practices in North 
Staffordshire, has been analysed to estimate that 8.75 million people in the UK have 
osteoarthritis (35) and that over 2 million consult their general practitioner (GP) each 
year in Britain with OA related symptoms (36).  
At the knee, the most commonly affected joint, estimates of the prevalence of knee 
pain in community-dwelling adults middle-aged and older adults (minimum 40 years) 
range from 6.5% to 28% and at least half of these report some restriction of daily 
activity (1).  An estimated 11-13% of adults will have symptomatic radiographic knee 
OA (1). The Global Burden of Disease project estimated the prevalence of 
symptomatic radiographic knee OA in the total population (i.e. all ages) to be 3.8% 
(37). 
Prevalence has been shown to be higher in women and increases with age (38, 39). 
The most common joints affected are the hip, knee, hand, foot, and spine (38). Knee 
osteoarthritis is one of the most prevalent conditions in later life (39, 40).  
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1.5.2 Incidence 
The incidence of osteoarthritis, that is the number of new cases during a specified 
time period, is much harder to define given the insidious onset to the condition. Using 
data from Spanish primary care, Prieto-Alhambra et al, found that consultation 
incidence rate for knee OA was  6.5 per 1000 person-years (95% CI: 6.4, 6.6). The 
incidence rate was higher for females than for males (8.3 cf 4.6 per 1000 person-
years) (41). This is likely to be an under-estimate as it relies on GPs being confident 
in their diagnosis and Read-coding this rather than reported symptoms, for example, 
knee pain. 
 
1.5.3 Lifetime risk 
Estimates of lifetime risk of knee OA in US populations range from 14% (diagnosed 
symptomatic knee OA from age 25 years) to 45% for symptomatic radiographic knee 
OA, from age 45 years in a predominantly rural, obese population with high 
proportions of African-American residents (42). Losina et al produced more recent 
lower estimates of lifetime risk of symptomatic knee OA of 13.8% (43). These results 
were based on nationwide household interview results so may be more generalisable 
to the wider population. No comparable estimates are published for the UK. 
However, an analysis of the UK General Practice Research Database suggests 
lifetime risks of total knee replacement at age 50 years in 2005 of 11.6% for women 
and 7.1% for men (44). This gives an indication of the number with severe symptoms 
and is likely to be a reliable estimate given the source of the data. 
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1.6 Economic burden 
A report in 2010 from Oxford Economics extrapolated evidence on direct costs, 
indirect costs and quality of life costs of osteoarthritis in the UK (45). Direct costs, 
which include GP and nurse consultations, hospital attendance, specialist services 
(physiotherapy, chiropractors etc), and prescription medication, were estimated at 
£5.2 billion per year. Indirect costs, from permanent retirement, absenteeism, 
reduced productivity and informal carers were estimated at £14.8 billion. However, 
these estimates were based in part on sources of data that included people with 
rheumatoid arthritis (RA), on US figures and generally relied on primary care data or 
information from patients who had sought healthcare. In higher income countries 
socio-economic costs of OA  are estimated to between  0.25-0.50% of Gross 
Domestic Product (GDP) (46). 
The Global Burden of Disease Study in 2010 estimated years lived with disability 
(YLD) in those with knee osteoarthritis to be 206 per 100, 000 (95% Confidence 
Interval (CI) 142-290) which was a 26.8% increase compared to the 1990 survey 
(47). Comparing this to the UK, the disability adjusted life years (DALY) for 
osteoarthritis in 2010 was estimated to be 351 (95% CI 221-520) per 100,000 (48). 
These estimates are important to consider in relation to funding challenges within the 
National Health Service (NHS) and how this impacts on primary care. In 2017/18 
8.1% of the NHS budget was spent on general practice compared to 9.6% in 2005/6, 
however, it has been estimated that 11% is needed to help sustain general practice 
and meet capacity (49).  Added to this, patient demand is rising with 312 million 
appointments estimated to have taken place between November 2018 to October 
2019 compared to 307 million appointments between November 2017 and October 
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2018(50, 51). With an ageing population, growing demand and a decrease in real 
terms funding, this will have consequences on the optimal management of OA. 
Improving patient education on the existence of flares, how they are different to 
chronic OA, how long they last, potential triggers and potential management 
strategies may help improve episode management. 
 
1.7 Pain experience  
One of the earliest markers of OA appears to be knee pain associated with increased 
knee loading, for example, climbing stairs which can be present up to 3 years prior to 
incident radiographic OA (52). Pain in OA can be classified by duration, quality, and 
intensity, for example intermittent, severe pain which is usually sharp, stabbing, and 
intense to longer acting, milder pain which is more likely to be described as dull, 
aching, and throbbing (53). Pain quality can also be classified by neuropathic 
descriptors such as burning and numbness (54). 
Symptoms other than pain that are usually reported in OA include morning stiffness, 
reduced range of movement, crepitus, effusion, joint instability, muscle weakness, 
fatigue, and psychological distress (28). Some of these factors were utilised in a 
diagnostic tool for identification of knee OA flare. The Knee Osteoarthritis Flare-up 
Score (KOFUS) tool is a weighted measure, developed using a primary care 
database and validated using a rheumatological database, which includes; morning 
stiffness for longer than 20 minutes, nocturnal awakenings, knee effusion, limping, 
joint effusion, and increased warmth (55). However, this has not been widely used in 
research or in clinical practice possibly due to time needed to complete the scoring or 
because the outcome may not alter management.  
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Once knee OA is diagnosed the disease trajectory is not necessarily one of 
consistent decline as was previously thought. A number of longitudinal studies have 
shown variability in the disease course (56-60). However, the design of these studies 
are unable to account for fluctuations of pain that take place during the day or over a 
few weeks. Qualitative studies have noted that osteoarthritis is interspersed with 
intermittent episodes of pain that may become more frequent and bothersome with 
time (61). Hawker et al, identified stages of OA which were characterised in the early 
stages with intermittent predictable pain that came on with activity that progressed to 
intermittent pain that became more severe, unpredictable, and had greater impact on 
function in the latter stages (53). Cedraschi et al noted patient descriptions of short 
and intense “stabbing pain” which came on suddenly and caused alarm (62). The 
existence of intermittent pain has also been noted in daily diary studies which have 
shown the daily variability of OA pain (63), and in focus groups on assessing chronic 
knee and hip pain (64). The duration of episodes of increased pain have been 
described in qualitative studies as lasting between a few seconds to 15 minutes (61). 
However, the distinction between variability of pain as part of the nature of the 
condition and a distinct disease flare have not been made.  
 
1.8 Flares in osteoarthritis 
Flares in osteoarthritis are starting to receive more attention in the medical literature, 
however, until recently they were only briefly mentioned in clinical guidelines (2) and 
reviews (65, 66). Most reference to flares is in Randomised Controlled Trials (RCTs), 
where flare design studies have been used for a number of years (67-69). In this type 
of study design, participants are usually required to stop their usual pain medication 
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and inform the study team when they experience a flare, at which point they are 
entered into the treatment part of the study. 
There is a small body of evidence that supports the role of inflammation in acute 
flares of knee OA. Despite small sample sizes, synovial fluid composition and volume 
of knee effusion have been shown to change during a flare-up (70, 71). Historically, 
OA was not thought of as an inflammatory disease as it did not have an underlying 
autoimmune process like rheumatoid arthritis. However, evidence in the past 20 
years have supported the role of inflammation by identifying inflammatory mediators 
and also results from pharmacological studies showing preference of NSAIDs over 
paracetamol for pain relief (72).  
The impact of intermittent pain in OA has been explored in terms of ability to carry 
out valued activities (53, 61, 62). The impact of OA flares were looked at specifically 
in a random telephone study of US workers aged 40-65 which found that over a 2 
week period, in which 38% of workers with arthritis self-reported an exacerbation. 
Those more likely to experience exacerbations were in low-demand/high control jobs 
(for example, labourers) and female (73). Understanding more about the impact of 
flares, who they are more likely to be problematic for, why some flares cause more 
disruption that others and how this can be minimised is important for improving 
patient understanding and promoting self-management.  
Disease flare seems to be more likely in the context of worse mental health, previous 
knee injury and a history of knee buckling (74, 75). However, there appear to be no 
studies identifying additional patient characteristics that might contribute to increased 
risk of flares or if there are certain short-term physical exposures (for example, heavy 
lifting) that might trigger them. Identifying those individuals who are more likely to 
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have disease flare is important to support early identification and self-management of 
episodes. 
Investigations of acute flares in other chronic conditions are more advanced. Bodies 
of evidence exist for what constitutes a disease flare, how to recognise them and 
how to best manage them.  For example, in the field of Chronic Obstructive 
Pulmonary Disease (COPD), exacerbations are generally defined as “an event in the 
natural course of the disease characterized by a change in the patient's baseline 
dyspnoea, cough, and/or sputum that is beyond normal day-to-day variations, is 
acute in onset, and may warrant a change in regular medication in a patient with 
underlying COPD” (76). A similar approach to defining osteoarthritis exacerbations 
may be possible.  
As has been done in the COPD literature, a larger body of work is needed to 
determine characteristics of those who frequently experience flares (77) to find out in 
who they are a problem, assess burden (78), and guide flare prevention (79). Only 
recently have a preliminary set of domains been agreed amongst expert, healthcare 
professionals and patients as to what constitutes a rheumatoid arthritis flare (80). 
 
1.9 Summary 
Osteoarthritis is a common condition with important consequences for individuals and 
societies. Individuals can experience acute episodes of pain and these may 
contribute to time spent in states of severe pain and disability. However, the nature, 
frequency, duration, and risk factors for these episodes or flares of pain are poorly 
understood.  
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The thesis has been designed to investigate and describe flares in osteoarthritis 
using a number of linked studies that include a secondary analysis of cohort data, a 
systematic review of knee OA flare definitions, prospectively gathered daily diary 
measurements and a qualitative study using semi-structured interviews. These 
preliminary studies are intended to inform future large-scale studies, and to support 
the future prevention, early recognition, and effective management of exacerbations 
as part of overall OA management.  
Evidence for flares at the time this PhD started (2012) was largely centred around 
qualitative work that described intermittent acute pain in OA  with the exception of a 
diagnostic tool (the Knee Osteoarthritis Flare-up Score) that had been proposed by 
Marty et al (55) but not widely adopted. During this thesis (2012-2019) there has 
been growing interest in these acute episodes of pain or flares. This has included 
further qualitative studies focusing on intermittent pain and flares in knee 
osteoarthritis (61, 62),  the formation of an OMERACT (Outcome Measures in 
Rheumatology) OA flare group in 2017 who are attempting to define disease flare in 
OA (81) and studies seeking to identify potential risk factors which are led by Hunter 
et al (75, 82) and the ACT-FLARE study which is led by Peat et al (83). These will be 
discussed further in light of study findings presented in this thesis. 
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2. Thesis aims and objectives  
This chapter introduces the overall aims of this thesis and how these will be met with 
the specific objectives. It also gives an overview of my position as a GP researcher in 
relation to this thesis. 
 
2.1 Thesis aims 
This thesis is a mixed methods study of acute flares in knee osteoarthritis, whose 
overall aim was to explore how to define them for the purposes of research, and 
understand their frequency, nature, impact, and possible causes.  
 
2.2 Thesis objectives 
The overall aim of this doctoral thesis will be achieved through the following 
objectives: 
2.2.1. Undertake a systematic review to compare and contrast definitions of knee 
osteoarthritis flares used in published medical journal articles in clinical trials, 
observational studies, reviews and qualitative studies (Chapter 4) 
2.2.2. Conduct a secondary analysis of cohort data to estimate what proportion of 
adults with knee pain report ‘significant symptom variability’ (a potential proxy for 
experiencing acute flare) and identify potential risk factors (Chapter 5) 
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2.2.3. Conduct a cross-sectional survey to further explore the self-reported frequency 
of flares and associated risk factors in patients with, or at high risk of, knee 
osteoarthritis (Chapter 6) 
2.2.4. To undertake a daily diary study to provide a detailed description of the natural 
history, associated features, self-management and potential short-term triggers of 
prospectively defined acute flares in patients with, or at high risk of, symptomatic 
knee osteoarthritis (Chapter 7) 
2.2.5. To conduct a qualitative study using semi-structured interviews to explore 
patients’ understanding on flare-ups or exacerbations in knee osteoarthritis and 
explore self-management and help-seeking strategies used (Chapter 8). 
These objectives will be addressed through a mixed methods approach, 
incorporating a systematic review of the medical literature (Chapter 4), secondary 
analysis of population cohort data (Chapter 5), cross-sectional survey and nested 
daily diary study (Chapters 6 and 7), and a qualitative study using semi-structured 
interviews with patients (Chapter 8). The qualitative study will provide a deeper 
understanding and explanation of findings found in the quantitative studies in addition 
to giving unique insights into patient experiences of flares.  
 
2.3 Author’s position in relation to thesis 
What attracted me to this research was the potential for the study findings to have a 
direct impact on patients, through improving education of patients and clinicians and 
identification of flares. It will provide further understanding to allow for comparison of 
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management options in flare design trials and also identify areas for further 
observational research. 
As a GP I regularly see people with musculoskeletal problems and am aware of the 
impact of these symptoms. This prior knowledge has shaped the approach I have 
taken to this research, the way in which the studies have been conducted, the 
analysis and findings. I have tried to remain reflexive throughout and to be 
transparent about my position and the impact this had on the study designs, data 
collection, analysis and interpretation of findings. 
 
2.4 Contributions and interests of the wider research team 
My lead supervisor Professor George Peat has a background in physiotherapy and 
epidemiology. His main research area is osteoarthritis and he provided the initial idea 
for the thesis. Associate Professor Reuben Ogollah provided statistical support for 
the studies in Chapters 5, 6 and 7. Professor Carolyn Chew-Graham is an academic 
GP who specialises in qualitative research with particular interest in mental health. 
Professor Lisa Dikomitis is a social anthropologist by background.  
 
Dr Martin Thomas (MJT) who is a physiotherapist with interests in epidemiology and 
osteoarthritis was second reviewer for the systematic review in Chapter 4. I received 
further support for the cross-sectional study and diary study presented in Chapter 6 
and 7 from a study administrator in Keele Clinical Trials Unit. They helped at the 
mailing stage with mailing out study packs and logging initial responses.  
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3. Methodology 
 
3.1 Introduction 
This chapter considers the ontological and epistemological assumptions of 
quantitative, qualitative, and mixed methods research with specific reference to the 
lines of inquiry used in this thesis. The importance of quality and reflexivity with 
regard to qualitative research will be discussed. Finally, the importance of Patient 
and Public Involvement and Engagement (PPIE) in this thesis will be described. 
 
3.2 Quantitative methodology 
Quantitative research generally produces numbers as data. It is concerned with 
estimation and deductive hypothesis testing (using evidence to support a 
conclusion), looking at associations between variables, and utilises methods to 
quantify variables (84). The findings in quantitative research are usually assumed to 
be potentially generalisable to a notional target population and replicable (84). One of 
the common underlying epistemological stances in quantitative research is 
positivism. Here the researchers remain detached from what they are studying, 
knowledge is gathered through observation and accumulating facts, only concepts 
that are observed are treated as knowledge, and there is thought to be one single 
objective reality (85, 86). However, positivism has been challenged as not everything 
we know about the world is directly observable and a theory cannot necessarily be 
proved by multiple observation (87). Post-positivists challenge the assumptions of 
positivism and state that truth can only be estimated from observation and cannot be 
explained perfectly (87). However, positivist and post-positivists both share the 
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underlying principle that an objective reality lies outside the individual who is 
experiencing it (85). 
There are a number of different quantitative methods and questionnaires or surveys 
are one of the most common tools used (87). Surveys have a number of advantages: 
they are cheap, time efficient, you can gather data from a large number of 
responders, responders can complete the survey in their own time, data analysis is 
generally straightforward, and it removes interviewer bias (87). Surveys or 
questionnaires can gather data on attributes, attitudes, beliefs, reported behaviour, 
health states, knowledge, or psychological traits (85).  Designing questionnaires, 
however, can be challenging. Items within the survey need to be valid and reliable, 
they require a certain level of literacy, the wording and structure may bias response, 
items should not be leading, it can also be difficult to interpret missing data, or 
ambiguous responses (85, 87).  
In the quantitative setting, diaries can collect similar data to surveys but over 
extended periods of time. Diaries are an important tool in research and its application 
ranges from collecting unstructured thoughts and reflections where the participant 
has more control over the data, to a more structured approach where the same 
information is collected each time and the participant has less control over the data 
collected (85). Inherent problems with diaries include: none or partial completion, 
retrospective completion, burden of data inputting, complexity of analysis, they 
require a certain of level of literacy and conditioning (85, 88). Daily diaries are 
thought to be sensitive to day-to-day changes in symptoms, they can provide rich 
information on health behaviour and help-seeking, help to reduce recall bias, and are 
thought to provide more valid and reliable descriptions of minor events and frequent 
events compared to interviews (88).  
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The above examples are methods of primary data collection and analysis, however 
secondary data analysis can be a valuable way of gaining new insights to existing 
information. Secondary data analysis can be defined as data collected by someone 
else for another purpose (89) or ‘any data that are examined to answer a research 
question other than the question for which the data was originally intended’ (90).  
Advantages of this method include its cost effectiveness and time efficiency as the 
data is already collected, inputted and cleaned for analysis, and it is convenient (87, 
89-91).  However, problems inherent in secondary data analysis include: inability to 
select all desired variables, difficulty gaining knowledge on how data variables have 
been collected, data quality, validity of items used, incomplete data,  and potential for 
data mining (87, 89, 90). In mixed methods research, secondary data analysis can 
have a number of advantages. It can identify initial themes and hypothesis, which 
may be tested through surveys and other research methods, in this way it also 
provides validity (87). 
 
3.2.1 Quantitative methods used in this thesis 
Secondary analysis of cohort data  
A secondary data analysis of the Clinical Assessment of the Knee (CAS(K)) study (a 
prospective, population-based cohort study that aimed to  investigate classification 
and prognosis of knee pain in older adults), was undertaken as one of the initial 
enquiries into the natural history of flares in knee osteoarthritis as part of this thesis 
(92). This dataset was used to gather preliminary estimates and early insights to help 
inform the original studies presented in this thesis. The data set used for this study 
was large and comprehensive including the majority of variables to be explored.  One 
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inherent challenge with secondary data collection is not being involved in the study 
design. The secondary data  researcher, therefore, may not have a comprehensive 
knowledge of data collection procedures, instruments selected and understanding of 
the variables chosen (89-91). To overcome these challenges, detailed information 
was sought about the data collection methods, cleaning process, how missing data 
was dealt with and the intended aim of the primary research was sought. 
Cross-sectional Survey 
Postal surveys are able to gather large quantities of data, over a large geographical 
area or problem space in a relatively quick time frame and at low cost (93). In 
designing my doctoral research, a survey was thought to be an efficient method to 
collect data on baseline characteristics and ‘normal’ knee symptoms, in a population 
of participants with knee OA or high risk of knee OA, who experienced flares. 
One of the disadvantages of surveys is the potential impact of non-response on bias 
and imprecision of estimates. A number of strategies to improve response to surveys 
have been studied (94). Strategies known to increase response that were utilised in 
this study include limiting the number of items, including the participants name on 
cover letters, stamped return address envelopes, follow-up contact with repeated 
mailings (a reminder postcard 2 weeks after the initial mailing followed by re-sending 
of the cross-sectional survey 4 weeks after the first mail-out), assuring confidentiality 
and university sponsorship. Incentives are known to improve response rates 
however; due to lack of funds this was not possible in this study (95). The cross-
sectional survey contained no open questions to ensure that it was quick to fill in and 
reduced responder burden (96).  
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Daily diary study 
The daily diary study used intensive repeated measurements to collect and analyse 
variables with reference to the baseline symptoms reported in the cross-sectional 
survey using a ‘what is normal for me’ approach adapted from a similar design used 
in the COPD literature (97). This allowed for comparison of baseline and 
prospectively collected measurements. 
A key strength of the diary data collection method was their ability to obtain frequent 
re-measurement. Daily measurements were chosen over, for example weekly 
measurements as they have been found to be more sensitive to individual changes 
over time, they reduce systematic and random sources of error and recall bias (98). 
Daily measurements are able to capture changes in pain and symptoms. Additional 
advantages of diaries include allowing causes and consequences to occur naturally 
and controls for third variables using participants as their own controls (98). This was 
important in this study, where triggers were also being assessed. Asking patients to 
recall symptoms over longer time periods has been shown to lead to overestimation 
of pain and symptoms (99). 
While recall bias may be reduced by obtaining frequent measurements with short 
recall periods, some bias related to pain recall can still remain. It has been 
demonstrated that in daily pain diaries that average pain is rated as higher on days 
where the participant has experienced more intense pain (100). One method of 
overcoming this would be to ask participants to record pain levels at a number of set 
times during the day or randomly after being instructed to by an alarm using 
Experience Sampling Methods. However, in this study in order to reduce burden it 
was decided to ask participants to complete the diary once a day in the evening. 
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Paper diaries have been shown to have better compliance rates compared to 
electronic and telephone diaries in a study looking at gastro-oesophageal reflux 
disease (GORD) symptoms over 4 weeks (101). However, it is difficult to determine 
the extent to which the diaries were filled in retrospectively. Participants in the GORD 
study found paper diaries more acceptable to use than telephone diaries. In contrast, 
a study lasting 12 months showed better compliance and satisfaction with electronic 
diaries over paper diaries (102). As the diary study in this thesis invited participants 
to complete diaries for a minimum of one month and a maximum of three months it 
was thought that paper diaries would have sufficient compliance rates and this was 
supported by the PPIE members (Table 6.1). 
Paper diaries are familiar to participants and easy to use. However, there is a risk of 
honest forgetfulness and retrospection error which leads to uncertain compliance 
which is difficult to estimate (98). To minimise this, diaries were sent and returned at 
monthly intervals. This also had the added benefit of maintaining contact throughout 
the study. Participants were also instructed to leave the day blank if they forgot to fill 
it in on the day.  
Electronic diaries have the benefit of allowing signalling, time stamps for responses, 
prevent out of range responses, minimise risk of skipped questions and for data 
entry, management and accuracy (98). Due to cost constraints electronic diaries 
were not available in this study. One of the major drawbacks to paper based diaries 
is the need to input large quantities of data which can lead to inaccuracies (98). To 
overcome this data was inputted by myself and each questionnaire and diary 
underwent 1 in 10 checks by an administrator. 
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A systematic review looking at pain measurement in electronic diaries found that 
completion was improved if the diaries were shorter, participants were older adults, 
they were manual and used alarms (103). The majority of diaries were 1-2 weeks in 
duration and had fewer than 20 items. The types of questions asked included pain 
intensity, location, quality, interference with normal daily activities, coping and mood. 
The number of items in the diaries in this thesis was decided on given compliance 
rates from previous studies and after discussion with members of the PPIE group. 
In a study which assessed asthma symptoms by daily diary for 4 weeks versus 
monthly retrospective recall of data, diaries were found to be a more sensitive tool 
and that the burden was worth the effort. Burden can be reduced and compliance 
increased with shorter instruments that take several minutes to complete (98) 
therefore the number of diary items in this study (Chapter 7) were minimised to 9 with 
an average completion time of one minute. 
Further problems with diary studies include reactivity which can occur where a 
participant changes their behaviour as a result of being in the study. This has less of 
an effect in longer studies due to habituation (98). However, this can lead to patients 
skimming over certain questions. In the diary study I tried to minimise the number of 
questions to reduce this and the PPIE group inputted into the sequence of questions. 
Missing data and frequently missing questions were analysed in the results to see if 
this was a phenomena that occurred. The PPIE group also suggested having a 
different colour for the front of the diary for each month and to include tips to ensure 
good compliance on the inside cover of the diaries for example ‘leave the diaries on 
your nightstand’. 
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3.3 Qualitative methodology 
Qualitative research emphasises the importance of the individual participants’ 
perspectives. It provides depth and richness of data allowing for an understanding of 
complex subjects (86, 104). It is concerned with understanding and exploring the way 
people interact with their environments and the meanings they attach to their own 
perception of reality (86, 105). The researchers are important in the data collection 
process, they are close to the data, they often interact with the participants and the 
outputs are influenced by the researcher’s own interpretations (86). Qualitative 
research, as described by Ritchie, 2003 (p.5) is therefore, good for “questions that 
require further explanation or understanding of social phenomena or their contexts” 
(86).  
One important epistemological standpoint in qualitative research is interpretivism. 
Interpretivist thinking is central to qualitative research, whereby emphasis is put on 
the participant’s and the researcher’s perspective on the observation, interpretation 
and reflection of peoples interaction with the social world; and what shapes their 
understanding of this world, for example social, cultural, and historical aspects (86). 
This contrasts with positivism where phenomena have to be directly observed to be 
counted as knowledge. In interpretivist thinking it is recognised that there are other 
methods of knowing about the world other than through observation (86). 
An important tradition in qualitative research, linked to interpretivism, is 
phenomenology which is concerned with experiences and understanding meaning 
within a world that is socially constructed.  It highlights the importance of the 
interpretations of the researcher along with the research participants in the study 
process (87).  Multiple realities are thought to exist due to the wide experiences and 
understandings of the individuals involved in the research (85). However, these 
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realities exist in different contexts and understanding these contexts is important 
(85). 
Constructivism is another important ontological position whereby there are multiple 
realities that are a product of the different way in which individuals interact with the 
world and this is in a constant state of change (106). In the research setting, 
constructivists believe reality is based on interaction of the researcher with the 
research participant, that this is “constructed” rather than “discovered” from the data 
and shaped by existing knowledge (107).  
The underlying epistemological stance in this thesis is pragmatism which will be 
discussed later. However, the qualitative study utilises phenomenological and 
constructivist approaches. The interviews were conducted to understand further 
participants’ experiences of flares and their understanding of them in the context of 
their own social reality.  
Qualitative research studies people in their own environment paying attention to how 
they interact with this. The role and background of the researcher and their 
interaction with participants is also important (87, 108). The main differences 
between quantitative and qualitative research are summarised below in Table 3.1. 
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Table 3.1. Differences between quantitative and qualitative research (Adapted from 
Bryman, 2012, p.408) (106) 
 Quantitative  Qualitative 
Data collected Numbers Words 
Point of view most important Researcher Participant 
Position of the researcher to the data Distant Close 
Underlying theory Testing Emergent 
Data collection and analysis Static Process, ongoing 
Design Structured Unstructured 
Findings Generalisable Contextual understanding 
Generated data Hard, reliable Rich, deep 
Sample size Large Small 
Focus of analysis Behaviour Meaning 
Study setting Artificial Natural 
 
The main methods used are interviews and focus groups (86). Focus groups involve 
bringing together a group of people to discuss a particular topic. They provide an 
insight into group discussions on a topic, how ideas are formed and they allow space 
for individual reflection which can provide deeper responses (86). Interviews provide 
rich detailed descriptions, gathering data on meanings and interpretations, within the 
social contexts of the research participants (109). They also offer flexibility allowing 
the interviewer to clarify points and encourage the interviewee to expand on their 
experiences (110). Face to face interviews provide in depth discussion and allow the 
interviewer to pick up on non-verbal cues (111). Compared to focus groups, 
interviews probe the individual experience, gaining a greater depth of personal 
perspectives along with clarification of points and understanding (86). Semi-
structured interviews allow the interviewer to explore specific areas and a topic guide 
helps provide the structure and prompts (86). Topic guides allow the researcher to 
introduce topics in a common way across interviews with non-leading questions and 
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prompts to facilitate participant elaboration of the key areas (112). Face-to-face 
interviews were chosen in this study to gain a greater depth of understanding of the 
topic area and to explore individuals’ experiences.  
Diagrams can be useful tools in interviews as they can provide clarification, prompt 
discussion, convey thoughts to others and they help in visualising complex 
information (113). In studies using diagrams, the diagrams may be created by the 
research subjects alone, in conjunction with the researcher or they may be performed 
by the research team. Diagrams can be helpful in interviews as a visual 
representation to illustrate important points (114). Diagrams can prompt participants 
to recall things they may have forgotten, they act as a source of further questioning 
and combined with verbal information can create a greater depth of understanding 
(115).  
Pain graphs have been used successfully in previous research looking at changes in 
back pain over time, for example in studies using the painDETECT questionnaire 
(116) and to assess pain patterns in ankylosing spondylitis. Pain graphs provide a 
tool by which patients can describe the temporal changes in their pain intensity and 
are generally easy to use, however they can be limited by patient recall (117). In the 
interviews in the qualitative study (Chapter 8) pain graphs were used to provide 
clarification and facilitate discussion. 
 
3.4 Mixed methodology 
Mixed methods research, as described by Creswell (118) is: 
An approach to research in the social, behavioural, and health sciences in 
which the investigator gathers both quantitative (closed-ended) and qualitative 
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(open-ended) data, integrates the two, and then draws interpretations based 
on the combined strengths of both sets of data to understand research 
problems. 
Mixed methods can strengthen the approach taken to a research question in a 
number of ways. Using different research methods allows for a more comprehensive 
approach to a research question (119) and can overcome the limitations of one 
method alone. The results can provide different perspectives or points of view and, 
can be used as a method to challenge previous findings (120) . A richer description 
of the underlying phenomenon can be gained from multiple observations and 
methods (121). Bringing together opposing philosophical stances has faced criticism 
and there are concerns that one method can dominate over the other (86, 122). 
Mixed methods research is therefore largely underpinned by pragmatism which is 
less concerned with philosophical assumptions and utilises both quantitative and 
qualitative research designs (123).  
In this thesis, a partly pragmatic stance was taken, whereby the research method 
was selected based on which would be better to answer the research question. 
Pragmatism, however, has been criticised for undermining the methodological 
underpinnings of research (124). Realism has been proposed as a stance that 
successfully incorporates both qualitative and quantitative approaches and involves 
the belief that there is more than one way of knowing about reality (124). It can be 
useful for research methods where you want to explore patient understanding, where 
hypothesis are not being tested and theories are emerging and where research is 
conducted in a more natural setting (124). This view, which incorporates both a 
‘critical’ and ‘subtle’ ontological realist stance ensured the aims of this doctoral thesis 
would be met. 
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There are a number of important considerations when undertaking mixed methods 
research as described by Creswell (118). These include timing of the quantitative and 
qualitative data collection in relation to each other, whether the two methods have 
equal or unequal emphasis overall, and how best to integrate them. The three main 
types of mixed methods designs are: exploratory sequential (where qualitative data 
collection and analysis is undertaken in the first phase, these results are then used to 
develop an instrument or intervention in the second phase  which is then assessed 
by a quantitative data collection and analysis methods), an explanatory sequential 
design (where quantitative data collection and analysis is initially undertaken followed 
by a qualitative phase which is used to explain the quantitative results), and a 
convergent design (where quantitative and qualitative data are collected separately 
and results are merged for data analysis) (118).  
This thesis used a predominantly explanatory sequential design, whereby the 
findings from an initial study were utilised in the design of the proceeding study. It 
was not practical to fully complete one study to the point of publication prior to the 
start of the next study, a pragmatic approach was therefore taken and a number of 
the studies were undertaken at different stages in parallel. In the explanatory 
sequential design, each data collection phase builds on and informs the next stage. 
Its key strength is the ability of the qualitative stage to build on the quantitative stages 
with inferences drawn at the end (125). This method was chosen as the initial plan at 
the start of this thesis was to undertake each study in stages, with each subsequent 
enquiry applying findings from previous ones. The qualitative interviews were 
designed to be the final study in this thesis as interviews can provide a deeper 
understanding, exploration and different perspectives on a subject matter (86, 120). 
Utilising this approach, it was planned that the qualitative study would enrich findings 
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from the quantitative stage and also allow exploration of further queries or gaps in 
knowledge that were identified from analysing the statistical data.   
An informal literature review was conducted in 2011-2012 to gain an initial 
understanding of the flare definitions that were being used in the literature to help 
inform the definition used in the planned secondary analysis of cohort data (Chapter 
5) and the cross-sectional and diary studies (Chapters 6 and 7). The range of ad hoc 
definitions being used led to a formal systematic review of the medical literature to 
gauge the extent to which there might be a shared definition of OA flares. The first 
review was conducted in 2012 however due to the complexity of the data, a similar 
review being published after mine had been sent for peer review (126) and two 
periods of maternity leave the search was repeated two further times and finally 
published in 2018. The secondary analysis of cohort data (Chapter 5) was conducted 
in 2013 and published in 2017. Data collection for the cross-sectional survey and 
diary study (Chapters 6 and 7) was conducted in 2013 and the final results were 
published in 2019. The data for the qualitative study (Chapter 8) was collected, 
analysed and written up  in 2019 (Figure 3.1).  
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Figure 3.1: Overview of the explanatory sequential design used in this thesis (Adapted 
from Creswell (125)) 
Despite the studies not being finished in the order in which they started, undertaking 
a sequential design meant that the findings from the initial studies could inform the 
latter studies. For example, understanding the risk factors that might be associated 
with flares in the secondary analysis of cohort data (Chapter 5) helped inform the 
independent variables to be included in the cross-sectional study (Chapter 6). The 
qualitative study (Chapter 8) aimed to understand flares from the patient’s 
perspective and to allow discussion of the findings from the diary study (for example, 
impact of variability in flare frequency and intensity and reasons for help seeking). 
Qualitative research is often used after statistical analysis where a greater 
understanding of the underlying problem is required, to provide further clarification or 
explanation, where more detail or depth is needed to further explore the research 
question (86, 120). In this thesis, once each studies results had been presented, 
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each study was revisited to enable reflection, assimilation and integration of all study 
findings. This enabled overall conclusions for the thesis to be drawn and also allowed 
for findings from the latter studies to explain findings from earlier studies that had 
previously been unclear. For example, the findings from Chapter 8 gave a potential 
explanation for the distribution of reported flare frequency seen in Chapter 6. This 
integration of findings and revisiting previous results helped strengthen the findings 
presented in this thesis and highlighted the importance of using a mixed methods 
approach for this PhD.   
 
3.5 Quality  
Triangulation helps to improve the reliability and validity of the data by using a 
number of different methods, for example from using different data collection 
methods, data types, and different investigators (85, 87, 123). Triangulation has been 
described as a method of overcoming the weaknesses of one study design used 
alone (123). Critics, however have pointed out that ontologically there is no single 
reality and using multiple methods cannot overcome this fact, secondly from an 
epistemological view a completely concordant standpoint can never be achieved 
(86). In this thesis, a number of different data collection methods, data types and 
observers (supervisors with different backgrounds of expertise) were used to gain a 
greater depth of understanding of the natural history of flare-ups and to improve the 
integrity of the findings.  
Approaches to improve quality include transparency during the data collection and 
analysis process, having a number of members of the study team involved in data 
analysis and interpretation (87, 127). Another important facet is credibility or member 
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checking whereby the interpretations of the data are discussed with the participants 
(87). This has a number of advantages, for example clarifications can be made 
where there are uncertainties, to get feedback on interpretations, and open up other 
areas for exploration (127). Disadvantages include the participant reflecting on their 
own experience and potentially discrediting the researcher’s interpretations as they 
view the data compared to themselves rather than as a whole (127). In this thesis,  
the PPIE group were consulted to sense check and corroborate the findings from the 
qualitative analysis and highlight areas in the data that might need exploring further. 
As people with personal experience of OA they provided a unique insight into the 
interpretation of the findings, however being expert patients and not participants in 
the research themselves they were able to look at the data as a whole rather than on 
just an individual level. 
 
3.6 Reflexivity 
It is important to understand the role of the researcher, their previous knowledge and 
background and the impact that has on the research question, the data collection 
methods chosen, data analysis, interpretation, and communication (128). When 
analysing and interpreting the data it is paramount to consider the relationship 
between the interviewer and the interviewee and how this may affect the responses 
(128). Being aware of how these prior assumptions and experiences can affect the 
research process helps to maintain quality (119) . 
The researcher and her/his background impacts on all stages of the qualitative study 
process, from the area of study they wish to pursue, to the methods they use, the 
results that are considered to be important, and communication of the findings. 
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Preconceptions about the research need not be seen as bias as long they are 
acknowledged (121). Acknowledging, reflecting and reporting on these issues and 
giving a detailed account of how the research is conducted helps to ensure quality 
and transparency (128, 129). I am a GP and had prior in-depth knowledge of OA 
flares. It was important to be aware of preconceived ideas throughout the study 
process and the influence this will have had on data collection and interpretation of 
that data.   
The setting of the interview and characteristics of the interviewer can impact on data 
collection. The interaction may be different depending on certain characteristics of 
the participant. For example, in a qualitative study that was conducted by a GP, 
differences were found between how people from different social classes and gender 
interacted with the researcher compared to a researcher from a non-medical 
background. Middle-class males were more likely to assume commonality with the 
GP researcher compared to those from working classes (128). When the same 
interviews were conducted by a sociologist, unfavourable comments related to health 
care professionals were more likely to be mentioned. When the interviewer initially 
communicates with the participant and during the interview, she/he should consider 
whether they introduce themselves as a researcher or whether to disclose their full 
professional background. Full disclosure may help with interview flow (130) however 
there are implications of the disclosure, for example being asked medical questions if 
the researcher is a health professional and may also limit discourse related to bad 
experiences in health care settings. This may be partly overcome by the researcher 
distancing themselves from their profession, for example when discussing advice 
given by health professionals use terms such as ‘they say..’ in order to encourage in 
depth discussion (130). 
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Previous experience as a GP may be beneficial to the interview process as there are 
some similarities with consultation skills, for example with asking open ending 
questions and responding to non-verbal cues (130). However, GPs are trained to ask 
their questions under a time pressure, and focus discussion down, rather than open 
the discussion up, in order to achieve a diagnosis or agreement with a patient on the 
problem so may be naturally inclined to cut answers short if they do not feel they are 
adding to the data. GP consultations are therefore very different to a research 
interview.  
 
3.7 PPIE involvement 
Patient and Public Involvement and Engagement (PPIE) is defined as “research that 
is carried out ‘with’ or ‘by’ members of the public rather than ‘to’, ‘about’ or ‘for’ them” 
(131). PPIE is important at all stages of the research process starting with prioritising 
research questions, ensuring that the research performed is relevant to consumers, 
they identify important questions, they highlight important outcomes and ensure 
resources are not wasted (132, 133). They give advice on recruitment strategies, 
input into participant information, undertake research, help interpret results, and help 
or give advice on dissemination (132, 133). There are some limitations of PPIE 
involvement that have been reported: those that are involved with PPIE may not be 
representative of the groups they are intended to represent, the more one takes part 
in PPIE the more ‘expert’ they become, individual opinions may be variable, and 
particularly for new members there may be unrealistic expectations of what the 
research can accomplish (132). However, despite this PPIE is generally viewed as 
valuable, and the greater the level of engagement on the part of the research team 
the richer the experience with PPIE (134). Within the context of a doctoral thesis, 
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PPIE engagement can be challenging due to funding, however it can add to the 
methodological rigour of the research, adding new perspectives and experiences, in 
addition to improving the skill set of the early career researcher (135).  
The PPIE group were involved at a number of stages during this thesis. The School 
of Primary, Community and Social Care (SPCSC) at Keele University hosts members 
of the PPIE group (136). It has 130 members, who have personal experience of a 
range of conditions who are actively supporting around 115 live projects. There is a 
PPIE Steering Group with 11 members who meet 6 times a year who provide an 
overall viewpoint of the wider PPIE group. The PPIE members are involved in 
projects in numerous ways: as an advisory group member, as a lay co-applicant on 
grant applications, and as Trial Steering Committee members. The PPIE members 
are recruited from social media, word of mouth, through PPIE recruitment leaflets in 
nearby hospitals and general practices, newspaper articles, and by invitation from 
academic clinicians.  
PPIE members involved in this thesis were recruited based on their personal 
experience with osteoarthritis. Due to the length of time of my doctoral research 
(seven years) members that inputted into planning the cross-sectional survey and 
diary study were not the same as those who inputted into planning the qualitative 
study and reviewing the analysis.   
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4. Defining acute flares in knee osteoarthritis: a 
systematic review 
 
This chapter reports on the design, conduct, and findings of a systematic review of 
the medical literature that sought to identify, describe and critically evaluate 
definitions of acute flares in knee osteoarthritis. The overall purpose of the review 
was to gauge the extent to which the phenomenon of acute exacerbations (or flare-
ups) of knee osteoarthritis is recognised and reported in the medical literature and 
the potential for a shared, common definition for use in research and clinical practice. 
 
4.1 Introduction 
In many chronic diseases, acute exacerbations appear to be a well-recognised 
feature of their natural history although the accepted language used to label these 
varies between diseases (e.g. an acute exacerbation of chronic obstructive 
pulmonary disease or asthma, an attack of gout, a rheumatoid arthritis flare). A 
determined effort to define these events has followed the recognition of their 
significance. Definitions for exacerbations in chronic obstructive pulmonary disease 
(COPD) (137, 138), asthma (139), systemic lupus erythematosus (SLE) (140), 
ankylosing spondylitis (AS) (117) presently exist or there are working groups trying to 
define them (e.g. rheumatoid arthritis (80), gout (141), atopic dermatitis/eczema (142) 
(Table 4.1)). These definitions, despite different terms being used, share some key 
components:  
• the onset or worsening of symptoms and signs above normal day-to-day 
variation;  
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• speed of onset;  
• duration of sustained worsening;  
• change in medication/healthcare usage. 
 
Table 4.1: Published definitions of acute exacerbation or flare in several chronic 
diseases 
Respiratory conditions 
  COPD “an acute worsening of respiratory symptoms that result in 
additional therapy”(138) 
 “a sustained worsening of the patient's symptoms from their usual 
stable state which is beyond normal day-to-day variations, and is 
acute in onset” (137) 
   Asthma “episodes of a progressive increase in symptoms of shortness of 
breath, cough, wheezing and a progressive decrease in lung 
function.” (139) 
Rheumatological conditions 
  SLE “a measurable increase in disease activity in one or more organ 
systems involving new or worse clinical signs and symptoms 
and/or laboratory measurements. It must be considered clinically 
significant by the assessor and usually there would be at least 
consideration of a change or an increase in treatment” (140) 
  AS “exacerbation of the disease that may have required additional 
treatment or necessitated a visit to a health care professional” 
(117) 
Gout Fulfil 3 of the following criteria: “patient defined flare,  pain at rest 
score of >3 on a 0-10 NRS, presence of at least 1 swollen joint, 
and presence of at least 1 warm joint”(141)  
Cancer  
Cancer 
breakthrough 
pain 
“transitory increase in pain to greater than moderate intensity (that 
is, to an intensity of “severe” or “excruciating”), which occurs on a 
baseline pain of moderate intensity or less (that is, no pain or pain 
of “mild” or “moderate” intensity)(143) 
AS Ankylosing Spondylitis; COPD Chronic Obstructive Pulmonary Disease; SLE Systemic 
Lupus Erythematosus 
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The process of finding a shared common definition is long and difficult. In the field of 
rheumatoid arthritis the OMERACT working group was initially established in 2006 
and first reported in 2009 (144). During this time a systematic literature review and 
two separate Delphi exercises with key stakeholders including experts, patients and 
health care professionals have been undertaken, followed by preliminary validation 
studies. In COPD, despite there being a widely accepted definition this is still subject 
to contention (145, 146). Despite some commonalities, the fundamental nature of 
these acute events is likely to represent pathophysiological processes specific to the 
underlying disease process and so it is unlikely that straightforward parallels between 
diseases can be drawn on how to define exacerbations.  
Yet the fact that such prolonged and difficult work has been undertaken testifies to 
the perceived and actual benefits of having a common shared definition. Firstly, a 
common shared definition facilitates communication between researchers, 
practitioners, patients and other relevant parties. Secondly, it may allow more direct 
comparisons between studies on the frequency, determinants, and course of these 
events. Thirdly, this effort may facilitate new insights into novel pathophysiological 
mechanisms and treatments by providing a valid, homogeneous case definition of 
these events. Fourthly, in clinical practice, a common, shared definition that is also 
practicable at the point of care may enable prompt diagnosis and management 
(including self-diagnosis and self-management where the definition is able to be 
applied by patients and their carers). 
While acute ‘exacerbations’, ‘flares’, or ‘attacks’ are common parlance in these 
chronic diseases and definitions for these have been derived (even if not universally 
agreed), this does not appear to be true of osteoarthritis. For gout, COPD, and 
asthma, an estimate from an EMBASE search suggests that 9%, 8% and 6% 
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respectively of journal articles published in the last 10 years contain the words 
“exacerbation”, “flare” or “attack” in their title or abstract. The corresponding figure for 
osteoarthritis is <0.7. These words do not appear in the NICE guideline on 
osteoarthritis (2). Yet the term “flare up” appears in patient literature on osteoarthritis 
(for example “Some people take an anti-inflammatory painkiller for short spells, 
perhaps for a week or two when symptoms flare up.”(147) ) and there is growing 
recognition of exacerbations in OA both in quantitative and qualitative studies. In 
qualitative interviews, Hawker et al (53) found that as disease progressed, patients 
reported sharper bouts of intermittent pain, initially predictable, but later on in the 
disease course becoming more unpredictable and associated with increasingly more 
distress. Furthermore, in 2009 Marty et al (55) proposed a knee OA flare-up score 
which included the following components: nocturnal awakenings, knee effusion, 
morning stiffness and limping. Marty et al, used general practitioners to determine 
whether patients with knee OA were experiencing a flare-up. Using a logistic 
regression model they found factors independently associated with flare-ups (55). 
Each factor was assigned a weighted score dependent on the odds ratio. This Score 
was then validated using a rheumatology database. It is not known how the general 
practitioners identified flare-ups in the initial study and one key disadvantage of the 
flare-up scoring tool is that it does not include pain, potentially due to collinearity of 
pain with other factors in the model.  
These different sources provide some indications that a concept of flares exists as 
part of the natural history of OA although it appears to be neither as prominent or 
well-recognised a feature in OA as in some other chronic diseases. OA may not 
receive the attention of other chronic diseases as it generally does not lead to 
hospital admission (there are 185 people admitted per day with asthma) and is not 
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listed as a cause of death (asthma contributes to >1200 deaths per year) (148). 
There is a perception amongst some that little can be done for OA and that doctors 
seem disinterested which may preclude consultation with a GP (15). Furthermore, by 
the time patients do present to a clinician their symptoms may have improved which 
is contrary to patterns in other diseases.  
The systematic review intends to examine the degree to which the medical literature 
provides a description of OA exacerbations or flares and the possibilities for a shared 
definition for research and clinical application.  
 
4.2 Aims and objectives 
Aim 
To compare and contrast definitions of knee osteoarthritis flare-ups used in published 
medical journal articles in clinical trials, observational studies, reviews and qualitative 
studies. 
Objectives: 
• To gauge the extent to which a concept of acute exacerbations or flare-ups in OA 
has been reported in the medical literature 
• To identify published medical journal articles that define and describe knee 
osteoarthritis “exacerbations” and the terminology used to label these 
• To evaluate whether and how each of the published definitions and descriptions 
cover the core domains featuring in other chronic diseases, namely (1) the onset 
or worsening of symptoms and signs above normal day-to-day variation; (2) 
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speed of onset; (3) duration of sustained worsening; (4) change in 
medication/healthcare usage 
• To identify any domains additional to those listed above 
• To critically examine the rationale and evidence of validity of published definitions 
and descriptions 
 
4.3 Method 
This study was registered with the International Prospective Register of Systematic 
Reviews (PROSPERO) in 2013 and the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines were followed.  
 
4.3.1 Eligibility criteria 
The following predetermined eligibility criteria was used (Table 4.2). 
Table 4.2: Eligibility criteria for systematic review 
Inclusion Exclusion 
• Adults aged 18 and over with knee 
osteoarthritis (diagnosed by physician, 
radiography or reported knee symptoms) 
• Inflammatory cause for knee pain, 
total knee replacement 
• Animal studies 
• Journal articles, conference abstracts 
and proceedings, review articles 
• Book chapters, guidelines, theses, 
dissertations 
• General population, community, primary 
care or hospital 
 
• Contained a description or definition, 
with or without classification criteria 
based on measurement(s), of an acute 
exacerbation of knee osteoarthritis (or 
flare or other synonym) 
 
• Clinical trials, observational studies, 
reviews, qualitative studies 
 
• All languages were included  
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4.3.2 Information sources 
The following databases were searched from inception to July 2017: ASSIA, 
EMBASE, Web of Science, HMIC (Health Management Information Consortium), 
SPORTDiscus, Medline, CINAHL, Psychinfo, AMED, Ageline and Cochrane 
Database of Systematic Reviews and Cochrane Controlled Clinical Trials 
(CENTRAL).  
 
4.3.3 Search Strategy 
The search strategy was developed with help from supervisors and the SPCSC 
(School for Primary, Community and Social Care) systematic review team. The 
search strategies for each database used are included in a separate Appendix A. 
Articles in all languages were included (translation was available for full text articles 
included).  Articles that were unable to be sourced through library request or contact 
with the author were excluded. Papers were also excluded if there was an 
inflammatory cause for knee pain or previous total knee replacement. 
To confirm findings the first 15 pages of Google Scholar were searched to ensure no 
eligible articles had been missed. Conference abstracts were included and used to 
find corresponding full text articles where possible. References of all included full text 
articles were hand searched. 
Where the definition of exacerbation was not included in the full text authors were 
contacted to clarify this.  
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4.3.4 Selection of studies 
The search strategy was initially piloted to ensure relevant articles were included in 
the search. The search and article retrieval was conducted by the first reviewer 
(myself). Articles were downloaded into RefWorks. Duplicates were deleted. All titles 
were screened by the first reviewer to meet inclusion criteria. The first 20 titles were 
checked by two reviewers to check consistency (myself and a co-author). For 
qualitative studies it was decided that full papers may need to be searched as the 
title and abstract may not give the full information about the article content. 
All abstracts were reviewed by two reviewers (myself and a co-author). Full texts 
were then screened by two reviewers to find full texts to be included in data 
extraction. Where there was disagreement a third reviewer (my lead supervisor) was 
asked to screen and their decision was final. 
The final articles were checked to ensure results from the same studies were not 
counted as separate studies as this is known to introduce bias as the dataset would 
more strongly affect the results of the review (149). For pooled studies the original 
studies were sought and included in the main analysis instead of the article showing 
the pooled studies if available. If the original articles were not referenced or not 
available the pooled studies were kept and a note made of this in the analysis.  
 
4.3.5 Data extraction process and items 
Information was extracted by the first reviewer, using a standard extraction table that 
was developed for this review. The results were recorded in an Excel spreadsheet. 
Every tenth article was independently checked by a blinded second reviewer.   
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The following data were extracted from full text-articles: Study characteristics 
(setting, participant characteristics, joint defined, baseline OA severity, and study 
design) and exacerbation definitions (terminology used to refer to ‘exacerbations’, 
coverage of core domains indicated from other chronic diseases: namely 
onset/worsening of symptoms and signs, temporal characteristics, change in 
medication or healthcare usage and additional domains such as minimum symptom 
threshold). In addition, the measurement tools and operational criteria used were 
noted and any evidence or rationale on validity of the definition.  
 
4.3.6 Analysis and synthesis 
A narrative synthesis using words and text to summarise and explain findings from 
multiple studies was performed and this enabled the development of a conceptual 
framework (150). In undertaking the narrative synthesis of findings for this review, the 
four-stage process proposed by Popay et al (2006) (151) was used as a guide. This 
comprises of: developing a theoretical model, undertaking the initial synthesis of 
included studies, explore relationships of the results, and then assessing the strength 
of the synthesis (151). This is an iterative process and the stages are not necessarily 
conducted in order.  
In the first stage a preliminary synthesis of findings from included studies was 
undertaken. This involved initial descriptions of studies and description of patterns. 
Extracted data including study design, patient characteristics and exacerbation 
definition was tabulated.  From this, groupings were made for example drug 
withdrawal design and non-drug-withdrawal design studies. ‘Vote-counting’ was used 
to tabulate the frequencies of components thought to be important in definitions, for 
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example: onset/worsening of symptoms; signs/symptoms above day-to-day variability 
(including minimum threshold); speed of onset of symptoms; duration of worsening 
and increased medication/healthcare usage. 
The following stages involved exploring relationships within the data. After tabulating 
and initial grouping of results the definitions and components used within these 
definitions were analysed for patterns. This was done thematically and inductively to 
identify the important themes and concepts across the multiple studies. Concept 
mapping was used to highlight key concepts and represent relationships. Differences 
between drug withdrawal (predominantly flare design studies where usual medication 
is withdrawn with the aim of inducing a ‘flare’) and non-drug withdrawal studies 
(predominantly non flare design) were examined. 
The robustness of the synthesis is usually examined using a quality assessment tool. 
Quality assessment tools consider the relevance of study design to the research 
objectives, risk of bias, choice of outcome measure, statistical issues, reporting 
quality, quality of intervention, and generalisability where applicable (CRD Systematic 
review guideline). The information of concern in this study was the description or 
definition of an osteoarthritis exacerbation that was used. Risk of bias in the 
treatment effect estimates within trials or exposure-outcome association in 
observational studies was of no direct interest and so conventional quality 
assessment/risk of bias directed at these was not at issue.  
However, the relative merits of those definitions which claimed some degree of 
‘validity’ and which provided some supporting evidence deserved critical scrutiny. 
Unfortunately, as there was an absence of available quality assessment tools for this, 
potentially relevant domains in diagnostic studies (e.g. QUADAS-2 (Quality 
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Assessment too of diagnostic accuracy studies) (152) and outcome measurement 
(e.g. COSMIN (Consensus-based standards for the selection of health measurement 
instruments ) (153), and classification criteria (e.g. ACR 2006) were not applicable to 
this review.  However, statements were sought that gave evidence of rationale 
behind the definitions chosen. 
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4.4 Results 
4.4.1 Description of studies 
The literature search produced 2194 results however 786 were duplicates (Figure 
4.1). After screening titles 336 abstracts were studied. Of these 223 were not 
relevant, and for 4 studies the complete article could not be obtained despite 
considerable effort to identify and contact principle investigators. 113 articles were 
fully analysed which resulted in a further 60 being excluded. In this phase a further 
16 were included from the reference lists of the papers chosen for the study. 
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Figure 4.1: Flow chart of stages of systematic review (Reproduced from Parry et al, 
2018 (154)) 
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Types of studies and setting 
In total, 69 studies were included in the systematic review. The studies included a 
range in participant numbers from 15 to 6085 (55, 155) with an age range of 18-91. 
In total 46 studies used a drug withdrawal randomised controlled trial (RCT) design 
(67-69, 155-197), 4 of these were from pooled studies (68, 159, 162, 186) and one 
used a cohort drug withdrawal design (198) (Table 4.3a). There were 17 
observational studies (55, 71, 73-75, 82, 199-209), 3 non-drug withdrawal RCTs 
(210-212), one survey (213) and one qualitative study (61) (Table 4.3b). 
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Table 4.3a: Characteristics of all included studies: drug withdrawal design studies 
First author, year of 
publication 
Setting, geographic 
location 
N 
  
Age Joint Severity Study design 
Altman, 2015 (67) Multi-centre, recruitment 
not specified, US 
403  ≥40y Knee and 
hip 
KL grade 2-3 RCT, flare design 
Baer, 2005 (157) 17 medical centres 
recruiting from community 
and physician private 
practice; Canada  
216  40-85y Knee Radiographic evidence of OA (severity 
not defined) 
RCT, flare design 
Baraf, 2011 (158) Primary care, internal 
medicine, orthopaedic, 
rheumatology; US 
602 ≥25y Knee Radiographically mild to moderate (KL 
grade 1-3) 
RCT, flare design 
Battisti, 2004 (159) Clinical centres, out 
patients; US 
3980 ≥40y Knee ACR functional class rating of I,II or III  RCT, pooled 4 trials, 
flare design 
Bingham, 2007 (156) 
Bingham 2011 (191) 
2x74 outpatient clinics; 
US 
1207 ≥40y Knee and 
hip 
ARA Functional capacity classification 
I-III 
RCT, flare design 
Birbara, 2006 (160) Investigative sites; US 808  ≥40y Knee ARA functional class, I, II, or III RCT, flare design 
Bocanegra, 1998 (161) Clinic; US 572  28-88y Knee and 
hip 
ARA Functional capacity classification 
I-III 
RCT, flare design 
Boswell, 2008 (162) 50 centres (Europe & 
Australia) + 187 centres 
(Europe & US) 
1908  ≥40y Knee KL scale 2 or 3 and ARA class rating 
of I,II or III 
Pooled RCTs (2; one 
flare design, one non-
flare), flare design 
Brandt, 2006 (198) 
(pilot studies) 
Community; US 30 mean 62y Knee KL ≥2 Cohort design, flare 
design 
Case, 2003 (163) Hospital-rheumatology 
centre; Chicago, US 
82  40-75y Knee  KL ≥1, and clinical criteria (pre-
enrolment ambulatory pain; moderate 
pain by a 5-point Likert scale or 
increased pain. 
RCT, flare design 
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First author, year of 
publication 
Setting, geographic 
location 
N Age Joint Severity Study design 
Day, 2000 (189) 49 investigative sites in 26 
countries 
809  mean 62-
65y 
Knee and 
hip 
ARA functional class I-III, symptomatic 
for at least 6 months 
RCT, flare design 
Ehrich, 1999 (164) Clinical centres; US 219  >40y Knee ARA functional class, I, II, or III RCT, flare design 
Essex, 2012 (165) Clinical centre; African-
American, US 
322 ≥45y Knee ARA Functional capacity classification 
I-III 
RCT, flare design 
Essex 2013 (192) Hispanic population, 31 
US centres 
318 ≥45y Knee ACR criteria, Functional capacity 
classification I-III 
RCT, flare design 
Gibofsky, 2014 (166) Not specified, US 305 41-90y Knee and 
hip 
KL 2-3 RCT, flare design 
Gineyts, 2004 (167) Subset of larger study; 
France 
201 mean 61-
62y 
Knee and 
hip 
ARA I-III RCT, flare design 
Goldberg, 1988 (168) Investigative sites; US 214 40-85y Knee and 
hip 
Radiographic evidence of knee OA-not 
further defined 
RCT, flare design 
Gottesdiener, 2002 
(169) 
Investigative sites; US 617 ≥40y Knee ARA functional class I,II,III RCT, flare design 
Hochberg, 2011 (68) Centres; US 1234 ≥50y Knee ACR functional class I-III Pooled RCTs (2), flare 
design 
Katz, 2010 (170) Clinical sites; US 113 28-83y Knee and 
hip 
OA of hip and knee as diagnosed 
using ACR criteria-no definition of 
severity 
RCT, flare design 
Kivitz, 2001 (171) Investigative sites; US 491 28-91y Knee Confirmation of OA on weight bearing 
radiograph- no definition of severity 
RCT, flare design 
Kivitz, 2004 (190) Outpatient sites; US 1042 ≥40y Knee ACR rating of I, II, III. RCT, flare design 
Leung, 2002 (172) Clinic; US 677 ≥40y Knee and 
hip 
ARA functional class, I, II, or III RCT, flare design 
Luyten, 2007 (172) Centres; Belgium 181 ≥40y Knee and 
hip 
ACR Functional capacity classification 
I-III 
RCT, flare design 
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First author, year of 
publication 
Setting, geographic 
location 
N Age Joint Severity Study design 
Manicourt, 2005 (174) Outpatient clinic; Belgium 90  50-81y Knee and 
hip 
Clinical and radiographic evidence of 
OA-severity not defined. 
RCT, flare design 
Mazzuca, 2002 (155) Not specified, US 15 ≥45y Knee KL 2-3 Observational, flare 
design 
McIlwain, 1989 (175) Investigative sites; US 139  mean 65y Knee Radiological evidence of moderate or 
severe osteoarthritis- not further 
defined 
RCT, flare design 
Mendelsohn, 1991 
(176) 
Investigative sites; US 139  21-88y Knee Radiological evidence of moderate or 
severe osteoarthritis- not further 
defined 
RCT, flare design 
Moskowitz, 2006 (177) Investigative sites; US 530  ≥45y Knee ACR Functional capacity classification 
I-III 
RCT, flare design 
Pareek, 2009 (69) Multi-centre study, India 199  40-70y Knee Lequesne criteria-score of 5 and above RCT, flare design 
Pareek, 2010 (178) Hospital; India 220  40-70y Knee Clinical and radiological evidence of 
OA- severity not defined. 
RCT, flare design 
Roth, 2004 (194) Physicians private 
practice or community; 
US 
326  40-85y Knee Radiological evidence of OA- severity 
not defined. 
RCT, flare design 
Rother, 2007 (197) Outpatient units; Germany 397 ≥40y Knee KL 2-3 RCT, flare design 
Schnitzer, 2005 (179) Investigative sites; 
International (7 countries) 
583 18-75y Knee and 
hip 
Diagnosis based on ACR criteria- 
severity not defined. 
RCT, flare design 
Scott-Lennox, 2001 
(180) 
Investigative sites; US 182 mean 61y Knee Not defined RCT, flare design 
Silverfield, 2002 (181) Centres; US 308 35-75y Knee and 
hip 
Clinical evidence of OA- severity not 
defined 
RCT, flare design 
Simon, 2009 (195) Outpatient centres; 
Canada, US 
775 40-85y Knee Clinical and radiological evidence of 
OA- severity not defined 
RCT, flare design 
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First author, year of 
publication 
Setting, geographic 
location 
N Age Joint Severity Study design 
Strand, 2011 (182) Investigative sites; 
Multinational-not specified 
including US 
875 18-80y Knee and 
hip 
OA according to ACR criteria and 
requiring NSAID treatment to control 
symptoms in the month preceding 
screening 
RCT, flare design 
Weaver, 1995 (196) Investigative sites; US 328 >50y Knee ACR clinical criteria-diagnostic RCT, flare design 
Wiesenhutter, 2005 
(183) 
Medical Centres; US 528 40-89y Knee and 
hip 
ARA functional class, I, II, or III RCT, flare design 
Williams, 2001 (184) Clinical sites; US 718  mean 61-
62y 
Knee ACR clinical and radiographic criteria I-
III 
RCT, flare design 
Wittenberg, 2006 (185) Centres (not specified); 
Germany 
364  50y Knee Moderate to severe symptomatic OA of 
the knee according to ACR criteria.  
RCT, flare design 
Yeasted, 2014 (186) 
(Pooled, abstract) 
US 219 
137 
>40y Not 
specified 
ACR criteria-diagnostic 2 longitudinal 
observational studies, 
placebo arms of 2 RCTs 
Yocum, 2000 (193) 62 study centres; US 774 ≥40y Knee or 
hip 
Diagnosis confirmed by XR and clinical 
symptoms (not further specified) 
RCT, flare design 
Young, 2014 (187) 
(abstract) 
Multicentre  305 >40y Knee or 
hip 
KL 2-3 RCT, flare design 
Zhao, 1999 (188) Centre (not specified); 
US, Canada 
1004  ≥18y Knee ACR Functional capacity classification 
I-III 
RCT, flare design 
ACR American College of Rheumatology;  ARA American Rheumatism Association; GP General Practitioner; KL Kellgren and Lawrence; RCT Randomised 
Controlled Trial; US United States of America 
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Table 4.3b: Characteristics of all included studies: non-drug withdrawal design studies 
First author, year of 
publication 
Setting, geographic 
location 
N Age Joint Severity Study design 
Atukorala, 2016 (204) 
(abstract) 
Not specified, Australia 213 mean 62y Knee Not specified 3-month, web based 
longitudinal study 
Atukorala, 2016 (199) 
(abstract) 
Not specified, Australia 345 mean 62y Knee Not specified 3-month, web based 
longitudinal study 
Bartholdy, 2016 (210) OA out-patient clinic, 
Denmark 
131 ≥40y Knee Radiographic evidence of OA 
(severity no defined) and BMI 20-35 
kg/m2 
RCT 
Bassiouni, 2015 (205) 
(abstract) 
Not specified, Egypt 60 Not 
specified 
Knee Not specified Observational 
Cibere, 2004 (211); 
Cibere, 2005 (212) 
Community, Canada 
 
137 40-83y Knee KL ≥2 on anteroposterior radiograph 
 
RCT 
 
Conrozier, 2012 (71) 
 
Hospital-rheumatology 
unit, France 
44 mean 68y Knee Radiographic evidence of knee OA-
not further defined 
Observational 
D'Agostino, 2005 (201) 
 
Hospital-European 
multicentre 
600 ≥18y  Knee KL grade 1-4 
 
Observational 
 
Erfani, 2014 (200), 
Erfani, 2014 (206), 
Ferreira, 2016 (82), 
Hunter, 2014 (207), 
Makovey, 2015 (208) 
Australia (from same 
study) 
268 
345 
345 
267 
Not 
specified 
≥40y Knee ACR criteria- meet at least one, KL ≥2 Web based cross over 
Jawad, 2005 (213) 
 
GPs in France 3000  Knee Not defined n/a, review of surveys. 
Definition relates to 
survey of 3000 French 
GPs 
Marty, 2009 (55) Community and hospital, 
France  
6085 mean 66y Knee OA diagnosis based on ACR criteria- 
severity not defined 
Observational 
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 641  
 
First author, year of 
publication 
Setting, geographic 
location 
N Age Joint Severity Study design 
Murphy, 2015 (61) Community based, pain 
clinics; USA 
45 37-83y Knee ACR criteria- severity not defined 
 
Qualitative 
 
Parry, 2017 (209) Community, UK 719 ≥50y Knee Self-reported knee pain in previous 12 
months 
Observational 
Ricci, 2005 (73) 
 
Community, USA 
 
329 40-65y Knee and 
hip 
Clinical evidence of OA- severity not 
defined 
Nested case control 
 
Wise, 2010 (74) 
 
Primary care, hospital, 
USA 
 
303 ≥50y 
 
Knee and 
hip 
Signal joint pain in a hip or knee on at 
least 15 out of the 30 days prior to 
enrolment- not further defined 
Observational 
 
Zhang, 2009 (202) 
 
Primary care, hospital, 
USA 
303 ≥50y Knee and 
hip 
Signal joint pain in a hip or knee on at 
least 15 out of the 30 days prior to 
enrolment-not further defined 
Observational 
 
Zhang, 2011 (203) 
(abstract) 
Not specified 52 50-72y Knee KL>2 
 
Case-crossover 
 
Zobel, 2016 (75) 
 
Hospital databases, 
Australia 
297 >40y 
 
Knee ACR criteria, KL ≥2, or patellofemoral 
OA on radiograph 
Web based case-cross 
over 
ACR American College of Rheumatology;  ARA American Rheumatism Association; GP General Practitioner; KL Kellgren and Lawrence; RCT Randomised 
Controlled Trial; US United States of America 
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4.4.2 Rationale given for flare definitions used  
Six studies attempted to validate or give rationale for the definition used in their study 
(55, 61, 73, 180, 209, 211). Marty et al sought to validate a diagnostic tool for OA 
flare-ups. A flare-up score was initially determined using a general practitioner 
database and this was then validated using a study with rheumatologists. The tool 
consisted of a number of weighted items including; knee effusion, limping, stiffness, 
and nocturnal awakenings (55).  
Scott-Lennox et al (180) explored whether certain measures for flare intensity could 
be combined to form a reliable and valid tool using data from an RCT using 
confirmatory factor analysis. These included: patient’s self-assessment of pain 
scores, physician’s assessment of pain scores, patient’s global OA assessment and 
physician’s global OA assessment. The group identified three flare intensity groups 
(low, moderate and severe). 
Cibere et al (211) highlighted their face validity checks with study rheumatologists. 
The flare definition used had been established by study rheumatologists to be a 
change in the WOMAC score that was thought to be clinically important. The 
definition used by Murphy et al (61) was determined using the researchers own 
experience and from two flare design studies. Ricci et al (73) used both previous 
experience and that determined by the data. Parry et al (209) specified that their 
definition was based on those used in flare design studies and exacerbation 
definitions used in other chronic disease, for example, COPD and back pain.  
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4.4.3 Exacerbation definitions in drug withdrawal studies 
4.4.3.1 Terminology used 
The majority of drug withdrawal design studies (n=42) used the term ‘flare’ in their 
definition or description (Table 4.4a) (67, 68, 155-160, 162, 165-175, 177-188, 190-
199). One used the term ‘flare-up’ (69), two referred to ‘worsening of symptoms’ in 
their description (161, 176) and for three no specific label was used (163, 164, 189).  
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Table 4.4a: Definition, terminology and measurement instruments used in all included studies: drug withdrawal design studies 
 
First author Terms 
used 
Change in symptoms/signs Minimum absolute level of 
symptoms/signs 
Speed of 
onset 
Duration; Change in 
medication/healthcare 
use; Rationale 
Altman, 
2015 (67) 
"Flare" Pain:  WOMAC Pain (0-100); increase 
≥15mm 
Pain: WOMAC Pain; ≥40mm - - ; - ; - 
Baer, 2005 
(157) 
"Flare" Pain: WOMAC LK3.1 Pain (0-20); 
increase ≥2 points and ≥25%   
Pain: WOMAC Pain (0-20); ≥6 and ≥1 item 
rated 'moderate, severe, or extreme' 
Unclear - ; - ; - 
Baraf, 2011 
(158) 
"Flare" Pain on movement: VAS (0-100mm); 
increase ≥5mm  
- 1w washout - ; - ; - 
Battisti, 
2004 (159) 
"Flare" Global assessment (investigator): 
single item, 5-point LK; Worsening ≥1 
point 
Pain: VAS (0-100mm); ≥40mm  - - ; - ; - 
Bingham, 
2007 (156) 
 
Bingham 
2011 (191) 
"Flare" 
  
 (1) Pain walking on flat surface: 
WOMAC VAS3.0 Q1 (0-100mm);  
increase ≥15mm 
(2) Global assessment of disease 
status (investigator):   single item, 5-
point LK; Worsening ≥1 point 
 
  
 (1) Pain walking on flat surface: ≥40mm 
on WOMAC VAS3.0 Q1 (0-100)  
(2) Global assessment (investigator):  
single item, 5-point LK; fair, poor, very poor 
(acetaminophen users only)   
(3) Global assessment of disease status 
(patient): VAS 0-100mm; ≥40mm 
(acetaminophen users only)                      
   
- 
  
- ; - ; - 
Birbara, 
2006 (160) 
"Flare" 
  
(1) Pain walking on flat surface: 
WOMAC VAS Q1 (0-100mm); increase 
≥15mm                                                                            
(2) Global assessment (investigator): 
single item, 5-point LK; Worsening ≥1 
point 
(1) Pain walking on flat surface:  WOMAC 
VAS3.0 Q1 (0-100); ≥40mm    
(2) Global assessment (investigator): 
single item, 5-point LK; Fair, poor or very 
poor (paracetamol arm only)                 
  
 4-15d 
washout 
  
- ; - ; - 
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First author Terms 
used 
Change in symptoms/signs Minimum absolute level of 
symptoms/signs 
Speed of 
onset 
Duration; Change in 
medication/healthcare 
use; Rationale 
Bocanegra, 
1998 (161) 
"Worsening 
of 
symptoms" 
Two out of the following three:                                  
(1) Global assessment (physician): 
single item, 5-point LK; Increase ≥1 
grade                                                                               
(2) Global assessment (patient): 
Patients global assessment (current 
symptoms and limitation of activity) 5-
point LK; Increase ≥1 grade                               
(3) Composite index: Lequesne OA 
Severity Index (0-24); Increase ≥2 
points 
(1) Global assessment (physician): single 
item, 5-point LK; 'poor/very poor'                         
(2) Global assessment (patient): Patients 
global assessment (current symptoms and 
limitation of activity) 5-point LK; 'poor/very 
poor'                              
(3) Composite index: Lequesne OA Severity 
Index (0-24); ≥7 
3-14d 
washout 
- ; - ; - 
Boswell, 
2008 (162) 
"Flare" (1) Pain walking on flat surface: 
WOMAC VAS Q1 (0-100mm); increase 
≥15mm  
(2) Global assessment (patient): 
Patient Global Assessment of Arthritis 
Condition (PGAC) (unspecified); 
Worsening ≥1 point 
- - - ; - ; - 
Brandt, 
2006 (198) 
"Flare" Not specified Pain: WOMAC LK Pain subscale (5-25); ≥15 
points  
5 half-lives 
of NSAID 
washout 
- ; - ; - 
Case, 2003 
(163) 
Not used (1) Pain walking on flat surface: VAS 
(0-100mm); Increase ≥10mm                      
(2) Ambulatory pain; 5-point LK; 
worsening ≥1 point 
Not specified 14d 
washout 
- ; - ; - 
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First author Terms 
used 
Change in symptoms/signs Minimum absolute level of 
symptoms/signs 
Speed of 
onset 
Duration; Change in 
medication/healthcare 
use; Rationale 
Day, 2000 
(189) 
Not used 
  
(1) Pain walking on a flat surface: 
WOMAC VAS Q1 (0-100mm); increase 
≥15mm 
(2) Global Assessment (investigator): 
single item, 5-point LK; worsening ≥1 
point 
(3) Global assessment (patient): VAS 
(0-100mm); increase ≥15mm  
(acetaminophen users only) 
(1)  Pain walking on a flat surface: 
WOMAC VAS Q1 (0-100mm); ≥40mm;  
(2) Global Assessment (investigator): 
single item, 5-point LK; 'Fair, poor, or very 
poor'; (3) Global assessment (patient): 
VAS (0-100mm); ≥40mm  
>5 plasma 
half-lives 
washout 
  
- ; - ; - 
Ehrich, 1999 
(164) 
Not used Pain: VAS (0-100mm); increase ≥15mm Pain: VAS (0-100mm); ≥40mm Longer than 
5 plasma 
half-lives 
washout of 
NSAID 
- ; - ; - 
Essex, 2012 
(165) 
"Flare" (1) Global Assessment (Physician): 5-
point LK; increase ≥1 grade                                               
(2) Global Assessment (patient): 5-
point LK; increase ≥1 grade     
(1) Global Assessment (Physician): 5-point 
LK; 'Fair, poor or very poor'                                         
(2) Global Assessment (patient): 5-point 
LK; 'Fair, poor or very poor'                                            
(3) Pain: VAS (0-100mm); 40-90mm 
48h 
withdrawal 
- ; - ; - 
Essex 2013 
(192) 
“Flare” Not specified (1) Global Assessment of arthritis 
(Physician): Minimum rating of 3                                         
(2) Global Assessment of arthritis  
(patient): Minimum rating of 3                                            
(3) Pain: VAS (0-100mm); 40-90mm 
48h 
withdrawal 
- ; - ; - 
Gibofksy, 
2014 (166) 
“Flare” Pain:  WOMAC Pain VAS; increase 
≥15mm 
Pain:  WOMAC Pain VAS; ≥40mm - - ; - ; - 
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First author Terms 
used 
Change in symptoms/signs Minimum absolute level of 
symptoms/signs 
Speed of 
onset 
Duration; Change in 
medication/healthcare 
use; Rationale 
Gineyts, 
2004 (167) 
“Flare” (1) Pain walking on a flat surface:  
WOMAC VAS Q1 (0-100mm); increase 
≥15mm                                                                
(2)Global Assessment (investigator): 
5-point scale: worsening ≥1 point 
(1) Pain walking on a flat surface:  
WOMAC VAS Q1 (0-100mm); ≥40mm 
5 half-lives 
of NSAID 
washout 
- ; - ; - 
Goldberg, 
1988 (168) 
“Flare” (1) Pain: Investigator assessed pain 
grade (None/mild/mod/severe): (i) at 
rest, (ii) on passive motion, (iii) on 
palpation, (iv) weight bearing; increase 
≥1 grade in two items OR increase ≥2 
grade in one item 
Not specified 2-14d 
washout 
until flare 
- ; - ; - 
Gottesdiener, 
2002 (169) 
“Flare” (1) Pain on walking: VAS (0-100mm); 
increase ≥15mm                                                            
(2)Global Assessment (Investigator): 
5-point LK; Increase ≥1 point 
(1) Pain on walking: VAS (0-100mm); 
≥40mm
3-15d 
washout 
- ; - ; - 
Hochberg, 
2011 (68) 
“Flare” (1) Pain walking on a flat surface:  
WOMAC VAS Q1 (0-100mm); Increase 
≥15mm                                    
(2) Global Assessment (patient): 5-
point LK; worsening ≥1 point 
(1) Pain walking on a flat surface:  
WOMAC VAS Q1 (0-100mm); ≥40mm 
- - ; - ; - 
Katz, 2010 
(170) 
“Flare” Not specified Pain: Pain score (0-10); ≥5 - - ; - ; - 
Kivitz, 2001 
(171) 
“Flare” Pain: Patients Assessment of Pain 
Score (0-10) (unspecified); increase ≥2 
points 
Pain: Patients Assessment of Pain Score (0-
10) (unspecified); ≥5 
5 drug half-
lives or 48h 
- ; - ; - 
Kivitz, 2004 
(190) 
“Flare” (1) Pain on walking: VAS (0-100mm); 
worsening ≥15mm                                                              
(2) Global Assessment (investigator): 
5-point LK; worsening ≥1 point 
Not specified NSAID 
dependent 
half-life 
washout 
- ; - ; - 
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First author Terms 
used 
Change in symptoms/signs Minimum absolute level of 
symptoms/signs 
Speed of 
onset 
Duration; Change in 
medication/healthcare 
use; Rationale 
Goldberg, 
1988 (168) 
“Flare” (1) Pain: Investigator assessed pain 
grade (None/mild/mod/severe): (i) at 
rest, (ii) on passive motion, (iii) on 
palpation, (iv) weight bearing; increase 
≥1 grade in two items OR increase ≥2 
grade in one item 
Not specified 2-14d 
washout 
until flare 
- ; - ; - 
Gottesdiener, 
2002 (169) 
“Flare” (1) Pain on walking: VAS (0-100mm); 
increase ≥15mm                                                            
(2)Global Assessment (Investigator): 
5-point LK; Increase ≥1 point 
(1) Pain on walking: VAS (0-100mm); 
≥40mm
3-15d 
washout 
- ; - ; - 
Hochberg, 
2011 (68) 
“Flare” (1) Pain walking on a flat surface:  
WOMAC VAS Q1 (0-100mm); Increase 
≥15mm                                    
(2) Global Assessment (patient): 5-
point LK; worsening ≥1 point 
(1) Pain walking on a flat surface:  
WOMAC VAS Q1 (0-100mm); ≥40mm 
- - ; - ; - 
Katz, 2010 
(170) 
“Flare” Not specified Pain: Pain score (0-10); ≥5 - - ; - ; - 
Kivitz, 2001 
(171) 
“Flare” Pain: Patients Assessment of Pain 
Score (0-10) (unspecified); increase ≥2 
points 
Pain: Patients Assessment of Pain Score (0-
10) (unspecified); ≥5 
5 drug half-
lives or 48h 
- ; - ; - 
Kivitz, 2004 
(190) 
“Flare” (1) Pain on walking: VAS (0-100mm); 
worsening ≥15mm                                                              
(2) Global Assessment (investigator): 
5-point LK; worsening ≥1 point 
Not specified NSAID 
dependent 
half-life 
washout 
- ; - ; - 
66 
 
First author Terms 
used 
Change in symptoms/signs Minimum absolute level of 
symptoms/signs 
Speed of 
onset 
Duration; Change in 
medication/healthcare 
use; Rationale 
Leung, 2002 
(172) 
“Flare” 
  
(1) Pain on walking on a flat surface: 
WOMAC VAS Q1 (0-100mm); Increase 
≥15mm 
(2) Global Assessment (investigator): 
5-point LK; worsening ≥1 point 
 
(1)Pain on walking on a flat surface: 
WOMAC VAS Q1 (0-100mm); ≥40mm 
(2 ) Global Assessment (patient): (0-
100mm); ≥40mm  
(acetaminophen users only) 
(3) Global Assessment (investigator): 5-
point LK; ‘Fair, poor, or very poor’ 
(acetaminophen users only) 
Determined 
by drug half-
life washout 
  
- ; - ; - 
Luyten, 
2007 (173)  
“Flare” 
  
(1) Global Assessment (Patient): 5-
point LK; Increase ≥1 grade                       
(2) Global Assessment (physician): 5-
point LK; increase  ≥1 grade 
(3) Composite definition: Lequesne 
Osteoarthritis Severity Index (0-24); 
increase ≥2 points  
(1) Global Assessment (Patient): 5-point 
LK; ‘Fair, poor or very poor’ (Not on treatment 
– ‘Poor or very poor’)  
(2) Global Assessment (physician): 5-point 
LK; ‘Fair, poor or very poor’  
(Not on treatment – ‘Poor or very poor’) 
(3) Composite definition: Lequesne 
Osteoarthritis Severity Index (0-24); ≥7 
(4) Pain: VAS (0-100mm); ≥40mm       
2-14d 
washout 
  
- ; - ; - 
Manicourt, 
2005 (174) 
“Flare” Pain when walking on a flat surface: 
VAS (0-100mm) ; ≥10mm 
- 7-10d 
washout 
- ; - ; - 
Mazzuca, 
2002 (155) 
“Flare” Pain on standing: WOMAC LK Pain 
Q5 ‘severe or extreme’ after the 
washout AND decreased after 
resumption of usual analgesic drugs 
and/or NSAIDs 
- Drug 
washout 5 
half lives 
- ; - ; - 
McIlwain, 
1989 (175) 
“Flare” No measurement instrument: Increase 
in pain on motion, swelling, tenderness, 
redness and/or heat (unspecified if 
patient/physician/investigator reported) 
- 2-14d 
washout 
- ; - ; - 
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First author Terms 
used 
Change in symptoms/signs Minimum absolute level of 
symptoms/signs 
Speed of 
onset 
Duration; Change in 
medication/healthcare 
use; Rationale 
Mendelsohn, 
1991 (176) 
“Worsening 
of arthritis 
condition” 
(1) Pain: Pain scale (0-3) (0=none, 
3=severe); worsening score                                                           
(2) Global (physician): (0-100); 
worsening score 
- Up to 14d 
washout 
- ; - ; - 
Moskowitz, 
2006 (177) 
  
“Flare” 
  
(1) Global assessment (patient): 5-
point LK; increase ≥1 grade                                      
(2) Global Assessment (physician): 5-
point LK; ≥ 1 grade increase                                                                                                                                                                                                                     
(3) Composite index: Lequesne OA 
Severity Index (0-24); increase ≥2 
points         
(1) Global assessment (patient): 5-point 
LK; ‘(Fair), poor, or very poor’                                        
(2) Global Assessment (physician): 5-point 
LK; ‘(Fair), poor or very poor’                                       
(3) Composite index: Lequesne OA Severity 
Index (0-24); Minimum ≥7 
(4) Pain walking on a flat surface: VAS (0-
100mm); ≥40mm 
NSAID 
washout of 
5 half-lives 
or at least 
2d 
  
- ; - ; - 
Pareek, 2009 
(69) 
“Flare-up” (1) Pain: 11-point NRS; increase ≥ 2 
points during previous 2-5 days                             
(2) Signs and symptoms suggestive of 
inflammation, morning stiffness and 
nocturnal pain interfering with sleep 
Pain: Pain intensity of at least 4 on a 11-point 
NRS during physical activity for past 24 hours 
Placebo 
washout 
for 24-48h  
2-5d; - ; - 
Pareek, 2010 
(178) 
“Flare” Flare symptoms noted but not part of 
definition: morning stiffness, erythema, 
nocturnal pain, and 
swelling/inflammation 
(1) Pain with physical activity: VAS 0-10; 
≥6                                                    
(2) Composite index: WOMAC Total LK; 
≥25.                                                  
(3) Composite index: Lequesne OA Severity 
Index (0-24); ≥5 
- 2-5d; - ; - 
Roth, 2004 
(194) 
“Flare” Pain: WOMAC LK3.1 Pain subscale (0-
20); increase ≥2 points and ≥25% 
Pain: WOMAC LK3.1 Pain subscale (0-20); 
Score ≥‘moderate’ on at least 1 of the 5 
items, (ii) Pain score ≥6 
Washout 
period ≥3d 
per week 
past month 
- ; - ; - 
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First author Terms 
used 
Change in symptoms/signs Minimum absolute level of 
symptoms/signs 
Speed of 
onset 
Duration; Change in 
medication/healthcare 
use; Rationale 
Rother, 2007 
(197) 
“Flare” (1) Pain on walking: VAS (0-100mm); 
Increase ≥15mm                                                                        
(2) Global Assessment (patient): 5-
point LK; increase ≥1 grade 
(1) Pain on walking: VAS (0-100mm); 
≥40mm                                                                                                   
(2) Global Assessment (patient): 5-point 
LK; 3-5 
- - ; - ; - 
Schnitzer, 
2005 (179) 
“Flare” No tool: increase in pain Pain: VAS (0-100mm); ≥40mm - 24h; - ; - 
Scott-
Lennox, 
2001 (180) 
“Flare” (1) Pain: VAS (0-100mm); ≥20mm  
(2) Pain (physician): 4-point LK; 
worsening ≥1 point 
(3) Global Assessment (patient): 4-
point LK; worsening ≥1 point  
(4) Global Assessment (physician):4 
point LK; worsening ≥1 point 
(1) Pain: VAS (0-100mm); ≥40mm at 
baseline)  
(2) Pain (physician): 4-point LK; ≥2 
(3) Global Assessment (patient): 4-point 
LK; ≥2  
(4) Global Assessment (physician): 4 point 
LK; worsening ≥2 
14d 
washout 
- ; - ; Confirmatory 
Factor Analysis 
Simon, 2009 
(195) 
“Flare” Pain: WOMAC LK3.1 Pain subscale; 
increase ≥2 and ≥25%  
Pain: WOMAC LK3.1 Pain subscale;  
≥’moderate’ on ≥1 item 
14d 
washout 
- ; - ; - 
Silverfield, 
2002 (181) 
“Flare” Pain: No measurement tool; significant 
increase 
- - - ; Pain requiring 
supplemental analgesic 
medication and/or an 
increase in NSAID dose 
; - 
Strand, 2011 
(182) 
“Flare” Global Assessment (patient): 5-point 
LK; Increase ≥1 
(1) Global Assessment (patient): 5-point 
LK; ‘Fair, poor or very poor’  
(2) Pain: (0-10 NRS); ≥4 but <9                                                         
(3) Global Assessment (physician): 5-point 
LK; ‘Fair, poor or very poor’ 
14d 
washout 
- ; - ; - 
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First author Terms 
used 
Change in symptoms/signs Minimum absolute level of 
symptoms/signs 
Speed of 
onset 
Duration; Change in 
medication/healthcare 
use; Rationale 
Weaver, 1995 
(196) 
“Flare” (1) Global Assessment (Physician): 5-
point Likert; increase ≥1 grade                                                 
(2) Global Assessment (patient): 5-
point LK; increase ≥1 grade                                                                              
(3) Pain: Worsening pain on motion and 
weight bearing 
(1) Global Assessment (Physician): 5-point 
Likert; ≥2                                                            
(2) Global Assessment (patient): 5-point 
LK; ≥2 
2-14d 
washout 
- ; - ; - 
Wiesenhutter, 
2005 (183) 
“Flare” (1) Pain on walking on flat surface: 
WOMAC VAS3.0 Q1 (0-100mm); 
increase ≥15mm 
(2) Global Assessment (Investigator): 
5-point LK; worsening ≥1 unit 
(1) Pain on walking on flat surface: 
WOMAC VAS3.0 Q1 (0-100mm); ≥40mm 
- - ; - ; - 
Williams, 
2001 (184) 
“Flare” 
  
(1)Global Assessment (patient): 5-
point LK; Increase ≥1 point                                      
(2) Global Assessment (physician): 5-
point LK; increase ≥1 point(3) 
Composite Index: Lequesne OA 
Severity Index (0-24); Increase ≥2 
points  
(1) Global Assessment (patient): 5-point 
LK; ‘(Fair), poor or very poor’                                             
(2) Global Assessment (physician): 5-point 
LK; ‘(Fair), poor or very poor’ 
(3) Composite Index: Lequesne OA Severity 
Index (0-24); ≥7 
(4) Pain: VAS (0-100mm); ≥40mm 
2-14d 
  
- ; - ; - 
Wittenberg, 
2006 (185) 
“Flare” Pain: VAS (0-100mm); Increase ≥10mm Pain: VAS (0-100mm); ≥40mm 2-7d 
washout 
- ; - ; - 
Yeasted, 
2014 (186) 
(Pooled, 
abstract) 
“Flare” Pain: 0-10 NRS; Increase ≥2 points 
over the mean pain score from the 
previous 3 days 
Pain: Average daily 0-10 NRS; 4-9 - - ; - ; - 
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First author Terms 
used 
Change in symptoms/signs Minimum absolute level of 
symptoms/signs 
Speed of 
onset 
Duration; Change in 
medication/healthcare 
use; Rationale 
Yocum 2000 
(193) 
“Flare” Disease activity 
(1) Global (Investigator): Reduction of 
≥ 1 grade 
(2) Global Assessment (Patient): 100-
mm VAS;  Increase of ≥10mm 
(3) Pain: Overall assessment 
(patient): 100-mm VAS; ≥35mm 
- ≥3d washout - ; - ; - 
Young, 2014 
(187) 
"Flare" (3) Pain:  WOMAC pain subscale; 
increase >15mm 
Pain: WOMAC Pain subscale  >40mm - - ; - ; - 
Zhao, 1999 
(188) 
"Flare" No measurement tool: Worsening of 
signs and symptoms after 
discontinuation of NSAIDs of analgesics 
- 2-7d washout - ; - ; - 
COPD Chronic Obstructive Pulmonary Disease; d day; h hour; KOFUS Knee Osteoarthritis Flare-up Score; LK Likert Scale; NRS Numerical Rating scale; VAS 
Visual Analogue Score; w week; WOMAC Western Ontario and McMaster Universities Osteoarthritis Index 
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4.4.3.2 Coverage of key components 
Onset/worsening of symptoms and signs above normal day-to-day variation  
All studies included increased pain intensity in their definition and 44 included onset 
or worsening of signs and symptoms (67, 68, 155-169, 171-197).  A further two 
specified other signs and symptoms including:  swelling, tenderness, erythema 
and/or heat (175) and morning stiffness, erythema, nocturnal pain and 
swelling/inflammation (178).  
Temporal characteristics 
Speed of onset was not specified in the drug withdrawal design studies however they 
did describe withdrawal or ‘washout’ periods. These were specified periods of time 
the potential participants had to experience ‘flare’ symptoms, after stopping usual 
medication, in order to be eligible for the study. Thirty studies stipulated a withdrawal 
period (69, 155, 158, 160, 161, 163-165, 167-169, 171-177, 180, 182, 184, 185, 188-
190, 192-196, 198). 
A minimum duration of symptoms was required in four studies and this ranged from 
24 hours to 5 days (69, 178, 179, 181). 
Change in medication or healthcare usage 
Only one study included increase medication; ‘pain requiring supplemental analgesic 
medication and/or an increase in NSAID dose’ (181). 
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Additional domains 
Thirty-six studies specified a minimum threshold, whereby the participant had to 
reach a certain pain intensity level to be classified as having a flare (67-69, 156, 157, 
159-161, 164-167, 169-174, 177-180, 182-187, 189, 191, 192, 194-198).  
 
4.4.4 Exacerbation definitions in non-drug withdrawal design studies 
4.4.4.1 Terminology used 
The majority of non-drug withdrawal design studies (n=11) used the term ‘flare’ in 
their definition or description (Table 4.4b) (55, 61, 71, 74, 199, 201, 204, 205, 209, 
210, 212). Eight used the term ‘exacerbation’ however 5 of these publications were 
from the same research team. Two studies used both ‘exacerbation’ and ‘flare’ (73, 
202). None of the studies referred to ‘worsening of symptoms’ or did not use a 
specific label. 
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Table 4.4b: Definition, terminology and measurement instruments used in all included studies: non-drug withdrawal design studies 
First author Terms used Change in symptoms/signs Minimum absolute level of 
symptoms/signs 
Speed of 
onset 
Duration; Change in 
medication/healthcare 
use; Rationale 
Atukorala, 
2016 (204); 
Atukorala, 
2016 (199) 
"Flare" Pain: (10-point NRS); increase >2 points 
from the mildest knee OA pain intensity 
reported at day 0 
- - - ; - ; - 
Bartholdy, 
2016 (210) 
“Flare” - Pain: (10-point NRS): Pain >5 - - ; - ; - 
Bassiouni 
2015 (205) 
“Flare” - Global Assessment (physician): 
KOFUS  ≥7 
- - ; - ; - 
Cibere, 2004 
(211); 
Cibere, 
2005 (212) 
 
"Flare" (1) Patients perception of worsening of 
symptoms                                                  
(2) Pain walking on flat surface: 
WOMAC VAS3.0 Q1 (0-100mm); increase 
≥20mm                                                                                                           
(3) Global Assessment (physician): 5-
point LK; worsening ≥1 grade 
- - - ; - ; Definition determined 
by study rheumatologists 
to be a clinically important 
change in WOMAC-
Ehrich2000/Bellamy 1998 
Conrozier 
2012 (71) 
 
"Flare" Fulfilled 4 following criteria:  
(1) Pain:  No measurement tool;     
‘sudden aggravation of knee pain’  
(2) causing nocturnal awakenings,  
(3) clinical evidence of effusion. 
- Sudden 
aggravation 
of knee pain, 
whose 
beginning 
was 
identifiable 
- ; - ; - 
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First author Terms used Change in symptoms/signs Minimum absolute level of 
symptoms/signs 
Speed of 
onset 
Duration; Change in 
medication/healthcare 
use; Rationale 
D'Agostino, 
2005(201) 
 
"Flare" - Pain intensity during physical 
activity: VAS-(0-100mm); ≥40mm 
- 48h ; - ; - 
Erfani, 2014 
(200); 
Erfani, 2014 
(206); 
Ferreira, 
2016 (82); 
Hunter, 
2014 (207); 
Makovey, 
2015 (208) 
Exacerbation Pain: VAS (0-100mm); Increase ≥20mm 
from mildest pain score reported at 
baseline 
- - - ; - ; - 
Jawad, 2005 
(213) 
 
Exacerbation Pain symptoms: Increased morning 
stiffness, night pain and synovial fluid 
effusion 
- - - ; - ; - 
Marty, 2009 
(55) 
 
"Flare" No measurement tool:                                    
Morning stiffness >20mins, nocturnal 
awakening, limping, knee effusion, 
increased warmth 
- - 48h ; - ; Regression 
analysis of cross-sectional 
data to validate proposed 
flare criteria 
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First author Terms used Change in symptoms/signs Minimum absolute level of 
symptoms/signs 
Speed of 
onset 
Duration; Change in 
medication/healthcare 
use; Rationale 
Murphy, 
2015 (61) 
 
"Flare" (1) Investigator definition: Inadequate pain 
relief for an episode of intense pain that is 
usually brought on by too much activity.     
(2) Participant definitions: Described in 
terms of pain quality, timing (onset and 
duration), antecedents and 
consequences. (3) Pain magnitude: 
increase in pain or 'intense' or 'severe' 
level of pain 
Pain: ≥40 of 100mm or ≥4 of 10 on 
NRS 
Patients 
described: 
'Quick' or 
'sudden' 
Patients: 10 seconds to 15 
minutes 
Patients: Rest or take 
additional medication 
For investigator definition: 
Battisti 2004, Pareek 
2010. Plus researchers 
own experience. 
Parry, 2017 
(209) 
“Flare” Pain: Recalled worst pain intensity in 
previous 6 months 0-10 NRS; ≥5 
Pain: Recalled worse pain to be ≥2 
points higher than recalled average 
pain (0-10 NRS) in previous 6 
months 
- - ; - ; Based on previous 
studies defining knee 
flares in OA and flares in 
diseases such as back 
pain and COPD. 
Wise, 2010 
(74) 
 
"Flare" - Pain: WOMAC Pain subscale (0-
10); score in highest 30% of all 
WOMAC scores 
- - ; - ; - 
Zhang, 2009 
(202) 
 
"Exacerbation 
or flare" 
- (1) Pain: WOMAC pain subscale 0-
10 (total score of 50 normalised to 
a 0-10 scale); score of ≥5, a score 
corresponding to highest 33% of all 
WOMAC scores 
- - ; - ; - 
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First author Terms used Change in symptoms/signs Minimum absolute level of 
symptoms/signs 
Speed of 
onset 
Duration; Change in 
medication/healthcare 
use; Rationale 
Zhang, 2011 
(203) 
"Exacerbation" Pain: WOMAC Pain score VAS (0-500); 
increase ≥100 units 
- - - ; - ; - 
Zobel, 2016 
(75) 
Exacerbation Pain: 0-10 NRS; Increase ≥2    (1) Disabling pain - 8h ; - ; - 
COPD Chronic Obstructive Pulmonary Disease; d day; h hour; KOFUS Knee Osteoarthritis Flare-up Score; LK Likert Scale; NRS Numerical Rating scale; VAS 
Visual Analogue Score; w week; WOMAC Western Ontario and McMaster Universities Osteoarthritis Index 
77 
 
4.4.4.2 Coverage of key components 
Onset/worsening symptoms and signs above normal day-to-day variation 
Onset or worsening of symptoms was used in 16 of 22 studies (61, 71, 73, 75, 82, 
199, 200, 203, 204, 206-209, 211-213)  in their definition. Pain intensity was not used 
as part of the definition in two studies (55, 205). In three studies, other symptoms 
were included as part of the definition (55, 71, 213): nocturnal awakenings, effusion, 
morning stiffness, night pain, limping and warmth.  
A mixed methods study by Murphy et al (61), included an investigator definition of 
flare-ups and explored participant experience and individual definitions of flare-ups 
through face-to-face interviews. Both the investigator and participant definitions 
included onset or worsening of symptoms and signs; however there was no 
differentiation of pain above day-to-day variation. 
Temporal characteristics 
Only one study attempted to define the speed of onset and this was simply described 
as ‘sudden’ (71). Participants in the Murphy et al study  used terms such as ‘quick’ 
and ‘sudden’ in their description of flare onset and participants described the duration 
lasting between 10 seconds to 15 minutes (61). In three studies, a minimum duration 
of symptoms was described ranging from 8 to 48 hours (55, 201, 214). 
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Change in medication or healthcare usage 
The study by Murphy et al, described that participants either rested or used additional 
medication in response to flares (61). No other studies described change in 
medication or healthcare usage. 
Additional domains 
Two studies from the Longitudinal Examination of Arthritis Pain Cohort used 
“distribution-based” minimum threshold for flare (189, 203). Amongst the participants 
this was the highest 30% (203) or 33% (189) of WOMAC Pain subscale scores (total 
score 50 was normalised on a 0-10 scale). 
 
4.4.5 Measurement Instruments and Operational Criteria 
Forty-four drug-withdrawal design studies used measurement tools (67-69, 155-174, 
176-180, 182-187, 189-198) and 20 non-drug withdrawal design studies used the 
tools (61, 71, 73-75, 82, 199-212). There were 19 different single-item scales and 6 
multi-item scales used. The most commonly used tools were the Pain VAS (0-
100mm), WOMAC Q1 3.0 VAS ‘pain walking on a flat surface’ (0-100mm), 
Investigators Assessment of Disease Status and the Patient Global Assessment of 
Arthritis (Table 4.5) 
 
  
79 
 
Table 4.5: Summary of number and type of single and multi-item measurement tools 
used. 
Single item scales:   
     Pain on activity: WOMAC Q1 3.0 VAS ‘pain on walking on a flat surface’ (0-
100mm) [n=11] 
Pain on walking VAS (0-100mm) [n=5] 
Pain on movement VAS (0-100mm) [n=1]; Ambulatory pain 
(5-point Likert) [n=1]; Pain with physical activity VAS 11-
point scale [n=2] 
     Pain (not further  
     specified): 
Pain VAS (0-100mm) [n=15] 
Patients Assessment of Pain Score (0-10) [n=1]; Pain Scale 
(0-3)[n=1]; Pain NRS (0-10) [n=11] 
     Standing knee pain Item 5 WOMAC pain scale [n=1] 
     Global rating     
     (physician/    
     investigator) 
Investigator Assessment of Disease Status [n=11]  
Physicians Global Assessment of Arthritis [n=6]  
Physician Global Assessment of OA [n=2] 
Physician Global Assessment of Disease Status [n=2]; 
Investigator Assessed Pain Grade [n=1]; (Physician) Overall 
Disease Activity (0-100) [n=1]; Physicians Pain Assessment 
(4-point LK) [n=3] 
     Global rating     
     (patient) 
Patients Global Assessment of Arthritis [n=7] 
Patient Global Assessment of OA [n=3] 
Patient Global Assessment of Disease Status [n=4] 
Multiple-item scales:  
 Lequesne OA Severity Index [n=5]  
WOMAC LK3.1 (0-20) [n=3] 
WOMAC LK Pain subscale (0-25); WOMAC OA Index 
Questionnaire [n=1]; WOMAC knee pain score (0-500) [n=7]; 
KOFUS (0-14) [n=1] 
KOFUS Knee Osteoarthritis Flare-up Score; n number of included studies; OA osteoarthritis; 
VAS visual analogue scale; WOMAC Western Ontario and McMaster Universities Osteoarthritis 
Index. 
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Onset/worsening of symptoms and signs beyond normal-day-to-day variability 
There were 52 studies that used measurement tools to define onset-worsening of 
symptoms and signs (67-69, 73, 75, 82, 155-169, 171-174, 176, 177, 180, 182-187, 
189-191, 193-197, 199, 200, 203, 204, 206-209, 211, 212). The most commonly 
used tools used for determining onset/worsening of signs and symptoms were: the 
Western Ontario and McMaster Universities Arthritis index (WOMAC) Q1 (pain on 
walking on a flat surface) 100mm Visual Analogue Scale (VAS) (n=10),the 
Investigator Assessment of Disease Status (n=10), Global Assessment of Disease 
Status (physician) (5-point Likert scale) (n=9) and Pain NRS (0-10) (n=7). 
There were some inconsistencies in the use of global scales and their format, as was 
use and reporting of the WOMAC (215). Despite this, the items used covered four 
general areas: pain on activity (for example, walking), pain (not further specified), 
physician or investigator global ratings and patient global ratings. 
Additional domains- minimum threshold  
In general the minimum thresholds used for the different measurement tools were the 
same. For example, threshold of 40mm on a 0-100mm scale was used in studies 
using the WOMAC VAS 3.0 Q1 ‘pain on walking on a flat surface’ (68, 156, 160, 167, 
172, 183, 189, 191). However, there were inconsistencies with scales and minimum 
thresholds used in reporting the Patient Global Assessment of Disease Status. Four 
studies using a 100mm VAS used a minimum threshold of 40mm (156, 164, 172, 
191) and those using a 5-point Likert used ‘fair, poor or very poor’ (165, 173, 182, 
184) or ‘poor, very poor’ (161). In studies using the Physician or Investigator Global 
Assessments the majority (n=10) used a minimum threshold of ‘fair, poor or very 
poor’ (156, 160, 165, 172, 173, 177, 182, 184, 189, 191). In studies using the 
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Lequesne index (0-10) the majority of studies (n=4) used a minimum threshold of 7 
(161, 173, 177, 184) and one used 5 (178).  
 
4.5 Discussion 
This review has found common core domains amongst the descriptions and 
definitions used for knee OA flare-ups in the medical literature. These domains will 
be helpful in reaching a consensus definition which can be used clinically to promptly 
identify these acute events and help focus management strategies. A consensus 
definition will also ensure reproducibility and comparability of results in research 
studies. 
The key core domains identified in this review were: onset/worsening of symptoms 
and signs above normal day-day variation, duration of symptoms, speed of 
onset/worsening of symptoms and minimum symptom threshold. Other domains 
which received less attention included change in medication and healthcare usage.  
The majority of studies required an increase in pain intensity above ‘usual’ or 
‘baseline’. A wide range of measurement instruments were used, but several 
selected an increase of at least 2 points on a 0-10 scale. This could indicate a 
starting point for reaching consensus. Distinguishing these increases in pain intensity 
from day-to-day variability, which is a known feature in OA (63, 216), is important and 
a definition with an increase in pain intensity alone is unlikely to achieve this. 
Duration of flare-ups, which ranged from 10 seconds to 5 days in this review, may be 
a critical component. Day-to-day variability in pain intensity is likely to encompass 
these short lived episodes of pain however it is probably unrealistic to include 
durations as short as 10 seconds in a definition of flares. Interestingly, duration does 
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not appear to be an important feature in other chronic diseases. In the COPD 
literature a ‘sustained worsening’ of symptoms (137) is described however this is not 
mentioned in other chronic diseases. Clinically, it might be more straightforward to 
rely on individual patient judgement as to whether symptoms have increased above 
normal variation. However, it remains unclear how accurately patients can report this. 
Speed of onset was not well defined in this review. When mentioned it was described 
descriptively, for example ‘sudden’. In drug withdrawal studies, washout periods 
between 2-15 days were specified, but this is unlikely to be synonymous with speed 
of onset. It may be unrealistic to operationalise time, and experience from the 
respiratory field, where the term ‘acute’ is often used (137),  seems to suggest that 
this has not been a barrier in making progress.   
There was general agreement with the minimum symptom threshold used, for 
example, 40mm on a 0-100mm scale. This may represent the level for minimally 
important clinical difference in symptoms. COPD exacerbation definitions describe a 
symptom increase ‘which is beyond normal day-today variations’ (137) and the SLE 
definition includes; ‘must be considered clinically significant by the assessor’ (140), 
both of which rely on judgement. 
Increase in medication or healthcare usage was not identified as a key component of 
definitions of OA flares despite it featuring in others: AS (117), SLE (140), IBD (217) , 
COPD (137). Interference with function was not a key feature in our review, nor did it 
feature in the definitions used in other chronic diseases, such as back pain (218), 
COPD (138), asthma (139), AS (117) and SLE (140). 
Reaching an agreed definition through consensus exercises can be a lengthy 
process and usually involves key stakeholders, experts and patients in addition to 
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appraisal of the relevant literature using numerous methods. Each component of the 
definition presents its own challenges in achieving a consensus. Following an 
OMERACT initiative from 2006 to find a consensus definition for RA flares the 
working group have undertaken a number of stages (Table 4.6).  
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Table 4.6: Progress of the OMERACT group in reaching a consensus definition for 
rheumatoid arthritis flare ups 
2009: Bingham CO et al. (144) 
Aim:  Literature review to identify publications and abstracts with flare 
definitions applied to RA, JIA and lupus RCT as well as concerning 
patient perspectives on disease worsening. SIG for patients (n=120) 
and investigators (n=11) held. Discuss various aspects of disease 
worsening. 
Outcome:  Following consensus obtained: working definition of flare should 
indicate worsening of disease activity (88%), persistence, and duration 
as critical elements (77%), and a consideration of change or increase 
in therapy (74%). “Worsening of signs and symptoms if sufficient 
intensity and duration to lead to change in therapy. 
2011: Bingham CO et al. (219) 
Aim:  Patient research partners-iterative driven Delhi process, preliminary list 
of key domains identified 
Outcome:  Consensus achieved in addition to existing core set for RA including 
fatigue, stiffness, symptom persistence, systemic features and 
participation. 
2012: Bartlett SJ et al. (220) 
Aim: 125 RA pts from 10 countries and 108 HCPs from 23 countries rated 
14 domains, Delphi consensus 
Outcome: Core domains: Pain (93%), function (89%), swollen joints (84%), tender 
joints (81%), participation (81%), stiffness (79%), patient global 
assessment (76%), and self-management (75%), fatigue 
2013: Lie E et al. (221) 
Aim: Assess construct and content validity of the potential RA flare domains. 
Assessed convergent and construct validity variables representing 
same domains. 
Outcome: Domains appeared to be discriminatory for flare 
2016: Bykerk et al. (80) 
Aim: Evaluate reliability of flare identification and construct validity of key 
components representing the OMERACT RA Flare Core Domain Set. 
Outcome: The 5 flare domains (pain, fatigue, stiffness, function and participation) 
showed good construct validity but reliability was not proven. 
HCP Healthcare professional; JIA Juvenile idiopathic arthritis; OMERACT RA Rheumatoid arthritis; 
RCT Randomised controlled trial; SIG Special interest group 
 
A consensus definition is important in order to ensure reproducible and comparable 
research than can accurately provide estimates of disease burden which will be 
helpful for resource planning. Furthermore, it allows consistent recognition and 
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identification in clinical practice. The characterisation of acute episodes in a number 
of chronic diseases, such as COPD (137, 138), asthma (139), and AS (117) rely on 
descriptive definitions. These definitions tend to be the ones adopted in clinical 
guidelines, for example, NICE and the Global Initiative for Chronic Obstructive Lung 
Disease (GOLD). However, they are generally not adopted for research purposes, 
where measurement-based criteria are preferred (222).  
Marty et al (55) and Scott-Lennox (180) et al were the only groups that attempted to 
propose and/or validate prediction models for OA flares, although these have not 
been widely implemented. This may be due to the difficulty in reaching a widely 
accepted model. Using different definitions can be problematic, hindering 
comparisons between studies, for example, comparing estimates of incidence (223) 
and effect sizes in RCTs (222). In this review, the majority of non-drug withdrawal 
design studies relied on patient reported outcomes which contrasts with the drug 
withdrawal studies which relied heavily on investigator or physician reported 
outcomes. The use of symptom versus healthcare-defined definitions (based on, for 
example, change in therapy or contact with healthcare professional) has also been 
shown to affect reported mean yearly rates with healthcare defined rates being 
higher (2.3 per year vs 2.8) when estimating COPD exacerbation rates (224). 
The main strengths of this systematic review are that it included a broad search 
strategy using a wide range of databases, bibliography checks, attempted contact 
with authors, included conference abstracts, did not have any language restrictions 
and there was a low threshold for inclusion (for example any description or definition 
of a flare was used). A similar review was conducted by Cross et al which aimed to 
identify the key domains in the medical literature that were used by patients and 
clinicians to described knee and hip OA flares. The review presented in this chapter 
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however was more comprehensive including 69 versus 23 studies (126). Five studies 
that were included in the Cross et al review were not included in ours as four did not 
contain a clear definition of flare and the Sands et al (225) paper was not included as 
the original study was included instead. The key components identified by Cross et al 
share some similarities with my study. These include pain onset (which 
encompassed timing, an increase in pain and duration), other symptoms (for 
example swelling, warmth, limping, taking medication) and change in scores on 
single and multi-item measurement tools, for example the WOMAC.  
Limitations of this study include not searching the grey literature. There were terms 
that may be synonymous with a flare that were not included in the search strategy: 
‘attack’, ‘fluctuation’ and ‘episode’. These terms were thought to be related to 
comorbidities and other phenomena and would have made the search strategy less 
efficient. Data extraction was only performed by a single reviewer. Only two of the 
included studies attempted to derive and validate a prediction model for OA flares 
(55, 180). Despite this, their models have not been widely adopted. The majority of 
definitions in this systematic review were from flare design trials. The participants 
generally underwent a period of drug washout in order to bring on a flare. These 
were ‘investigator-induced’ flares and so may be different to ‘naturally occurring’ ones 
both in the symptomatology, severity and speed of onset. Despite this, flare design 
trials might give some useful information with regards to naturally occurring flares for 
those people whose flares are triggered by them stopping their medication.  A further 
limitation of the study is lack of validation of definitions used within the literature. The 
majority of pain measurement tools used have been previously validated, for 
example, WOMAC. However, they have not been specifically validated for their ability 
to detect flares. 
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My review was conducted three times over the course of this thesis; initially in 2013, 
secondly in 2016 to update the search after returning from maternity leave and finally 
in 2017 after a similar review had been published. Since 2017 there have been a few 
studies published that would have been relevant to my review; the Flare in OA 
OMERACT group published their study identifying preliminary domains for a 
consensus definition (81), the protocol for the ACT-Flare web cased crossover study 
assessing risk factors for knee OA flares (83),  a cross-sectional study exploring flare 
onset following sit to stand activities (226), and a study exploring daily pain 
trajectories in knee and hip OA and their association with certain patient 
characteristics (227). 
This review has highlighted the range of ad hoc definitions used for knee OA flare-
ups in the literature. Despite this they share common core domains: onset worsening 
of symptoms and signs, attainment of minimum symptom threshold, speed on onset 
or worsening of symptoms, and duration of increased symptoms. Reaching a 
consensus definition can be a lengthy process. However, achieving a widely 
accepted definition that is reliable, sensitive to repeated measures, feasible, 
acceptable and validated would help ensure research findings were comparable. 
Furthermore, a definition that provides prompt diagnosis and is acceptable clinically 
would ensure prompt management through healthcare providers or though self-
management strategies. 
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4.6 Conclusion 
This review has shown that the cardinal features of a flare-up of knee osteoarthritis 
include; increased pain intensity with a minimum symptom threshold. The findings 
show the range of definitions that currently exist and demonstrate the need for a 
consensus definition that is reliable, validated, feasible and acceptable to use in 
clinical practice and research.  
The core domains described in this chapter informed the definitions used for acute 
events in the secondary analysis of cohort data (Chapter 5), the cross-sectional 
survey (chapter 6) and the diary study (Chapter 7), and that used in the patient 
literature of the qualitative study (Chapter 8). 
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5. Significant pain variability in persons with, or at 
high risk of, knee osteoarthritis: preliminary 
investigation based on secondary analysis of cohort 
data 
 
This chapter describes the design and findings of a secondary analysis of cohort data 
intended to provide estimates of significant pain variability or potential flare-up 
intervals and the factors associated with these as a preliminary investigation of the 
frequency and risk factors for acute flare.  
 
5.1 Introduction 
Longitudinal studies with repeated measures over 5-6 years have shown that 
trajectories in osteoarthritis symptoms and disabilities, for the majority of participants, 
are relatively stable over periods lasting up to 10 years (56-59, 228). However, these 
studies mask the variability of pain intensity that occurs within persons (62, 229, 
230). This variability in pain may represent day-to-day variation but more importantly 
may represent acute events or flares of pain which are suggested to occur in early 
and advanced OA and be associated with distress and impact on function, 
particularly when unpredictable (53) 
More frequent pain measurements are more sensitive to changes in pain intensity. 
Schneider et al (230) gathered pain intensity data daily for 7 and 28 days and 
demonstrated high within and between-person variability in pain. However, this 
sample was recruited from rheumatology clinics and only half of the population had a 
diagnosis of OA as it also included those with RA, lupus and fibromyalgia so it is not 
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clear who these findings are generalisable to. Baseline factors that might determine 
variability in symptoms and help understand who might be more at risk of an unstable 
disease course were not presented, for example gender, age, baseline severity, 
employment and duration of symptoms. Despite this increased variability was seen in 
those with depression and persistent pain. Variability in OA pain is likely to exist on a 
spectrum with part of this variability being attributed to episodes of 
uncharacteristically severe pain or acute flares. It was suggested by Hawker et al that 
these events take place in both the early stages of OA where they are usually 
predictable and in the late stages where they become unpredictable (53). Hawker et 
al, undertook focus groups on patients that were recruited from advertisements and 
flyers and had a radiographic diagnosis of OA. Response bias may have led to those 
with more severe symptoms replying, however the authors did try to sample across 
the spectrum of OA severity. Despite this it is not reported how many fell into the 
mild, moderate or severe pain groups. Furthermore, there were few people in the 
‘early’ OA group. It is therefore difficult to draw conclusions on whether flares are 
more likely to occur at a certain disease stage, something which may be helpful for 
resource planning and identifying those patients at greatest risk of flares.   
Findings from the systematic review (Chapter 4) undertaken to identify, describe and 
evaluate definitions of knee OA flare used in the medical literature found a number of 
common domains including: onset/worsening of symptoms above normal day-to-day 
variability, speed of onset, duration of sustained worsening, and a minimum threshold 
of pain. The majority of these studies were from flare design trials, in which usual 
medication is withdrawn in order to bring about an acute increase in symptoms 
during a specified time period. Findings from the systematic review and definitions 
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from the flare design studies have been used to define symptom variability or ‘flares’  
in this study. 
Induction of flares in the context of drug withdrawal trials is well established. Usual 
medication is withdrawn with the aim of inducing a ‘flare’ within a specified time 
period to evaluate a new regime or pharmacological therapy (158, 161, 162, 178, 
231). A recent systematic review assessing NSAID response found 22 flare design 
and 11 possible flare design trials in the literature. These ‘induced’ flares however 
are likely to be different to ‘naturally’ occurring flares which in comparison have 
received less attention. Increasingly, studies on these phenomena, termed ‘acute 
events’, ‘flares’, or ‘exacerbations’ are starting to emerge. Studies include those that 
have attempted to identify diagnostic criteria for a flare-up (55), identify triggers (74), 
explore impact on productivity (73) and the role of inflammation (70, 71).  
Few studies have attempted to estimate flare frequency. Those that have attempted 
this have only used short observation periods of 1-2 weeks (73, 232). Amongst 
participants in these studies nearly 80% experienced a flare. In one study this was 
based on predetermined flare criteria which required a minimum increase of 2 points 
(on a 0-10 scale) from baseline (73) and in the second it was based on participant 
self-identification (232). The short but intensive data collection period suggests that a 
high proportion of people with OA seem to experience something we might call 
‘flares’.  
While previous short-term studies support the idea that many patients with 
osteoarthritis may experience significant variability in pain over time, population-
based studies could usefully estimate the proportion and characteristics of patients 
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experiencing such variability. To attempt this, I undertook a secondary analysis of 
available data from the Clinical Assessment Study of the Knee (CAS-K) cohort. 
 
5.2 Aims and Objectives 
Aim 
The aim of this study was to estimate what proportion of adults with knee pain in the 
general population report ‘significant symptom variability’ (a potential proxy for 
experiencing flare) and how those individuals differ from those who do not report 
significant symptom variability. 
Objectives 
• To estimate potential frequency of symptom variability 
• To determine risk factors for symptom variability  
 
5.3 Methods 
5.3.1 Description of dataset: Clinical Assessment Study of the Knee (CAS(K)) 
Descriptive summary of cohort and dataset 
The secondary dataset used in this study was the Clinical Assessment Study of the 
Knee (CAS(K)) which comprised a large prospective community based cohort study 
of 819 participants with knee pain and knee OA based in North Staffordshire, UK. 
The CAS(K) study was granted approval by the North Staffordshire Local Research 
Ethics Committee (project number 1430 baseline, 03/94 18 months, 05/Q2604/72  3 
years, 06/Q2707/327 54 months, 08/H1206/171 6 years). 
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All patients aged 50 years and over registered at three general practices in North 
Staffordshire were eligible for inclusion. Patients were recruited between 2002 and 
2003 and followed up at 18 month intervals until 2009. The general aim of the 
longitudinal aspect of this study was to describe the clinical course of healthcare 
utilisation of older adults with knee pain in the general population, developing 
prognostic indicators of clinical course and consultation (92). 
The dataset is held by the SPCSC and data was requested to answer specific 
questions relevant to this thesis. No further ethical application was required for this 
study.  
 
5.3.2 Sampling and data collection 
Eligible patients were mailed a Health Survey questionnaire that included socio-
demographic characteristics, general health status, and questions on recent knee 
pain. Those who reported knee pain in the past 12 months and consented to further 
contact were sent a Regional Pain Survey questionnaire which included the Western 
Ontario and McMaster Universities OA index (WOMAC LK 3.0) (233). Participants 
who completed both questionnaires were invited to a research clinic where they 
underwent digital photography of the lower limbs and hands, plain radiography of 
both knees and both hands, a standardised clinical interview and physical 
examination of the knees and hands by a trained physiotherapist, simple 
anthropometric measurements and a brief self-complete questionnaire. 
The content of the standardised clinical interview and physical examination had been 
developed using literature review and consensus methods, and underwent initial 
testing and evaluation of inter- and intra-rater reliability (234-236). A brief, 
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standardised examination of both hands was conducted which allowed for clinical 
classification of hand OA (237) and nodal OA. Reliability was good for much of the 
clinical history (236) but several items in the physical examination were found to have 
relatively high inter- and intra-observer variability (234) leading to some of these 
items being dropped or amended before the main study. 
At the baseline clinic visit three radiographic views of the knees were undertaken 
according to standardised protocols: weight bearing posteroanterior (PA) semi-
flexed/metatarsophalangeal (MTP) (238), a supine skyline view and supine lateral 
view; the latter two with the knee flexed to 45o. Films were scored by a single reader 
blinded to all questionnaire and clinical data using Kellgren and Lawrence (K&L) 
score, and standard atlases (239-241). Severity of radiographic OA in the knee as a 
whole (across tibiofemoral and patellofemoral joints) was classed as none, mild, 
moderate, or severe, according to a pre-defined scheme (242).  Intra-reader reliability 
scores were very good (unweighted κ = 0.81–0.98); inter-reader scores were also 
good (κ = 0.49–0.76). 
For the purposes of the current analysis, interview, examination and radiographic 
variables were used only for the index knee (the most painful as rated by the 
participant). If both knees were rated equally painful, the index knee was randomly 
assigned by a statistician. 
Body mass index (BMI) was calculated from weight and height measured in baseline 
clinic. 
At baseline and at each of the follow up surveys (mailed at 18, 36, 54 and 72 
months), the Von Korff Chronic Pain Grade (243)  was collected and related to the 
previous 6 months. This is a measure of global severity of knee pain, consisting of 7 
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items relating to pain intensity, disability, and interference with activities. Using 
simple scoring rules pain severity was graded into four hierarchical classes. Only 
selected items were used in this secondary analysis, and these will be discussed in 
further detail in the next section.  
 
5.3.3 Study participants 
The study population at baseline, i.e. those that had responded to the Health Survey, 
reported knee pain in the previous 12 months, consented to further contact, 
responded to the Regional Pain Survey and attended the research clinic was 54%  
female. The age categories were as follows: 50-59 (29%), 60-69 (38%), 70-79 (27%) 
and 80 and over (6%). 
 
5.3.4 Response at baseline and follow-up 
Information about participation rates from baseline to 3 years was extracted from 
publications from the CAS(K) and from the custodian of the data set.  
Baseline 
There were 2226 responders reporting knee pain and consenting to further contact of 
which 819 attended the research clinic for assessment and radiographs. 
Follow up 
A postal survey was sent to participants at 18, 36, 54 and 72 months (n=776, 707, 
602 and 512 responders respectively) (59). 
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An analysis of the baseline and 18 month follow up found that the following were 
associated with selective non-participation: age over 80, not being 
married/cohabiting, lower educational attainment, manual occupations and possible 
or probable anxiety or depression symptoms (244). The majority of responders were 
Caucasian (99.5%) (244). These factors limit the generalisability of findings.  
Physical SF-12 mean scores from the Health Survey at the initial mail out was 41.0 
(12.5) compared to 37.6 (11.90) at the research clinic. This may suggest that those 
with worse physical symptoms were less likely to attend the research clinic. However, 
WOMAC scores were stable between initial mailing and the research clinic. 
 
5.3.5 CAS(K): Critical evaluation of CAS(K) as a secondary data source for this 
thesis 
The CAS(K) dataset was chosen for this study as it was easily accessible, free, 
known to contain potentially relevant items, and based within a UK population. An 
estimate of frequency of symptom variability could be determined from answers given 
to the chronic pain grade and the baseline variables were those that have been 
previously been shown to be associated with knee OA progression (245, 246). As 
this was a preliminary study of symptom variability and risk factors it was decided to 
look initially at factors that had already been identified to be associated with knee 
OA. 
Bias  
A longer duration of recall period and increased pain close to the measurement time 
point has been shown to affect accuracy of pain recall leading to recall bias (100, 
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247). The Chronic Pain Grade has been shown to be more sensitive to change when 
used over a 4-week recall period (248). Furthermore, a long period of recall can be 
subject to forward telescoping where an event is reported more recently than it 
actually happened (249), thus leading to an overestimate in pain rating which may 
have influenced ‘worst pain’ scores. Selection bias, whereby the inclusion of 
participants in the study depends on the exposure of interest, may in this study have 
led to selective non-response and loss to follow up.  
Summary  
The CAS(K) dataset had a number of advantages and key limitations. The definition 
of symptom variability was possible with the available data and it contained the range 
of variables that I wanted to explore further. However, limitations included the long 
recall period for worst and average pain intensity: the sampling frame was restricted 
to one geographical area, limited to those over 50 years of age and Caucasians; and 
the additional selection bias from selective non-response and loss to follow-up. 
 
5.3.6 Availability of key data 
The CAS(K) study provided a wide range of baseline data including demographics, 
physical function status, knee pain, psychological status, social factors, knee history, 
knee examination findings, knee symptoms and results from knee radiographs. 
From the initial mailing stage 2226 responders reported knee pain and consented to 
further follow up and 819 attended the research clinic (59).  
Follow up surveys, which included assessment with the Von Korff Chronic Pain 
Grade(243) over the past 6 months and current pain on an 11-point numerical rating 
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scale, which was also assessed at baseline, were mailed to participants at 18 
months, 36 months, 54 months and 72 months (n= 776, 707, 602 and 512 
responders) (59). 
Patients were excluded at baseline if they had incomplete radiographs, inflammatory 
arthritis, total knee replacement and a diagnosis of gout from medical record review 
at baseline or at 18 month follow up. Participants who reported total knee 
replacement (TKR) in either knee after baseline and up to 3 years were also 
excluded. Patients reporting TKR in either knee at 3-6y were excluded at the 3-year 
time point. 
The outcome variable chosen was worst and average pain in the past 6 months on a 
0-10 scale. On this scale ‘0’ was no pain and ‘10’ was as bad as it could be (250). 
Variables that were selected from the CAS(K) data were those that have been shown 
to be risk factors for knee OA (251, 252), incidence of knee OA progression (253-
255), association with pain outcomes (256) or triggers of acute exacerbations (74). 
Those included are described below. 
Age and gender 
Age (“date of birth”) and gender (“male/female”) was determined using standard 
single questions. 
Anthropometric measures 
Body Mass Index (BMI) was calculated from height and weight recorded at the 
baseline clinic visit. 
Measures of severity and function 
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Measures of disease severity and function included SF-36 (257), WOMAC knee pain 
score (258), WOMAC knee function score (258) and severity of knee effusion. 
Measures of radiographic severity included were overall severity of index knee and 
radiographic component compartment combinations of index knee. 
The WOMAC is designed to assess pain, stiffness and physical function in those with 
hip or knee OA. It consists of 24 items divided into 3 subscales: pain (5 items), 
stiffness (2 items) and physical function (17 items) (258). The pain and physical 
function items were included in this analysis. The pain items ranged from a scale of 
01-20 and the physical function items from 0-68. 
For small and large effusions the ‘bulge’ test was performed (259). For moderate 
effusions, where the bulge sign could not be elicited due to too much fluid but where 
the patellar tap sign was not present the ‘balloon sign’ was used. These tests were 
assigned a dichotomous rating and in addition to this an ordinal-scale was used 
regarding overall judgement of the severity of the effusion (259) where 1 is no 
effusion, 2 is mild, 3 is moderate and 4 is gross effusion. This was based on direct 
observation and palpation to closely reflect clinical practice. 
Knee related factors 
Knee related factors requiring dichotomous responses included previous knee injury, 
new knee problem in the last 12 months, experience difficulty to get moving in 
morning, knee given way in last 12 months and seen a hospital doctor about knee. 
Duration of knee symptom was subdivided into the following categories: less than 12 
months, 1-less than 5 years, 5-less than 10 years and over 10 years. If the 
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participant indicated difficulty in getting moving (also known as inactivity gelling 
(236)) they were asked to categorise this as ≤30minutes or over 30 minutes. 
Psychological factors  
Severity of anxiety and depressive symptoms were assessed by the respective 
subscales of the Hospital Anxiety and Depression scale (HADS) (0-21 each) (260). 
This brief self-complete scale includes seven items for anxiety and seven for 
depression each scored on a scale of 0-3, where 3 indicates more frequent 
symptoms and higher total scores on the HADS indicating more distress.  
Nodal OA 
The presence of nodal hand osteoarthritis was determined if KL score was ≥2 in two 
or more inter-phalangeal joints (IPJs) and if there were at least 2 Heberden or 
Bouchard nodes present across either hand (261). 
Physical activity 
Of the twenty-one physical activity items in the Health Questionnaire, six items were 
chosen (based on those items that were felt to be more objective, for example ’walks 
of 2 miles or more’), grouped into broad levels of physical activity intensity, and item 
responses dichotomised to yield three binary predictor variables (Table 5.1) 
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Table 5.1: Derived variables for physical activity 
Derived variable Items* used to construct 
derived variable 
Positive response defined 
as 
Frequent sedentary activity Spend most or all of day in 
bed or chair 
Responded “all, most or 
some days” 
Frequent moderate physical 
activity 
(a) Walks of a least a 
quarter of a mile  
(b) Walks of two miles 
Responded “all, most or 
some days” to at least one 
item 
Frequent vigorous physical 
activity 
(a) Play a sport 
(b) Heavy gardening  
(c) Heavy DIY work at home 
Responded “all, most or 
some days” to at least one 
item 
* Items relate to reported frequency of doing each activity in the past 4 weeks 
 
5.3.7 Defining symptom variability 
The components that constituted the flare-up definition used for the current study 
were items that were adapted from the Von Korff Chronic Pain Grade in the CAS(K) 
study. The Chronic Pain Grade was originally validated in primary care patients with 
lower back pain, headache and temporomandibular joint disorder. It was adapted for 
the CAS(K) for knee pain. The two pain intensity items used for the flare definition 
asked participants to rate their worst and average pain in the past 6 months on a 0-
10 scale. On this scale ‘0’ was no pain and ‘10’ was as bad as it could be. It has been 
shown to have good reliability and convergent through correlations with similar items 
on the SF-36 general health questionnaire and construct validity by assessing 
whether patients scored higher if they had recently sought help for their pain or 
frequently took analgesia (250). 
Using these items the following a priori definition of a flare up was composed; an 
interval within which one or more periods of symptom variability had occurred was 
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defined by ‘recalled worst pain intensity in the past 6 months that was (a) ≥5, and (b) 
≥2 points higher than recalled average pain intensity in the same 6 month period’.  
This definition was chosen after referring to previous studies of osteoarthritis 
exacerbations where flares were described as worsening usual pain (55, 70), within 
defined limits using pain scales from flare design trials (157, 178, 180-182). 
Definitions used in other musculoskeletal conditions such as lower back pain (218) 
and non-musculoskeletal conditions such as COPD were used (76, 262) where 
worsening of symptoms is used in addition to requiring different or extra medication. 
The definitions are all reliant on change and difference in pain. The core domains 
identified from OA flare definitions identified in the systematic review (Chapter 4) 
were included within the limitations of the data available. The definition composed 
included onset/worsening of symptoms and minimum threshold.  
To be included in the denominator, individuals had to be ‘at risk’ during that follow-up 
interval (i.e. average pain intensity <9 out of 10). Participants were classed as not 
having a flare if they returned the self-complete survey but there was missing data at 
all time points on average and worst pain, if they had an average pain score of ≥9 at 
all-time points or they did not meet the flare criteria. For example, if a participant 
scored an average pain of ≥9 at three time points and had missing data at the other 
two time points they would be classified as not having a flare. 
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5.3.8 Statistical analysis 
Selective loss to follow up 
A chi-squared test was used to test for differences in the proportions lost to follow-up 
at each time point in those reporting significant pain variability at baseline compared 
to those reporting no significant pain variability at baseline  
Frequency of symptom variability at each time point 
The frequency and proportion of participants experiencing at least one exacerbation 
was reported for each time point. A baseline table was presented to compare the 
demographic and clinical characteristics of patients experiencing at least one flare-up 
over the 5 time-points against those with no flare-up. All continuous variables were 
summarised using mean and standard deviation, or medial and interquartile range as 
appropriate while frequency and percentages of observed levels were reported for all 
categorical measures.  
Association between putative predictors and symptom variability 
To estimate the association between the putative predictor variables and time to 
potential flare-up, discrete-time survival analysis was used. This was because the 
flare-up, though continuous in the sense that it may occur literally at any time, was 
recorded in discrete time as only the time interval in which the event occurred was 
known (263). Furthermore, there was a wide interval (18 months) between each 
measurement time point which also supports the use of this type of analysis. Discrete-
time hazard survival models become models for dichotomous response when the data 
have been expanded to person-period data with one observation for each year the 
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person is at risk (264). At each follow up time point, an indicator variable was created 
to determine whether a potential flare-up or episode of pain variability had been 
experienced in the previous 6 month period and estimated the hazard of flare-up using 
logistic discrete-time hazards model (263). This ensured that sample hazard 
probabilities would be computed for each time period that a flare-up occurred and no 
data was ignored (264). Right censoring was performed on the outcome at 72 months 
(the last follow-up period).  Censoring was also implemented for those that were lost 
to follow-up or withdrew from the study before their follow-up data was recorded. To 
account for variation in flare-up rates over time, at each follow-up period dummy 
variables were included in all models. The following 2 sets of analysis were performed:   
a) modelling the time to first flare-up or period of symptom variability, disregarding 
additional flare-ups i.e. after a flare-up occurs no additional records are included for 
that case; b) taking into account the recurrent flare-ups or periods of significant 
symptom variability. To take into account the recurrent flare-ups, multilevel discrete-
time survival (frailty) models were used. In the frailty model, the association between 
flare-up times was explicitly modelled as a random-effect term (265). The frailty model 
was estimated using logistic discrete-time hazards model with random effects. All 
analyses were performed using Stata 13 (StataCorp, 2013). 
Based on the literature, a large number of baseline variables were selected to be tested 
for an association with symptom variability (266). The method used to select the 
significant variables to use in the final multivariable model involved two steps. The first 
step involved the test of each variable to symptom variability association. In this case 
the alpha-level for rejecting the null hypothesis of no association was raised to 0.20 
(267). Since some of these variables were strongly correlated among themselves, and 
including all of them in the model would inflate the variance of the parameter estimates, 
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a test of multicollinearity was performed (268). This was done by first examining the 
correlations (continuous) and associations (categorical) between the independent 
variables, followed by multicollinearity diagnostic statistics for linear regression 
analyses (variance inflation factor), to check for the existence of multicollinearity when 
several potential predictors are adjusted for simultaneously (269). If multicollinearity 
existed, one of the correlated variables was dropped from the model; the choice of the 
variable to be included in the model was based on how strong it was related to the 
outcome (267). The second step involved simultaneous adjustment of all significant 
variables in the univariable model, followed by deletion in sequence of the least 
significant variables (270). The significance of each variable in the model was 
examined and if a variable appeared non-significant it was removed from the model 
and the model was refitted. The reduced model was compared with the complex model 
using the likelihood-ratio test. This was repeated until only factors with a p<0.05 were 
retained in the final model (267). 
 
5.4 Results 
Of 819 participants that attended the research clinic, 761 were eligible for data 
analysis at baseline (54% female; mean age 64.5 (SD 8.7) years; mean BMI 29.4 
(SD 5.1) kg/m2; average knee pain score (0-10 NRS) 4.4 (SD 2.4) ). 
The flowchart in Figure 5.1 gives a description of data available for analysis at each 
time point and exclusions. 
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Figure 5.1: Flow chart of data available for analysis at each time in CAS(K) 
 
  
Participants attending 
research clinic (n=819) 
Excluded: 
Previous TKR (n=15) 
Inflammatory knee pain (n=16) 
Gout (n=16) 
 
Incomplete radiographs (n=9) 
Declined (n=2) 
Participants available for 
baseline analysis (n=761) 
Participants available for 
18m analysis (n=679) 
Exclusion: 
TKR between baseline and 
36m (n=27) 
Loss to follow-up (n=55) 
Exclusion: 
Loss to follow-up (n=69) 
Participants available for 
36m analysis (n=610) 
Participants available for 
54m analysis (n=503) 
Exclusion: 
Loss to follow-up (n=94) 
TKR between 36m and 54m (n=13) 
Participants available for 
72m analysis (n=410) 
Exclusion: 
Loss to follow-up (n=93) 
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Selective loss to follow-up  
There was no evidence of selective loss to follow up amongst those who experienced 
significant pain variability versus those that did not experience significant pain 
variability (Table 5.2). 
Table 5.2: Comparison of responder status and presence of symptom variability at 
each follow-up time point 
 Responders 
(%) 
Non-
responders (%) 
Chi2 (p-value) 
18 months 207 (32) 20 (29) 0.31 (0.58) 
36 months 188 (32) 39 (29) 0.45 (0.50) 
54 months 156 (32) 71 (30) 0.40 (0.53) 
72 months 134 (34) 93 (29) 2.48 (0.12) 
 
Frequency of significant symptom variability  
At baseline 32% of participants experienced symptom variability, this reduced to 23% 
at 36 months and increased to 30% at 72 months (Table 5.3). There did not appear 
to be any trend over time. 
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Table 5.3: Proportion of patients reporting significant pain variability or flare-up at each time point  
 Measurement point 
 Baseline 
(n=761) 
18 months 
(n=679) 
36 months 
(n=610) 
54 months 
(n=503) 
72 months 
(n=410) 
Eligible responders reporting significant pain variability†: 
n (%) 
227 (32) 163 (26) 126 (23) 129 (27) 114 (30) 
     Average pain intensity in past 6 months (0-10NRS) 4.7 (1.7) 4.6 (1.8) 4.5 (1.6) 4.4 (1.5) 4.9 (1.9) 
     Worst pain intensity in past 6 months (0-10NRS) 7.6 (1.6) 7.5 (1.5) 7.3 (1.5) 7.1 (1.5) 7.6 (1.6) 
Eligible responders reporting no significant pain 
variability: n (%) 
493 (68) 462 (74) 433 (77) 336 (72) 260 (70) 
     Average pain intensity in past 6 months (0-10NRS) 3.9 (2.3) 3.5 (2.5) 3.9 (2.6) 3.5 (2.7) 3.8 (2.5) 
     Worst pain intensity in past 6 months (0-10NRS) 4.1 (2.3) 3.7 (2.4) 4.1 (2.6) 3.8 (2.7) 4.1 (2.5) 
Ineligible responders‡: n (%)   41 (5) 42 (6) 40 (7) 31 (6) 30 (7) 
Missing: n (%) 0 (0) 12 (2) 11 (2) 10 (2) 6 (1) 
Figures are mean (standard deviation) unless otherwise stated. NRS Numerical Rating Scale 
†worst pain intensity in past 6 months ≥5 and ≥2 points higher than average pain intensity in past 6 months 
‡average pain intensity in past 6 months ≥ 9/10 
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Participants classed as having at least one period of ‘significant pain variability’ 
Across the entire cohort follow up period 363 (47%) participants reported no periods, 
202 (27%) reported one period, 90 (12%) reported two periods, 63 (8%) reported 
three periods, 30 (4%) reported four periods and 13 (2%) reported five periods of 
significant pain variability. Table 5.4 presents the descriptive statistics for participants 
reporting at least one period of significant pain variability. 
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Table 5.4: Comparison of patient baseline characteristics of participants reporting at 
least one period of significant pain variability or potential flare. 
 
Periods of significant pain variability 
 
≥1 
n=398 
None 
n=363 
Female gender 211 (53) 191 (56) 
Age (years): mean (SD) 63.6 (8.2) 67.4 (8.7) 
Employed  106 (27) 59 (17) 
Attended full time education after school 68 (17) 45 (13) 
Married/cohabiting 317 (76) 236 (68) 
Current smoker 43 (11) 36 (10) 
Body Mass Index (kg/m2): mean (SD) 30.01 (5.28) 28.75 (4.76) 
Routine/manual occupational class† 191 (48) 191 (56) 
PF-10 physical function subscale (0-100): mean (SD)  56.06 (27.91) 58.73 (30.09) 
WOMAC knee pain (0-20): mean (SD) 6.51 (4.18) 5.56 (4.27) 
WOMAC knee function (0-68): mean (SD) 21.06 (14.48) 18.53 (14.70) 
HADS Anxiety (0-21): mean (SD) 6.84 (4.06) 6.28 (4.02) 
HADS Depression (0-21): mean (SD) 4.77 (3.36) 4.20 (3.10) 
Compartmental distribution of radiographic OA – index knee   
    Normal 133 (33) 105 (31) 
    Isolated tibiofemoral 18 (5) 12 (3) 
    Isolated patellofemoral 90 (23) 87 (25) 
    Combined tibiofemoral and patellofemoral 158 (40) 139 (41) 
Overall severity of radiographic OA - index knee   
    Normal  133 (33) 105 (31) 
    Mild 111 (28) 104 (30) 
    Moderate/severe 155 (39) 134 (39) 
Severity of knee effusion – index knee   
    None 261 (67) 219 (66) 
    Mild 94 (23) 82 (23) 
    Moderate/gross 44 (10) 42 (11) 
Nodal symptomatic hand OA 59 (15) 61 (18) 
Previous knee injury 
    None 
    Unilateral 
    Bilateral 
 
244 (65) 
101 (26) 
35 (9) 
 
216 (71) 
67 (23) 
15 (5) 
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Factors associated with time to first period of significant pain variability 
Based on the outcome of time to first period of significant symptom variability, 
baseline measures associated with a higher risk of symptom variability in the 
adjusted analysis were: younger age (OR (per year): 0.96; 95% CI 0.94, 0.97), higher 
BMI (per kg/m2: 1.03; 1.01, 1.06), higher WOMAC knee pain scores (per unit: 1.05; 
1.03, 1.10), longer time since onset (e.g. 1-5 yrs vs < 1 yr: 1.79; 1.16, 2.75) and 
morning stiffness ( 30 minutes vs none: 1.43; 1.10, 1.85) (Table 5.5). 
  
 Periods of significant pain variability 
 
≥1 
n=398 
None 
n=363 
Time since onset of knee problem 
    < 12 months 
    1 year to < 5 years 
    5 years to < 10 years 
    ≥ 10 years 
 
32 (8) 
143 (36) 
83 (21) 
141 (35) 
 
60 (16) 
116 (35) 
64 (19) 
103 (30) 
Duration of morning stiffness  
   None 
    ≤ 30 minutes 
    > 30 minutes 
 
135 (35) 
238 (60) 
25 (6) 
 
155 (46) 
174 (50) 
14 (4) 
Knee given way during past month 129 (32) 91 (27) 
Seen hospital doctor about knee 106 (27) 69 (20) 
Frequent sedentary activity 43 (11) 27 (8) 
Frequent moderate activity 211 (54) 186 (55) 
Frequent vigorous activity 110 (28) 95 (28) 
Figures are column percentages unless otherwise stated.  
HADS Hospital Anxiety and Depression scale [54]; OA Osteoarthritis; PF-10 Medical 
Outcomes Study SF-36 Physical Functioning subscale [55]; SD Standard deviation; WOMAC 
Western Ontario & McMaster Universities Osteoarthritis Index [56] 
†  Derived from National Socio-economic Classification [57] 
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Table 5.5: Patient baseline characteristics associated with significant pain variability 
or potential flare based on discrete-time logit model (first outcome) 
  Unadjusted  Adjusted* 
 Reference OR (95% CI)  aOR (95% CI) 
Male gender Female 1.15 (0.92, 1.45)  1.22 (0.96, 1.55) 
Age (years) per year 0.96  (0.95, 0.98)  0.96 (0.94, 0.97) 
Body mass index (kg/m2) per kg/m2 1.05 (1.03, 1.08)  1.03 (1.01, 1.06) 
Occupational class Managerial/ 
professional   
   
Intermediate  0.90 (0.56, 1.45)    
Routine and manual  0.76 (0.51, 1.12)    
PF-10 physical function      
(0-100) 
per unit 0.99 (0.99, 0.99)  ns ns 
WOMAC knee pain (0-20) per unit 1.08 (1.05, 1.11)  1.06 (1.03, 1.10) 
WOMAC knee function     
(0-68) 
per unit 1.02 (1.01, 1.03)  mc mc 
Compartmental distribution 
of radiographic OA† 
Normal      
   Isolated tibiofemoral  1.03 (0.58, 1.81)    
   Isolated patellofemoral  0.94 (0.70, 1.28)    
   Combined tibiofemoral 
and patellofemoral 
 1.06 (0.81, 1.38)    
Overall severity of 
radiographic OA† 
Normal      
   Mild  0.94 (0.70, 1.25)    
   Mod/severe  1.08 (0.82, 1.41)    
HADS anxiety (0-21) per unit 1.04 (1.01, 1.07)  mc mc 
HADS depression (0-21) per unit 1.07 (1.03, 1.10)  ns ns 
Previous knee injury None    ns ns 
   Unilateral  1.25 (0.95, 1.64)    
   Bilateral  1.82 (1.17, 2.85)    
Time since onset of knee 
problem† 
<1 year      
    1 year to < 5 years   1.97 (1.29, 3.01)  1.79 (1.16, 2.75) 
    5 years to < 10 years  1.94 (1.23, 3.05)  1.82 (1.15, 2.89) 
    ≥ 10 years  2.02 (1.32, 3.08)  1.82 (1.18, 2.82) 
Duration of morning 
stiffness† 
None      
    ≤ 30 minutes  1.63 (1.28, 2.07)   1.43 (1.10, 1.85) 
   > 30 minutes  2.26 (1.34, 3.81)  1.44 (0.83, 2.50) 
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  Unadjusted  Adjusted* 
Knee given way during past 
month† 
No 1.38 (1.08, 1.77)  ns ns 
Seen hospital doctor about 
knee† 
No 1.61 (1.23, 2.10)  ns ns 
Severity of effusion† None      
  Mild  0.99 (0.77, 1.30)    
  Moderate/gross  1.15 (0.79, 1.67)    
Nodal symptomatic hand 
OA 
No 0.90 (0.66, 1.24)    
Frequent sedentary activity No 1.59 (1.07, 2.35)    
Frequent moderate activity No 0.85 (0.68, 1.07)    
Frequent vigorous activity No 0.88 (0.68, 1.13)    
* Adjusted for all other variables; - indicates variables entered but not retained in multivariable model 
† For index (most problematic) knee 
HADS Hospital Anxiety and Depression scale [54]; OA Osteoarthritis; OR Odds ratio; PF-10 Medical 
Outcomes Study SF-36 Physical Functioning subscale [55]; WOMAC Western Ontario & McMaster 
Universities Osteoarthritis Index [56]; 95%CI 95 percent confidence interval 
ns Non-significant in multivariable model  
mc Variables omitted in the multivariable model due to multi-collinearity 
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Factors associated with recurrent periods of significant pain variability 
Based on the outcome of recurrent periods of significant symptom variability, i.e. 
allowing for those experiencing more than one episode, baseline measures 
associated with a higher risk of potential symptom variability in the adjusted analysis 
were: younger age (0.94; 0.91, 0.98), higher BMI (1.04; 1.00,1.08),  higher WOMAC 
knee pain scores (1.10; 1.03,1.17), longer time since onset (e.g. 1-5 yrs vs < 1 yr: 
(2.23; 1.11, 4.46), and morning stiffness  ( 30 minutes vs none: 1.67; 1.07, 2.61) 
(Table 5.6). Longer time since onset and morning stiffness had a slightly stronger 
association in comparison to the time to first episode of symptom variability analysis. 
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Table 5.6: Patient baseline characteristics associated with significant pain variability 
or potential flare based on discrete-time frailty model (recurrent outcome) 
  Unadjusted  Adjusted* 
 Reference OR (95% CI)  aOR (95% CI) 
Male gender Female 1.30 (0.86, 1.97)  1.40 (0.93, 2.09) 
Age (years) per year 0.95 (0.92, 0.98)  0.94 (0.91, 0.98) 
Body mass index (kg/m2) per kg/m2 1.07 (1.02, 1.12)  1.04 (1.00, 1.08) 
Occupational class Managerial/ 
professional 
     
Intermediate  0.95 (0.53, 1.70)    
Routine and manual  0.77 (0.49, 1.22)    
PF-10 physical function    
(0-100) 
per unit 0.99 (0.99, 0.99)  ns ns 
WOMAC knee pain (0-20) per unit 1.12 (1.04, 1.21)  1.10 (1.03, 1.17) 
WOMAC knee function      
(0-68) 
per unit 1.03 (1.01, 1.05)  mc mc 
Compartmental distribution 
of radiographic OA† 
Normal      
   Isolated tibiofemoral  1.05 (0.49, 2.24)    
   Isolated patellofemoral  0.93 (0.62, 1.40)    
   Combined tibiofemoral 
and patellofemoral 
 1.07 (0.75, 1.53)    
Overall severity of 
radiographic OA† 
Normal      
   Mild  0.93 (0.63, 1.36)    
   Mod/severe  1.10 (0.77, 1.57)    
HADS anxiety (0-21) per unit 1.05 (1.00, 1.10)  mc mc 
HADS depression (0-21) per unit 1.11 (1.02, 1.21)  ns ns 
Previous knee  injury No    ns ns 
   Unilateral  1.27 (0.92, 1.76)    
   Bilateral  1.96 (1.02, 3.79)    
Time since onset of knee 
problem† 
<1 year      
    1 year to < 5 years   2.38 (1.14, 4.97)  2.23 (1.11, 4.46) 
    5 years to < 10 years  2.32 (1.10, 4.89)  2.20 (1.08, 4.48) 
   ≥ 10 years  2.40 (1.18, 4.92)  2.11 (1.12, 4.05) 
Duration of morning 
stiffness† 
None      
    ≤ 30 minutes  2.23 (1.17, 4.23)  1.67 (1.07, 2.61) 
   > 30 minutes  3.75 (1.16, 12.16) 
 1.71 (0.73, 3.98) 
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  Unadjusted  Adjusted* 
 Reference OR (95% CI)  aOR (95% CI) 
Knee given way during past 
month 
No 1.42 (1.06, 1.90)  ns ns 
Seen hospital doctor about 
knee 
No 1.89 (1.41, 3.13)  ns ns 
Severity of effusion None      
  Mild  0.99 (0.69, 1.42)    
  Moderate/gross  1.18 (0.72, 1.92)    
Nodal symptomatic hand 
OA 
No 0.80 (0.48, 1.35)    
Frequent sedentary activity No 2.00 (0.96, 4.19)    
Frequent moderate activity No 0.79 (0.56, 1.13)    
Frequent vigorous activity No 0.79 (0.51, 1.23)    
* Adjusted for all other variables; - indicates variables entered but not retained in multivariable model 
†relates to index (most problematic) knee 
Hospital Anxiety and Depression scale [54]; OA Osteoarthritis; OR Odds ratio; PF-10 Medical Outcomes 
Study SF-36 Physical Functioning subscale [55]; WOMAC Western Ontario & McMaster Universities 
Osteoarthritis Index [56]; 95%CI 95 percent confidence interval 
ns Non-significant in final model  
mc Variables omitted in the multivariable model due to multi-collinearity 
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5.5 Discussion 
This study estimated that up to a third of adults aged over 50 years with knee pain 
experienced significant symptom variability or disease flare. These were associated 
with younger age, longer duration of knee problem, higher BMI and more severe 
knee symptoms at baseline. Potential flare-ups were also more common in males, 
those who reported prior bilateral knee injury, regular sedentary behaviour, increased 
functional limitation, and higher baseline scores for anxiety and depression scores 
although these correlations were not statistically significant after covariate 
adjustment. 
Estimates of flare frequency vary depending on definition used, period of time and 
frequency of data collection. In this study the definition of ‘significant pain variability’ 
used was based on recall to provide an initial approximate estimate of what 
proportion of people with knee symptoms/OA might experience symptom variability 
over a 6-month period. In previous studies, estimates amongst those with 
osteoarthritis ranged from 37-78% (55, 61, 73) . Results from this study may be an 
underestimate of actual frequency within this population due to one off 
measurements recording pain at 18 month intervals. The definition of symptom 
variability or ‘flare’ used in this study is limited to worsening of symptoms and a 
minimum threshold.  However, as noted by Marty (55) and in consensus work on 
flare-ups in other musculoskeletal conditions (271, 272), flare-ups are most likely to 
consist of a number of components. Information that was shown to be important in 
the systematic review (Chapter 4): speed of onset, duration, associated features (e.g. 
stiffness, swelling) and change in medication usage was not available in this data. 
These features may be important in distinguishing flare-ups from day to day 
variability in symptoms. 
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Associations found in this study are comparable for some studies but not others. 
Increased BMI has been shown to be associated with increased risk of flares in other 
studies (273). In previous case-crossover studies physical activity (203), buckling and 
knee injury (75), and worsening mental health (74) have been associated with flares. 
This study did not find a significant association with these factors which may be due 
to the need to consider these factors as time-varying, proximal triggers. No 
correlation was found between severity of radiographic OA and flares in this study 
which suggests flares may occur throughout the disease course. Removing those 
who had a TKR during study follow up is likely to have removed those with more 
severe disease from the analysis. This may partly explain the lack of correlation 
between severity of radiographic OA and flares, as those who went onto have a TKR 
may have been more likely to experience flares.   
Frequency of flare-ups in this study is less than has been reported in other studies. 
Ricci et al’s (73) estimate from telephone consultations of US workers found that 
38% of those aged 45-65 years reported exacerbations. A similar magnitude of pain 
increase was used to define exacerbation (2 or more on a 0-10NRS), however a 2-
week recall period was used.  
An important limitation of this study is the potential misclassification bias as a result 
of recall error. It is hypothesised that patients with increased pain closer to the 
measurement time points may have overestimated their average and worst pain 
scores whereas those with fewer pain fluctuations or no increase in pain close to the 
measurement time points are likely to have underestimated their pain scores over the 
previous 6 months. The overall impact of this on the results is uncertain. In addition, 
the long period of recall may be particularly prone to ‘forward telescoping’ where an 
event is reported more recently than it actually happened (274). In this analysis 
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‘average’ and ‘worst’ pain scores were taken from the Von Korff pain grade. These 
were chosen as they were similar but unfortunately not comparable to outcomes 
used in flare design trials. Flare-ups are identified in drug withdrawal trials by 
comparing baseline pain scores to worst pain scores. These limitations are only likely 
to be resolved by prospective studies with frequent repeated measures over clinically 
relevant time periods incorporating the concept of pain variability.  
Limitations of using secondary datasets include the potential for the study population 
and measures available to not match what the secondary data researcher would 
have collected, and it may be difficult to fully understand the data collection 
processes or why certain tools were selected to gather data (90, 91). If I was involved 
in the design of the secondary dataset I would have tried to overcome some of its 
limitations. This would have included measuring time-varying variables such as 
mental health markers, BMI and physical activity at all data collection time points as 
my secondary analysis was not able to detect short term changes in these variables 
and assess their impact. Furthermore, I would have asked about patient recall of 
flares over the previous 6 months and compared this to the imposed definition of 
flares that I used in this study. This would have given an estimate of self-reported 
flare frequency and how this item compared with an imposed definition. 
This study has given a preliminary estimate of frequency of symptom variability and 
factors associated with them. These findings will help in the design of the diary study 
both in terms of estimating sample size but also to help decide on which factors to 
assess in the daily diary study. Interviews with patients will help gain an insight into 
triggers patients believe are attributable to flares and how and if they explain the 
differences between flare-ups and symptom variability. 
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5.6 Conclusion 
The results from this study have shown that up to a third of community dwelling 
symptomatic adults recall significant variability in their knee pain in a given 6 month 
period. Younger males may be a higher risk group for experiencing symptom 
variability which may be occupation related and may be an area of focus for further 
research. Daily intensive longitudinal measurement may help give a more precise 
measure of frequency estimates of flares, allow them to be more accurately 
described and discover if associated factors in this secondary analysis are 
consistent. The following chapters will report on a cross-sectional survey and a daily 
diary study which will explore the natural history of flares in further detail.  
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6.  ‘Acute flare-ups’ in patients with, or at high risk of 
knee osteoarthritis: a cross-sectional survey 
 
Building on flare definitions used in previous studies, this chapter reports a study that 
uses patient recall of flares to estimate flare frequency, determinants of flares, and 
variables associated with them. Importantly, it also establishes participants’ baseline 
or ‘normal’ level of knee symptoms which was critical for the linked study presented 
in Chapter 7. A consideration of developmental work and lay member input will be 
presented prior to the methods and results.  
 
6.1 Developmental work 
The developmental work for both the cross-sectional survey and diary study (Chapter 
7) are inextricably linked. They will therefore be presented together in this chapter. 
The systematic review (Chapter 4) revealed disparity in the way flare-ups of knee 
osteoarthritis were being defined in the medical literature and highlighted the paucity 
of evidence for which these definitions were based on. The secondary analysis of 
cohort data undertaken in Chapter 5 was an exploratory study which gave an 
estimate of flare frequency but also identified important potential associated factors 
with flare-ups. These two key pieces of work informed the definition for flare-ups 
used in the cross-sectional and diary study and identified key factors of interest to be 
explored further; for example, duration of knee problem, previous knee injury, BMI, 
physical activity measures, and questions on symptoms such as knee stiffness. At 
the time this study was designed, to my knowledge, there were no other studies that 
had set out to identify factors associated with flares. Ricci et al, who aimed to explore 
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the relationship between OA pain exacerbation and lost productive time at work in 
the US found that exacerbations were more likely in those who were younger and 
female, although non-significant (73). However, this study is limited in that it was a 
telephone study conducted during the day time which may not be generalisable to 
the entire working population. 
The items included in the cross-sectional survey were informed by a number of 
sources including standardised questions previously used in studies; for example, 
those capturing demographical data and from other larger scale studies, such as the 
Osteoarthritis Initiative which was used to establish the presence of knee symptoms 
and previous knee injury. These studies were also a source of estimates for 
anticipated response rates and consent rates. 
The format and duration of data collection of the diary, length of the data collection 
instrument and methods to improve response rates and completeness of data entry 
were informed by: i) a non-systematic search conducted 2011-12 to identify daily 
diary studies in the literature (63, 98, 101, 102, 275), ii) the SPCSC Patient and 
Public Involvement and Engagement (PPIE) group, and iii) discussion with SPCSC 
experts with experience in diary studies. 
The domains of interest that were included in the diaries for example, the pain 
descriptors and knee symptoms were adapted from previous studies (53, 55, 276, 
277). The methods for recruitment were informed by the PPIE group, SPCSC 
experts, and the West Midlands North Clinical Research Network team who also 
advised on the number of practices to approach to reach the necessary response 
rate. 
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The SPCSC’s Clinical Trials Unit’s Standard Operating Procedures (SOP) were 
consulted for information on standardised and validated data collection instruments 
and study procedures. This was complemented by completion of in-person Good 
Clinical Practice training which covered the wider role of research within the NHS, 
standards, study set up, informed consent, data entry and safety reporting. 
The knee was chosen because it is the most common joint affected by knee 
osteoarthritis (278), diagnostic criteria include those 45 years and over (2), and 
clinical signs are easily recognisable, for example, swelling (55).  
 
6.1.1 Patient and Public Involvement and Engagement 
The aims of PPIE group in relation to the cross-sectional survey and daily diary study 
were: 
• To ascertain overall acceptability of the studies 
• Discuss format and design of the data collection instruments 
• Discuss content of the data collection instruments 
• Discuss strategies to improve response rates of the data collection 
instruments 
• Advise on individuals to approach for the study and how best to approach 
them 
• Advise on acceptable terminology 
Two meetings were held with the PPIE group 11 months apart. Both meetings were 
attended by members of the research team, a lay facilitator, and a senior researcher 
with responsibility for oversight of the group. At the first meeting six PPIE members 
attended and nine were present at the second. 
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The length of the diary stage of the study was discussed and it was advised that 
twelve months would be too long, and that six months might be more acceptable. 
The group felt that the length of the diary stage depended on how often these flare-
ups occur. It was suggested that they might not be more frequent than every 2-3 
months and estimated that each individual would contribute a maximum of 2 flare-
ups in a 6-month period.  
Discussion on the format of the diary centred on participants themselves graphing 
their symptoms versus entering data through the use of tick boxes and numbers. It 
was suggested that there should be one page per day to minimise potential for 
people to modify their entries in response to previous days or weeks.  
Several members of the PPIE members had previously been involved in diary 
studies. Although incentives were not specifically discussed the group strongly 
supported the idea of reading the diary entries when they came in (possibly entering 
the data at the same time) and keeping in touch with people during the study (such 
as by telephone). Participants could be offered the option of whether they wanted to 
be contacted. 
With respect to diary content, it was advised to discuss this with other researchers 
within the SPCSC who had undertaken diary studies particularly those that were 
about OA although it was noted that most of these differed from the current proposal 
in collecting qualitative data and adopting a flexible, participant-centred approach to 
diary entries. Copies of published articles from these studies were forwarded to the 
research team for consideration (275, 279).   
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The group agreed that pain intensity should be included. There were no objections to 
swelling, stiffness, nocturnal pain and limp. It was also mentioned that weather and 
fatigue, which may be an early warning sign, should also be included. This naturally 
led on to discussions on potential triggers for flare-ups. A striking point made by 
members of the PPIE group was that people may consciously undertake activities 
that they know will result in a flare-up but judging that it was worth the consequences 
(‘pay for it later’). This may reflect concepts of activity-rest cycling (280) and activity 
pacing (281) that have been described in chronic pain management. It was also 
noted that participants may already have established patterns of activity avoidance to 
reduce or prevent the occurrence of flare-ups. Although the exact implications for this 
on study design were not fully explored there was encouragement for the study to 
explore this and for the research team to consider collecting self-reported information 
on potential triggers.  Linked to this was the role of medication in masking pain. 
Without knowing what analgesia individuals were taking, it would be difficult to 
interpret pain intensity ratings. A range of other possible factors, namely seasonal 
variation due to patterns of activity (e.g. gardening) were also mentioned.  
On the issue of selecting potential participants, two main points were made in the 
discussion. Firstly, that the nature of osteoarthritis flare-ups may vary markedly 
between joints and this implied the need either to focus the study on a particular joint 
(e.g. knee) or to record the joint site being reported and be cautious of combining 
data from different joints in the analysis. Secondly, there was support for a pre-diary 
questionnaire to: (a) identify potential participants who have a recent history of flare-
ups; (b) collect descriptive information (e.g. duration of problem, treatments). This 
stepped approach would identify those with recent history of flare ups and those 
willing to take part and comply with the diary stage.  
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The discussions were, in general, highly constructive and the response was 
supportive. The PPIE members also helped refine the outcomes of the study and 
suggested a number of future avenues for research arising from this work. They 
advised that this study might help identify early warning signs for a flare-up and that 
this might lead to the development of interventions. It was thought that diaries could 
be used as an educational tool for patients with long term conditions in order to help 
them understand the pattern of their symptoms and identify any potential triggers for 
increases in their pain. In addition, findings could help educate patients with newly 
diagnosed knee OA. Furthermore, the study could help identify if flare-ups do exist 
and if there are shared features across patients. 
The PPIE recommended several features that could encourage diary completion and 
minimise respondent burden. These included having a bright colour for the cover of 
the diary to ensure that it stood out and acted as a reminder to the patient, using a 
minimum of 12-point font, and having one day per page with the day clearly labelled 
at the top of the page. To ensure conformity in answering questions, it was 
recommended to use tick boxes for all questions. The use of a filter question, to 
direct participants to fill out all of the items for the day or just a reduced number 
based on whether their pain score had changed from the previous day, was 
discussed but the PPIE group felt that this was too confusing and that it would not be 
much extra burden to ask participants to fill out all questions every day. 
The wording was discussed and it was agreed to avoid using the terms that patients 
may not understand such as; ‘exacerbation’ or ‘flare-up’ in the patient literature but 
instead to use ‘we understand that symptoms can go up and down, we are interested 
in....’. This lack of clarity in terminology was seen also among published studies that 
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used a variety of terms and phrases to denote an exacerbation or flare-up (See 
Chapter 4). The terminology for the patients’ usual or normal pain for them was 
discussed and it was decided that ‘normal for me’ should be used. It was also 
recommended that all questions be in the same format to avoid confusion and ensure 
it was clear what the patient should do, such as ‘tick box’ or ‘write comment’. 
There were miscellaneous comments regarding the format and content of specific 
sections of the diary. For example, for knee pain descriptors the PPIE members felt 
that some patients’ pain might not fit into the suggested descriptors included, and 
they proposed the addition of an ‘other’ response option box with space for comment.  
Finally, on the inside of each diary, and in the patient information sheet, tips for 
remembering to fill out the diary were included as suggested by the PPIE members. 
Tips included leaving the diary on the nightstand, next to the television, or near 
evening medication.  
Summary and critical reflection 
Table 6.1 provides a summary of the main observations and proposals made by 
PPIE members over the two meetings, the decision made for the main study design 
and any relevant comments or justification for those decisions.  
The PPIE group were invaluable in determining the main study design, they helped 
modify the aims and objectives, and their feedback on format of the diary and 
wording of questions was informative. The main advice adopted included font, layout 
and colour, and wording of questions and responses. The PPIE group were keen to 
explore psychological impacts of pain and fatigue however that was beyond the 
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scope of this research; nevertheless this was identified as an area for future 
research. 
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Table 6.1: Summary of observations and proposals at PPIE meetings and final 
decisions on main study design 
Aspect PPIE group 
observation/proposal 
Decision for 
main study 
design 
Comments/justification 
Length of diary stage 12 months too long; 
consider 6 months 
3 months Following discussions with 
researchers who had 
previously completed diary 
studies 3 months was 
agreed as a suitable time 
length as longer periods 
had worse compliance 
rates 
Diary format Monthly/weekly format 
might encourage people 
to modify entries in 
response to previous 
days; try day per page 
One day per 
page 
 
Engagement with 
participants 
Read diaries as they are 
returned; offer option of 
telephone contact during 
study period 
No telephone 
contact 
planned; 
monthly thank-
you letters with 
reminder of the 
number to 
contact if they 
should have 
any queries 
The ethical review 
committee thought that 
regular telephone follow-up 
would be burdensome for 
patients. Furthermore, there 
were resource implications 
with making regular 
telephone contact (no 
independent study co-
ordinator or research nurse; 
insufficient administrative 
resource) 
Diary content Discuss and learn from 
lessons from previous 
diary studies with SPCSC 
researchers 
Completed  
 Include items on weather 
and fatigue 
Not included Not main objective; concern 
regarding respondent 
burden 
 Offer ‘other’ option for 
pain descriptors 
Adopted  
 Gather information on 
triggers 
Information on 
selected 
physical 
triggers 
included 
Emotional triggers and life 
events not included. These 
had been studied 
previously (e.g. Wise et al., 
2010) and concerns again 
re respondent burden 
 Information on analgesia 
may be needed to 
interpret pain ratings 
Adopted  Challenge to find suitable 
short format of questions 
(type, dose, frequency, 
accuracy of report, 
respondent burden) 
Selection/recruitment 
of participants 
Nature of flare-ups likely 
to vary between joints 
Restrict to 
knee 
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Aspect PPIE group 
observation/proposal 
Decision for 
main study 
design 
Comments/justification 
 Use stepped approach to 
recruitment 
Adopted; 
cross-sectional 
survey then 
daily diary to 
consenting 
responders 
 
Encouraging diary 
completion / 
minimising respondent 
burden 
Use bright coloured cover  Adopted  
 12 point minimum font Adopted  
 Clearly label each day   Adopted  
 Use standard tick box 
response options where 
applicable  
Adopted  
 Remove daily filter 
question 
Adopted Potentially increases 
respondent burden by 
requiring completion of all 
questions everyday but this 
was felt on balance to be 
better than potentially 
confusing filter question 
and loss of data 
 Include list of tips on 
remembering to complete 
the diary  
Included on 
the inside of 
each diary, 
and in the 
patient 
information 
sheet 
 
Terminology / 
language / jargon 
Avoid using the terms 
‘exacerbation’ or ‘flare-
up’; instead ‘we 
understand that 
symptoms can go up and 
down, we are interested 
in....’ 
Adopted  
 Use “‘normal’ for me” Adopted  
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6.2 Aims and objectives 
Aim 
The overall aim was to identify self-reported flares and associated risk factors among 
participants with, or at high risk, of knee osteoarthritis. 
Objectives 
In a sample of community dwelling adults with, or at high risk of symptomatic knee 
osteoarthritis: 
• Estimate flare frequency based on patient recall in the previous 12 months 
• Explore association of self-reported flares and selected risk factors 
• Establish participants ‘normal’ knee symptoms (linked to subsequent diary 
study (Chapter 7) 
 
6.3 Methods  
6.3.1 Study Design Type 
Observational study, comprising a cross-sectional survey component and a 
longitudinal daily diary component (detailed methods in Chapter 7). 
6.3.2 Setting 
Two General Practices based in market towns in Shropshire. 
6.3.3 Sampling and Recruitment 
Target Population 
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The target population were community-dwelling adults with, or at high risk, of knee 
osteoarthritis. Inclusion and exclusion criteria for the cross-sectional survey are listed 
in Table 6.2. 
 
Table 6.2. Inclusion and exclusion criteria for cross-sectional survey 
Inclusion criteria 
Aged 45 years and over 
Registered with a participating practice at the time of the survey 
Read-coded consultation for knee osteoarthritis or knee pain/arthralgia in the previous 
2 years 
Male or female 
Exclusion criteria 
No knee pain in the last 12 months 
Patient reported diagnosis of inflammatory or crystal disease (rheumatoid arthritis, 
ankylosing spondylitis, polymyalgia rheumatica, gout) 
Previous total knee replacement in index knee 
Those judged to be vulnerable/inappropriate to survey by their general practitioner 
(e.g. dementia, terminal illness) 
 
Sampling frame 
Population registers from local general practices was chosen as the sampling frame 
in order to obtain a sample of primary care patients. Adverts in local papers were 
thought to be too costly, had ethical implications and would create extra 
administration in terms of having to notify participants GP. Orthopaedic clinics were 
initially considered but ultimately not used due to the fact that patients in this setting 
would selectively represent those with more severe disease; intermittent pain has 
been shown to occur in those with milder, less advanced osteoarthritis and so may 
have been missed (53). It is difficult to assess the adequacy of this sampling frame 
due to the challenge of estimating the proportion of the population registered with a 
general practice. This is due to inaccuracy of population registers and over-counting 
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amongst general practices (282). Attempts have been made using hospital 
attendances in England by unregistered patients, to estimate inpatient and outpatient 
attendances in 2009/10 (which were 99, 000 and 370, 000 respectively) (283). The 
majority of these patients were male and either asylum seekers, prisoners, homeless 
or military personal. It is likely that our sampling frame did not have coverage of 
these groups. 
Sampling method 
Census sampling of adults aged 45 years and over registered with participating 
practices at the time of the study and with evidence of a consultation for knee 
osteoarthritis or knee pain/arthralgia in the previous 2 years. 
Sampling procedures 
Participants involved in this study were recruited from general practice members of 
the Primary Care Research Network (PCRN) of Central England North Spoke. 
Participating practices were given a study pack containing the study protocol and 
data collection instruments (cross-sectional survey: Appendix C; Sample Diary: 
Appendix D) and the patient information sheet (Appendix E) 
Using electronic registers, all registered patients aged 45 years and older at the time 
of the study, with a Read-coded general practice consultation for knee osteoarthritis 
or knee pain/arthralgia in the past 2 years were identified (Appendix F). This list was 
given to the patients’ general practitioners, who were asked to exclude patients who 
were in vulnerable groups; for example, those patients with new onset dementia or 
severe/terminal illness. 
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Members of the West Midlands Clinical Research Network downloaded details of 
potential participants from the electronic registers. All participants were given a 
unique study identification number, to allow anonymisation of data. A secure 
database was designed for this study to ensure the protection of confidential 
information. 
 
6.3.4 Data Collection Procedures 
The SPCSC’s standard three-stage mailing procedure of initial mailing-reminder-
repeat mailing was used.  
Stage 1: Potential participants were sent study packs including a cross-sectional 
survey (Appendix C), patient information sheet (Appendix E), and sample diary 
template (Appendix G), together with a cross-sectional survey cover letter (Appendix 
H) from their general practice inviting them to take part in the study; this was mailed 
in June/July 2013. Participants were asked to complete their cross-sectional survey 
and provide written informed consent to take part in the diary study on the final page. 
All patients were given the contact number of a researcher working on the project 
who would give any other information about the project as needed. 
Stage 2: Non-responders at 2 weeks were sent a reminder postcard (Appendix I). 
Stage 3: Non-responders at 4 weeks were sent another study pack with reminder 
Cover Letter from their general practice (Appendix J). 
Non-responders after 6 weeks were assumed to have declined participation and 
were not contacted again for the study. 
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Replies to the cross-sectional survey mailing were collected and logged on the 
survey mailing database. Responses to pre-selected questions were also inputted, at 
this stage, into the mailing database in order to identify eligible participants for the 
diary stage of the study.  
Patients who indicated they did not wish to take part in the cross-sectional survey 
had this recorded in the database and all their identifiable data was stripped from the 
mailing database at this point. If patients returned the cross-sectional survey but 
declined to participate in the diary study, this was recorded and data from the survey 
inputted. They received no further mailing. 
 
6.3.5 Data Collection Instrument 
Cross-sectional survey 
The initial step in data collection was a 5-page, self-complete survey. The cross-
sectional survey contained 29 questions, split into 4 sections: (1) participant’s knee 
pain in their worst affected knee and exclusion of selected non-OA causes of knee 
pain; (2) participants knee symptoms on a ‘normal’ day for them; (3) demographic 
data and general health; (4) consent to take part in the diary study (Table 6.3) 
(Appendix C). 
The purpose of the cross-sectional survey was to: 
• Gather simple descriptive information on participants and non-consenting 
responders, including their recall of flare-ups in the past 12 months. 
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• Permit the exclusion of non-eligible responders. 
• Obtain written informed consent to take part in the diary study 
• Establish a baseline level of ‘normal’ pain severity and analgesic intake for 
participants against which researchers and participants can judge day-to-day 
variations in the diary study. 
• Establish frequency of self-reported flare-ups 
• Explore risk factors associated with flare-ups 
 
Section One-Knee Symptoms 
Items in section one collected data on current and past knee symptoms, healthcare 
utilisation and established whether a flare-up of knee pain had occurred in the 
previous 12 months (Table 6.3). Of particular note, self-reported recalled frequency 
of acute flare-ups of knee pain in the past 12 months was defined using the following 
single item: “In the last 12 months how many times have you had an increase of 
your knee pain (that is times when your knee pain is worse than normal which may 
have stopped you from doing your normal activities or meant you have had to take or 
increase your pain medication)?”. This item was created de novo as a validated 
patient self-report measure for identifying OA flare-ups does not exist. The phrasing 
of the item was adapted from results of the systematic review in Chapter 4, from 
wording of flares in other chronic diseases (117, 137, 140) and with help from the 
SPCSC’s PPIE group.   
 
Section Two-What is ‘normal’ for me? 
Items in section 2 reflected the questions that were included in the diaries. These 
were based on a daily diary card produced by Trappenburg et al for patients with 
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COPD (97). They established the participants’ baseline symptoms by asking them to 
describe ‘what is normal for me’.  
 
Section Three- demographic data 
Section three collected demographic and lifestyle data and were largely reproduced 
from standardised questionnaires used within the SPCSC. 
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Table 6.3: Items included in the cross-sectional survey 
Domain Empirical measure 
Demographic/ socioeconomic 
Age Free text 
Sex Female/ male 
Lives alone Yes/no 
Marital status Married, separated, divorced, widowed, cohabiting, single 
Ethnicity White UK or European, African, Afro-Caribbean, Asian, Chinese, 
other 
Employment status Employed, not working due to ill health, retired, unemployed/seeking 
work, housewife/husband, other 
Job title  Free text 
Job title for most of working      
life  
Free text 
Educational attainment O-level/ CSE/GCSE or equivalent, A-level/BTEC/HNC or equivalent, 
degree or postgraduate education, other work related or vocational 
qualification, other qualification, no qualification 
Lifestyle 
Smoking status Never smoked, previously smoked, currently smoking 
Alcohol consumption Daily or most days, once or twice a week, once or twice a month, 
once or twice a year, never 
 
Height and weight Free text 
Current/previous knee symptoms 
Presence of knee symptoms Pain, aching or stiffness in left or right knee in past 12 months (yes/no 
for each knee) (284)  
Worst affected knee Right/left 
Pain intensity Normal level of pain intensity (0-10 NRS), adapted from IMMPACT 
(285) 
  
Description of knee 
symptoms 
Normal day: knee swelling, limping, knee stiffness for more than 20 
minutes, being woken at night by knee pain (yes/no for each), 
adapted from (55)  
Pain descriptors Normal day: dull, throbbing, numbness, sharp, aching, burning, 
stabbing, pins & needles, other (yes/no for each), adapted from (53, 
276, 277)   
Knee history 
Total length of history from 
problem onset 
1 year or less, 2-5 years, 6-10 years, more than 10 years, adapted 
from (92) 
Frequency of flare-ups in 
past 12 months 
0, 1-2, 3-4, 5-6, 7-8, 9-10, more than 10 
Previous knee injury Yes/no (284) 
Knee-related healthcare utilisation 
GP consultation Whether the GP has been consulted for knee pain in past 12 months 
(yes/no)  
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Domain Empirical measure 
Previous knee replacement     
surgery 
Yes/no (left/right/both) 
Medication Normal day usage of prescribed or over the counter medication 
(yes/no; 
State name, dose, regular/as needed) 
Past medical history 
Inflammatory knee pain Previous diagnosis: polymyalgia rheumatic, rheumatoid arthritis, gout, 
ankylosing spondylitis (yes/no for each) 
Physical activity exposures 
Potential triggers Normal day, undertake following activities: kneeling for 30 minutes or 
more, climbing more than 5 flights of stairs, lifting/moving heavy 
objects, squatting for 30 minutes or more, climbing ladders (yes/no for 
each), adapted from (32)   
Vigorous physical activity Times a week 20 minutes or more vigorous intensity physical activity 
(none, 1-2 times, 3 or more), adapted from (286)  
Moderate physical activity 30 minutes or more of walking; 30 minutes or more of moderate 
intensity activity (none, 1-2, 3-4, 5 or more for each), adapted from 
(286) 
BTEC Business and Technology Education Council; CSE Certificate of Secondary Education; GCSE 
General Certificate of Secondary Education; GP General practitioner; HNC Higher National 
Certificate; NRS Numerical rating scale 
 
 
6.3.6 Database and Data Handling 
In line with the SPCSC’s Research and Governance Framework all personal 
identifiable information were kept separately from the cross-sectional survey and 
diary database during the mailing period. Participants were identified by the study 
codes. Only the research team had access to the research data and this information 
was kept on the SPCSC’s central network secure drive. No information on patients’ 
details or research data were stored on personal computer hard drives, laptops, 
disks, or other means where data could be transferred. Future linkage of the study 
codes to personal identifiable data may only be achieved through re-contacting the 
patients’ GP. 
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There are secure, physical storage arrangements for the hard copy data at the 
SPCSC within lockable filing cabinets. Personal information in the questionnaire, 
such as on the consent form, was removed on arrival to SPCSC and locked in 
cabinets. In addition, any hard copy research data that has been printed for checking, 
will be destroyed by shredding. The SPCSC also operates a key code entry system 
to ensure only appropriate persons are within the building. 
All staff at the SPCSC have an explicit requirement with the duty of confidentiality, 
equivalent to standards maintained within the NHS and written into their contracts of 
employment. Staff induction includes training and awareness relating to data security 
and confidentiality and the Data Protection Act. Identifiable data is only held as long 
as it is needed and removed as soon as is feasible. 
Data collected from the cross-sectional survey and diaries (Chapter 6 and 7) were 
manually inputted by myself into a customised Microsoft Access database. One in 
ten checks were performed at all stages by the study administrator.  
 
Data cleaning 
Data cleaning was undertaken by myself and the study statistician to ensure 
accuracy of inputted data. Prior to data analysis the data was checked for missing 
data, anomalies and any ambiguous data. 
During the data cleaning process frequency tables were produced for variables to 
check for missing data, check the coding of the missing data and to check that 
coding was within the acceptable range. Where anomalies were identified the original 
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questionnaire or diary was referred back to for clarification. Any errors that were 
found were described.  
One in ten checks for accuracy of inputted data was performed for the cross-
sectional survey and monthly diaries by the study administrator. Out of the 11 
sampled cross-sectional surveys, one error was reported where 11.0 stone was 
recorded instead of 11.9.  
Derived and recoded variables 
The variables were labelled and recoded accordingly. Body mass index (BMI) was 
calculated from height and weight and categorised for analysis into normal, 
underweight, and overweight using established cut-offs. For several variables 
categories were collapsed due to insufficient numbers within one or more of the 
original categories  
 
6.3.7 Ethical Considerations 
The study was submitted for proportionate ethical review to the North of Scotland 
NRES committee on 29th April 2013. REC reference: 13/NS/0049. Favourable ethical 
approval was received on 7th May 2013 following minor amendments (Appendix N).  
  
 142 
 
6.3.8 Statistical Analysis 
Power Calculation 
The selection of the survey sample size was based not on formal power calculations 
but on practical considerations of feasibility and cost with attention ultimately on 
potential numbers of responders likely to participate in the linked diary study. Based 
on an annual person-consulting rate for diagnosed knee osteoarthritis of 69 per 
10,000 registered population, and 170 per 10,000 if knee pain/arthralgia cases were 
also included, it was anticipated that three practices with an average registered 
population of 6,000 each, would provide approximately 306 potentially eligible 
participants. Searching the previous 2 years was expected to increase this by a 
factor of 1.67 on the assumption that a third of consulters in a given year also consult 
in the previous year, which gave an estimated 511 potentially eligible responders. 
Response rates for observational daily diary studies range from 37-54%, however 
most diary studies are only for a period of one month. Response rates to previous 
SPCSC (School for Primary, Community and Social Care) studies using a single 
postal questionnaire in this age group tended to range from 50-70%. Using a range 
of conservative estimates: 50-70% response to cross-sectional survey, 80-90% 
responders’ eligible, gives an estimated response rate of 204-322 survey responders.  
Analysis 
The primary planned analysis is briefly summarised below. The data were analysed 
using Stata Version 13 (Stata Corporation, College Station, Texas, USA).  
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Flow of response 
A flowchart was completed to summarise the flow of participants from the initial 
mailing through to analysis. 
Evaluation of selective response 
The response rate to the cross-sectional survey was calculated. 
Key baseline patient characteristics (age, sex) were compared between responders 
and non-responders using descriptive statistics; mean (SD), median (inter-quartile 
range) or frequencies (percentages) as appropriate. 
Descriptive characteristics and missing data 
After excluding ineligible responders, such as history of inflammatory disease, 
previous TKR, no knee problem last 12 months, the descriptive characteristics of 
eligible responders were summarised using descriptive statistics as previously 
mentioned. Within eligible responders, the amount of missing data for each 
questionnaire item was also described. 
Frequency and determinants of recalled flare-ups 
A flare-up, in the cross-sectional survey was determined using patient recall of 
increases in knee pain in the previous 12 months that stopped the participant from 
doing their normal activities or led to an increase in pain medication. This was 
presented using simple percentages. 
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Variables potentially associated with recalled flare-ups 
A number of baseline factors were examined for an association with recalled flare-
ups. These were chosen based on results from the secondary analysis performed in 
Chapter 5. 
• Demographic variables: age, gender, living alone, marital status, employment 
status, socioeconomic class (individual occupational class), ethnicity, 
educational attainment 
• Lifestyle variables: alcohol, smoking status, physical activity, BMI 
• Knee related: previous knee injury, duration knee problem, normal knee pain 
intensity, normal knee symptoms 
The frequency of flare-ups was categorised into three groups; 0-2 flares, 3-10 and 
over 10. These were chosen as there were a subset of participants reporting 10 
flares or more so the decision was made to divide the sample into those who 
reported flares frequently, moderately or infrequently. Ordinal logistic regression was 
initially performed to analyse for any association between these groups and the 
predictor variables (287). This method keeps categories ordered unlike multinomial 
models for example. The model has to meet a number of assumptions, the most 
important being the proportional odds assumption, assuming the same effects for 
different cumulative logits i.e. each independent variable has the same effect at each 
cumulative split of the ordinal dependent variable (287, 288) .  
Univariable models were fitted initially. Variables for the univariable model were 
chosen based on previous known associations from previous studies (289). Each 
variable was then tested for the proportional odds assumption using firstly a 
 145 
 
likelihood ratio test with the null hypothesis that there is no difference in the 
coefficients between the cumulative response categories and then a Brant test (290). 
A significant test statistic (p<0.05) indicated that the assumption had been violated. 
The assumption was violated for 4 variables (climbing stairs, NRS, aching, and 
walking) and for 4 variables the Brant test could not be calculated due to insufficient 
numbers (squatting, numbness, stabbing, pins and needles). As the proportional 
odds assumption was not met for all variables, a generalised ordered logit model also 
known as the partial proportional odds model (291) was used. This model takes into 
consideration the potential different weightings of the categories and produces a 
regression coefficient for each of the compared groups (290). The model was fitted 
using gologit2 routine in Stata (292) 
For variables where the proportional odds assumption was not met, two sets of odds 
ratios were estimated, one comparing the category 0-2 versus (3-10, and >10) and 
the second comparing category (0-2, and 3-10) to >10. The effects of the variables 
that met the proportional odds assumption was presented as one parameter and 
interpreted similar to ordinal logistic regression model. 
The method used for the multivariable model involved two stages. The first step 
involved selecting variables from the univariable model which had a p value of ≤0.20, 
this is the alpha level for rejecting the null hypothesis (267). A test of multicollinearity 
was then performed. This was done by first examining the correlations (continuous) 
and associations (categorical) between the independent variables, followed by 
multicollinearity diagnostic statistics for linear regression analyses (variance inflation 
factor) to check for the existence of multicollinearity when several potential predictors 
are adjusted for simultaneously (269). A variance inflation factor of greater than 5 
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was considered as evidence of collinearity. All variables that were not correlated 
were included in a multivariable model and a manual backward elimination performed 
to remove variables from the multivariable model until only variables with a p-
value <0.05 were retained in the final model .  
 
6.4 Results 
 
6.4.1 Response rate 
The survey was mailed out to 330 adults aged 45 years and over at two general 
practices. There were 214 responders (67%) (Figure 6.1). 
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Figure 6.1: Flowchart of baseline response for cross-sectional survey 
 
  Mailed cross-sectional survey 
(n=330) 
Excluded during mailing 
(n=1) 
 Refusals/non-respondents 
(n=115) 
Respondents to cross-sectional survey 
(n=214) 
Excluded at baseline 
(n=98) 
Returned blank survey (6) 
No knee pain in past 12 months (14), 
TKR(27), inflammatory knee pain: 
PMR(5),gout (22), AK (5), RA(35),  
missing data [TKR (4), PMR (10), NRS 
(2)] 
Cross-sectional survey analysis 
sample 
(n=116) 
 148 
 
Compared with non-responders, responders to the cross-sectional survey were more 
likely to be female, older, and to live in less deprived neighbourhoods (Table 6.4).  
Table 6.4: Comparison of survey responders and non-responders 
 All mailed 
participants  
Non responders   Responders  
 (n=330) (n=116) (n=214) 
Female gender, n (%) 182 (55) 61 (53) 121 (57) 
Age (years), mean (SD) 63.8 (11.7) 62.4 (12.5) 64.6 (11.2) 
Area-level deprivation†, n (%)    
Most deprived 110 (33) 45 (39) 65 (30) 
Middle 137 (42) 46 (40) 91 (43) 
Least deprived 83 (25) 25 (22) 58 (27) 
† Tertiles of Index of Multiple Deprivation based on patient postcode 
 
Completeness of data items 
Of 38 variables, 5 had no missing, the median percentage missing for the remaining 
33 items was <3%, with 8 items having >5% missing (pain in left knee, pain in right 
knee, worst knee, kneeling, climbing stairs, heavy lifting, squatting and climbing 
ladder.   
 
6.4.2 Responders eligible for inclusion in cross-sectional survey analysis 
After excluding ineligible responders (TKR, no knee pain reported in past 12 months, 
self-reported inflammatory disease) and those with blank questionnaires and missing 
data for pain intensity on a ‘normal’ day), the total number included in the cross-
sectional survey analysis was 116 (35%). Of the 116 eligible responders 59% were 
female; mean age 62.1 (SD 10.7); mean BMI 23.9 (SD 4.9). There were 115 
participants who were from white UK or European background. 
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6.4.3 Frequency of reported flares 
The majority of eligible responders recalled experiencing at least one flare-up in the 
previous 12 months with only 10% stating that they had experienced no flares. Over 
a quarter of participants reported experiencing more than 10 flare-ups in the previous 
12 months (Figure 6.2). 
Figure 6.2: Histogram of frequency of recalled flare-ups over the previous 12 months 
presented as proportions 
 
 
 
 
  
0
5
10
15
20
25
30
0 1-2 3-4 5-6 7-8 9-10 >10
 150 
 
6.4.4 Comparison of baseline characteristics and recall of flare frequency over the 
previous 12 months  
The categories used in the questionnaire to collect data on recalled frequency of 
flare-ups in the previous 12 months were collapsed for analysis into those reporting a 
low frequency of flare-ups (0-2), those reporting a medium frequency of flare-ups (3-
10) and those reporting a high frequency of flare-ups (>10). 
The mean (SD) age was lower in those reporting a high frequency of flare-ups (61.3 
(10.1) vs 65 (10.3)). Those in current employment reported a higher frequency of 
flare-ups (20 (63%) vs 9 (32%) (Table 6.5). 
The final multivariable model consisted of only two variables: being employed and 
normal knee pain intensity. An alternative model of 4 variables: having seen GP, 
currently employed, previous surgery and taking medication was possible but this 
excluded normal knee pain intensity. When normal knee pain intensity was in this 
model the other variables became insignificant. The initial model was selected as 
these variables better explained the probability of having a flare-up.  
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Table 6.5: Demographic and socioeconomic characteristics of eligible responders, by 
recalled frequency of flares in the previous 12 months 
 Recalled frequency of flares in previous 12 
months 
 Low 
0-2 
Medium 
3-10 
High 
>10 
 (n=28) (n=55) (n=33) 
Age (years): mean (SD) 65 (10.3) 61.2 (11.2) 61.3 (10.1) 
Age (years) categories:    
   45-64 14 (50) 35 (64) 21 (64) 
   65-74 9 (32) 10 (18) 9 (27) 
   75+ 5 (18) 10 (18) 3 (  9) 
Female gender  15 (54) 36 (66) 18 (55) 
Highest qualification:    
O-level, CSE, GCSE or equivalent 5 (18) 10 (19) 9 (28) 
A-level, BTEC, HNC or equivalent 2 (  7) 7 (13) 2 (  6) 
Degree or postgraduate 
qualification 4 (14) 4 (  8) 6 (19) 
Other work related or vocational 
qualification 2 (  7) 12 (23) 4 (13) 
Other qualification 3 (11) 5 (  9) 0 
No qualification 8 (29) 14 (26) 7 (22) 
Ambiguous answer 4 (14) 1 (  2) 4 (13) 
Living alone 2 (11) 8 (15) 4 (12) 
Married 23 (82) 35 (64) 23 (70) 
Currently employed 9 (32) 21 (38) 20 (63) 
Figures are column percentages unless otherwise stated 
BTEC Business and Technology Education Council; CSE Certificate of Secondary Education; 
GCSE General Certificate of Secondary Education; HNC Higher National Certificate 
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Younger age and being employed were associated with a higher frequency of flare-
ups. However, only the association with current employment was statistically 
significant (Table 6.6). 
Table 6.6: Association of selected demographic and socioeconomic characteristics 
with recalled frequency of flares based on an ordered logistic regression model 
  Unadjusted outcome comparison (frequency of flare) 
  Medium/High vs Low High vs Med/Low 
 Reference OR (95% CI) OR (95% CI) 
Older age per year 0.98 (0.95, 1.01)† 
Female gender Male 1.01 (0.50, 2.06) † 
Highest qualification No 
qualification 
 
O-level, CSE, GCSE 
or equivalent  
2.11 (0.70, 6.33) † 
A-level, BTEC, HNC 
or equivalent  
1.24 (0.33, 4.73) † 
Degree or 
postgraduate 
qualification 
 
0.87 (0.22, 3.51) † 
Other work related or 
vocational 
qualification 
 
1.45 (0.46, 4.58) † 
 
Other qualification  0.46 (0.10, 1.98) † 
Living alone Not living 
alone 
1.12 (0.41, 3.06) † 
Married No 0.66 (0.31, 1.37) † 
   
Employed Not Employed 2.45 (1.19, 5.07) †* 
OR unadjusted odds ratio from partial proportion odds model; 95%CI 95 percent confidence interval 
† Where only one odds ratio is presented, this indicates the partial proportional odds model fit the data 
and proportional odds assumption was not violated 
* aOR (95% CI): 0.27 (0.12, 0.59) 
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More frequent flares were reported by those who were underweight or 
overweight/obese and higher levels of physical activity (Table 6.7; Table 6.8). 
Table 6.7: Lifestyle characteristics, including knee-specific physical exposures, of 
eligible responders, by recalled frequency of flares in the previous 12 months 
 Recalled frequency of flares in previous 12 
months 
 Low 
0-2 
Medium 
3-10 
High 
>10 
 (n=28) (n=55) (n=33) 
BMI (kg/m2): mean (SD) 23.5 (4.1) 23.7 (5.4) 24.5 (4.6) 
BMI (kg/m2):    
   Underweight (<18.5) 2 (  7) 6 (11) 4 (12) 
   Normal weight (18.5 -24.9) 17 (61) 30 (55) 15 (46) 
   Overweight/obese (≥25.0) 9 (32) 19 (35) 14 (42) 
Smoking status:    
Never smoked 12 (43) 19 (35) 17 (52) 
Previously smoked 15 (54) 28 (52) 10 (30) 
Currently smoking 1 (  4) 7 (13) 6 (18) 
Alcohol intake:    
Never 3 (11) 6 (11) 4 (12) 
Once or twice a year 3 (11) 10 (18) 4 (12) 
Once or twice a month 5 (18) 9 (16) 10 (30) 
Once or twice a week 10 (36) 19 (35) 6 (18) 
Daily or most days 7 (25) 11 (20) 9 (27) 
Physical activity:    
   Vigorous activity 10 (36) 23 (42) 15 (46) 
   Moderate intensity 13 (46) 30 (55) 20 (61) 
   Walking 21 (75) 48 (87) 23 (70) 
Knee-specific physical exposures:    
   Prolonged kneeling 4 (14) 9 (17) 4 (12) 
   Repetitive stair climbing 5 (18) 21 (39) 6 (18) 
   Lifting/moving heavy objects 4 (14) 17 (32) 10 (30) 
   Prolonged squatting 0 2 (  4) 3 (  9) 
   Climbing ladders 2 (  7) 9 (17) 3 (  9) 
Figures are column percentage unless stated otherwise 
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Table 6.8: Association of lifestyle characteristics with recalled frequency of flares 
based on an ordered logistic regression model 
  Unadjusted outcome comparison (frequency of flare) 
  Medium/High vs Low High vs Med/Low 
 Reference OR (95% CI) OR (95% CI) 
BMI (kg/m2)     
   Underweight Normal 1.75 (0.55, 5.57)† 
  Overweight/obese Normal 1.48 (0.70, 3.12) † 
Smoking status: Never smoked  
Previously smoked  0.59 (0.28, 1.25) † 
Currently smoking  1.96 (0.64, 6.04) † 
Alcohol intake No alcohol  
Once or twice a year  0.94 (0.25, 3.61) † 
Once or twice a 
month  1.32 (0.36, 4.85)
 † 
Once or twice a week  0.61 (0.18, 2.02) † 
Daily or most days  0.90 (0.25, 3.22) † 
Vigorous activity‡ No 1.42 (0.71, 2.87) † 
Moderate activity¶ No 1.50 (0.75, 3.01) † 
Walking§ No 1.46 (0.53, 4.02) † 
Prolonged kneeling†† No 0.77 (0.29, 2.03) † 
Repetitive stair 
climbing‡‡ No 
0.49 (0.17, 1.44) 2.41 (0.83, 7.00) 
Lifting/moving heavy 
objects No 0.62 (0.29, 1.35)
 † 
Prolonged squatting¶¶ No cne - 
Climbing ladders No 1.12 (0.41, 3.05) † 
BMI Body mass index; cne could not estimate due to small n; OR unadjusted odds ratio from partial 
proportion odds model; 95%CI 95 percent confidence interval 
† Where only one odds ratio is presented, this indicates the partial proportional odds model fit the data 
and proportional odds assumption was not violated 
‡ Vigorous activity for 20 minutes or more (e.g. heavy lifting, jogging, aerobics) 
¶ Moderate intensity physical activity for 30 minutes or more (e.g. carrying light loads, bicycling at a 
regular pace) 
§ Walking for 30 minutes or more 
†† Kneeling for 30 minutes or more 
‡‡ Climbing more than 5 flights of stairs (only variable where proportional odds assumption was violated)  
¶¶ Squatting for 30 minutes or more 
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Those with a previous knee injury, previous knee surgery, who visited their GP in the 
last 12 months and take regular medication appeared to have a higher frequency of 
flare-ups (Tables 6.9, 6.10). 
Table 6.9: Knee past history and healthcare use among eligible responders, by 
recalled frequency of flares in the previous 12 months 
 Recalled frequency of flares in previous 12 
months 
 Low 
0-2 
Medium 
3-10 
High 
>10 
 (n=28) (n=55) (n=33) 
Duration knee problem:    
<1 year 8 (29) 11 (20) 8 (29) 
1-5 years 12 (43) 23 (42) 21 (38) 
>5 years 8 (29) 21 (38) 13 (39) 
Previous knee surgery 4 (15) 9 (16) 14 (42) 
Previous knee injury 10 (36) 20 (36) 16 (49) 
Seen GP in last 12 months  12 (43) 38 (70) 24 (73) 
Takes medication regularly 5 (19) 27 (49) 19 (58) 
Figures are column percentages unless otherwise stated 
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Table 6.10: Association of knee history and healthcare use with recalled frequency of 
flares based on an ordered logistic regression model 
  Unadjusted outcome comparison (frequency of flare) 
  Medium/High vs Low High vs Med/Low 
 Reference OR (95% CI) OR (95% CI) 
Duration of knee 
problem 
    
   1-5 years <1 year 1.11 (0.45, 2.76)† 
> 5 years < 1 year 1.43 (0.56, 3.62) † 
Previous knee 
surgery No 3.66 (1.53, 8.73)
 † 
Previous knee injury No 1.59 (0.78, 3.25) † 
Seen GP in last 12m No 2.59 (1.22, 5.52) † 
Takes regular 
medication No 3.28 (1.57, 6.86)
 † 
OR unadjusted odds ratio from partial proportion odds model; 95%CI 95 percent confidence interval 
† Where only one odds ratio is presented, this indicates the partial proportional odds model fit the data 
and proportional odds assumption was not violated 
 
 
Amongst those reporting a high frequency of flare-ups normal knee pain intensity 
was higher, knee symptoms such as swelling, limping, stiffness and night pain were 
reported more frequently and knee pain descriptors such as throbbing, sharp, 
burning, and stabbing were reported more frequently. Amongst those experiencing a 
low frequency of flare-ups knee descriptors such as dull and numbness were 
reported more frequently (Tables 6.11, 6.12). 
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Table 6.11: ‘Normal’ knee symptoms among eligible responders, by recalled 
frequency of flares in the previous 12 months 
 Recalled frequency of flares in previous 12 
months 
 Low 
0-2 
Medium 
3-10 
High 
>10 
 (n=28) (n=55) (n=33) 
Normal knee pain intensity (0-10 
NRS): mean (SD)  1.7 (1.8) 4.3 (2.3) 5.0 (2.1) 
Other knee symptoms:    
   Knee swelling 10 (36) 32 (58) 20 (61) 
   Limping 9 (32) 37 (67) 25 (76) 
   Stiffness 7 (25) 24 (44) 19 (58) 
   Night pain 5 (18) 22 (40) 20 (61) 
Knee pain descriptors:    
   Dull  9 (32) 16 (29) 8 (24) 
   Throbbing 3 (11) 13 (24) 9 (27) 
   Numbness 2 (  7) 3 (  6) 0 
   Sharp 5 (18) 21 (38) 15 (46) 
   Aching 10 (36) 44 (80) 20 (61) 
   Burning 3 (11) 11 (20) 9 (27) 
   Stabbing 0 13 (24) 13 (39) 
   Pins and needles 1 (  3) 1 (  2) 0 
Figures are column percentages unless otherwise stated 
NRS Numerical rating scale; SD standard deviation 
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Table 6.12: Association of ‘normal’ knee symptoms with recalled frequency of flares 
based on an ordered logistic regression model 
  Unadjusted outcome comparison (frequency of flare) 
  Medium/High vs Low High vs Med/Low 
 Reference OR (95% CI) OR (95% CI) 
Normal knee pain 
intensity (0-10NRS) per unit 1.92 (1.47, 2.53)* 1.39 (1.15, 1.69)* 
Other knee symptoms   
Knee swelling No 2.20 (1.08, 4.48) † 
Limping No 4.46 (2.05, 9.74) † 
Stiffness No 2.54 (1.23, 5.21) † 
Night pain No 3.99 (1.88, 8.50) † 
Knee pain descriptors   
Dull No 0.72 (0.34, 1.56) † 
Throbbing No 2.02 (0.88, 4.64) † 
Numbness No - 
Sharp No 2.45 (1.17, 5.11) † 
Aching No 5.24 (2.10, 13.04) 0.98 (0.41, 2.31) 
Burning No 2.16 (0.91, 5.14) † 
Stabbing No cne 3.89 (1.54, 9.82) 
Pins and needles No - 
cne could not estimate due to small n; NRS Numerical Rating Scale; OR unadjusted odds ratio from 
partial proportion odds model; 95%CI 95 percent confidence interval 
† Where only one odds ratio is presented, this indicates the partial proportional odds model fit the data 
and proportional odds assumption was not violated 
*aOR (95% CI): 1.66 (1.38, 2.00) 
 
 
6.5 Discussion  
The modest sized cross-sectional survey found that the majority of patients 
accessing healthcare for knee pain likely to be attributable to osteoarthritis, recalled 
experiencing what might be called ‘acute flare-ups’ in the previous 12 months; 25% 
reported more than 10 such episodes in the previous 12 months. Patient factors that 
appear to be associated with higher frequency of flare-ups included being currently 
employed, being under/overweight, higher levels of physical activity, longer duration 
 159 
 
of knee problems, previous knee surgery, and (to a lesser degree and statistically 
non-significant) injury. Patients reporting frequent flares also reported higher knee 
pain intensity, knee swelling, limping, morning stiffness, night pain, a sharp, 
throbbing, stabbing or burning pain, and higher levels of healthcare use for their knee 
problem. 
A large proportion of people (n=104) reported flare-ups highlighting that it is a 
common problem. The distribution of those reporting frequency of flare-ups has a 
very large tail and a suggestion of a bimodal distribution. It is possible that people are 
reporting two different phenomena when thinking about ‘flare-ups’. These may be 
short-lived flares that occur frequently as observed by Murphy et al (61) and those 
that last longer leading to higher pain intensities and have a greater impact on activity 
limitation. This leads to questions on whether these are separate phenomena and 
whether they should be more clearly defined for research purposes and in the clinical 
setting. Minimum duration was important as a criterion for flare definition in the earlier 
systematic review (Chapter 4). The existence of this, particularly in the research 
setting, may be to exclude minor episodes or ‘twinges’ of pain that are part of the 
daily variability in the condition. The definition of flare based on patient recall in this 
cross-sectional survey, did not use a minimum duration and may therefore be 
capturing these ‘minor’ episodes of pain. In a 2-week study of flare-up rates among 
US workers, 38% reported flare-ups during the study period (73). Although the study 
periods are not comparable and mine was based on recall, the Ricci et al study 
highlights that flare-ups can have a significant impact on workers in terms of lost 
productive time. Studies using pre-defined flare criteria tend to have lower estimates 
(209). 
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There is some agreement with factors in this study and those found to be associated 
with flare-ups in the CAS(K) secondary analysis (Chapter 5); younger age (albeit 
non-significant), longer history of knee problem, increased BMI and increased 
severity of knee symptoms. Patients who are a younger age are likely to still be 
working and may be undertaking more activities that cause stress on the knee joint. 
BMI is a known factor for OA onset and progression and puts undue stress on the 
knee. The higher the pain rating scale at baseline or the worse the severity of 
symptoms at baseline appears to be associated with flare-ups. 
Strengths of the study include items contained within the data collection instruments 
being from standardised questions where possible; such as, previous SPCSC studies 
or from the Osteoarthritis Initiative. The pain intensity measure, for example, was 
chosen after careful consideration of existing literature. Studies looking at the validity 
of pain scales, found the NRS to be the most responsive (293) and have confirmed 
its validity (294). The NRS was therefore chosen for the thesis study. Validity is 
important as it relates to the soundness of the data. A high degree of validity also 
assumes a high degree of reliability (85).  
Key limitations include the small sample size and the use of some non-validated 
measures; for instance, flare frequency, descriptors of knee symptoms, pain 
descriptors, medication usage, self-report of inflammatory knee pain and potential 
triggers. Use of non-validated measures  and uncertainty surrounding reliability may 
lead to systematic and random  error (85). These items were therefore based on 
findings from previous research where possible, for example, the description of knee 
symptoms were based on the KOFUS (55), the pain descriptors were based on those 
that were described in interviews (53); however it is difficult to assess the extent to 
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which the information provided in response is reliable and valid as they were not pre-
tested. A COSMIN (Consensus based standards for the selection of health 
measurement instruments) checklist could not be followed for these items, however, 
consensus within the study team and PPIE was reached with regard to their 
suitability as no other validated measures existed for measuring these domains.  
Generalisability of results is limited due to the sampling frame where responders 
were predominantly white ethnicity and more likely to be female, older and from less 
deprived neighbourhoods. The sampling frame was not as large as intended. The 
original plan was to mail out to 511 potential participants from 3 general practices. 
However, due to capacity within the CRN this was not possible. Despite this, the 
response rate of 214 still fell within the anticipated range of 204-232 and was thought 
sufficient to base preliminary estimates on. Formal power calculations were not 
undertaken however an estimate of sample size was performed in order to establish 
the number of potential participants who may have participated in the linked diary 
study. Ideally, a formal sample size calculation would have been performed to 
minimise bias when interpreting the results, to ensure the results were more 
generalisable and to detect differences between groups (85). Due to practical and 
resource implications this was not performed.  
There is potential for selection bias related to response where those experiencing 
flare-ups were more likely to respond (295), which may have led to an overestimation 
of flares. Inaccuracy of flare frequency may also have stemmed from 
misclassification of flare-ups due to recall bias, which may have affected validity and 
reliability (296). It is possible that those with greater pain intensity closer to the data 
collection period were more likely to report an increased frequency of flare-ups.  
Certain factors that could have been important but were not included, for example, 
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were assessments of mental health status including depression. The cross-sectional 
nature of associations gives potential for the possibility of reverse causality which 
could be likely for some physical exposures, for example, some individuals 
experiencing flare-ups may adapt and stop or cut down on self-identified provocative 
activities like kneeling or squatting (297). 
     
6.6 Summary 
This modest-sized cross-sectional survey found that around 90% of responders with 
knee pain/OA recalled frequent flares within the previous year. A higher frequency of 
such recalled flares appeared to be associated with patient factors such as being 
currently employed, abnormal BMI, higher levels of physical activity, longer duration 
of knee problems, and previous knee surgery. Frequent flares were also reported in 
those with higher knee pain intensity, associated symptoms such as swelling, 
morning stiffness, night pain and limping, and pain was described as stabbing, sharp, 
throbbing or burning. Overall these findings corroborate with findings in Chapter 5 
apart from sex and physical activity measures, however these did not reach statistical 
significance in either study. In addition to the small size of this study, flares were 
defined based on recall and an operational definition that used a single item and 
which imposed no minimum duration or other quantitative criteria to define a flare. 
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7. ‘Acute flare-ups’ in patients with, or at high risk of, 
knee osteoarthritis: a daily diary study with case 
crossover analysis 
 
Previous studies in this thesis have relied on patient recall to define flares. In the 
study reported in this chapter it was possible to define acute flare-ups using 
prospectively collected daily ratings of pain from a sample of survey responders. 
After considering the characteristics of this sample, the findings on the rate, nature 
and severity of flare-ups are presented, followed by a case-crossover analysis of 
potential triggers and prodromal symptoms for flare-ups. 
 
7.1 Aims and objectives 
Aim 
To provide a detailed description of the natural history, associated features, self-
management and potential short-term triggers of prospectively defined acute flares in 
patients with, or at high risk of symptomatic knee osteoarthritis. 
Objectives 
In a sample of community dwelling adults with, or at high risk of, symptomatic knee 
osteoarthritis: 
• To describe the time course of flares  
• To describe the rate of flares 
• To describe the nature of a flare 
• To describe severity of a flare. 
• To explore the role of selected physical exposures in triggering flares and the 
presence of prodromal symptoms. 
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• To describe how people manage flares, with specific reference to analgesic 
intake and seeking help from health professionals. 
 
7.2 Method 
A detailed description of the recruitment process can be seen in Chapter 6. 
 
7.2.1 Eligibility criteria for diary study 
Those that consented (using the consent form attached to the cross-sectional survey) 
and were willing to complete at least one diary and had filled out question 2.1 and 2.2 
on the cross-sectional survey (questions on normal knee pain and knee symptoms) 
(Appendix C) were invited to take part in the diary study. 
 
7.2.2 Data Collection procedures 
Daily diary 
Eligible, consenting responders to the cross-sectional survey (presented in Chapter 
6) were included in the diary phase of this study. Participants were invited to 
complete at least one diary and up to a maximum of three diaries over 3 consecutive 
months between August and October 2013. 
Participants were mailed the Daily Diary Booklets (Appendix D) one week prior to the 
start of the month to be completed. They were asked to return the diaries at the end 
of each month in pre-paid envelopes which were provided.   
For each month, if the completed diary had not been returned within 1 week of that 
month’s diary completion, a Diary Return Reminder Letter (Appendix L), with a 
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further prepaid envelope, was sent out. If the diary was not received following this, 
the response variable was left blank. The participant was still sent future diaries 
unless they contacted us to withdraw from the study. Refusals and withdrawals were 
recorded along with the reason, where applicable, at each stage. 
At any stage if the participant contacted the SPCSC to state they had lost or not 
received the diary the relevant documents were resent with a repeat covering letter 
for that month. 
All of the diaries contained a sticker on the inside cover of the first page which 
showed the participants responses to certain questions in the cross-sectional survey. 
These included the responses participants had indicated for their ‘normal’ level of 
knee pain on the NRS scale, knee descriptors, usual medication, and potential knee 
triggers on a normal day for them.  
At the end of the study, patients who had been involved in the diary stage were 
mailed a thank you letter (Appendix M). 
 
7.2.3 Data collection instruments 
The diaries were A4 sized, 12-point font, with bright colours on the outside pages 
which changed for each month. Each day took up one side. There were nine items to 
be filled each day. Participants were asked to fill out each item at the end of each day 
and to consider their answers in relation to the previous 24 hours. The questions 
required the answer to be either a cross in a box or free text (Table 7.1).   
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Table 7.1: Items included in the daily diaries (note all measurements relate to past 24 hours) 
Domain Description Empirical measure 
Pain intensity Average knee pain over the preceding 24 hours 0-10 NRS (adapted from (195)) 
Description of knee 
symptoms 
Presence of any knee swelling, limping, knee stiffness for 
more than 20 minutes, being woken at night by knee pain in 
preceding 24 hours 
Yes/no (adapted from (17))  
Pain descriptors Description of pain experiences in preceding 24 hours Single items: dull, throbbing, numbness, sharp, 
aching, burning, stabbing, pins & needles, other  
(adapted from (16,176,177)) 
Changes in 
medication  
Changes to normal medication in preceding 24 hours Same/more/less; free text comments 
Potential triggers Activities undertaken in preceding 24 hours kneeling for 30 
minutes or more, climbing more than 5 flights of stairs, 
lifting/moving heavy objects, squatting for 30 minutes or more, 
climbing ladders 
Yes/no (adapted from (197))   
Pain interference 
with activities 
Pain interference with activities in preceding 24 hours Yes/no 
GP consultation Been to see GP because of knee pain in preceding 24 hours Yes/no (adapted from (196)) 
Triggers Perception of triggers for any changes in knee pain in 
preceding 24 hours 
Free text 
Comments Space for additional comments thought important by 
participant 
Free text 
GP General practitioner; NRS Numerical rating scale 
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Numerical Rating Scale (NRS) 
To determine pain severity a number of scoring methods were considered. From 
previous studies numerical rating scales were found to be easier to use and have 
better compliance rates (298). The NRS as a tool for pain assessment has been 
validated in a number of studies (294, 299-302).  
Characteristics associated with knee flare up 
Characteristics associated with a flare up: knee swelling, limping, knee stiffness for 
more than 20 minutes, and woken at night from knee pain, were adapted from 
Marty’s validation of the Knee Osteoarthritis Flare-Up Score (55). 
Pain descriptors 
Description of pain experiences have been adapted from a qualitative study with 
focus groups and one-to-one interviews, part of which was describing pain 
experienced (53). The answers included an ‘other’ box so that if the participants 
description of their pain did not fit into any of the descriptors included they had the 
option to free text this. They are also adapted from the McGill Pain Questionnaire 
(276, 277). 
Physical triggers  
A study looking at previous occupational exposure and risk of knee osteoarthritis 
asked participants about the following activities: bending for 2 or more hours, walking 
for 2 hours or more on level ground, kneeling for 30 minutes or more, squatting for 30 
minutes or more, climbing a total of 5 or more flights of stairs, lifting or moving heavy 
objects weighing 25lbs, and driving for 4 hours or more (32, 303). Occupational 
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exposure to frequent squatting kneeling and heavy lifting were associated with risk of 
cartilage degeneration.  
A systematic review looking at long- term cumulative occupational exposure and 
knee OA found strong associations between squatting and kneeling (304). There was 
also an association with climbing ladders (in males), climbing stairs, and lifting heavy 
objects. In the diary study these exposures were included to assess short-term 
transient exposure (on the assumption that there is sufficient within-person day-to-
day variability in whether or not people are ‘exposed’ to these activities) and that 
these might constitute short-term triggers for flare-ups. 
Participants were also invited to free text any triggers they thought may have caused 
a change in their pain, in order to try and capture triggers not included in the diaries 
or identify new ones. 
Change in pain medication 
This item ascertained if there were any changes in medication usage compared to 
baseline and was created de novo. 
Interference with normal activities 
In studies that have used definitions for knee OA flares, interference with normal 
activities was sometimes included (55, 180). It has also been used in the definition of 
worsening back pain (305). 
Consultation with GP 
This has been included to see if there is an association between consultation rates 
and increases in knee pain. 
 170 
 
Other comments 
A free text space was included at the end of each day for comments. 
 
7.2.4 Data cleaning 
One in ten checks for accuracy of inputted data was performed for the completed 
diaries by the study administrator. All diaries were subsequently re-checked by 
myself to ensure the agreed coding framework had been followed. 
A number of important coding decisions were made during the cleaning process. For 
example, where an entire page was left blank then all the items for that day were 
coded as missing. If two numbers were crossed on the NRS the higher number was 
used. On days where at least one item had been filled in correctly then responses to 
Q2, Q3, and Q5, if not crossed were presumed to be ‘no’ and coded as such.  
During the cleaning process it became clear that three of the study participants, who 
had reported exclusions (one indicated a diagnosis of rheumatoid arthritis and two 
others had left the ‘previous inflammatory disease’ question blank in the cross-
sectional survey) had received diaries, some of which had been completed. The 
decision was made to delete these diary observations from the diary analysis. 
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7.2.5 Statistical analysis 
Evaluation of selective participation 
Descriptive characteristics of responders and non-responders to the diaries were 
compared, using information in the cross-sectional survey (age, gender and 
deprivation). In all instances simple descriptive statistics (mean, SD; median, inter-
quartile range; frequencies and percentages) were used. A flowchart of response 
was also completed. 
Frequency of missing data 
The proportion of completed entries in returned diaries was described, in total (e.g. 
3000 out of a total of 5000 person-days), by month (for example 2000 of 3000 for 
Month 1; 750 of 1500 for M2, 250 of 500 for M3), and by person (for example 40% of 
responders to M1 diary had complete entries for all days; 50% had 1-7 entries 
missing; 10% had >7 entries missing). 
Objective 1: Nature of flare-ups 
Definition of a flare-up: 
The following a priori definition of a flare-up was used:  
1. Increase of at least 2 points from baseline in the average pain in the past 24 
hours reported on an 11-point NRS  
2. The increase to have occurred for at least 2 consecutive days 
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This definition was chosen after referring to previous studies of osteoarthritis flare-
ups (55, 70, 157, 178, 182), OA flare design trials (180, 181), and flare-ups in other 
musculoskeletal (218) and non-musculoskeletal conditions (76, 306). 
The following a priori definition of the resolution of a flare-up was used: 
1. Reduction of average pain in the past 24 hours reported on an 11-point NRS to at 
or below baseline level 
2. The return to at or below baseline levels to have occurred for at least 5 
consecutive days 
 
Flare-up rate 
The proportion of persons experiencing at least one flare-up was calculated and, 
among those experiencing at least one flare-up, the number of flare-ups per person. 
The overall rate of flare-ups for the study period was calculated as an incidence 
density using Poisson regression in order to take into account recurrent events (307). 
The incidence density was expressed per 100 person-days at risk along with the 
95%CI. 
Flare-up nature 
Scatterplots of individual daily NRS scores 
Scatterplots were used to display daily reported NRS score per individual.  
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Scatterplot of time course of NRS scores across flare-ups 
For each participant’s initial flare-up, the mean NRS score for the 7 days prior and 30 
days after the flare up, was calculated and plotted on a scatterplot. The same method 
was used for plotting the time course of symptoms such as swelling, limping, 
stiffness, night pain and for medication changes. 
Baseline characteristics of those experiencing flare-ups  
The baseline characteristics of those experiencing flare-ups was reported using 
descriptive statistics (mean (SD) or frequency (proportions) where appropriate). 
A logistic regression model was used to assess associations between those 
experiencing flare-ups in the diary study and baseline characteristics. Odds ratios 
were calculated for each variable (267). A multivariable model was not possible due 
to the small number of events. 
Changes in diary variables during a flare-up, resolution and at-risk period 
Descriptive statistics (means, SD or proportions) were used to describe how often a 
flare-up, resolution or at-risk period was accompanied by change in certain diary 
variables. A mixed-effect model appropriate for each outcome (logistic for binary and 
linear for continuous outcomes) was used to compare the occurrence (expressed as 
odds ratios) and severity (expressed as regression coefficients) of symptoms on 
flare-up versus non-flare-up days accounting for the clustered nature of the 
observations (308). 
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Variability 
The Variability Index (VI) was obtained by splitting the diary data into half monthly 
blocks (14-16 days). The standard deviation of the daily pain intensity scores within 
each block was calculated for each participant and used as the primary measure of 
variability. The standard deviation was chosen as it is the most common measure of 
variability which averages the absolute deviation of each day’s pain intensity from the 
mean pain over the 14-16 days period, thus capturing any pain fluctuations.  This 
method has also been used in a previous study investigating pain variability of 
patients with fibromyalgia (309). Single days were not used due to varying length of 
the month over the three months study period hence the block size slightly varied 
from 14-16. The 14-16 block was chosen based on the number of available data 
points and to allow for reliable estimation of SD due to the distribution assumptions. 
The Variability Index was calculated for the population as a whole, for only 
participants who had not experienced a flare, for only those who had experienced a 
flare, and for all the population but only using ‘at-risk’ days.  
The association of baseline factors with differing levels of variability was then 
calculated. A histogram to assess the distribution of the SD was created which 
showed that the data was not normally distributed. The SD was therefore log 
transformed. A linear mixed model was used to examine the association between 
variability in the daily pain scores and a number of baseline factors. The model 
accounted for the correlation of the variability index within each time period (each 
time period having the same VI). The coefficient and 95% confidence intervals are 
presented in a univariable model. 
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Objective 2: Duration and severity of flare-ups  
The duration of flare-ups was calculated as the number of days between the first day 
of flare-up to the first day of the resolution period and was summarised across all 
flare-ups as median (IQR) and range.  
 
Severity of flare-ups  
The severity of flare-ups was calculated as the change from baseline to peak pain 
intensity during a flare-up. 
 
Comparison of normal NRS score reported at baseline and frequency of flare-up for 
each pain rating 
A comparison of the ‘normal’ NRS score reported in the cross-sectional survey and 
frequency of flare-ups for each pain rating was reported using a table, i.e., the 
number of flare-ups reported in the diary study was compared to each pain intensity 
rating in the cross-sectional survey.  
Objective 3: Triggers and prodromal symptoms  
To determine whether certain triggers were associated with a flare-up, a case-
crossover type approach (310, 311) was used with individuals used as their own 
control. A case-crossover analysis is useful where the outcome of interest is acute in 
onset and the triggers occur over a brief time period (312). Case windows for 
exposure were defined as the 48 hours prior to the first day of a flare-up. Each case, 
where possible had four matched controls. Controls were the 48-hour periods prior to 
a period of time that did not precede a flare-up but were from corresponding days to 
the case to account for any differences in activity that might occur on particular days. 
Where possible, two controls were selected prior to the case period and two after the 
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case period. Controls were not selected from days when the participant was having a 
flare-up or when they were in a resolution period. If there were insufficient days to 
select two controls before and two controls after the case period, then controls were 
selected from available days. The assumption in a case-crossover analysis is that 
risk is similar throughout the study period and is called the exchangeability 
assumption (312). 
The frequency of different exposures (for instance heavy lifting), prodromal 
symptoms (such as increased limping), and changes to medication in the case and 
control windows was described.  
Unadjusted exposure odds ratios (OR) were calculated based on the conditional 
maximum likelihood estimate with 95% mid-P exact confidence intervals using 
OpenEpi (www.OpenEpi.com). 
 
Objective 4: Actions in response to flare-ups  
Proportion changes for days in a flare, resolution and ‘at risk’ period were reported 
for seeing a GP and changes in medication using percentages. Changes in 
medication usage compared to baseline were presented as a proportion change for 
combined data for the 7 days prior to and 30 days proceeding a flare-up.  
 
7.3 Results 
7.3.1 Evaluation of selective participation 
Figure 7.1 displays the response rate to each of the monthly diaries. The Month 1 
Diary was mailed out to 106 participants who were eligible and consented from 
responders of the cross-sectional survey. There were 63 responders (61%) to the 
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Month 1 Diary. Four participants withdrew after month 1, and 58/100 (58%) 
responded to the Month 2 Diary. Nine participants withdrew after month 2 and 58/91 
(64%) responded to the Month 3 Diary.  
Overall 52 participants completed three monthly diaries, 8 participants completed two 
diaries and 7 participants completed only one diary during the data collection period. 
Of the 67 responders who completed at least one diary over the 3 months, 37 (55%) 
were female, mean (SD) age was 62.2 (10.6) with a mean (SD) BMI of 24.6 (5.3), 
and ethnicity of White UK or European 66 (99%). 
 
Figure 7.1: Flowchart for response to Month 1, Month 2 and Month 3 Diaries. 
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Mailed Month 1 diary 
(n=106) 
 Refusals/non-respondents 
(n=43) 
Non-response (43) 
Completed Month 1 diary 
(n=63) 
Excluded prior to mailing 
(n=6) 
Withdrawn (6) 
Mailed Month 2 diary 
(n=100) 
Completed Month 2 diary 
(n=58) 
 Refusals/non-respondents 
(n=42) 
Non-response (42) 
Excluded prior to mailing 
(n=9) 
Withdrawn (9) 
Mailed Month 3 diary 
(n=91) 
Completed Month 3 diary 
(n=58) 
 Refusals/non-respondents 
(n=33) 
Non-response (33) 
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There were no major differences between responders and non-responders to the 
monthly diaries in terms of age and gender (Table 7.2), and for the subsequent 
diaries. However, those that lived in the most deprived areas were less likely to 
complete the diaries.  
Table 7.2: Comparison of those that completed at least one diary versus non-
completers 
 
Responders 
(n=67) 
Non-
responders 
(n=39) 
Female, n (%) 37 (55) 25 (64) 
Age, years (mean (SD) 62.2 (10.6) 61.7 (11.0) 
Area-level deprivation*, n (%):   
     Most deprived 17 (25) 13 (33) 
     Mid 33 (49) 17 (44) 
     Least deprived 17 (25) 9 (23) 
* Tertiles of Index of Multiple Deprivation based on patient postcode 
 
 
7.3.2 Frequency of missing data of daily diary items 
There were 111 of a total of 5491 (2%) person days where all items were missing 
and 4328 (79%) person days where all items were completed. The most common 
items which were missed were change in medication, whether a GP had been seen 
that day, and if pain stopped usual activities. Items with the least amount of missing 
data included the pain descriptors and triggers. 
The number of complete missing days increased throughout the study: 17 (0.9%) 
person days in month 1, 36 (2%) person-days in month 2, and 58 (3%) person-days 
in month 2.  
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7.3.3 Objective 1: Nature of flare-ups 
Flare-up rate 
There were 54 flare-ups in the sample amongst 30 participants over the three month 
period. The majority experienced only one flare-up (16 participants). However, six 
experienced 2 flare-ups, six experienced 3 flare-ups and two participants 
experienced 4 flare-ups. 
The incidence density of flare-ups for the entire study period was 1.12 (95% CI 0.80, 
1.57) per 100 person days.  
There was no difference in overall response rate between responders and non-
responders and those that did and did not experience flare-ups. 
Flare-up nature 
The daily reported average NRS per individual was plotted for all person-days 
available and annotated to show where a flare-up had occurred where applicable. 
Some participants reported large fluctuations in daily pain and had frequent flare-ups 
(patient ID 19 and 315 in Figure 7.2). Other participants reported minimum variability 
in pain scores (ID 11 in Figure 7.2) and some showed stable pain scores throughout 
(ID 105 in Figure 7.2). See Appendix O for all Daily NRS graphs. 
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Figure 7.2: Daily NRS for ID 11, 19, 105 and 315.       
Flare-ups are indicated in blue. 
 
Analysing combined mean NRS scores of all first flare-ups, for all individuals who 
experienced a flare-up for the 7 days preceding and 30 days proceeding the start of a 
flare-up it can be seen that the mean NRS does not appear to gradually increase 
prior to a flare. After the first 2 days the pain appears to gradually reduce back to pre-
flare levels and which takes up to 30 days (Figure 7.3). 
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Figure 7.3: Time course of pain intensity for all first flare-ups during the study period. 
(Reproduced from Parry et al, 2019 (313)) 
 
Footnote: Expressed as mean NRS-score for each of the 7 days prior and 30 days 
proceeding onset of a flare-up where day 0 is the first day of the flare. 
The proportions of certain knee symptoms reported, for example, swelling, stiffness, 
limping and night pain were plotted to see if there was a change in these symptoms 
leading up to a flare and proceeding it (Figure 7.4). All of the symptoms appear to 
increase suddenly in terms of proportion of participants reporting them on the first 2 
days of a flare-up. For stiffness there appears to be an upward trend prior to the 
onset of a flare-up then a greater increase on day 1 of the flare-up, followed by a 
generalised decline. Night pain follows a similar pattern with a potential increase in 
participants reporting night pain prior to a flare-up, with a peak during the flare-up 
and a decline afterwards. Swelling and limping do not have a similar pattern. 
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Figure 7.4: Time course of symptoms of swelling, limping, stiffness and night pain for 
each first flare-up in the 30 participants who experienced flare-ups. (Expressed as 
proportion for each of the 7 days prior and 30 days proceeding onset of a flare-up 
where day 0 is the first day of the flare.) 
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Looking at how participants might manage flare-ups it appears that more medication 
is taken at the onset of a flare-up and the following day but after this the proportion of 
participants reporting taking an increase in their medication gradually declined. There 
does not appear to be any increase in medication prior to a flare-up (Figure 7.5).  
Figure 7.5: Time course changes in medication where more or less medication was 
taken than normal for each first flare-up in the 30 participants who experienced flare-
ups. (Expressed as proportion for each of the 7 days prior and 30 days proceeding 
onset of a flare-up where day 0 is the first day of the flare.) 
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Baseline characteristics of those experiencing flare-ups 
Mean age of those experiencing flare-ups was 62.4 (SD 8.2) years which was similar 
to those who did not experience flare-ups (62.8 years (SD 11.9)). The proportion of 
females experiencing flare-ups was less than those who did not experience flare-ups 
(15 (50%) versus 22 (60%)). Mean BMI was higher in the flare-up group (25.5 kg/m2 
(SD 5) versus 23.9 kg/m2 (SD 6)). There were no significant associations at the 
p>0.05 level between any baseline factors assessed and experiencing a flare-up in 
the diary studies. However, there were positive associations with being male, 
younger age, having a higher BMI, longer duration of knee problem, previous knee 
injury, previous surgery, certain triggers (kneeling, climbing stairs, climbing ladders), 
certain knee symptoms (swelling, limping), certain knee descriptors (sharp, aching, 
throbbing, burning), and taking medication (Table 7.3).  
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Table 7.3: Comparison of baseline characteristics of those experiencing flare-ups and those not experiencing flare-ups in the diary   
 
Reference 
Flare-up 
(n=30) 
No flare-up 
(n=37) 
  
 OR (95% CI) 
Demographic and socioeconomic 
Age (years): mean (SD)  62.4 (8.2) 62.8 (11.9) 1.00 0.96, 1.18 
Gender Male 15 (50) 22 (60) 0.68 0.27, 1.80 
Lives alone No 3 (10) 5 (14) - - 
Married Not married 23 (77) 27 (73) 1.22 0.40, 3.71 
Employed Not employed 14 (47) 18 (49) 0.92 0.35, 2.42 
Educational qualification No qualification 24 (80) 27 (75) 1.33 0.41, 4.30 
Lifestyle 
Current smoker Current non-smoker 11 (37) 18 (49) 0.61 0.23, 1.63 
Alcohol consumption*      
Low Low 7 (23) 10 (27) 1 1 
Medium  17 (23) 19 (51) 1.19  0.34, 4.14 
High  6 (20) 8 (22) 0.93 0.22, 3.91 
BMI (kg/m2): mean (SD)  25.5 (5) 23.9 (6) 1.06 0.96, 1.18 
Current/previous knee symptoms 
Pain intensity (NRS 0-10): mean (SD)  3.2 (2.0) 2.6 (2.4) 0.90 0.71, 1.13 
Description of knee symptoms      
Swelling No 17 (57) 17 (46) 1.54 0.58, 4.06 
Limping No 19 (63) 23 (62) 1.05 0.39, 2.85 
Stiffness No 13 (43) 17 (46) 0.90 0.34, 2.37 
Night pain No 11 (37) 17 (46) 0.68 0.25, 1.82 
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Reference 
Flare-up 
(n=30) 
No flare-up 
(n=37) 
  
 OR (95% CI) 
Pain descriptors      
Dull No 8 (27) 12 (32) 0.76 0.26, 2.19 
Throbbing No 8 (27) 7 (19) 1.56 0.49, 4.94 
Numbness No 1 (3) 1 (3) - - 
Sharp No 11 (30) 11 (37) 1.37 0.49, 3.81 
Aching No 23 (77) 25 (68) 1.58 0.53, 4.69 
Burning No 5 (17) 6 (16) 1.03 0.28, 3.79 
Stabbing No 6 (20) 10 (27) 0.68 0.21, 2.14 
Pins and needles No 1 (3) 0 - - 
Knee history 
Duration of knee problem      
1 year or less  4 (13) 8 (22) 1 1 
2-5 years  13 (43) 16 (43) 1.63 0.40, 6.63 
6-10 years  6 (20) 2 (5) - - 
More than 10 years  7 (23) 11 (30) 1.27 0.28, 5.87 
Previous knee injury None  13 (43) 13 (35) 1.41 0.53, 3.79 
Previous surgery to index knee No 7 (23) 8 (21) 1.10 0.35, 3.49 
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Reference 
Flare-up 
(n=30) 
No flare-up 
(n=37) 
  
 OR (95% CI) 
Physical activity exposures 
Potential triggers      
Kneeling for 30 minutes or more No 4 (14) 4 (11) - - 
Climbing more than 5 flights of stairs No 8 (28) 8 (22) 1.38 0.45, 4.27 
Lifting/ moving heavy objects No 6 (21) 11 (30) 0.62 0.20, 1.93 
Squatting for 30 minutes or more No 0 3 (8) - - 
Climbing ladders No 5 (17) 4 (11) - - 
Exercise      
20 mins vigorous activity ≥1 x week None 12 (40) 19 (51) 0.63  0.24, 1.67 
Walk for 30 minutes or more ≥1 x week None 27 (90) 29 (78) 2.48 0.60, 10.3 
Moderate exercise ≥1 x week None 15 (50) 21 (57) 0.76 0.29, 2.00 
Knee related healthcare utilisation      
Seen GP in past 12m re knee problem No 18 (60) 25 (70) 0.66 0.24, 1.83 
Takes medication No 15 (50) 18 (50) 1.00 0.38, 2.64 
Figures are column percentages unless otherwise stated 
BMI Body Mass Index; NRS Numerical Rating Scale; OR crude odds ratio; SD Standard Deviation 
* Alcohol: High frequency= daily or most days, medium frequency= once a month to twice a week, low frequency= maximum twice a year 
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Change in diary variables during a flare-up, resolution and being in an at-risk period 
A comparison was made between changes in mean or proportions of diary variables 
dependent on person days in a flare-up, in a resolution, or an at-risk period. During 
flare-up days the mean NRS was higher, there was a higher proportion of knee 
symptoms reported (stiffness, limping, effusion, night pain), there was a higher 
proportion of certain knee descriptors (throbbing, numb, sharp, aching, burning, 
stabbing), there was a higher proportion of increased medication taken compared to 
baseline and a higher proportion of those experiencing pain that had stopped usual 
activities. The mean NRS on flare-up days was 5.4 (SD 1.9), on resolution days 3.8 
(SD 1.7), on at-risk days for only those participants who experienced a flare-up 3.1 
(SD 2.0), and on all at risk days regardless of whether a participant experienced a 
flare-up or not 2.8 (SD 2.2) (Table 7.4).  
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Table 7.4: Severity and occurrence of symptoms and impact experienced during flare-up, resolution or at-risk days among 
participants  
 Total days  
 
 
(n=5491) 
During flare-up 
period  
 
(n=299) 
During 
resolution 
period  
(n=258) 
During at-risk 
period 
(flarers only) 
(n=1958) 
During at-risk 
period (all 
patients)  
(n=4934) 
Relative 
frequency/severity on 
flare-up days vs non-
flare-up days * 
Pain intensity (0-10NRS) (mean, 
SD) 
3.0 (2.3) 5.4 (1.9) 3.8 (1.7) 3.1 (2.0) 2.8 (2.2) 2.49 (2.34, 2.64) 
Presence of associated symptoms       
Knee swelling 1375 (32) 149 (50) 73 (29) 668 (35) 1513 (31) 14.53 (8.31, 25.41) 
Limping 1783 (33) 191 (64) 133 (53) 804 (42) 1459 (30) 12.37 (7.36, 20.78) 
Knee stiffness 1493 (28) 178 (60) 90 (36) 505 (26) 1225 (25) 10.92 (6.96, 17.14) 
Woken at night 861 (16) 103 (35) 33 (13) 189 (10) 725 (15) 6.99 (4.35, 11.23) 
Pain descriptors       
Dull 1705 (32) 52 (17) 86 (34) 673(35) 1567 (33) 0.40 (0.25, 0.66) 
Throbbing 723 (13) 95 (32) 52 (21) 301 (16) 576 (12) 18.10 (9.83, 33.32) 
Numb 106 (  2) 72 (24) 15 (  6) 15 (<1) 19 (<1) 6.68 (1.93, 23.15) 
Sharp 989 (18) 146 (49) 51 (20) 206 (11) 792 (16) 11.22 (6.77, 18.58) 
Aching 2931 (55) 218 (73) 162 (64) 1122 (59) 2551 (53) 6.87 (4.08, 11.56) 
 
Burning 338 (6) 73 (24) 32 (13) 171 (  9) 233 (  5) 6.70 (4.04, 11.11) 
Stabbing 837 (16) 108 (36) 56 (22) 269 (14) 673 (14) 11.82 (7.15, 19.54) 
Pins and needles 10 (<1) 1 (<1) 2 (<1) 1 (<1) 7 (<1) 3.44 (0.33, 35.89) 
Other 452 (  8) 9 (  3) 4 (  2) 45 (  2) 439 (  9) 1.33 (0.58, 3.08) 
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 Total days  
 
 
(n=5491) 
During 
flare-up 
period  
(n=299) 
During 
resolution 
period  
(n=258) 
During at-risk 
period 
(flarers only) 
(n=1958) 
During at-risk 
period (all 
patients)  
(n=4934) 
Relative 
frequency/severity on 
flare-up days vs non-
flare-up days * 
Change in medication       
Same as normal 3048 (68) 165 (59) 165 (70) 1100 (73) 2718 (68) - 
More than normal 551 (12) 94 (34) 22 (  9) 181 (12) 435 (11) 23.90 (13.81, 41.38) 
Less than normal 886 (20) 19 (  7) 48 (20) 225 (15) 819 (21) 0.81 (0.41, 1.60) 
Pain stopped usual activities 407 (  8) 44 (15) 15 (  6) 76 (  4) 348 (  8)  
Seen GP 58 ( 1) 8 ( 3) 1 (0.4) 7 (0.4) 49 ( 1) 0.84 (0.44, 1.59) 
Figures are frequencies in person-days and column percentages unless stated otherwise 
Flare-up =period Flare-up days 
Resolution period= Defined as the 5 days following a flare-up 
At-risk period= Days not classified as flare-up or resolution days 
* From mixed- effect model based on participants who had experiences a flare-up (n=30) (logistic for binary and linear for 
continuous outcome). Results are expressed as odds ratios (95% CI) except average knee pain intensity which is expressed as 
a regression coefficient (i.e., mean difference) and 95% CI. 
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Variability analysis 
To examine the degree of variability across all subjects the Variability Index was 
calculated. The mean Variability Index was 0.76 (SD 0.54), median 0.68 (IQR 0.41-
1.05). The minimum Variability Index was 0 and maximum 3.26. The between subject 
histogram is seen in Figure 7.10. This is skewed to the left towards lower values. 
The Variability Index for only at-risk days was 0.68 (SD 0.49) with a range of 0 to 
3.15. 
The Variability Index was calculated for only those participants who had not 
experienced a flare. The mean Variability Index was 0.62 (SD 0.47), range 0 to 2.07. 
The Variability Index was calculated for only those participants who had experienced 
a flare. The mean Variability Index was 0.92 (SD 0.57), range 0 to 3.26. 
The variability Index was found to violate the normality assumptions (Figure 7.6); a 
log transformation was therefore performed into order to fit a linear mixed model to 
assess the association between variability and baseline factors (Figure 7.7). 
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Figure 7.6: Between subject histogram showing the Variability Index 
 
A logarithmic transformation reduced the variability in the data and produced a 
variable that conformed closely to a normal distribution (Figure 7.7). 
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Figure 7.7: Logarithmic transformation of the Variability Index 
 
Significant baseline factors associated with increased variability in pain scores 
include younger age, higher NRS score, and reporting a stabbing pain quality. Other 
factors with a positive association include being female, employed, undertaking at 
least 20 minutes of vigorous or 30 minutes of moderate intensity exercise a week, 
knee symptoms such as stiffness and limping, previous knee injury, previous knee 
surgery, longer duration knee problems, activities such as kneeling, climbing stairs, 
squatting, climbing ladders and reporting pain quality as throbbing sharp, aching, 
burning, or pins and needles (Table 7.5). 
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Table 7.5: Relationship of variability and baseline factors using linear mixed model. 
  Log 
transformed β 95% CI  Reference 
Demographic and socioeconomic 
Age (years)  -0.14 -0.02, -0.00 
Gender Male -0.89 -0.31, 0.14 
Employed Not employed 0.18 -0.04, 0.40 
Lifestyle 
BMI (kg/m2)  0.11 -0.01, 0.33 
Current/previous knee symptoms 
Pain intensity (0-10 NRS): mean (SD)  0.06 0.01, 0.12 
Description of knee symptoms    
Swelling No -0.13 -0.28, 0.01 
Limping No 0.14 -0.00, 0.28 
Stiffness No 0.09 -0.05, 0.23 
Night pain No -0.13 -0.29, 0.04 
Pain descriptors    
Dull  No -0.04 -0.16, 0.09 
Throbbing No 0.14 -0.02, 0.29 
Numbness No -0.01 -0.88, 0.86 
Sharp No 0.03 -0.13, 0.18 
Aching No 0.01 -0.10, 0.13 
Burning No 0.07 -0.14, 0.27 
Stabbing No 0.34 0.17, 0.51 
Pins and needles No 0.12 -0.72, 0.96 
Knee history 
Duration knee problem: <1 year   
1-5 years  0.09 -0.22, 0.41 
>5 years  0.18 -0.06, 0.42 
Previous knee injury No 0.09 -0.14, 0.32 
Previous knee surgery No 0.04 -0.22, 0.30 
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  Log 
transformed β 95% CI  Reference 
Physical activity exposures 
Potential triggers 
Kneeling for 30 minutes or more No 0.05 -0.15, 0.25 
Climbing more than 5 flights of 
stairs 
No 0.13 -0.05, 0.32 
Lifting/ moving heavy objects No -0.11 -0.29, 0.07 
Squatting for 30 minutes or more No 0.12 -0.14, 0.37 
Climbing ladders No 0.05 -0.23, 0.31 
Exercise    
20 minutes vigorous activity  1 x 
week 
None 0.14 -0.09, 0.36 
30 minutes + moderate intensity  1 
x week 
None 0.12 -0.10, 0.34 
Knee related healthcare utilisation 
Seen GP in last 12 months No -0.00 -0.24, 0.23 
Takes medication regularly No -0.02 -0.24, 0.21 
BMI Body Mass Index; NRS Numerical Rating Scale; SD Standard Deviation 
  
 
 
 
 
197 
7.3.4 Objective 2: Duration and severity 
The median duration for a flare-up was 8 days (IQR 3, 23). The durations ranged 
from 2-30 days. 
The majority of participants experiencing flare-ups reported an increase of 3 and over 
in their NRS score between baseline and peak pain intensity (Table 7.6). For 
example, 44% of participants experienced a peak pain intensity which was 2 points 
greater than their ‘normal’ reported pain at baseline, for 2% (1) of participants their 
peak pain was 6 points greater than their ‘normal’ pain.  
Table 7.6: Difference between baseline reported NRS and peak intensity during a 
flare-up 
NRS point difference Frequency (%) 
2 24 (44) 
3 21 (39) 
4 7 (13) 
5 1 ( 2) 
6 1 ( 2) 
Data are from 54 flares from 30 participants 
 
Comparison of recalled flare-ups reported at baseline in the preceding 12 months 
and flare-ups experienced within the diary period 
Comparing recalled flare-ups reported at baseline versus flare-ups experienced 
during the three months of data collection suggests that there may be an element of 
recall bias and suggests that participants may not be able to recall accurately the 
flare-ups they experience. Alternatively, their interpretation of a flare-up may differ 
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from that imposed in this study. Those reporting a high frequency of flare-ups at 
baseline do not necessarily appear to be experiencing a higher frequency in the dairy 
studies (Table 7.7). 
Table 7.7 Comparison of recalled flare-ups reported at baseline in the preceding 12 
months and flare-ups experienced within the diary period 
Recalled frequency of 
flares in previous 12 
months at baseline 
Flares during diary 
period n (%) 
0 1 (  3) 
1-2 6 (20) 
3-4 5 (17) 
5-6 6 (20) 
7-8 1 (  3) 
9-10 3 (10) 
10+ 8 (27) 
 
 
7.3.5 Objective 3: Triggers and prodromal symptoms 
A case-crossover analysis using conditional logistic regression was used to examine 
if there was an association between certain triggers, prodromal symptoms and 
descriptors and a flare-up. The analysis used discordant pairs to calculate odds 
ratios (310) (Table 7.8). A worked example can be seen in Appendix P. 
  
  
 
 
 
 
199 
Table 7.8: Illustration of how discordant pairs were used in the case-crossover 
analysis 
 
 Ca+Co+ Ca+Co- Ca-Co+ Ca-Co- OR (95%CI) 
Exposure X n n n n Ca+Co- / Ca-Co+ 
Ca+ = exposed in the case window (i.e. prior to flare) 
Ca- = not exposed in the case window 
Co+ = exposed in the control window (i.e. prior to no flare) 
Co- = not exposed in the control window 
n = number of paired observations 
 
In the 48 hours prior to a flare-up there is an association between any physical 
exposure and flare onset (Table 7.9). Climbing ladders was the only single variable 
significantly associated with flare-ups. 
 
Table 7.9: Case crossover analysis of physical activity exposures using discordant 
pairs 
 Ca+Co+ Ca+Co- Ca-Co+ Ca-Co- OR (95%CI) 
Any exposure 36 35 16 77 2.19 (1.22, 4.05) 
Kneeling for 30 
minutes or more 0 12 9 143 1.33 (0.56, 3.29) 
Climbing more than 5 
flights of stairs 21 19 13 111 1.46 (0.72, 3.04) 
Lifting/moving heavy 
objects 2 22 11 129 2.00 (0.98, 4.28) 
Squatting for 30 
minutes or more 0 4 3 157 1.33 (0.28, 7.15) 
Climbing ladders 5 18 1 140 18 (3.29, 378.9) 
Ca+Co+ Pairs of observations where there was exposure to the risk factor in the 48-hour case 
window and also in the matched 48-hour control window 
OR Odds ratio, calculated from discordant pairs (Ca+Co- / Ca-Co+) 
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In the 48 hours prior to a flare-up there is a positive association with symptoms such 
as stiffness and night pain (Table 7.10).  
Table 7.10: Case crossover analysis of potential prodromal symptom exposures 
using discordant pairs 
 Ca+Co+ Ca+Co- Ca-Co+ Ca-Co- OR (95%CI) 
Knee swelling 45 8 10 101 0.80 (0.30, 2.06) 
Limping 70 7 11 76 0.64 (0.23, 1.65) 
Stiffness 44 30 15 75 2.00 (1.09, 3.81) 
Night pain 18 16 6 124 2.67 (1.07, 7.43) 
Ca+Co+ Pairs of observations where there was exposure to the risk factor in the 48-hour case 
window and also in the matched 48-hour control window 
OR Odds ratio, calculated from discordant pairs (Ca+Co- / Ca-Co+) 
 
In Table 7.11 the results suggest that in the 48 hours prior to a flare-up participants 
may increase their usual medication. They are less likely to continue their normal 
medication. 
Table 7.11: Case cross over analysis of potential medication changes prior to flare-
ups using discordant pairs 
 Ca+Co+ Ca+Co- Ca-Co+ Ca-Co- OR (95%CI) 
Increased medication 9 19 14 122 1.36 (0.68, 2.77) 
Reduced medication 27 12 13 112 0.92 (0.41, 2.05) 
Normal medication 86 19 16 43 1.19 (0.61, 2.35) 
Ca+Co+ Pairs of observations where there was exposure to the risk factor in the 48-hour case 
window and also in the matched 48-hour control window 
OR Odds ratio, calculated from discordant pairs (Ca+Co- / Ca-Co+) 
 
The pain descriptors that participants reported appeared to change prior to a flare-up 
(Table 7.12). Sharp and burning pain descriptors were significant factors. Other 
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factors, although non-significant include; throbbing, burning and stabbing. 
Participants were less likely to report a dull pain in the 48 hours prior to a flare-up. 
Table 7.12: Case cross over analysis of potential pain descriptors present prior to 
flare-ups using discordant pairs 
 Ca+Co+ Ca+Co- Ca-Co+ Ca-Co- OR (95%CI) 
Continuous pain descriptors 
(Dull, aching, throbbing) 118 12 9 25 1.33 (0.56, 3.29) 
Dull 46 10 18 90 0.56 (0.25, 1.20) 
Throbbing 27 20 17 100 1.18 (0.61, 2.28) 
Aching 86 21 13 44 1.62 (0.81, 3.32) 
Intermittent pain descriptors 
(stabbing, sharp) 48 29 9 78 3.22 (1.56, 7.19) 
Stabbing 34 14 7 109 2.00 (0.81, 5.29) 
Sharp 26 24 10 104 2.40 (1.17, 5.25)  
Neuropathic pain 
descriptors (numbness, 
burning, pins and needles) 
21 23 9 111 2.56 (1.20, 5.81) 
Numbness - - - - - 
Burning 20 20 9 115 2.22 (1.03, 5.13) 
Pins and needles - - - - - 
Ca+Co+ Pairs of observations where there was exposure to the risk factor in the 48-hour case 
window and also in the matched 48-hour control window 
OR Odds ratio, calculated from discordant pairs (Ca+Co- / Ca-Co+) 
 
7.3.6 Objective 4: Actions in response to flare-ups 
The frequency of participants reporting seeing their GP was low, however the results 
suggest that more participants saw their GP on flare-up days compared to resolution 
or non-flare days (Table 7.4). How often a flare-up is accompanied by seeing a 
medical professional was described using proportions. On flare-up days the 
proportion of participants taking more medication than normal increased and those 
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taking less than normal reduced (Table 7.4). Figure 7.9 demonstrate the changes in 
medication taken prior to and after flare-up onset. It is only at flare onset that 
participants appear to be increasing medication and the proportion doing this steadily 
declines after day 2 of the flare-up. 
 
7.4 Discussion 
This study supports evidence that for some people knee OA is characterised by 
intermittent, acute, sudden episodes of pain with associated changes in pain quality, 
knee symptoms, medication and interference with activity.  
In this study population, where participants were eligible for inclusion based on a 
recent history of knee symptoms, pain intensity was highly variable for some and 
relatively stable for others. It is interesting that within this highly selected group pain 
profiles showed considerable variation. Those with higher variability tended to 
experience more flare-ups. These findings are similar to those in other diary studies 
of OA pain (227, 314) and in other chronic diseases such as fibromyalgia (309). In a 
study by Murphy et al (61), 78% of the participants reported pain flare-ups, however 
these were short-lived so may in fact represent ‘minor’ episodes of pain rather than 
flares. Those with higher variability in pain scores experienced multiple flare-ups, 
were of a younger age, had higher pain intensity levels at baseline and were more 
likely to report a stabbing pain. Those with higher variability in pain scores may be 
undertaking activities that lead to an increase in their pain or their pain may not be 
controlled with their pain medication.  Trouvin et al, showed similar variability in pain 
  
 
 
 
 
203 
scores after undertaking a 28 day daily diary study recording daily pain intensity and 
presence of other symptoms such as stiffness in patients with hip and knee OA, 
finding that over half of the participants fell into a ‘stable’ pain trajectory (n=59.5%) 
(227).  
Nearly half of participants within this sample experienced flare-ups and 
approximately half of these experienced multiple flare-ups. This compares to the 
CAS(K) analysis where nearly a third were estimated to have had a flare and the 
cross-sectional survey where 90% experienced flares. These estimates will be 
sensitive to the definition and the population used. However, they suggest that flare-
ups are a common occurrence for certain patients with knee osteoarthritis.  
Identifying potential triggers are important in the management of flare-ups in terms of 
activity avoidance and prevention. Results from this study suggest that kneeling for 
30 minutes or more, climbing more than 5 flights of stairs, lifting/moving heavy 
objects, squatting and climbing ladders all have some association with triggering a 
flare-up; climbing ladders being the only significant variable. These variables were 
also shown to be risk factors for OA onset (32). Recognising early changes before 
flare onset, such as knee stiffness, swelling, limping and night pain, which are items 
included in tools for diagnosing flares (55), could also be important for early episode 
management and prevention.  
In response to a flare, over a third of participants increased their medication and a 
small number stopped usual activities. Some were found to take less medication prior 
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to a flare and it could be speculated that this contributed to flare onset. This notion is 
relied upon in the context of flare-design drug withdrawal studies, where participants 
are asked to stop their usual pain medication in order to bring on an acute event (69, 
160). 
Interestingly those who reported a higher frequency of flare-ups at baseline over the 
previous 12 months were not necessarily those who were found to have a higher 
frequency of flare-ups in the diary study. This may suggest inaccurate recall or 
misclassification. Patients may have different interpretations on what constitutes as 
flare. The term flare, may encompass the less and more severe episodes of pain for 
some people. 
The strengths of this study include repeated, intensive measurement of variables to 
try and minimise recall bias. The diary was developed with input from the PPIE 
group. The diaries were well completed with only 2% of person days where all of the 
items were missing. 
Limitations of the study include the small sample size, inclusion of non-validated 
items, and potential for retrospective completion of diary entries. To minimise this 
participants were advised to leave the day blank if it was missed and to return diaries 
at monthly intervals.  
The study population was based on two general practices in two market towns in 
Shropshire. This population is a highly selective sample with a mostly white ethnicity, 
higher education levels and lower deprivation which limits the overall generalisability 
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of the findings. Furthermore, those who responded to the questionnaires may have 
been those more likely to experience flares . 
The most common missing items were change in medication, whether pain had 
stopped usual activities and whether a GP had been seen that day. This may reflect 
the ordering of questions or habituation which is a known problem in daily response 
studies . The amount of missing items increased as the study progressed which may 
be due to fatigue. 
There was a trend for reducing frequency of flare-ups over the study period. This 
may impact on validity assumptions in the case-crossover analysis as this analysis 
assumes risk of event stays stable over the study period. It is uncertain why flares 
reduced over the study period however qualitative studies have highlighted how 
patients avoid activities that may trigger their pain (53, 64). The reduction in flare-ups 
may be due to participants avoiding activities that may bring them on. This has 
implications for future studies, which have longer flare-ups due to the diminishing 
returns. 
The study findings will contribute to patient education about the probable duration of 
flare-ups, symptoms that might be expected, and to be aware of individual potential 
triggers. Further larger scale research is needed to explore physical triggers and the 
types of activities that cause these acute events. Exploring patient understanding of 
flares is important in moving forward to a consensus definition of a flare that is able to 
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differentiate between flares and within person variability. This would be best achieved 
through a qualitative study. 
 
7.5 Summary 
This study with intensive longitudinal data collection confirms the earlier observations 
that acute flare-ups may be experienced by a substantial number of patients. It adds 
new evidence that these episodes often last a week or longer, are disruptive, prompt 
changes in self-management, and may be triggered by high-loading physical 
activities such as heavy lifting. It has also highlighted areas to be explored further 
from the patient perspective.  
  
  
 
 
 
 
207 
 
 
  
  
 
 
 
 
208 
8.  Patients’ perspectives of flares in knee 
osteoarthritis: a qualitative study 
 
The previous studies in this thesis have used quantitative methods to understand 
knee OA flares. This chapter uses qualitative methods to explore patients’ 
understanding of flares particularly with reference to help-seeking and self-
management strategies employed.  
 
8.1 Introduction 
Previous chapters have contributed to our understanding of how flares might be 
defined, temporal changes, variability of symptoms, potential triggers and responses 
to flares. However, there is a need to increase our understanding of the patients’ 
perspective: patients’ understanding and experience of flares, experience of 
symptom variability, self-management strategies and help-seeking behaviours, their 
understanding of triggers, and the overall impact of flares.  Previous qualitative 
studies have described experiences of intermittent acute pain and the variability of 
OA symptoms in the context of chronic OA (53, 62, 64). Gooberman-Hill et al (2007) 
conducted focus groups on 14 men and 14 women aged between 57-89 years from 
the Somerset and Avon Health Survey who reported hip or knee pain in the previous 
12 months (64). The participants described pain that was intermittent and variable 
changing monthly, daily and throughout the day, pain that was triggered by certain 
  
 
 
 
 
209 
functions and the avoidance of activities that might bring on pain which highlights the 
broad spectrum of onset and duration of pain in those with potential OA. Hawker et al 
(2008) undertook focus groups involving 143 people aged 40 years and over with hip 
and knee OA from the community and previous OA cohorts (53). Participants 
described pain that was intermittent and predictable early on in the disease course 
which became unpredictable and distressing, more burdensome and interfered more 
with activities as it progressed. The patients included, however, were more likely to 
have had OA for a longer duration and few had mild disease which means 
conclusions on pain experience related to severity of OA should be interpreted 
cautiously.  Cedraschi et al (2013) also undertook focus groups on 14 people aged 
40-75 years with severe hip and knee OA recruited from primary and secondary care 
clinics (62). Participants also described the variability of OA pain and highlighted that 
this could vary daily, and how they managed the pain by avoiding certain activities. 
Participants in this study had severe OA and so may not represent the pain 
experience of patients with less severe symptoms. Participants in these initial focus 
groups all described the variability of pain in OA, the potential impact of intermittent 
pain, avoidance and adaptation strategies, and its predictability.  However, focus 
groups do not allow for the individual experience to be explored in detail and there 
can often be a ‘group’ effect (86).The majority of participants in these studies were 
white so this limits generalisability of findings.  To understand these intermittent 
increases in pain further face-to-face individual interviews would allow flares to be 
explored in more depth, gaining an understanding of patient perceptions of flares, 
  
 
 
 
 
210 
whether patients can differentiate between different severities of flares, 
understanding different management strategies employed, the impact of flares, their 
predictability, and whether this changes over time. These are key areas that have not 
previously been explored in depth that I hope to address further. Murphy et al 
focussed specifically on flares in their study of 45 participants aged 50 years and 
over with confirmed knee OA recruited from pain clinics (61). They undertook a brief 
interview to understand patient perceptions of flares at baseline and then asked 
participants to record their pain 8 times a day in a logbook along with descriptions of 
their pain experiences that were recorded in logbooks. Participants described mostly 
short lived episodes of pain lasting up to 15 minutes which may not encompass the 
full spectrum of flares that has been reported in the previous studies presented in this 
thesis (61). A high frequency of this population (78%) experienced flares during the 7 
day  period, however the participants are likely to have had more severe symptoms 
than those managed in primary care as they were recruited from pain clinics. 
Furthermore, experiences with regards to predictability, pain descriptions reported 
and frequency of flares may not be generalizable. Although all of the qualitative 
studies mentioned intermittent pain or flares being brought on by activity, none seem 
to mention the concept of undertaking an activity despite knowing it would trigger a 
painful episode, e.g. attending an importance event, or the ability of an activity to 
cause delayed onset pain, for example, one to two days later. Exploring this further 
would be interesting in the context of the findings from the case-crossover analysis in 
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Chapter 7 and highlight the patient perspective of this and whether they are aware of 
any proximate triggers for their intermittent pain. 
Gaining a deeper understanding of flares from the patients’ perspectives, how they 
impact on their lives, increasing understanding on severe and less severe flares, 
patients’ awareness and response to knowledge around triggers is important. 
Furthermore, reasons for help-seeking have not been explored before and 
understanding this could have an impact on how flares are managed in the 
community setting.  Differentiating between different severities of flares may helpful 
for patients and clinicians in terms of how they are identified and managed. The 
findings from my interviews will highlight which aspects of flares are important to 
patients and this may guide the key components that should be considered in a 
consensus definition of a flare.  The findings will also guide patient education material 
and discussions with clinicians about what is important to patients when 
understanding flares. Using a mixed methods approach, by comparing and 
contrasting findings from different methodologies, will provide a deeper and broader 
understanding of flares from the patient perspective and will help improve the value 
and quality of the findings from this thesis. 
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8.2 Aims and objectives 
Aim 
The aim of this qualitative study was to explore patients’ understanding on flare-ups 
or exacerbations in knee osteoarthritis and explore self-management and help-
seeking strategies used. 
Objectives 
Using qualitative methods to: 
• Explore patients’ views on the nature of exacerbations or flare-ups 
• Explore patients’ views on how best to define exacerbations or flare-ups 
• Explore patients’ views on precipitants and time course of flare-ups 
• Describe how patients report managing flare-ups of pain including self-
management strategies and help-seeking behaviours 
 
8.3 Patient and Public Involvement and Engagement 
The aims for the PPIE in this study were to strengthen the study design and 
comment on the initial interpretation of the data and illustrative model. These were 
achieved through the following objectives: 
• Evaluate the study design with specific reference to the aims and objectives 
• Evaluate the topic guide 
• Explore the use of pain graphs during the interviews 
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• Explore lay members’ views on interpretation of results 
Two PPIE meetings were held at Keele University. PPIE group members recruited for 
this study had personal experience of osteoarthritis. The first meeting was held 
during the design stages of the study and was attended by a study researcher (EP), 
a PPIE project coordinator (Adele Higginbottom) and five PPIE group members with 
osteoarthritis. During this meeting an overview of the study was given and each 
member was given a topic guide and a copy of example pain graphs to help stimulate 
discussion.  As a result of this meeting the order of the questions in the topic guide 
was amended. The PPIE discussed the use of pain graphs over time to give an idea 
of patient perceptions of their experiences of pain over the previous six months. The 
lay members drew their own pain graphs and felt this was a useful exercise for 
reflecting on how their pain had changed over time. Six months was felt to be an 
appropriate time frame and the PPIE felt that participants could produce informative 
diagrams.  The PPIE suggested that these graphs could be used as discussion 
points for certain interview questions, for example triggers and management during 
flare ups. In addition, the PPIE group advised to use example graphs to give 
participants an idea of what a graph might look like and then ask them to draw their 
own. These suggestions were incorporated into the study design. 
The second meeting was held during the analysis phase of the study when data 
generation was complete. This was facilitated by study researchers (EP and CC-G), 
a PPIE project support worker (Laura Campbell), and 3 PPIE group members. 
Members of the group were presented with data extracts from transcripts which were 
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used to illustrate the emerging themes and sub themes. The PPIE group members 
were asked if they agreed with the researchers’ interpretation of the data extracts 
and the grouping into the overarching themes: patient understanding, experiencing 
pain, managing pain, help-seeking, and anticipating future. They were also asked for 
their additional insights and perspectives. Overall, there was agreement with the 
researchers’ overarching themes and they provided additional insights which could 
be explored further, which included: guilt felt by participants after undertaking an 
activity they thought brought on a flare,  the importance of impact of flares on quality 
of life and social life, use of the term ‘flare’ by patients, understanding the participants 
living status; for example if they lived alone or not and co-morbidities were thought  
important to understand how flares were managed, flare prevention, and help 
seeking from family and friends. The majority of these were explored further by the 
study team by revisiting the transcripts and codes, and incorporating them into the 
analysis. The PPIE members also commented on the proposed model to illustrate 
findings; this is presented at the end of the findings section (Figure 8.6) 
Following the PPIE meeting, the comments on the models and the additional insights 
provided on the quotations were used to revisit the data. This led to the development 
of the final overarching themes and a new model (Figure 8.7) that highlighted the 
importance of the impact of flares on the individual. 
The PPIE group also provided advice on dissemination, which included putting up 
posters in GP waiting rooms, writing patient material for Versus Arthritis, presenting 
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at conferences, and publication in medical journals with a primary care and/or OA 
focus.  
The PPIE group contributed to refine the data collection methods and gave their own 
perspectives on the research findings. Their key contributions included ordering of 
the questions in the topic guide and asking participants to draw their own pain graphs 
and to use these as discussion points. In the analysis phase, they supported the 
study team’s interpretations of the overall themes and suggested furthers areas to 
explore in the analysis. The number who attended the second PPIE meeting was 
small (n=3), however all members made contributions and the group gave different 
perspectives that had not previously been considered.  
 
8.4 Methods 
8.4.1 Study design 
A qualitative study using semi-structured interviews was conducted using a topic 
guide to generate data. 
 
8.4.2 Recruitment and sampling 
8.4.2.1 Study population 
Potentially eligible participants were identified from the patients registered at two 
general practices in the West Midlands. Inclusion criteria: patients who were at least 
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45 years or older, with a Read-coded problem in the last two years for knee 
osteoarthritis or knee pain/arthralgia and who were not in a vulnerable group (for 
example, those with cognitive impairment or a terminal illness) as judged by their 
general practitioner (Table 8.1). Those identified were sent the initial mailing pack 
after GP list screening. This included the invite letter with the consent to contact form, 
eligibility questions and the patient information sheet (Appendix Q).  
Patients were purposively sampled and invited to take part in the interviews if they 
returned the reply slip indicating a willingness to take part in the study and reported a 
recent knee flare-up in the past 12 months by answering ‘yes’ to the following 
question: In the last 12 months have you had an increase of your knee pain, that is 
times when your knee pain is worse than normal which may have stopped you from 
doing your normal activities or meant you had to increase your pain medication? 
8.4.2.2 Eligibility criteria 
Inclusion and exclusion criteria are listed in Table 8.1. 
Table 8.1: Inclusion and exclusion criteria for qualitative study 
Inclusion criteria 
Aged 45 years and over 
Read-coded consultation for knee osteoarthritis or knee pain/arthralgia in the previous 
2 years 
Male or female 
Returned the reply slip indicating a willingness to take part in the interviews and 
reported a recent knee flare-up in the past 12 months 
  
 
 
 
 
217 
Exclusion criteria 
No knee pain in the last 12 months 
Diagnosis of inflammatory disease (rheumatoid arthritis, polymyalgia rheumatic), 
crystal disease (gout), spondyloarthropathy (e.g. ankylosing spondylitis), and 
fibromyalgia at GP list screening  
Previous total knee replacement in index knee 
Those judged to be vulnerable/inappropriate to survey by their general practitioner 
(e.g. dementia, terminal illness) 
 
8.4.2.3 Mailing 
 
Practice staff supported by members of the National Institute for Health Research 
(NIHR) Clinical Research Network (CRN) of West Midlands and informatics teams, 
who are contracted to work in the participating GP practices and are considered part 
of the GP practice team, liaised with the GP practices and the study team. GP 
practice staff screened records to identify adults aged 45 years and over who 
consulted with knee pain/OA in the previous two years. 
GPs were invited to screen the sample list for patients whom they considered should 
be excluded from the invitation mailing (e.g. vulnerable individuals).  
The purpose of the initial mailing was to: 
• Identify eligible responders. 
• Obtain consent to contact to take part in the study. 
 
  
 
 
 
 
218 
A one stage mailing procedure was used and eligible participants were mailed study 
packs via Docmail. The study packs (Appendix Q) included a letter of invitation with 
attached reply slip and eligibility questions, patient information sheet and stamped 
return envelope from the patient’s GP inviting them to take part in the study. The 
patient invitation letter contained my work telephone number and email address to 
give patients the option of registering interest in the study via this method, rather than 
by returning details by post. Patients were also able to use the contact number and 
email address to request any further information about the project if needed.  
8.4.2.4 Consent 
Participants were asked to complete a reply slip attached to the initial invite letter 
(Appendix Q). This enabled potential participants to register their interest in the study 
and allowed the study team to contact them about arranging a face-to-face interview.  
At the start of the interview, each participant was asked to provide written informed 
consent by signing a consent form (Appendix S).  
8.4.2.5 Purposive sampling 
Those that returned reply slips and were eligible to take part in the interviews were 
purposively sampled based on age (in order to include a wide range of ages) and 
gender (to provide even numbers of males and females). This was to ensure the 
participants that were included in the study contributed data reporting a range of 
views and experiences (110). 
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8.4.2.6 Participants  
Recruitment and interviews were continued until data saturation was achieved (85, 
105). Prior to this however, an estimation of the number of potential participants to 
approach was required. This estimation helped guide the CRN in their selection of 
general practices to ensure they had an adequate population size. For this study, it 
was estimated that between 12-15 participants would likely be required to achieve 
data saturation based on one previous qualitative study using in-depth interviews by 
Guest et al 2006, who found that by 12 participants very few new codes were being 
generated and little new information was being produced (315). Based on the sample 
size calculation required to estimate the number of eligible participants with knee 
pain or knee osteoarthritis in Chapter 6, it was decided to approach two general 
practices to produce approximately 511 eligible responders. This estimate was partly 
based on known response rates to previous qualitative studies; an interview study 
exploring knee pain from within the SPCSC received a response rate of 15% after 
writing to those already participating in a cohort study (316). Given that in this study 
not all responders would be eligible and to allow for purposeful sampling (whereby a 
broad range of ages and even distribution of gender would be achieved) it was 
deemed acceptable to mail out from two general practices to recruit sufficient 
participants. In total 235 people were mailed the initial mailing pack from the two 
practices. Of the 76 that returned the reply slip, 47 were eligible (see Table 8.1 for 
eligibility criteria) and were purposively sampled (Figure 8.2). To ensure an even 
distribution of gender and age the potential participants were split by gender and 
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arranged by age category (for example, 45-54 years, 55-64 years, 65-74 years, 75-
84 years and 85 years and older). Contact was made to ensure each age category 
was represented and that this included an even distribution of gender.  
 
8.4.3 Data saturation 
Interviews were conducted until data saturation was achieved. Data saturation is 
when a point is reached where gathering more data does not add any new 
information or insights in terms of the development of categories or of the 
relationships between them and additional data would be counterproductive (85, 
105). It is difficult to predict when data saturation might be achieved as it depends on 
a number of factors including method, design, topic and scope of the study (127).  
Data saturation is important to achieve to ensure the data reflects the views and 
perspectives of the participants (317).  
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Figure 8.1: Flowchart of response for the qualitative study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.4.4 Ethical considerations 
Favourable ethical opinion was granted by the Office for Research Ethics 
Committees Northern Ireland on 8th May 2017. REC reference: 17/NI/0091 (Appendix 
V). 
 
Mailed study pack 
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Returned reply slip 
(n=76) 
Eligible to take part in 
interviews 
(n=47) 
Interviewed 
(n=15) 
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8.4.5 Data collection 
Interviews were conducted by me. All participants chose to be interviewed at home. 
The lone worker policy for Keele University was followed 
(https://www.keele.ac.uk/policyzone/data/loneworkingpolicy/). During the interviews I 
did not disclose to participants that I was a GP unless I was asked. I felt this would 
allow the participants to discuss their experiences, particular those of healthcare 
more freely. 
 
8.4.5.1 Topic guide 
A topic guide was developed to maintain structure during the interviews and to 
ensure all relevant topics were discussed. The topic guide was informed by the 
literature, previous studies presented in this thesis and was reviewed and refined by 
the PPIE group.  
The topic guide explored the participants’ experiences of knee OA flares which 
included how participants’ described flares, how they managed them, and help-
seeking strategies used (Appendix U). During the interview the participants were also 
invited to draw a diagram to represent disease course over time and to indicate flare-
ups diagrammatically. Participants were shown example pain graphs overtime, which 
were adapted from Stone et al (117), to give participants an idea of different types of 
pain graphs (Appendix T).  For participants who were not able to or were 
uncomfortable drawing their pain graph, they were asked to identify which of the 
example graphs best described their pain experience. The graphs also served as a 
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talking point to generate further discussion during the interview on triggers for flares 
and management strategies.  
As interviews were undertaken and transcripts reviewed with the study team, the 
topic guide was modified as themes emerged (Appendix U).  
 
8.4.6 Transcription 
Interviews were digitally recorded and stored on an encrypted audio recording 
device. They were uploaded onto the SPCSC secure network drive in a password 
protected folder. The first three interviews were transcribed verbatim by me. The 
remaining interviews were transcribed verbatim by a transcription company approved 
by the SPCSC. Transcripts were upload using a secure web link. The transcripts 
were delivered via email. Following this they were saved onto the SPCSC’s secure 
network drive in a password protected folder and the email was deleted. All 
transcripts were assigned ID numbers, checked through for accuracy and any 
identifiable information was removed prior to analysis. The transcriptions were 
managed in QSR NVivo 12, a qualitative data analysis software package (318).   
 
8.4.7 Reflection on data collection 
After each interview, I made reflective notes on thoughts that arose, potential 
emergent themes, what went well and what could have been improved (107). Notes 
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and reflections were also made during the transcription process, reading of 
transcripts, when undertaking coding and after supervision meetings.  
 
8.4.8 Data analysis 
8.4.8.1 Thematic analysis 
Analysis began as the interviews were conducted, and the process was iterative. The 
data was analysed using constant comparison methods (319), where the researcher 
interacts and is actively involved in the data and the emerging analysis, making 
comparisons at each stage. The method involves comparisons of text segments 
through coding, recoding, and memo writing in order to generate themes and 
concepts. 
The analysis was undertaken separately by myself and two supervisors (CC-G and 
LD) followed by team discussions at each of the coding stages in order to arrive at an 
agreed coding framework. CC-G is an academic GP and experienced qualitative 
researcher.  LD is a social scientist and ethnographer with extensive knowledge of 
qualitative research methods.  
 
8.4.9 Practical process of data analysis 
The first step, also known as ‘open coding’, that was undertaken was code 
generation. Reading through transcripts and using the topic guide as a reference the 
initial categories were generated using NVivo software (Table 8.2). The next step, 
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also known as ‘axial’ coding, allowed connections to be made between the 
categories by comparing and asking questions of the data (317). During the final 
stage of coding, called ‘selective coding’, the codes were read through again, making 
further comparisons and connections. This was done by constructing a table to easily 
view similarities and differences of the codes in order to form the core categories 
(105) (Appendix W).  Coding took place after each interview was transcribed. This 
enabled early identification of emergent themes, modification of the topic guide, and 
allowed the researchers to identify when data saturation had been achieved. At each 
of the coding stages, memos were recorded in NVivo. 
Table 8.2: Stages of data analysis (adapted from Braun and Clarke, 2013) (320) 
Step 1 Familiarization with transcripts 
Step 2: Initial code generation  
Step 3: Comparison of codes across transcripts 
Step 4: Identification of emergent themes 
Step 5: Agreement of final themes with PPIE 
 
8.4.9.1 Maintaining quality 
Ensuring methodological rigour in qualitative research is important. An audit trail was 
kept and notes were written at each point of the research process to help maintain 
quality. It also ensured transparency of the data collection process and analysis 
(119). The analysis was undertaken as part of a team, who had different professional 
backgrounds which allowed group comparisons of data interpretation and review of 
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coding frames and emergent themes (86, 321). A sample of transcripts were coded 
independently which helped improve the quality of the data (322). Multiple coding of 
parts of the data helped guide discussions particularly around disagreements in order 
to refine coding frames and provide alternative interpretations (321) . 
 
8.5 Findings 
The demographics of the 15 participants are given in Table 8.3.  
Table 8.3: Characteristics of interviewees 
ID Gender Age Duration of 
knee pain 
(years) 
Living status 
001 Male 51 3 Lives with partner 
002 Male 78 50 Lives with spouse 
003 Female 66 1 Lives alone 
004 Female 81 11 Lives with spouse 
005 Male 59 20 Lives with spouse 
006 Female 68 7 Lives with spouse 
007 Male 83 3 Lives with spouse 
008 Male 66 30 Lives with spouse 
009 Male 64 2+ Lives alone 
010 Female 69 6 Lives with spouse 
011 Female 70 5 Lives with spouse 
012 Male 81 60 Lives alone 
013 Female 78 4-5 Lives with spouse 
014 Male 85 6 Lives with spouse 
015 Female 85 1 Lives with daughter 
 
Verbatim quotes are presented using the following format: 
 ID (age, gender) 
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To gain a greater depth of understanding of the results Leventhal’s self-regulatory 
model (SRM) was used during the analysis stage to help illustrate and understand 
findings. During the initial and final stages of coding and when organising codes into 
themes, memos were made which highlighted links to the five components in the 
SRM.  
The SRM provides a framework to understand the perceptions, thoughts and 
behaviours individuals have on their own health conditions and is one of the most 
tested models for understanding behaviours in healthcare research (323). It has also 
been used to understand the patient’s approach to management of their condition 
(324). The SRM comprises five components linked to how patients identify they have 
a condition, beliefs on how long it may last, the impact the condition may have, its 
potential causes and the extent to which symptoms can be cured or controlled (Table 
8.4). These beliefs are important to understand as they can over-reaching effects, for 
example, they can influence beliefs on how effective a treatment is likely to be which 
in turn may impact on compliance.  Each component of the model aligned better with 
the aims and objectives of this study compared to other models such as the health 
beliefs model where six constructs such as risk benefit are thought to determine 
health behaviour (325), the Burden of Treatment Theory which explores the added 
burden of patient self-management (326) and the Candidacy model whereby patients 
judge their own eligibility for healthcare based on individual experiences and the 
healthcare services (327).   
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Table 8.4: Five components of Leventhal’s Self-Regulatory Model (adapted from 
Leventhal et al 2016 and Hale et al 2007 (324, 328)) 
Core component Description 
Identity The label or name given to a condition and perceptions of its 
associated symptoms or conditions. 
Timeline Beliefs on temporal characteristics (e.g. onset and duration). For 
medication, the expected benefits incongruous to  that 
experienced may lead to non-adherence to treatment.   
Consequences Beliefs on consequences of their illness and the impact it will 
have on them physically, cognitively and socially. With regard to 
management, the consequence of unwanted side effects of a 
treatment may lead to non-adherence. 
Causes Beliefs on causes of their condition or symptoms. These will be 
based on and modified by a number of different sources, for 
example, peers, healthcare professionals and previous 
experiences. These beliefs will also have a role in the perceived 
effectiveness of certain management options. 
Control The extent to which symptoms or the disease can be cured or 
controlled. Beliefs can impact on choice of management options. 
 
8.5.1 Experiencing pain: Identifying flares 
Participants identified and described flares in a number of ways: change in pain 
descriptors, change in intensity and magnitude of pain, the speed of onset, their 
duration, and how frequently they occurred. This resonates with the ‘identity’ and 
‘timeline’ components of the SRM.  
Several participants used graphic and descriptive terms to communicate the intensity 
of pain during flares, for example “pumping”, “red-hot poker” and “tonnes of knives” 
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(Table 8.5).  ‘Sharp’ was also a term that was commonly used to describe pain 
quality alongside the graphic descriptors.  
Table 8.5: Terms used to describe flare pain experience  
Graphic pain descriptors “it’s like pumping in my knee” P001 (M, 51) 
“it’s stronger, it’s not an ache, it’s a definite pain” 
P004 (F, 81) 
“it’s sharp and well you know it makes you 
wince” P008 (M, 66) 
“sharp intense pain” P012 (M, 81) 
“Just like a red-hot poker” P015 (F, 85) 
“tonnes of knives” P003 (F, 66) 
“…it’s just as though someone’s twisting me , 
twisting me leg” P014 (M, 85) 
“Sharp stabbing pain” P009 (M, 64) 
“Well just a sudden impact of pain… when it 
becomes unbearable erm” P007 (M, 83) 
 
The first flare or knee event seemed to be important to participants; they tended to 
recall this event with clarity, which may indicate they had ‘rehearsed’ their story. 
These events were described in detail despite, for some, it happening a number of 
years beforehand. Several participants were able to recall a specific injury that 
preceded their knee pain but for others it came “out of the blue”. P004 recalled the 
surprise of her first knee symptoms 11 years previously. 
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 “But, er, no I have no reason why it should happen at all, as I say I was just 
walking quite normally in [deleted name of town] down towards [deleted 
name of department store] and it just suddenly gave way….I had no 
premonition of it, no pain before, or aches or anything, it just happened totally 
out of the blue.” P004 (F, 81) 
The descriptions of flares mapped onto the ‘identity’, ‘timeline’ and ‘consequence’ 
components of the self-regulatory model. Participants identified they were having 
flares when there was an increase in pain intensity and magnitude of pain, and a 
change in pain quality. The timeline of flares was described in relation to speed of 
onset and duration. The impact or consequence of the flares, usually in terms of 
limiting ability to undertake activity was also discussed. Intensity and speed of onset 
featured in most participant accounts.  Participants described understanding what a 
‘flare’ was despite it not being a term they usually used.  
“To me it suggests something that erm it sort of comes out of the blue and just 
sort of suddenly attacks the knee sort of thing you know, yeah, yeah but I’ve 
never said I’ve had a flare-up of my knee, it’s not a term I would use truly you 
know.” P008 (M, 66) 
Several participants described the variability of pain intensity and differentiated 
between different severities of flare-ups in their narratives. They described “slight” or 
“minor” flares that occurred more frequently and did not have too much impact on 
daily life and “major” or “big” flares that were less frequent but had more of an impact. 
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These were also apparent in participants diagrams representing their pain 
experience (see Figure 8.2 as an example). Participants expressed their 
apprehension and fear of experiencing these in the future. P006 in Figure 8.2 
described a low-level background pain the majority of the time, which was interrupted 
by minor increases in pain that usually lasted for short periods of time. However, she 
described experiencing an unexpected sudden increase in pain intensity that was 
severe and markedly above usual increases in pain intensity.  
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Figure 8.2: Diagram with quotations by P006 (F, 68) illustrating pain variability over the previous 6 months on a 0-10 numerical 
scale 
 
“So this is no pain, but I am in pain all the time. 
But as I say, it isn’t anything that I would – I 
suppose I probably wouldn’t class it as pain, 
although I know it is. I mean it may really irritate 
some other people, but it’s – it doesn’t for me – 
say if that’s no pain, my pain probably starts about 
here and then as I say, it’s pretty constant all the 
way along until I might just get what you class as 
a slight flare.” 
“But to me it’s probably just where the pain has increased a bit. So that probably would go 
up, only slightly and then it’d be down within a couple of days. Erm, so that would be 
probably the pattern and then I’d go again and it’d be fine and then probably again about 
the same .” 
“ But then as I say, the other one 
I’ve just got along with a bit of pain, 
but then it just hit and it went right 
up, really right up.” 
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Participants gave descriptions of more severe flares and recalled, with clarity the 
symptoms they experienced, the impact it had, and the dates. These were contrasted 
to ‘minor’ flares that occurred more frequently, had minimal impact and were more 
likely to be referred to as “just one of those days”. 
“Oh no there was a definite difference in that one last year because it stiffened 
it all. Really did I shouldn’t have walked on it really…No just the big one was a 
flare-up yeah. I think that’s fair to say…No, no. These minor ones I have had 
them for many years and I can live with it.” P002 (M, 78) 
The majority of participants distinguished flares or episodes of increased pain from 
their usual background pain. They did this by referring to the change in magnitude 
and intensity of the pain during a flare. The diagrams drawn by the participants in 
Figures 8.2 and 8.3 highlights the variability in the magnitude of the pain intensity, the 
frequency of increased episodes of pain and the usual level of background pain on 
which these episodes or flares occurred. For some the flares occurred on a 
background of no pain and for others it occurred on a background level of pain 
intensity. Figure 8.3 demonstrates this difference in background pain in two 
individuals, in both cases after a flare or increase in pain, the intensity returned back 
to baseline level. For seven participants who identified their pain experience using 
the example pain diagrams (Appendix T), they reported a similar pattern.   
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Figure 8.3: Diagrams illustrating pain variability over the previous 6 months on a 0-10 
numerical scale for P005 and P015 
P005 distinguished between 
the “big flare-up” and the minor 
episodes of increased pain in 
terms of level of pain intensity 
and impact on usual activities. 
The flares seen here were 
reported to be triggered by 
activity, such as, golf. 
 
 
 
P015 described how she 
experiences the increases in 
pain every 1-2 months, 
however in the previous 6 
months an injection helped to 
reduce their severity. The 
increases in pain were 
attributed to walking. 
 
The pain graphs in Figure 8.3 highlight the changes in pain intensity compared to 
‘normal’ and the variability in intensity of flares and duration. The graphs encouraged 
Knee joint 
injection given 
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the participants to reflect on causes for their pain (e.g. playing golf, walking) and 
reasons for change in severity of flares (e.g. knee joint injection). 
For other individuals the magnitude of pain intensity related to flares was stable over 
time (Figure 8.4). There did not appear any related factors in terms of gender, age, 
duration of knee symptoms or living status to explain the variability of pain intensity.  
P004 and P014, although they had slightly different pain experiences to P005 and 
P015, identified flares on their diagrams and related increases in pain to activity. 
P014 reflected on their diagram and was able to highlight that the frequency of his 
flares was increasing, depicted by the “spikes” getting closer together. 
Figure 8.4: Diagrams illustrating pain variability over the previous 6 months on a 0-10 
numerical scale for P004 and P014 
 
 
 
 
 
 
The perception of timeline of flares featured in all participant accounts of flares. This 
included speed of onset, duration and frequency. Onset was described as sudden or 
gradual, however, this could be variable and often changed over time.  
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 “…well I think it is starting to do it sort of straight away now whereas when I 
used to go up the ceilings, it was the next day, it would show up the next 
day.” P012 (M, 81) 
Short lived symptoms, for instance, those lasting 10-15 minutes were usually 
described as occurring with everyday activities. The majority of participants felt the 
shorter lived episodes were not ‘flares’; however there was some discussion that 
labelling an episode as a ‘flare’ should be based on pain intensity rather than 
duration. 
“The ones that last longer I would say are the flare ups. Erm, cos I mean like I 
say, when it does – like I say – when it does flare up, erm it does start jumping 
that I have a job to sometimes keep it still.” P003 (F, 66) 
Participants tended to classify episodes as severe if they lasted longer. Pain intensity 
was not reported as consistent during flares, it tended to gradually ease off the longer 
it persisted.  
“It can last for weeks before it completely settles down. It eases off, but 
it doesn’t go. It can take a couple of months really for it to really settle 
down.” P006 (F, 68) 
Duration of flares was reported as being variable. Pain that was severe and 
‘unbearable’ could last for varying time periods. Some could be short-lived and some 
could last longer. Several participants described the length of episodes as changing 
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over time. For some participants, during the early stages the flare-ups  were reported 
as only lasting a few days but as time progressed they lasted much longer, for 
example up to 10 days. This highlights how illness perceptions are changed and 
updated and how a change in one component of the self-regulatory framework, for 
example timeline can impact on another; such as change in how people identify with 
their condition. 
“Erm, something damaged it in there and it just flares-up, it aggravates it when 
I do what I said I do, you know, if I twist it, if I’ve got it straight, I'm okay but if I 
twist it erm, that’s when the pain comes and then takes me a lot longer to get 
over it now. It used to be a couple of days and I’d be okay but now, it drags on 
for like perhaps ten days, a week, ten days to get over it…” P012 (M, 81) 
Frequency of flares was reported to range from daily, to fortnightly, to every 2 
months, and this was often variable between participants. Over time, participants had 
noted how their symptoms had changed. The descriptions of these changes mapped 
onto three trajectories: reduced frequency over time, increased frequency over time, 
or relatively stable over time. Participants had their own health beliefs on causes for 
their trajectories and put this down to lifestyle changes (positive and negative), for 
instance reduced activity and the weather. 
“I think I’m getting them more often but it’s probably because I don’t do so 
much erm, they say if you don’t use it, you lose it, don’t they? So I mean I'm 
not anywhere near as active as I used to be, I mean, ride bikes and football 
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and all sorts of things, swimming, but I don’t do that now, so I'm not getting 
any exercise that I used to have so that might be affecting it cause I’m not 
doing the exercises which is back down to the physio, which is what the world 
is trying to tell me but doing the exercises they want me to do, aggravated me 
pain so I knocked that on the head, rightly or wrongly I don’t know but I did…” 
P012 (M, 81)  
Associated symptoms that participants mentioned included swelling (which was 
variable and sometimes present before the pain), stiffness (particularly after being 
sedentary), and interference with sleep due to night-time pain. Despite these 
symptoms, a number of participants did not align themselves with the diagnosis. 
When explored further this was often because they did not feel they had the full 
range of symptoms that they linked to OA, or because their symptoms were different 
to someone who they knew did have OA. These participants challenged how they 
identified with OA or flares based on their experiences and that of peers. Views on 
diagnosis were also influenced by health professionals, some still using the term 
“wear and tear”. 
 “I think the doctor said, 'It's probably wear and tear but you have got some 
arthritis there…” P013 (F, 78) 
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8.5.2 Impact of OA flares 
 
The impact or ‘consequence’ (beliefs on consequences and impact on physical, 
cognitive and social abilities) of illness is a key component of the self-regulatory 
framework (328, 329). Impact of flares was central to the participants’ understanding 
of flares. The impact of flares, for several participants, was more influential of their 
flare experience than pain intensity and duration.  
The ability to carry on with usual activities, despite having to adapt to them was a key 
part of managing their condition and minimising the impact of flares. Participants 
frequently talked about their frustration when flares impacted on their ability to 
participate in certain activities and this seemed more important than the actual 
severity of the symptoms. 
 “…it’s not so much the pain that I can’t cope with, it’s the inability to, that I 
can’t do things that I find is more debilitating than the actual pain.” P004 (F, 
81) 
Flares impacted on the participants’ abilities to undertake normal everyday activities 
such as those that were related to work and those that were household-related, such 
as shopping and gardening. For several participants this led to adaptations so that 
they could still pursue these valued activities.  
 “It does stop me from doing what I need to do work-wise you know, it’s not the 
most physical of work that I do. You know, it’s a lot of just going in and saying 
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hello to people. So you know, I’m not constantly sort of taking stuff from the 
car into the retailers that I visit. Erm and occasionally I suppose I have to be 
careful because I’ve got a sample storage which is probably like the size of 
this place [house] erm and that’s stacked to the gunnels with stuff and I just 
have to be a little bit careful when I’m – if I’m having to step up there or step 
back down really.” P005 (M, 59) 
However, flares sometimes led to the patients having to completely stop the activities 
that they used to do. These were often recreational activities that the participants got 
enjoyment from.  This could result in a sense of loss. 
 “Erm, but erm it started playing up and then so I was glad when I retired. But 
then it started to slowly get worse, I was restricting myself in things, I was 
getting no pleasure out of some stuff, you know. I couldn’t go out much and 
erm couldn’t go dancing or nothing like that you know, them days are gone.” 
P010 (F, 69) 
Flares also impacted on social life. For example, participants described how flares 
stopped them from fulfilling regular commitments like weekly meet ups with friends 
and family. There  was also a sense that when meeting up with friends and family 
that they did not want to be burdensome. One participant explained that she has to 
pause regularly when out and mentioned that whoever she is with has to keep 
stopping to wait for her. 
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 “It is stopping me from doing stuff. You know, because I’ve got two sisters and 
we used to go shopping every week and there’s only sometimes I can go, like 
I can phone up and say ‘I can come to this week’ you know. But they keep 
slowing down for me, I have my stick and we only go to town. I sit down and I 
have to say ‘Right, I’ve gotta find a seat’ and have to sit down for ten minutes, 
then I’m alright for a little bit longer and that’s how it is. And they’re ever so 
good, they wait and hang on for me you know, so. And I go on the bus, it’s 
nice, it’s as easy to get on the bus than drive and if it’s hurting, cos of this leg, 
it hurts, yeah. And so I’ve got a bus pass, I go free on the bus, but yeah, if my 
knee’s hurting I don’t drive, it really hurts then. And I’m trying to change gear 
and oh, it hurts.” P010 (F, 69) 
From such an account, it is apparent that flares impacted on the participant’s feeling 
of independence. However, flares were also described as having a significant impact 
on the independence of their spouses. This ranged from the unaffected spouse being 
burdened with extra household chores to activity limitation in terms of going shopping 
together or undertaking shared recreational activities together.  
Several participants reflected that the impact of flares was kept to a minimum if they 
did not interfere with their ability to carry out activities. In these examples, the flares 
were not described as bothersome and activities could still be completed albeit at a 
slower pace. 
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[On change in frequency over time]. “No, no they are more regular. But as I 
say, I can honestly say they don’t really – I wouldn’t say bother me, but I know 
that they’re there and yes I have the pain, but they don’t stop me doing 
anything other than if I have to take it a bit steadier up the stairs or an incline.” 
P006 (F, 68) 
For some participants there was an acceptance of flares and they had come to terms 
with the notion that these were part of their OA experience. They wanted to carry on 
doing their normal activities despite the pain.  
“Erm, to me it’s just normal I think now, just to have a flare-up. I get a pain and 
erm, yeah there maybe the odd day when it’s only minimal pain, not much, but 
there’s never not pain. Cos whenever I do anything, it hurts, but you have to 
do things. You know, I can’t not do it.” P010 (F, 69) 
Flares could make patients feel vulnerable. They were anxious about the potential for 
their knee to give way and the consequences of that. Some participants described 
how they only felt comfortable going out if they had someone else with them or a 
walking aid.   
“When I’m walking I feel very insecure, I don’t feel safe, very vulnerable, I 
keep thinking my knee’s going to give way and I’m going to fall.  Er, I’m alright 
if my husband’s with me and I can hold his arm, or in the supermarket and I 
can hold  a trolley or if I’ve got a walking stick that gives me confidence.  But 
  
 
 
 
 
243 
without that just walking from the back door to my washing line, I feel very 
vulnerable, very insecure yes.” P004 (F, 81) 
Stoicism ran throughout the participants’ accounts. There was a strong sense, 
amongst the majority of participants, of “getting on with things” despite the pain. They 
did not want the pain to interfere with their ability to participate in activities. However, 
continuing despite the pain meant activities had to be adjusted, they often took 
longer, and required the patient to direct more thought towards what actions might 
bring on or prevent a flare of pain. Impact of flares also varied, sometimes 
participants were able to continue activities despite the pain, and other times the pain 
would cause them to stop activity. 
“It’s when I’m doing stuff, as soon as I’m doing stuff I do get a pain and I just 
have to grit my teeth and go through it and sometimes it’s that bad I have to 
stop and go and sit down and erm just make my cup of tea and I’ll wait till it 
eases off, then I can do a little bit more.” P010 (F, 69) 
To minimise the impact of flares, several participants described how they adapted in 
order to undertake activities, this could be at home, for example climbing the stairs 
using their “good leg” first, or being more observant about foot placement when out 
walking. These adaptations however, were described as being intrusive and 
participants seemed to be resentful about having to make them.  
“I just have to be very, very careful, watch where I’m walking.  I hate having to 
keep looking down to see where I’m going and it’s tiring, like last week.  
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Happened to look up and didn’t notice this paving stone sticking up and just 
caught it with my toe.” P014 (M, 85) 
 
8.5.3 Predicting and avoiding flares 
Predicting and avoiding flares was understood in relation to the ‘cause’ (beliefs on 
causes of symptoms) and ‘consequence’ components of the SRM (324, 328).   
For some participants flares were described as coming on without warning and they 
could not think of any attributable cause. The onset, duration and intensity were all 
noted to be unpredictable for some. The unpredictable pain was associated with 
distress and seemed to have more of an impact on mental wellbeing and quality of 
life in terms of having to cancel planned activities. 
“Yeah, it’s quite depressing cos if I’m planning to do something and then I sort 
of can’t because it’s started to hurt and I know it’s not gonna go away quick. 
You know, erm it could take a while for it to calm down and I don’t know why it 
flares up.” P010 (F, 69) 
For others pain could be predicted and it was often low bearing, everyday activities 
that brought on more frequent increases in their symptoms, for example standing, 
walking, or climbing stairs. 
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“I, as I say it’s if I go in the kitchen or stand up in the kitchen for any length of 
time, well three quarters of an hour, half an hour, three quarters of an hour.” 
P014 (M, 85) 
Amongst the participants that could predict their flares and were aware of certain 
triggers (for example, walking) they were able to plan ahead in order to participate in 
planned activities. This helped to minimise the impact of them. 
“I’ve been in pain since June of last year with it. And there are days when I 
don’t have as much pain as normal, erm but I rested up on Monday because I 
was going out yesterday and it was a lot of walking. So this morning it is 
playing me up a bit.” P003 (F, 66) 
 
For some participants who experienced variability in their ability to predict flares, the 
unpredictable flares seemed to be more distressing. This was partly linked to not 
being able to identify an underlying cause.  
 
“Yes definitely because you’re aware. You think ‘I won’t do that again’. You 
know and if it’s caused you a sharp pain, you’re definitely aware that you won’t 
be stepping on that foot again that way or whatever. But as you say, it’s the 
unknown. It’s when it comes and I have no idea why it’s just suddenly started 
again. So I don’t know, I really don’t know.” P006 (F, 68) 
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Being able to predict pain onset, however, did have some negative connotations. For 
some there was associated regret with doing the activity that brought on the pain and 
a sense of guilt for having overdone things. 
 
 “Erm, I suppose I'm like that really, I haven’t got no pain, if I press on there, I 
can feel something, there's an ache in there but I don’t class that as a pain, so 
I’ve got no pain and then if I do something, it shoots up, I get me pain and then 
it takes X amount of days for it to go back down again and then I haven’t got 
any pain again until I do something similar again which you think, you stupid 
person, why do you keep doing things but you’ve got to be active haven’t you, 
you’ve got to do something.” P012 (M, 81) 
The ability to predict flares seemed important to participants as they were able to 
utilise strategies, such as activity avoidance, adjusting physical movements, and 
being observant of potential hazards in their environment to better manage their 
flares.  
“I’m aware that – like yesterday, I’d had it a bit, so erm we had to go to 
[deleted name of town] and there were steps. So I really have to take my time, 
I have to think about it. I can’t just go for the steps, I have to stop and think 
‘Oh, no’ you know, which is you know, I know which is my good leg and which 
is my bad leg and I have to remember which leg I’m going up on. Erm, but 
other than that, I mean that’s not a life changing thing, you know, it’s just 
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something I have to be aware of. So it doesn’t stop me from doing anything, 
so from that point of view you know, it’s okay, it’s manageable.” P006 (F, 68) 
 
8.5.4 Response to OA flares 
Response to OA flares resonates with the ‘consequence’ and ‘control’ (extent to 
which symptoms can be controlled) components of the self-regulatory model (328, 
329). Immediate responses to a flare included stopping any current activity, 
employing self-management strategies, taking medication, or just ignoring them. In 
the short to medium term, people undertook adaptations, avoidance of certain 
activities, and sought help in the form of peers and health professionals. In the long-
term people anticipated the future of the management of their knee symptoms. 
8.5.4.1 Self-management of flares 
Immediate response to a flare depended on what was readily available at home. 
Medication used ranged from over-the-counter analgesia such as paracetamol, 
ibuprofen and topical NSAIDs (non-steroidal anti-inflammatories) to prescribed 
medication such as higher strength co-codamol.  There were a number of health 
beliefs with regards to medication. For example, some only took medication sparingly 
as they were either worried about the consequences, for instance masking 
underlying disease activity, reduced efficacy with continued use, or wanting to avoid 
dependence. Several participants felt that not taking medication was a positive sign 
as this meant their symptoms were not severe.  
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“Erm, Naproxen. But as I say, I do try not to take them unless it’s absolutely 
necessary. And then when I do, I do take them until the pain has gone and 
then once the pain has gone, then I think ‘Right, now I’ll stop’. Erm cos I just 
think well if I keep taking them I’m never going to know whether the pain has 
really gone and then I think – the other thing I thought, well if I do keep taking 
them, then I’m not gonna feel the benefit if anything, if it does occur it’s 
probably not gonna have the effect that it should have. So I do only take them 
when I really need them, yeah.” P006 (F, 68) 
A number of participants signalled the control they had of their own condition and the 
active role they took in self-managing their pain flares. These included strategies 
such as: rest, ice packs, rubbing the joint, and hot baths. These strategies varied 
depending on the severity of their symptoms. 
“Err well see here again I am one of these people who will try and get rid of it 
so I was having really having hot baths, really soaking it. Really rubbing it er 
sitting with maybe a small hot water bottle on it so really the real pain did not 
last long.” P002 (M, 78) 
Participants described taking control of the management of their illness in different 
ways, for some, not taking medication was a method they used to stay in control. 
Participants’ beliefs affected management choices; for example, one participant 
described how paracetamol had not helped them for a previous complaint and so 
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opted not to take any analgesia. Other participants seemed resolved to their 
condition but did not want to give up.  
 “How do I manage; I struggle to be honest. Erm, but I mean I keep getting on  
and that’s it, that’s what's it about isn’t it?” P007 (M, 83) 
Use of mobility aids, walking sticks, and adaptations around the house were methods 
used to help prevent and minimise the impact of flares and to help avoid accidents, 
such as falls. They also ensured that participants could maintain a sense of 
themselves and continue doing usual activities like shopping.  
“I’ve got a mobile scooter that gets me about if I have to go to the shop or go 
up to town.  I have to have a walking stick as well cos if I walk without the 
walking stick I could fall over... I have a special chair in there [shower] and I 
got all like the framework where I can sit down on the toilet and get myself up.” 
P001 (M, 51) 
8.5.4.2 Help-seeking behaviour 
Participants sought help from healthcare professionals when their flare experience 
did not match with their usual illness perception. Reasons for seeking help included 
effect of symptoms on sleep, reached emotional limitations, exhausted self-
management options, and pain experience worse than normal; for example 
increased severity, sustained, and a longer duration than normal. Participants 
consulted the health professional that they thought would be more able to help them 
or meet their expectations based on previous experience. 
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“But it was – I mean I can stand a fair bit of pain, but I think I got to the point 
with it because I was having no sleep, I was just worn out with it in the end. 
And that’s why I rang the hospital, because I didn’t know what else to do. Erm, 
I thought ‘Well I could ring my doctor’ but really, they’re brilliant GPs, but 
they’re GPs. I needed somebody with the arthritis [specialist knowledge].” 
P006 (F, 68) 
For some participants, where they were under a specialist service that they could 
access this would be their first point of contact because they had a ‘way in’. Having 
greater choice allowed the participant more control over their management.  For 
those who had only been treated in primary care, their first point of contact would be 
their GP or allied primary care based health professional.  In general, those that had 
previously been treated in secondary care did not see a role for their GP in the 
management of their OA. 
 “…when I had the flare up, as you call it, last year, I mean I tried everything on 
my knee. I tried the heat pad, I sat one day, nearly all day with a heat pad on, 
but it just did nothing at all. I had a hot water bottle on it, you just try anything 
in the end just to get some relief. Erm, but the night I just used to dread…I was 
just – I was at my wits’ end with it in the end. And I’ve never got to that point 
that last year was the first time where I’d really got to that point. But I was just 
desperate that day I rang the hospital… when I did get to the hospital, I thought 
it was just a nurse I was going to see, but it was a doctor and he examined it 
and he said ‘I think we need’ he said ‘We don’t normally give these injections 
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to you’ he said ‘But I think in this case you probably do need one’.” P006 (F, 
68) 
For several participants a sense of futility about seeking help was described due to 
previous experiences; for example, being told not much could be done or 
dissatisfaction with previous management meant they did not consult. The 
consequences of recursivity (330) strongly shaped who the patients consulted, 
whether they consulted or not and expectations if they did consult.  
“So when they told me they couldn’t do anything with it I ain’t bothered the 
doctor.” P009 (M, 64) 
Participants also sought help from friends and family. The power of peer advice was 
important and shaped theories on the relative importance of and opinions on, certain 
management strategies such as those that could be undertaken at home  
“But a friend of mine who had had problems with, I think it was arthritic hip, a 
friend of mine who played golf and he [deleted name]… said “I tell you one 
thing I was told  to take”  he says,  he ate plenty of pineapple.” P002 (M, 78) 
 
The effect of others’ views on health beliefs was highlighted by the participants’ 
negative views on knee replacement after hearing disparaging comments by their 
peers.   
“I mean a lot of people have knee surgery don’t they?  I’ve got my golfing 
colleagues they’ve all had some say yes some have had 2 done over the 
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years. And wish they hadn’t have done and it’s not what they expected it to 
be.” P002 (M, 78) 
In contrast where favourable comments had been heard the participants were more 
encouraging.  
“So I think by then, if it hasn’t eased off I’ll just tell him, just do it, get it over 
with. Because my friend had it, my mate, she had the injection and it didn’t 
work and she had erm the replacement and it’s been brilliant. I know one or 
two people have had problems with it, but I think on the whole it’s been mostly 
successful. And she had it done nine years ago and she says ‘I’ve never had a 
day of pain since’ you know, so she said it was worth every little bit you know. 
Cos you do worry, you don’t want surgery unless you have to, but erm I can’t 
carry on like this forever more, it’s  quite depressing and it’s stopping me doing 
stuff.” P010 (F, 69) 
8.5.4.3 Anticipating the future 
Total knee replacement featured in a number of participants’ accounts and this was 
particularly evident in those whose symptoms were worsening and where they were 
impacting on quality of life.  
“But then it started to slowly get worse, I was restricting myself in things, I was 
getting no pleasure out of some stuff, you know. I couldn’t go out much and 
erm couldn’t go dancing or nothing like that you know, them days are gone. So 
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I have a funny feeling I’ll end up having to have a replacement… you don’t 
want surgery unless you have to…” P010 (F, 69) 
Several participants described previous conversations with orthopaedic surgeons on 
knee replacement. A number of participants were either given the option of 
replacement but were put off it due to the risks or were told they were ineligible due 
to comorbidities. This led to resentment and frustration; firstly about their own lack of 
confidence to speak up and secondly toward the consultant specialist. Limiting 
potential management options may have impacted on patients by taking away their 
sense of control. 
“I do have quite a lot of pain.  Er, the surgeon that I had, first of all let’s start at 
the beginning.  About four years ago I, I had it, er, cleaned, scraped, which 
improved things for a while and then it started getting worse so I went back to 
see the surgeon and he advised me not to have anything done.  I was going to 
have a replace, well I’d asked for a replacement and he, he said…Yeah, I’d, 
I’d be approaching 80 I would think when I went to see him and he said, ‘You 
think you’re in trouble now’, he said, ‘You think you’re in pain now.  If you have 
a replacement done you will be in even more pain afterwards’, he said, 
‘because I cannot guarantee it.  Cannot guarantee anything’.  He said, ‘My 
advice, put up with it’.” P014 (M, 85) 
In addition to ruminating over knee replacement surgery, some patients had 
concerns about the future management options of their knee. Some participants were 
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unsure about the potential management options aside from injections and knee 
replacement, and this may have impacted on the sense of control that participants 
felt they had with regards to management of their illness.   
“You know, I'd - it's normally - I can go about every, say, six months for an 
injection and I've had, I think, three.  So, at the moment, I'm alright to go back.  
Mmm, I'm not sure what I'm going to do after that.” P011 (F, 70) 
 
8.5.5 Model illustrating findings 
A model was created to illustrate the findings from the participant interviews. The 
initial model was presented to the PPIE members during workshop 2 (Figure 8.5).  
They felt that the arrows were not helpful as one theme did not necessarily lead onto 
the next one as suggested. They felt impact was important and should be more 
prominent in the model.  
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Figure 8.5: Model presented to PPIE group in Workshop 2 
 
 
 
 
 
 
 
 
 
The model was revisited and the final model incorporates the four overarching 
themes that have been presented and highlights how the notion of variability runs 
throughout all of these themes (Figure 8.6). I felt that patient understanding was 
central to the participant’s narratives on flares and therefore has a central place in 
the final model. The four overarching themes are placed around this: experiencing 
pain, impact of flares, predicting and avoiding flares and response to them. 
Experiencing pain incorporates how participants identified they were having a flare 
and how they described them which included temporal changes. Experiencing pain 
relates to ‘identity’ and ‘timeline’ of the Self-Regulatory Model The impact of flares, 
which links to ‘consequences’ of the SRM, was another key theme which included 
the effect flares had on ability to perform valued activities and was an important part 
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of patient’s understanding. Predictability of flares and avoidance strategies employed 
was also critical to patients. The predictability part of the model resonates with 
‘cause’ and ‘consequences’ of the SRM. Response to flares encompassed both 
immediate and longer term strategies to manage their pain as well as discussions on 
the future of their knee and possible joint replacement surgery. Response linked to 
‘consequence’ and ‘control’ in the SRM. Variability was seen in all of these themes 
from variability in duration, frequency and severity of pain intensity to the impact of 
flares, their predictability and management of them. The final model encompasses all 
of these components. As one theme did not necessarily lead onto another theme the 
arrows from the initial model were removed. 
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Figure 8.6: Final model illustrating findings 
8.6 Discussion 
This qualitative study aimed to explore patients’ understanding of flares with 
reference to self-management and help-seeking strategies used. The findings 
highlight that when discussing acute episodes of pain, participants referred to minor 
episodes that tended to represent daily variability in pain and more severe episodes 
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more likely to be referred to as ‘flares’. The descriptions of these events, the impact 
and responses to them was different. 
 
Strengths of the study include the number of potential participants that responded to 
the mailing invite which enabled purposive sampling to give a range of different ages 
and gender. Data was collected until data saturation was achieved (85, 105). The 
analysis was conducted by a team of clinicians and researchers from different 
backgrounds (85, 105), which included a senior academic GP with extensive skills in 
qualitative research, a senior social anthropologist and myself an academic GP with 
knowledge of OA flares.  Furthermore, the PPIE group made important contributions 
to the study by helping develop the study design, modify the topic guide, giving their 
insights into data analysis, and advising on dissemination.  
Limitations of the study include all participants being white British and from the West 
Midlands and so limits any inferences made to the general population of people with 
OA. During review of my first interview both my supervisor (CC-G) and I noted where 
I potentially asked leading questions and areas that I could have explored further but 
did not, for example, when the participant mentioned about impact on mental health. 
During the initial interviews I found it difficult to switch from  ‘GP’ consultation mode 
where patients are seen and managed within 10 minutes to using more explorative 
and probing techniques as are commonplace in qualitative interviews (86). 
Furthermore, my professional status as a GP may have impacted on the participants’ 
account of flares, particularly with regard to opinions on health professionals. The 
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professional status of the interviewer has been shown to impact on participant 
responses. Interviewees are less likely to make unfavourable comments about 
healthcare professionals if a healthcare professional is the researcher (128). In 
addition, I did not seek information on co-morbidities which, in retrospect, are 
important as they can affect impact of pain, management of pain and help-seeking, 
however, this identifies an area to be explored in  future research, including exploring 
how flares are prioritised and managed by patients and clinicians in the context of 
other conditions. Ideally, the participants would have been drawn from the same 
sample as the daily diary study. This would have allowed comparisons from the 
interview data directly with the individual findings in the diary study. Due to time 
constraints and ethical considerations this was not possible as permission for further 
contact was not obtained in the original ethics application. Lastly, the PPIE group 
members were presented with quotes rather than the whole transcripts during the 
analysis meeting which  have impacted on interpretation of the meaning behind the 
quotes. 
The concept of flares or acute episodes of intermittent pain has been observed in 
previous qualitative studies (53, 61, 62, 64). Notable similarities with these studies 
include the pain descriptors used, impact of the pain, variability of symptoms, and 
activity related pain (which has also been highlighted in quantitative studies (226)). 
However, findings from my qualitative study have highlighted the consequences of 
activity related pain: loss of confidence, feelings of vulnerability, and dependence on 
others in order to participate (for example only going shopping with someone else).   
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Predictability was found to be an important theme in previous qualitative studies (53, 
61, 62). Whilst the patient accounts in these studies focused mostly on the 
unpredictability of flares, findings from my study found that this could be variable and 
was not based on stage of OA as previously described by Hawker et al (53). In my 
study, predictable flares allowed patients to plan ahead in order to participate in 
planned activities. However, participants also described feelings of guilt and regret at 
knowingly participating in an activity they thought would trigger a flare, for example 
participating in an activity regardless of the known consequences. Unpredictable 
flares were described as being more bothersome due to the distress and 
disappointment caused at having to cancel plans.   
Murphy et al (2015) noted that patient reported flares could be of variable intensity 
and duration (61). Participants in the current study also gave descriptions of acute 
episodes of pain of varying intensity. Firstly, the ‘major’ flares which were greater in 
intensity, infrequent, often sustained (up to 2 months in some cases), impacted on 
social and daily activities, and caused anxiety. Secondly, the ‘minor’ flares which 
were more frequent, of less intensity, shorter and often associated with everyday 
activities, such as climbing stairs or walking, often ceasing when the activity stopped. 
These ‘minor’ episodes, which some participants did not recognise as flares most 
likely represent normal variability of the pain experience in OA rather than distinct 
events.  
Help-seeking for flares, which has not previously received much attention in the 
literature was often due to a change in usual symptoms. This included where flares 
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impacted on sleep, emotional limitations were reached, self-management options 
exhausted, and when the pain experience worse than normal. This compares with 
previous studies and reviews that have demonstrated that a change in symptoms, 
symptoms lasting longer than usual, and where symptoms are disruptive are reasons 
for help seeking (331, 332).  
Participants’ sought help from who they thought would be most likely to help them 
and meet their expectations given their past experiences. Recursivity has been 
shown in previous qualitative studies on help-seeking (330). Peer advice and peer 
observation seemed to have a powerful impact on patients’ perceptions on 
management strategies and modified views on total knee replacement, which has 
been observed in previous qualitative studies (333).  
A few participants, despite describing symptoms synonymous with OA, did not 
identify with having the condition. This may be due to patient factors such as: only 
identifying with having the disease during an acute attack (334), and the symptoms 
being atypical so not aligning with lay beliefs which can lead to a delay in or failure to 
present to a healthcare professional (324, 335). Once help has been sought, clinician 
factors such as prioritisation of OA and time spent on education and management 
(331)  can also affect how patients’ identify with OA. The OA consultation therefore 
provides an important opportunity to counsel and educate on OA and flares to 
improve their management and identification. 
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One aspect of this study was the use of pain graphs to enable patients to visually 
describe their pain experience over the previous 6 months. The graphs demonstrated 
clearly episodes of increased pain intensity and variability of these. The majority of 
patients identified that their pain pattern consisted of flares but returning to a 
background level of pain or no pain in between. 
Mapping the overarching themes onto the SRM (329) helped gain a greater 
understanding of the participants’ health beliefs and perceptions. Participants 
identified they were experiencing flares by a change in pain quality and intensity 
(identity beliefs), which was usually sudden and was sustained (timeline beliefs).  
Flares affected participants ability to participate in valued activities (consequence 
beliefs). Flares were managed through a number of self-management strategies and 
consultation with healthcare professionals (control beliefs). Triggers for flares could 
sometimes be identified and these beliefs were modified based on previous 
experience (cause beliefs). 
This study has a number of implications for clinical practice. Not all participants in this 
study were familiar with term ’flare’ however they understood what it meant. It is 
important for health professionals to use language that is acceptable and 
understandable to patients when discussing these episodes, therefore the term ‘flare’ 
may not be useful in the patient setting. The pain graphs could be a helpful tool within 
the primary care consultation to enable the clinician to gain a deeper understanding 
of the pain experience of flares particularly where patients have difficulty describing 
them verbally. Clinicians could either ask the patient to point out an example pain 
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graph or guide them in drawing their own. This study highlighted the importance of 
educating patients about acute episodes of pain in those with OA so that they 
understand it can be part of its natural history. Some people felt there was a 
disconnect between flares and OA and did not always link the two.  
 
8.7 Summary 
Findings from this study highlighted the differences between flares and daily 
variability in symptoms. Flares in this study were described as a worsening of 
symptoms that are sudden in onset, sustained and impacted on daily activities (which 
was further exacerbated by unpredictable pain). Pain graphs were a helpful in 
understanding more about flares from the patient perspective and encouraged 
discussion on potential triggers, impact and self-management strategies.  
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9. Discussion 
The overall aim of this thesis was to explore the natural history of flares in knee OA. 
The findings have provided further understanding of how flares are defined, their 
clinical course, how they can be triggered, who may be at risk, how they can be 
managed, and their impact using mixed methods. This chapter will summarise and 
synthesise the key findings before evaluating the main strengths and limitations. The 
implications of the findings for clinical practice and future research will also be 
discussed. 
 
9.1 Summary of key findings 
9.1.1 Describing and defining acute flares in osteoarthritis 
A range of ad hoc definitions exist in the literature but several components used to 
define acute events in other long-term conditions appear relevant. These include: 
onset/worsening of symptoms and signs above normal day-day variation, duration of 
symptoms, speed of onset/worsening of symptoms, and a minimum symptom 
threshold. Definitions developed and applied in this thesis demonstrate the sensitivity 
of estimates of flare frequency to the definition chosen. Estimates from the secondary 
analysis of CAS(K) and the diary study ranged from 23% to nearly 50%.  Such 
variation in estimates can be understood in the context of qualitative findings from my 
semi-structured interviews in which participants highlighted a spectrum of variability 
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that might be counted in quantitative studies as ‘flares’ depending on how wide the 
definition was. At one end participants described ‘minor’ symptom increases, that 
were short lived, more frequent, brought on by everyday activity and resolved with 
activity avoidance akin to day-to-day variability, and were often not perceived as 
‘flares’ by participants. This contrasted to the severe symptom increases which lasted 
longer, were sometimes unpredictable, occurred infrequently, and had greater impact 
on valued activities. Furthermore, this daily variability may provide an understanding 
for the bimodal distribution of recalled flares in the cross-sectional survey (Chapter 
6). The qualitative study highlights the shortcomings in the definition used for flares in 
the cross-sectional survey (“an increase of your knee pain (that is times when your 
knee pain is worse than normal) which may have stopped you from doing your 
normal activities or meant you have had to take or increase your pain medication”). 
This definition does not appear sufficient to separate the flares from the day-to-day 
variability of pain and suggests that specifying a minimum duration is important. 
Participants described pain quality as being similar for minor and major episodes of 
pain in the qualitative study (Chapter 8). Pain was generally reported as being ‘sharp’ 
and associated symptoms included swelling (in the qualitative, cross-sectional and 
diary study) and morning stiffness, lasting less than 30 minutes (in the cross-
sectional survey and diary study).  
There is some evidence to suggest from the diary study (Chapter 7) that a prodromal 
phase, lasting at least 48 hours may exist where participants may experience 
stiffness, nocturnal pain, an increase in intermittent pain descriptors such as a 
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sharper pain, and neuropathic pain descriptors such as burning prior to flare onset. 
These are important to identify as they may form a basis for early detection and 
prompt self-management to reduce risk of developing a full blown ‘severe’ flare which 
participants in the qualitative study reported being fearful of.  
 
9.1.2 Management of acute flares 
In response to a flare, patients reported help-seeking and taking more medication 
than usual. The interviews explored this further by discovering other self-
management strategies people employed, such as rest, adaptations, activity 
avoidance, and rubbing the knee. Findings from the diary study showed that 
participants were more likely to see their GP during a flare (Chapter 7). The 
qualitative study explored reasons for this: instances where the pain was worse than 
normal, was persistent, where self-management strategies failed and the symptoms 
led to exhaustion (Chapter 8). Who patients sought help from was modified by past 
experiences and could be primary or secondary care. Peer advice was important in 
modifying views on certain management strategies, for example, those that could be 
done at home (for instance eating pineapple) to total knee replacement. 
 
9.1.3 Risk factors and triggers for acute flares 
It is harder to understand the type of people that might be affected by flares as few 
risk factors came out consistently in the secondary analysis of the CAS(K) data 
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(Chapter 5), the cross-sectional survey (Chapter 6) and diary study (Chapter 7). 
Notably these were increased BMI, previous knee injury, increased duration of knee 
pain and previous knee surgery suggesting that these were less sensitive to case 
definition. In the diary study participants were more likely to report their pain as 
sharp, throbbing and burning. This compared with descriptors used for the increased 
episodes of pain experienced in the qualitative study (Chapter 8). Climbing stairs was 
consistently associated with flares across the cross-sectional survey and diary study, 
and participants identified this as a cause in the qualitative study. Stair climbing along 
with any physical activity exposure (kneeling, heavy lifting, squatting and climbing 
ladders), was found to be triggers for flare onset in the case-crossover analysis. The 
qualitative study corroborated with findings from the quantitative studies in the pain 
descriptors used and potential physical triggers for flares identified. The interviews 
explored further the impact of these everyday physical triggers (some unavoidable 
such as stair climbing) and highlighted the effect of predictability. Unpredictable flares 
were described as distressing and had greater impact, such as having to cancel 
planned activities. Flares that could be predicted allowed the participant to plan 
ahead; for example, they rested the day before a planned outing. However, several 
participants described the guilt they felt after perceiving they had ‘overdone’ things. 
Participants reported avoiding or adapting activities, such as climbing stairs to 
prevent flares, sometimes resentfully. 
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9.2 Summary and critical reflection on the use of mixed methods 
An explanatory sequential approach was adopted to conduct and integrate the 
studies presented in this thesis (125). Using this approach, findings from the 
quantitative studies were able to shape the study design of future studies. The 
systematic review of OA flare definitions (Chapter 4) identified a number of common 
core domains including: onset/worsening of symptoms above normal day-to-day 
variability, speed of onset, duration of sustained worsening, and a minimum threshold 
of pain. These domains along with definitions used in flare design studies were used 
to define symptom variability, a proxy for ‘flares’, in the secondary analysis of CAS(K) 
data presented in Chapter 5. The secondary analysis gave an initial estimate of 
potential flare frequency in those with a history of knee pain and identified potential 
variables associated with flares, for example: being a younger age, having a longer 
duration of knee problem, higher BMI and more severe symptoms at baseline. These 
findings were used to help determine the variables included in the cross-sectional 
survey (Chapter 6). The flare definition used in the secondary analysis of CAS(K) 
data partly informed the definition chosen in the diary study (Chapter 7) alongside 
definitions used in flare design studies and flare definitions in other chronic diseases. 
Once the quantitative data had been collected, findings were compared and 
contrasted to identify areas to be explored further in the qualitative study. This 
intermediate stage, in a mixed methods study is a common place to pause, integrate 
findings from the quantitative studies and determine the final study design for the 
next phase (336). After review of the quantitative study findings areas to be explored 
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further in the qualitative study included the impact of flares, their predictability, 
determinants of management strategies employed, help seeking behaviours and if 
people were aware of triggers and what they did with this knowledge.  
 
Once each study had been completed the findings were connected and integrated in 
the overall discussion. The findings from each component study were compared and 
contrasted to see if there were any similarities or if findings from one study helped 
understand findings from another study. Findings from the qualitative study, for 
example, helped me to understand the reasons for the bimodal distribution of 
recalled flares reported in Chapter 6 (Figure 6.2). Findings from the patient interviews 
highlighted that people were reporting what seemed to be two different experiences 
when describing flares; a minor short lived flare that was short and had little impact 
on daily activity and a more severe flare, that lasted longer and had a greater impact 
on valued activities. When asked to recall the frequency of flares in the cross-
sectional survey people may have been reporting both of these phenomena which 
highlights the importance of including a minimum duration to differentiate between 
the two. In addition, integrating findings from the different quantitative studies helped 
strengthen subsequent studies, for example, the ability to explore the impact of 
including different domains in the flare definitions was important.  
In an explanatory sequential design, the patients that take part in the quantitative 
studies are often sampled for the qualitative study. It was my original intention to 
sample participants from the diary study for the qualitative study, however, due to 
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ethical constraints this was not possible. Utilising this sample, I would have been able 
to ask participants about specific questions pertaining to their diary answers, for 
example, I could have asked them if they could idetnify triggers for increases in their 
pain and if my interpretation of a flare from their diary entries matched theirs. These 
specific questions relating to their diary entries, however, would probably have been 
impacted by recall bias. In addition, the potential population to purposively sample 
from would have been smaller due to withdrawals and those lost to follow up. In 
summary, I do not think using a different sample of participants had a huge impact on 
the results. 
Although the studies in this thesis did not follow an idealised explanatory sequential 
design, whereby one study was completed prior to the next study starting a 
pragmatic approach was taken. A number of studies in the quantitative phase were 
run in parallel, however, this did not prevent initial findings from earlier studies from 
feeding into subsequent studies. In this way the findings from earlier studies were 
utilised in the later studies as is seen in an explanatory sequential design.   
The use of mixed methods enabled each successive component study to draw on 
findings from the previous study. Comparing and contrasting results across studies 
helped to strengthen and validate study findings through triangulation and helped in 
the clarification, and understanding  of certain results. The qualitative study also 
helped to ensure that the overall thesis findings were considered in light of 
participant’s own experiences. 
  
 
 
 
 
271 
9.3 Strengths and limitations 
This work has a number of key strengths. The use of a mixed methods approach, 
whereby qualitative interviews were used to compare and contrast the results from 
the quantitative studies in more depth, helped to strengthen the overall findings. For 
example, the interviews enhanced understanding on variability of acute episodes of 
pain, this provided some understanding for the bimodal distribution of recalled flares 
in the cross-sectional survey. Inclusion of several methods, including qualitative 
interviews, permitted a more comprehensive investigation of acute flares. The timing 
and sequence of these reflected practical concerns (for example, obtaining additional 
funding for the qualitative study) and it might be argued that a different sequence 
(such as undertaking the qualitative study before the cross-sectional survey and diary 
study) would have offered other advantages; for instance, modifying the definition of 
flares used in the cross-sectional survey to ensure just flares were recorded rather 
than also capturing day-to-day variability of pain. 
PPIE members were involved at a number of different stages during the development 
and analysis of findings from the survey, diary and qualitative study. Their 
contributions helped ensure that the studies were relevant to patients, the terms 
would be easily understood (for example they advised not to use the terms 
‘exacerbation’ or ‘flare’ in patient information sheets or data collection instruments), 
offered advice on areas to explore further (such as the extent to which patients might 
predict flares, and take extra medication to prevent them during the diary study), and 
gave unique insights during the analysis stage of the qualitative study (for instance, 
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guilt felt after doing something that may have triggered a flare). The PPIE members 
involved in the survey/diary study, and first, and second  meeting for the qualitative 
study, were not the same. This was due to the long duration between meetings. It 
would have been more favourable to have the same members throughout so that 
they would have had more insight into the previous studies and commitment. This 
was overcome by briefly summarising previous studies and their findings at each 
workshop. All of the lay members actively participated during the meetings and 
seemed engaged in the study, therefore it is unlikely that having different lay 
members affected the overall outcomes of the meetings.    
As a GP researcher interested in flares in OA, I had extensive prior knowledge of the 
topic area. It is important to consider how my skills and knowledge as a GP may 
have affected the study designs, data collection and analysis. During the qualitative 
study, for example I had to quickly switch from GP consultation mode (i.e. identifying 
and managing problems within 10 minutes) to a technique that involved probing, 
encouraging dialogue, and allowing the participants to reflect and speak freely. I had 
to be mindful in the interviews to not ask leading questions. After my first interview, 
my supervisor (CC-G) and I identified where I may have done this and so I tried to 
avoid this in subsequent interviews. After each interview and during the analysis 
process I reflected on how my prior knowledge and experience may have affected 
the outcomes of these.  I think my position as a GP strengthened this thesis as I was 
able to bring clinically relevant insights and draw experiences from other chronic 
diseases, for example, in relation to definitions for flares or exacerbations used.    
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Recall bias is a key limitation across a number of the studies included in this thesis. 
The qualitative study highlighted how patients tend to ruminate over causes for their 
pain; this can be linked to recall bias in the quantitative studies, where participants 
have a tendency to recall and report prior exposures when experiencing a flare 
compared to when experiencing their usual symptoms. This may have led to a 
potential overestimation of reported exposures when experiencing a flare or increase 
in pain in the secondary analysis of CAS(K) data and cross-sectional survey.  This is 
potentially highlighted in the mismatch between recalled flares in the cross-sectional 
survey and those that were actually seen in the diary study. However, part of this 
may have been due to misclassification, whereby people were reporting day-to-day 
variability as flares.  
The participant numbers in the cross-sectional survey and diary study were small 
which restricts the precision of the estimates derived. This factor, in addition to some 
variables being sensitive to case definition used, may have led to the inconsistency 
of some of the reported risk factors across the studies.  In the survey and diary study, 
the populations were largely white British and from less deprived backgrounds, 
limiting the generalisability of the findings.  
 
9.4 Comparisons with previous literature 
Drawing on findings from the systematic review and from understanding of what was 
important to patients with respect to flares, key components of a flare definition were 
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identified. These included symptoms that were worse than normal (pain intensity 
above daily variability in symptoms), sustained (lasting longer than 24 hours), 
impacted on activity (this may be ability to carry out recreational and social activities) 
and potentially required additional medication. A similar systematic review of OA flare 
definitions, although not as comprehensive as the review in this thesis, also 
established that pain was a common feature (126). Recent definitions in the 
literature, however, are moving away from the completely symptom based 
identification tool developed by Marty et al (55). Although not always included in 
definitions used in other chronic disease (117, 137, 139-141), my qualitative study 
and other qualitative interviews have established the importance of the impact of 
acute pain for patients (53, 61, 62). This is further supported by findings from the 
OMERACT RA Flare Group aimed at developing a consensus definition for RA 
flares, who established that pain and function were the most important components 
to patients (220).    
The definition proposed through consensus led by the OMERACT OA Flare Group  
(81) (who cite my systematic review in their paper) and that included in the ACT-
Flare study (83) share similar domains: worsening of symptoms above usual pain or 
usual pain variation, a minimum duration (24 hours to a few days), impact (for 
example, ability to perform activities), and increased analgesia. The OMERACT 
group also specifies that flares should be transient and have an impact on sleep, 
functioning and psychological aspects. These domains share similarities with those 
that were important to participants in the qualitative study (Chapter 8): impact on 
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valued activities, pain intensity level worse than normal and persistent pain. This 
corroborates with domains that were important to patients in the development of a 
definition for RA: pain and function (220). The findings from this thesis also link 
directly to the stated concept of flares being more than an exacerbation of pain. 
Caution must be taken when developing definitions to ensure they do not overburden 
patients and the clinicians using them. Definitions with too many domains can lead to 
under-ascertainment (337).  A more acceptable and useful definition is likely to be 
one that limits the number of domains it contains but is still sensitive to identifying 
flares. Ensuring that the domains included are important to patients is paramount if a 
definition is to be applicable for clinical use.  
Differentiating between day-to-day variability and flares, by including minimum 
duration and impact in the definition, may be important both clinically and in the 
research setting. Although the existence of intermittent pain (53, 62, 64) and 
heterogeneity of within person variability in OA over shorter periods (for example, 
daily) and longer periods (for example, monthly) has previously been established (63, 
314) my studies add to this by considering flares. The bimodal distribution of 
frequency of flares reported in the cross-sectional survey, the within and between 
person variability demonstrated in the diary study and patient discussions in the 
qualitative study on frequent, ‘minor’ episodes of pain and less frequent, ‘major’ 
episodes highlight where flares might be placed on this ‘spectrum’. The importance of 
differentiating between them lies in what aspect of osteoarthritis is trying to be 
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understood; for example, this might be the impact of daily variability in pain or the 
impact of flares.  
The predictability of these acute episodes was important to patients. Unpredictable 
flares seemed to have the greatest impact on ability to take part in valued activities; 
this distress has previously been described (53, 62). My study highlighted how 
participants tried to navigate predictable flares by planning ahead, such as resting 
the day before a planned activity to go shopping. An understanding of triggers may 
lead to a reduction in the frequency of flares in the short to medium term due to 
adaptive and avoidance strategies, which may partly be related to fear avoidance 
(338).  Despite the advantages of understanding the cause of flares, some 
participants reported feeling guilty at knowingly ‘overdone’ things. It seems that there 
are some activities that patients will do anyway despite knowing the consequences.  
 
9.5 Implications for clinical practice 
The findings from this thesis provide a key set of domains (onset/worsening of signs 
and symptoms above normal day-to-day variation, that is sustained and may impact 
on valued activities, require additional medication, and may lead to emotional 
exhaustion) that could be helpful in defining OA flares. This will help in prompt 
identification and management of flares by patients and clinicians. Patient education 
on the existence of flares, although long term benefits are conflicting (339-341), is an 
important part of any chronic disease management. Clinician and patient awareness 
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of variability in OA, recognition of flares, potential triggers, likely duration, change in 
pain quality, and potential associated symptoms is crucial. Participants found that 
drawing pain graphs was helpful during the interviews and this may be one tool that 
could be useful during the consultation for understanding variability and experience 
of flares.  If patients feel that the clinician has not addressed their concerns or 
provided them with the knowledge to manage their OA, they may not return for help 
for their OA or other conditions in the future (331).  
There is still work to be done to acknowledge that flares are part of the natural history 
of OA for some people. It would be encouraging to see clearer guidance on flares 
being provided by key bodies such a NICE to highlight the significance of flares to 
clinicians and I have ensured continued discussions on flares through my position as 
a NICE OA guideline committee member which commenced September 2019. It 
would also be encouraging to see patient education resources, such as those 
provided by Versus Arthritis to give clear patient information on flares.  
 
9.6 Implications for further research 
Although reaching consensus definitions for flares or exacerbations of chronic 
disease can be a lengthy processes (342), further work is required to develop and 
validate a usable flare definition. A unified definition will aid comparisons across 
studies and help gather more accurate data on frequency estimates, healthcare 
usage, and consequences (e.g. absenteeism at work) which will help inform policy. A 
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similar body evidence, as provided in this study, may be helpful in OA affecting other 
joints, such as the hip, hand and foot.  
Understanding the types of people who are affected by flares and who are likely to 
experience greater variability in pain is important to identify those at risk and try to 
minimise the impact of them. This could be achieved through larger studies with 
repeated measures, such as online based case-crossover studies. Prevention and 
reduction of flares or exacerbations are key areas of interest in other chronic 
diseases (343-345). Reducing the impact of flares may partly be achieved by 
promoting self-management through action plans to enable prompt treatment and 
reduce burden on healthcare resources (346-348). This may be achieved through a 
trial comparing a flare action plan to usual care. Use of symptom diary cards as flare 
detection tools, have found to be useful in the field of COPD (349) and a similar tool 
may be helpful for flare identification in OA. 
 
9.7 Reflexivity 
As a GP I had my own assumptions about what constituted a knee OA flare prior to 
the start of my PhD. I assumed that a flare was something that was clinically 
significant, i.e. a state that led to a patient consulting their healthcare practitioner for 
example a pain experience that was worse than normal, that lasted a number of 
days, interfered with activity and might not be controlled with usual medication. My 
presumption was based on my own clinical experience. It was important whilst 
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understanding more about flares from the literature that I kept an open mind as to 
what a flare actually was. The PPIE groups were really helpful in highlighting the 
different types of flares that people might experience, how they might be managed 
and what might prompt them to seek further help. Taking on board the discussions 
with the PPIE group and my supervisory team I was able to gain a better 
understanding of flares and appreciate them from different perspectives. 
 
My prior knowledge of flares and osteoarthritis influenced some of the choices I 
made in the study design and analysis phases of a number of the studies. For 
example, the selection of variables for the studies in Chapter 5 and 6 were partly 
influenced by previous research and my own clinical experience. For example, 
including having seen a GP, impact on activity and duration of knee problem. 
During the interviews in Chapter 8 I chose not to disclose my background as a GP 
unless specifically asked. I was concerned that this might affect the openness of 
answers from the participants particularly with reference to opinions of management 
and interactions with healthcare professionals. I found my background as a GP 
enabled me to put the patients at ease at the start of the interviews by asking direct 
questions and prior to the interviews talking about the weather for example. I utilised 
skills such as mirroring, eye contact and leaning forward to show that I was 
interested in what the participants were saying. However, during the first interview 
myself and my supervisor noted that I used a leading question and that I did not 
explore certain areas for example, when the patient offered that the knee pain 
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sometimes affected their mental health. After the first interview I was conscious of 
this and ensured questions were phrased so they were not leading and I picked up 
on areas to explore further, for example using phrases such as “can you describe 
that in a bit more detail?” 
In being aware of my background as a GP and a researcher I have tried, at each 
stage to mitigate any influence my past knowledge and experiences have had on my 
research. This has included involving PPIE in my research and have regular 
discussions with my supervisory team who all have different backgrounds. 
 
9.8 Reflection on my doctoral training 
Before embarking on my doctoral studies I had undertaken introductory courses on 
research methods in health which gave an introduction to quantitative and qualitative 
research method and statistics and epidemiology. I had little in the way of practical 
experience of undertaking a research study. My PhD gave me exposure to a number 
of methodologies by undertaking new studies which included a systematic review 
with narrative synthesis, a cross-sectional study, a self-complete prospective daily 
diary study and a qualitative study using semi-structured interviews, in addition to a 
secondary analysis of cohort data.  
Using mixed methods I was able to triangulate the results of individual studies to 
strengthen the overall findings. Comparing and contrasting results also enabled a 
deeper understanding of the findings, for example analysis of the qualitative data 
helped to understand the distribution of recalled flares seen in the cross-sectional 
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study (Figure 6.2, pg 147). However, using mixed methods had a few disadvantages, 
for example when undertaking the qualitative study I found it difficult at first to switch 
from a predominately quantitative synthesis and to avoid frequency counting. 
Furthermore, I found it difficult describe overall themes using more patient focussed 
language and avoiding medical terminology, for example using the term ‘temporal 
characteristics’ to describe changes in frequency and duration of flares.  
During my PhD I gained extensive experience in the practical aspects of conducting 
research from engaging with PPIE groups, writing protocols, submitting ethics 
applications, database design, developing data collection instruments, liaising with 
the Clinical Research Network, writing patient letters and information sheets, 
inputting data, data cleaning, using STATA and disseminating results. Undertaking 
these processes I have learnt the importance of good team communication, planning 
and having a good grasp of key people involved in getting a research project started.  
My background as a GP helped in the design of the individual studies from selection 
of putative risk factors, terminology included in the systematic review and 
development of the topic guide for the qualitative study. It also allowed me to 
understand the findings in light of my own clinical experience. 
 
9.9 Conclusions 
Unlike in other chronic disease areas, acute flares in OA are not a widely recognised 
characteristic of the natural history of the condition. Even in those fields (for example, 
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COPD, asthma, RA) agreeing a definition has been challenging requiring numerous 
rounds of consensus exercises. This is even more so given the spectrum of 
variability and varying uses and terminology in OA. 
This studies in this thesis have identified core components of an OA flare definition 
that are important to patients, it has increased our understanding of flares in terms of 
what people experience, how long they last, potential triggers and early warning 
features. These are important for patient education and to improve self-management 
and early identification. Further work to understand the types of people likely to 
experience flares, developing a personalised care approach and to reach a 
consensus definition are needed, in order to assess who is more at risk of flares and 
to help guide prompt identification and management of them. 
  
 
 
 
 
283 
10. References 
 
1. Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in older adults: a 
review of community burden and current use of primary health care. Ann Rheum Dis. 
2001 02;60(2):91-7. 
2. National Institute for Health and Care Excellence (NICE).  
Osteoarthritis: care and management (CG177). London: NICE; 2014. 
3. Zhang W, Doherty M, Peat G, Bierma-Zeinstra M, Arden NK, Bresnihan B, et al. 
EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. 
Ann Rheum Dis. 2010 03/01;69(3):483. 
4. Altman RD. Criteria for the classification of osteoarthritis of the knee and hip. 
Scandinavian journal of rheumatology Supplement. 1987;65:31-9. 
5. Bedson J, Croft PR. The discordance between clinical and radiographic knee 
osteoarthritis: a systematic search and summary of the literature. BMC 
musculoskeletal disorders. 2008 09/02;9:116. 
6. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JWJ, Dieppe P, et al. 
EULAR Recommendations 2003: an evidence based approach to the management 
of knee osteoarthritis: Report of a Task Force of the Standing Committee for 
International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum 
Dis. 2003 12/01;62(12):1145. 
7. Fernandes L, Hagen K, Bijlsma JWJ, Andreassen O, Christensen P, Conaghan 
PG, et al. EULAR recommendations for the non-pharmacological core management 
of hip and knee osteoarthritis. Ann Rheum Dis. 2013 07/01;72(7):1125. 
8. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-
Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee 
osteoarthritis. Osteoarthritis and Cartilage. 2014 March 2014;22(3):363-88. 
9. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. 
American College of Rheumatology 2012 recommendations for the use of 
nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and 
knee. Arthritis Care & Research. 2012;64(4):465-74. 
  
 
 
 
 
284 
10. da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P, et al. 
Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in 
knee and hip osteoarthritis: a network meta-analysis. The Lancet. 2017 8–14 July 
2017;390(10090):e21-33. 
11. Zeng C, Wei J, Persson MSM, Sarmanova A, Doherty M, Xie D, et al. Relative 
efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: 
a systematic review and network meta-analysis of randomised controlled trials and 
observational studies. Br J Sports Med. 2018 05;52(10):642-50. 
12. Egerton T, Nelligan RK, Setchell J, Atkins L, Bennell KL. General practitioners' 
views on managing knee osteoarthritis: a thematic analysis of factors influencing 
clinical practice guideline implementation in primary care. BMC Rheumatology. 2018 
10/26;2(1):30. 
13. Navickas R, Petric V, Feigl AB, Seychell M. Multimorbidity: What do we know? 
What should we do? Journal of comorbidity. 2016 02/17;6(1):4-11. 
14. Paskins Z, Sanders T, Croft PR, Hassell AB. The Identity Crisis of Osteoarthritis 
in General Practice: A Qualitative Study Using Video-Stimulated Recall. Annals of 
family medicine. 2015 11;13(6):537-44. 
15. Paskins Z, Sanders T, Hassell AB. Comparison of patient experiences of the 
osteoarthritis consultation with GP attitudes and beliefs to OA: a narrative review. 
BMC family practice. 2014 03/19;15:46. 
16. Downie F, McRitchie C, Monteith W, Turner H. Physiotherapist as an alternative 
to a GP for musculoskeletal conditions: a 2-year service evaluation of UK primary 
care data. Br J Gen Pract. 2019 05/01;69(682):e314. 
17. Nelson P, Martindale A, McBride A, Checkland K, Hodgson D. Skill-mix change 
and the general practice workforce challenge. Br J Gen Pract. 2018 
02/01;68(667):66. 
18. Lane NE, Brandt K, Hawker G, Peeva E, Schreyer E, Tsuji W, et al. OARSI-FDA 
initiative: defining the disease state of osteoarthritis. Osteoarthritis and Cartilage. 
2011 05/01; 2019/09;19(5):478-82. 
19. Bijlsma JWJ, Berenbaum F, Lafeber FPJG. Osteoarthritis: an update with 
relevance for clinical practice. The Lancet. 2011 06/18; 2019/09;377(9783):2115-26. 
20. Felson D, Niu J, Sack B, Aliabadi P, McCullough C, Nevitt MC. Progression of 
osteoarthritis as a state of inertia. Ann Rheum Dis. 2013 06;72(6):924-9. 
  
 
 
 
 
285 
21. Loeser RF. Osteoarthritis year in review 2013: biology. Osteoarthritis and 
cartilage. 2013 10;21(10):1436-42. 
22. Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, et al. 
Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med. 
2000;133. 
23. Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. 
Bone. 2012 08;51(2):249-57. 
24. Benito MJ, Veale DJ, FitzGerald O, van den Berg,W.B., Bresnihan B. Synovial 
tissue inflammation in early and late osteoarthritis. Ann Rheum Dis. 2005 
09;64(9):1263-7. 
25. Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not 
osteoarthrosis!). Osteoarthritis and Cartilage. 2013 01/01; 2019/09;21(1):16-21. 
26. Johnson VL, Hunter DJ. The epidemiology of osteoarthritis. Best Practice & 
Research Clinical Rheumatology. 2014 February 2014;28(1):5-15. 
27. Neogi T, Zhang Y. Epidemiology of osteoarthritis. Rheum Dis Clin North Am. 
2013 02;39(1):1-19. 
28. Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. The Lancet. 2019 04/27; 
2019/09;393(10182):1745-59. 
29. Arden N, Nevitt MC. Osteoarthritis: Epidemiology. Best Practice & Research 
Clinical Rheumatology. 2006 2017/04;20(1):3-25. 
30. Silverwood V, Blagojevic-Bucknall M, Jinks C, Jordan JL, Protheroe J, Jordan 
KP. Current evidence on risk factors for knee osteoarthritis in older adults: a 
systematic review and meta-analysis. Osteoarthritis and Cartilage. 2015 04/01; 
2019/02;23(4):507-15. 
31. Ke X, Jin G, Yang Y, Cao X, Fang R, Feng X, et al. Synovial Fluid HMGB-1 
Levels are Associated with Osteoarthritis Severity. Clin Lab. 2015;61(7):809-18. 
32. Cooper C, McAlindon T, Coggon D, Egger P, Dieppe P. Occupational activity and 
osteoarthritis of the knee. Ann Rheum Dis. 1994 02;53(2):90-3. 
33. Pereira D, Peleteiro B, AraÃºjo J, Branco J, Santos RA, Ramos E. The effect of 
osteoarthritis definition on prevalence and incidence estimates: a systematic review. 
Osteoarthritis and Cartilage. 2011 11/01; 2019/09;19(11):1270-85. 
  
 
 
 
 
286 
34. Jordan K, Clarke AM, Symmons DPM, Fleming D, Porcheret M, Kadam UT, et al. 
Measuring disease prevalence: a comparison of musculoskeletal disease using four 
general practice consultation databases. The British journal of general practice : the 
journal of the Royal College of General Practitioners. 2007 01;57(534):7-14. 
35. Arthritis Research UK. Osteoarthritis in General Practice: Data and Perspectives. 
(https://www.bl uk/collection-items/osteoarthritis-in-general-practice-data-and-
perspectives) [Internet]. 2013;2019:35. 
36. McCormick A, Fleming D, Charlton J. Morbidity Statistics from General Practice: 
Fourth National Study 1991-1992. London:HMSO. 1995. 
37. Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global 
burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 
2010 study. Ann Rheum Dis. 2014 07/01;73(7):1323. 
38. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World 
Health Organ. 2003;81(9):646-56. 
39. Thomas E, Peat G, Croft P. Defining and mapping the person with osteoarthritis 
for population studies and public health. Rheumatology (Oxford). 2014 02;53(2):338-
45. 
40. Guccione AA, Felson DT, Anderson JJ, Anthony JM, Zhang Y, Wilson PW, et al. 
The effects of specific medical conditions on the functional limitations of elders in the 
Framingham Study. Am J Public Health. 1994 03;84(3):351-8. 
41. Prieto-Alhambra D, Judge A, Javaid MK, Cooper C, Diez-Perez A, Arden NK. 
Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: 
influences of age, gender and osteoarthritis affecting other joints. Ann Rheum Dis. 
2014 09;73(9):1659-64. 
42. Murphy L, Schwartz TA, Helmick CG, Renner JB, Tudor G, Koch G, et al. 
Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum. 2008 
09/15;59(9):1207-13. 
43. Losina E, Weinstein AM, Reichmann WM, Burbine SA, Solomon DH, Daigle ME, 
et al. Lifetime risk and age at diagnosis of symptomatic knee osteoarthritis in the US. 
Arthritis care & research. 2013 05;65(5):703-11. 
44. Culliford DJ, Maskell J, Kiran A, Judge A, Javaid MK, Cooper C, et al. The 
lifetime risk of total hip and knee arthroplasty: results from the UK general practice 
research database. Osteoarthritis and Cartilage. 2012 06/01; 2019/09;20(6):519-24. 
  
 
 
 
 
287 
45. Oxford Economics. The economic costs of arthritis for the UK economy. Oxford: 
Oxford Economics; 2010. 
46. Puig-Junoy J, Ruiz Zamora A. Socio-economic costs of osteoarthritis: A 
systematic review of cost-of-illness studies. Seminars in Arthritis and Rheumatism. 
2015 April 2015;44(5):531-41. 
47. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years 
lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-
2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 
(London, England). 2012 12/15;380(9859):2163-96. 
48. Murray CJL, Richards MA, Newton JN, Fenton KA, Anderson HR, Atkinson C, et 
al. UK health performance: findings of the Global Burden of Disease Study 2010. The 
Lancet. 2013 03/23; 2019/09;381(9871):997-1020. 
49. British Medical Association. Investment in general practice in England. 
(file:///C:/Users/emma parry/Downloads/Investment-in-General-Practice-report-2018 
pdf) [Internet]. 2018;[Accessed 2019]. 
50. NHS Digital. Appointments in General Practice October 2019. https://digital nhs 
uk/data-and-information/publications/statistical/appointments-in-general-
practice/october-2019 [Internet]. 2019:24.02.2020. 
51. NHS Digital. Appointments in General Practice October 2018. (https://digital nhs 
uk/data-and-information/publications/statistical/appointments-in-general-practice/oct-
2018) [Internet]. 2018;[Accessed 2019]. 
52. Case R, Thomas E, Clarke E, Peat G. Prodromal symptoms in knee 
osteoarthritis: a nested case-control study using data from the Osteoarthritis 
Initiative. Osteoarthritis and cartilage. 2015 07;23(7):1083-9. 
53. Hawker GA, Stewart L, French MR, Cibere J, Jordan JM, March L, et al. 
Understanding the pain experience in hip and knee osteoarthritis – an 
OARSI/OMERACT initiative. Osteoarthritis and Cartilage. 2008 4;16(4):415-22. 
54. Hochman JR, French MR, Bermingham SL, Hawker GA. The nerve of 
osteoarthritis pain. Arthritis Care Res. 2010 07/01; 2019/01;62(7):1019-23. 
55. Marty M, Hilliquin P, Rozenberg S, Valat JP, Vignon E, Coste P, et al. Validation 
of the KOFUS (Knee Osteoarthritis Flare-Ups Score). Joint Bone Spine. 2009 
5;76(3):268-72. 
  
 
 
 
 
288 
56. Holla JFM, van dL, Heymans MW, Roorda LD, Bierma-Zeinstra S, Boers M, et al. 
Three trajectories of activity limitations in early symptomatic knee osteoarthritis: a 5-
year follow-up study. Ann Rheum Dis. 2014 06/06;73(7):1369. 
57. Collins JE, Katz JN, Dervan EE, Losina E. Trajectories and risk profiles of pain in 
persons with radiographic, symptomatic knee osteoarthritis: data from the 
osteoarthritis initiative. Osteoarthritis and Cartilage. 2014 5;22(5):622-30. 
58. Bastick AN, Wesseling J, Damen J, Verkleij SPJ, Emans PJ, Bindels PJE, et al. 
Defining knee pain trajectories in early symptomatic knee osteoarthritis in primary 
care: 5-year results from a nationwide prospective cohort study (CHECK). Br J Gen 
Pract. 2015 12/30;66(642):e32. 
59. Nicholls E, Thomas E, van der Windt DA, Croft PR, Peat G. Pain trajectory 
groups in persons with, or at high risk of, knee osteoarthritis: findings from the Knee 
Clinical Assessment Study and the Osteoarthritis Initiative. Osteoarthritis and 
Cartilage. 2014 12;22(12):2041-50. 
60. Leffondre K, Abrahamowicz M, Regeasse A, Hawker GA, Badley EM, McCusker 
J, et al. Statistical measures were proposed for identifying longitudinal patterns of 
change in quantitative health indicators. J Clin Epidemiol. 2004 10/01; 
2019/09;57(10):1049-62. 
61. Murphy SL, Lyden AK, Kratz AL, Fritz H, Williams DA, Clauw DJ, et al. 
Characterizing pain flares from the perspective of individuals with symptomatic knee 
osteoarthritis. Arthritis Care and Research. 2015;67(8):1103-11. 
62. Cedraschi C, Delézay S, Marty M, Berenbaum F, Bouhassira D, Henrotin Y, et al. 
"Let's talk about OA pain": a qualitative analysis of the perceptions of people 
suffering from OA. Towards the development of a specific pain OA-Related 
questionnaire, the Osteoarthritis Symptom Inventory Scale (OASIS). PLoS One. 
2013;8 (11):e79988. 
63. Allen KD, Coffman CJ, Golightly YM, Stechuchak KM, Keefe FJ. Daily pain 
variations among patients with hand, hip, and knee osteoarthritis. Osteoarthritis and 
Cartilage. 2009 2016/11;17(10):1275-82. 
64. Gooberman-Hill R, Woolhead G, Mackichan F, Ayis S, Williams S, Dieppe P. 
Assessing chronic joint pain: lessons from a focus group study. Arthritis Rheum. 
2007;57(4):666-71. 
65. Buttgereit F, Burmester G, Bijlsma JWJ. Non-surgical management of knee 
osteoarthritis: where are we now and where do we need to go? RMD Open. 2015 
January 01;1(1). 
  
 
 
 
 
289 
66. Porcheret M, Healey E, Dziedzic K, Corp N. Ostoearthritis: a modern approach to 
diagnosis and management. Arthritis Research UK. 2011;Series 6. 
67. Altman R, Hochberg M, Gibofsky A, Jaros M, Young C. Efficacy and safety of 
low-dose SoluMatrix meloxicam in the treatment of osteoarthritis pain: A 12-week, 
phase 3 study. Curr Med Res Opin. 2015;31(12):2331-43. 
68. Hochberg MC, Fort JG, Svensson O, Hwang C, Sostek M. Fixed-dose 
combination of enteric-coated naproxen and immediate-release esomeprazole has 
comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials. Curr 
Med Res Opin. 2011 06/01;27(6):1243-53. 
69. Pareek A, Chandurkar N, Sharma VD, Desai M, Kini S, Bartakke G. A 
randomized, multicentric, comparative evaluation of aceclofenac-paracetamol 
combination with aceclofenac alone in Indian patients with osteoarthritis flare-up. 
Expert Opin Pharmacother. 2009 APR;10(5):727-35. 
70. Eşen S, Űlkű A, Aydın FY, Unalan H. Clinical evaluation during the acute 
exacerbation of knee osteoarthritis: the impact of diagnostic ultrasonography. 
Rheumatol Int. 2013;33(3):711-7. 
71. Conrozier T, Mathieu P, Vignon E, Piperno M, Rinaudo M. Differences in the 
osteoarthritic synovial fluid composition and rheology between patients with or 
without flare: a pilot study. Clinical and experimental rheumatology. 2012;30(5):729-
34. 
72. Pincus T. Clinical evidence for osteoarthritis as an inflammatory disease. Curr 
Rheumatol Rep. 2001 12/01;3(6):524-34. 
73. Ricci JA, Stewart WF, Chee E, Leotta C, Foley K, Hochberg MC. Pain 
Exacerbation as a Major Source of Lost Productive Time in US Workers With 
Arthritis. Arthritis & Rheumatism: Arthritis Care & Research. 2005;53(5):673-81. 
74. Wise BL, Niu J, Zhang Y, Wang N, Jordan JM, Choy E, et al. Psychological 
factors and their relation to osteoarthritis pain. Osteoarthritis and Cartilage. 2010 
7;18(7):883-7. 
75. Zobel I, Erfani T, Bennell KL, Makovey J, Metcalf B, Chen JS, et al. Relationship 
of Buckling and Knee Injury to Pain Exacerbation in Knee Osteoarthritis: A Web-
Based Case-Crossover Study. Interactive journal of medical research. 2016;5(2):e17. 
76. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and 
prevention. The Lancet. 2007 9/1–7;370(9589):786-96. 
  
 
 
 
 
290 
77. Beeh KM, Glaab T, Stowasser S, Schmidt H, Fabbri LM, Rabe KF, et al. 
Characterisation of exacerbation risk and exacerbator phenotypes in the POET-
COPD trial. Respiratory research. 2013 10/29;14(1):116. 
78. Barnes N, Calverley PMA, Kaplan A, Rabe KF. Chronic obstructive pulmonary 
disease and exacerbations: patient insights from the global Hidden Depths of COPD 
survey. BMC pulmonary medicine. 2013 08/23;13:54. 
79. Larsson K, Janson C, Lisspers K, JÃ¸rgensen L, Stratelis G, Telg G, et al. 
Combination of budesonide/formoterol more effective than fluticasone/salmeterol in 
preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS 
study. J Intern Med. 2013 06/01; 2019/09;273(6):584-94. 
80. Bykerk VP, Lie E, Bartlett SJ, Alten R, Boonen A, Christensen R, et al. 
Establishing a Core Domain Set to Measure Rheumatoid Arthritis Flares: Report of 
the OMERACT 11 RA Flare Workshop. The Journal of Rheumatology. 2014 April 
01;41(4):799-809. 
81. Guillemin F, Ricatte C, Barcenilla-Wong A, Schoumacker A, Cross M, Alleyrat C, 
et al. Developing a Preliminary Definition and Domains of Flare in Knee and Hip 
Osteoarthritis (OA): Consensus Building of the Flare-in-OA OMERACT Group. J 
Rheumatol. 2019 09/01;46(9):1188. 
82. Ferreira ML, Zhang Y, Metcalf B, Makovey J, Bennell KL, March L, et al. The 
influence of weather on the risk of pain exacerbation in patients with knee 
osteoarthritis - a case-crossover study. Osteoarthritis and cartilage. 
2016;24(12):2042-7. 
83. Thomas MJ, Rathod-Mistry T, Harper S, Parry EL, Pope C, Neogi T, et al. Acute 
Flares of Knee Osteoarthritis (the ACT-FLARE Study): Protocol for a Web-Based 
Case-Crossover Study in Community-Dwelling Adults. JMIR research protocols. 
2019 04/22;8(4):e13428. 
84. Creswell JW. Research Design: Qualitative, quantitative and mixed methods 
approaches. London: Sage; 2009. 
85. Sim J, Wright C. Research in Healthcare; Concepts, designs and methods. 
Cheltenham: Stanley Thornes Ltd; 2000. 
86. Ritchie J, Lewis J. Qualitative Research Practice. London: Sage; 2004. 
87. Gray DE. Doing research in the real world. London: Sage; 2018. 
  
 
 
 
 
291 
88. Richardson A. The health diary: the examination of its use as a data collection 
method. J Adv Nurs. 1994;19:782-91. 
89. Boslaugh S. Secondary Data Sources for Public Health: A Practical Guide. New 
York: Cambridge University Press; 2007. 
90. Vartanian T. Secondary Data Analysis. New York: Oxford University Press; 2011. 
91. Smith AK, Ayanian JZ, Covinsky KE, Landon BE, McCarthy EP, Wee CC, et al. 
Conducting High-Value Secondary Dataset Analysis: An Introductory Guide and 
Resources. Journal of General Internal Medicine. 2011;26(8):920-9. 
92. Peat G, Thomas E, Hand J, Wood L, Dziedzic KS, Myers H, et al. The Knee 
Clinical Assessment Study- CAS(K). A prospective study of knee pain and knee 
osteoarthritis in the general population. BMC Musculoskel Disord. 2004;5. 
93. Kelley K, Clark B, Brown V, Sitzia J. Good practice in the conduct and reporting 
of survey research. intqhc. 2003 05/01; 10/7;15(3):261-6. 
94. Edwards PJ, Roberts I, Clarke MJ, DiGuiseppi C, Wentz R, Kwan I, et al. 
Methods to increase response to postal and electronic questionnaires. Cochrane 
Database Syst Rev. 2009;8(3)(- 3):MR000008. 
95. de Vaus D. Chapter 8: Administering Questionnaires. In: Surveys in Social 
Research. Abingdon: Routledge; 2014. p. 121-43. 
96. O'Cathain A, Thomas KJ. "Any other comments?" Open questions on 
questionnaires- a bane or a bonus to research? BMC Medical Research 
Methodology. 2004;4(1):25. 
97. Trappenburg JCA, Monninkhof EM, Bourbeau J, Troosters T, Schrijvers AJP, 
Verheij TJM, et al. Effect of an action plan with ongoing support by a case manager 
on exacerbation-related outcome in patients with COPD: a multicentre randomised 
controlled trial. Thorax. 2011 10/14;66(11):977. 
98. Bolger N, Davis A, Rafaeli E. Diary Methods: Capturing life as it is lived. Annual 
Review of Psychology. 2003;54:579-616. 
99. Sorbi MJ, Peters ML, Kruise DA, Maas CJM, Kerssens JJ, Verhaak PFM, et al. 
Electronic Momentary Assessment in Chronic Pain I: Psychological Pain Responses 
as Predictors of Pain Intensity. Clin J Pain. 2006;22(1):55-66. 
  
 
 
 
 
292 
100. Schneider S, Stone AA, Schwartz JE, Broderick JE. Peak and End Effects in 
Patients' Daily Recall of Pain and Fatigue: A Within-Subjects Analysis. Journal of 
Pain. 2011 2017/06;12(2):228-35. 
101. Lauritsen K, Degl'Innocenti A, Hendel L, Præst J, Lytje MF, Clemmensen-Rotne 
K, et al. Symptom recording in a randomised clinical trial: paper diaries vs. electronic 
or telephone data capture. Controlled Clinical Trials. 2004 December 
2004;25(6):585-97. 
102. Jamison RN, Raymond SA, Levine JG, Slawsby EA, Nedeljkovic SS, Katz NP. 
Electronic diaries for monitoring chronic pain: 1-year validation study. Pain. 2001 
April 2001;91(3):277-85. 
103. Morren M, van Dulmen S, Ouwerkerk J, Bensing J. Compliance with momentary 
pain measurement using electronic diaries: A systematic review. European Journal of 
Pain. 2009;13(4):354-65. 
104. Howitt D, Cramer D. Introduction to Research Methods in Psychology. Fourth 
Edition. Harlow: Pearson Education Limited; 2014. 
105. Strauss A, Corbin J. Basics of Qualitative Research: Techniques and 
procedures for developing grounded theory. London: Sage Publications; 1998. 
106. Bryman A. Social Research Methods (4th edition). Oxford: Oxford University 
Press; 2012. 
107. Charmaz K, Thornberg R, Keane E. Evolving grounded theory and social justice 
inquiry. In: Denzin NK, Lincoln YS, editors. The Sage Hanbook of Qualitative 
Reseach. 5th Edition. London: Sage; 2018. p. 411-43. 
108. May T, Perry B. Reflexivity: The essential guide. London: Sage; 2017. 
109. Jordens CFC, Little M. "In this scenario, I do this, for these reasons": narrative, 
genre and ethical reasoning in the clinic. Soc Sci Med. 2004 05;58(9):1635-45. 
110. Silverman D. Doing Qualitative Research. London: Sage; 2017. 
111. Novick G. Is there a bias against telephone interviews in qualitative research? 
Res Nurs Health. 2008 08/01; 2019/08;31(4):391-8. 
112. Freeman C, Tyrer P, editors. Research Methods in Psychiatry. London: 
RCPsych Publications; 2006. 
  
 
 
 
 
293 
113. Buckley CA, Waring MJ. Using diagrams to support the research process: 
examples from grounded theory. Qualitative Research. 2013 04/01; 
2019/08;13(2):148-72. 
114. Umoquit MJ, Tso P, Burchett HED, Dobrow MJ. A multidisciplinary systematic 
review of the use of diagrams as a means of collecting data from research subjects: 
application, benefits and recommendations. BMC Medical Research Methodology. 
2011 01/27;11(1):11. 
115. Varga‐Atkins T, O’Brien M. From drawings to diagrams: maintaining researcher 
control during graphic elicitation in qualitative interviews. International Journal of 
Research & Method in Education. 2009 04/01;32(1):53-67. 
116. Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: a new screening 
questionnaire to identify neuropathic components in patients with back pain. Curr 
Med Res Opin. 2006 10/01;22(10):1911-20. 
117. Stone MA, Pomeroy E, Keat A, Sengupta R, Hickey S, Dieppe P, et al. 
Assessment of the impact of flares in ankylosing spondylitis disease activity using the 
Flare Illustration. Rheumatology. 2008 August 01;47(8):1213-8. 
118. Creswell JW. A concise introduction to mixed methods research. London: Sage; 
2015. 
119. Mays N, Pope C. Assessing quality in qualitative research. BMJ. 2000 
01/01;320(7226):50. 
120. Flick U, von Kardoff E, Steinke I, editors. A Companion to Qualitative Research. 
London: Sage Publications Ltd; 2004. 
121. Malterud K. Qualitative research: standards, challenges, and guidelines. The 
Lancet. 2001 08/11; 2019/07;358(9280):483-8. 
122. Denzin NK, Lincoln YS. The discipline and practice of qualitative research. In: 
Denzin NK, Lincoln YS, editors. The Sage Handbook of Qualitative Research, fifth 
edition. London: Sage; 2018. p. 1-65. 
123. Tashakkori A, Teddlie C. Mixed methodology: Combining qualitative and 
quantitative approaches. London: Sage; 1998. 
124. Maxwell JA. Realism as a stance for mixed methods research. In: Tashakorri A, 
Teddlie C, editors. SAGE Handbook of Mixed Methods Research  in Social and 
Behavoural Research, 2nd edition. London: Sage; 2010. p. 145-67. 
  
 
 
 
 
294 
125. Cresswell J. A concise introduction to mixed methods research. London: Sage 
publications; 2015. 
126. Cross M, Dubouis L, Mangin M, Hunter DJ, March L, Hawker G, et al. Defining 
Flare in Osteoarthritis of the Hip and Knee: A Systematic Literature Review- 
OMERACT Virtual Special Interest Group. J Rheumatol. 2017 07/01;44(12):1920-7. 
127. Bazeley P. Qualitative Data Analysis: Practical strategies. London: Sage; 2013. 
128. Richards H, Emslie C. The 'doctor' or the 'girl from the University'? Considering 
the influence of professional roles on qualitative interviewing. fampra. 2000 02/01; 
8/12;17(1):71-5. 
129. Chew-Graham C, May CR, Perry MS. Qualitative research and the problem of 
judgement: lessons from interviewing fellow professionals. fampra. 2002 06/01; 
7/18;19(3):285-9. 
130. Hoddinott P, Pill R. Qualitative research interviewing by general practitioners. A 
personal view of the opportunities and pitfalls. fampra. 1997 08/01; 7/18;14(4):307-
12. 
131. INVOLVE. What is public involvement in research?(https://www.invo.org.uk/find-
out-more/what-is-public-involvement-in-research-2/). INVOLVE [Internet]. 
2019:[2019]. 
132. Boote J, Telford R, Cooper C. Consumer involvement in health research: a 
review and research agenda. Health Policy. 2002 August 2002;61(2):213-36. 
133. Entwistle VA, Renfrew MJ, Yearley S, Forrester J, Lamont T. Lay perspectives: 
advantages for health research. BMJ. 1998 02/07;316(7129):463-6. 
134. Dudley L, Gamble C, Preston J, Buck D, EPIC Patient AG, Hanley B, et al. What 
Difference Does Patient and Public Involvement Make and What Are Its Pathways to 
Impact? Qualitative Study of Patients and Researchers from a Cohort of Randomised 
Clinical Trials. PloS one. 2015 06/08;10(6):e0128817. 
135. Troya MI, Chew-Graham C, Babatunde O, Bartlam B, Higginbottom A, Dikomitis 
L. Patient and Public Involvement and Engagement in a doctoral research project 
exploring self-harm in older adults. Health expectations : an international journal of 
public participation in health care and health policy. 2019 08;22(4):617-31. 
136. Jinks C, Carter P, Rhodes C, Taylor R, Beech R, Dziedzic K, et al. Patient and 
public involvement in primary care research - an example of ensuring its 
sustainability. Research involvement and engagement. 2016 01/14;2:1-. 
  
 
 
 
 
295 
137. National Institute for Health and Care Excellence (NICE). Chronic obstructive 
pulmonary disease in over 16s: diagnosis and management (CG101). London: NICE; 
2010. 
138. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the 
diagnosis, management and prevention of COPD. GOLD; 2016. 
139. Global Initiative for Asthma. Global Strategy for Asthma Management and 
Prevention. GINA; 2015. 
140. Ruperto N, Hanrahan L, Alarcón G, Belmont H, Brey R, Brunetta P, et al. 
International consensus for a definition of disease flare in lupus. Lupus. 2011 April 
01;20(5):453-62. 
141. Gaffo AL, Dalbeth N, Saag KG, Singh JA, Rahn EJ, Mudano AS, et al. Brief 
Report: Validation of a Definition of Flare in Patients With Established Gout. Arthritis 
Rheumatol. 2018 03/01; 2019/03;70(3):462-7. 
142. Langan SM, Schmitt J, Williams HC, Smith S, Thomas KS. How are eczema 
‘flares’ defined? A systematic review and recommendation for future studies. Br J 
Dermatol. 2014;170(3):548-56. 
143. Hagen NA, Biondo P, Stiles BN. Assessment and management of cancer 
breakthrough pain in cancer patients: Current approaches and emerging research. 
Current pain and headache reports. 2008;12:241-8. 
144. Bingham CO, Pohl C, Woodworth TG, Hewlett SE, May JE, Rahman MU, et al. 
Developing a Standardized Definition for Disease "Flare" in Rheumatoid Arthritis 
(OMERACT 9 Special Interest Group). J Rheumatol. 2009 10/01;36(10):2335. 
145. Hurst JR, Wedzicha JA. What is (and what is not) a COPD exacerbation: 
thoughts from the new GOLD guidelines. Thorax. 2007 March 01;62(3):198-9. 
146. Makris D, Bouros D. COPD exacerbation: Lost in translation. BMC Pulmonary 
Medicine. 2009;9(1):6. 
147. Imm N. Osteoarthritis (https://patient.info/bones-joints-
muscles/arthritis/osteoarthritis). Patient info [Internet]. 2017:[Accessed 2019]. 
148. Asthma UK. Asthma Data Visualisations (https://www.asthma.org.uk/get-
involved/campaigns/data-visualisations/). [Internet]. 2019:[Accessed 2019]. 
  
 
 
 
 
296 
149. Higgins J, Green S, editors. Cochrane handbook for systematic reviews of 
interventions Version 5.1.0. Available from www.handbook.cochrane.org.: The 
Cochrane Colloboration; 2011. 
150. Thomas J, Harden A, Newman M. Synthesis: Combining results systematically 
and appropriately. In: Gough A, Oliver S, Thomas J, editors. An introduction to 
systematic reviews. London: Sage publications limited; 2013. p. 191-2. 
151. Popay J, Roberts H, S, A., P, M., Arai L, Rodgers M, et al. Guidance on the 
conduct of narrative synthesis in systematic reviews: A product of the ESRC methods 
programme Lancaster: ESRC Method Programme. . 2006. 
152. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. 
QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy 
Studies. AIM. 2011 10/18; 10/9;155(8):529-36. 
153. Mokkink LB, de Vet,H.C.W., Prinsen CAC, Patrick DL, Alonso J, Bouter LM, et 
al. COSMIN Risk of Bias checklist for systematic reviews of Patient-Reported 
Outcome Measures. Quality of life research : an international journal of quality of life 
aspects of treatment, care and rehabilitation. 2018 05;27(5):1171-9. 
154. Parry EL, Thomas MJ, Peat G. Defining acute flares in knee osteoarthritis: a 
systematic review. BMJ Open. 2018 British Medical Journal Publishing Group;8(7). 
155. Mazzuca S, Brandt K, Lane K, Katz B. Knee pain reduces joint space width in 
conventional standing anteroposterior radiographs of osteoarthritic knees. Arthritis 
Rheum. 2002 MAY;46(5):1223-7. 
156. Bingham CO, Sebba AI, Rubin BR, Ruoff GE, Kremer J, Bird S, et al. Efficacy 
and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis 
in two identically designed, randomized, placebo-controlled, non-inferiority studies. 
Rheumatology. 2007 March 01;46(3):496-507. 
157. Baer PA, Thomas LM, Shainhouse Z. Treatment of osteoarthritis of the knee 
with a topical diclofenac solution: a randomised controlled, 6-week trial 
ISRCTN53366886]. BMC Musculoskeletal Disorders. 2005;6(1):44. 
158. Baraf HSB, Gloth FM, Barthel HR, Gold MS, Altman RD. Safety and Efficacy of 
Topical Diclofenac Sodium Gel for Knee Osteoarthritis in Elderly and Younger 
Patients. Drugs Aging. 2011;28(1):27-40. 
159. Battisti WP, Katz NP, Weaver AL, Matsumoto AK, Kivitz AJ, Polis AB, et al. Pain 
management in osteoarthritis: A focus on onset of efficacy—a comparison of 
  
 
 
 
 
297 
rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials. The 
Journal of Pain. 2004 11;5(9):511-20. 
160. Birbara C, Ruoff G, Sheldon E, Valenzuela C, Rodgers A, Petruschke RA, et al. 
Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly 
designed osteoarthritis studies. Curr Med Res Opin. 2006 01/01;22(1):199-210. 
161. Bocanegra T, Weaver A, Tindall E, Sikes D, Ball J, Wallemark C, et al. 
Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of 
the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study 
Group. Journal of Rheumatology. 1998;25(8):1602-11. 
162. Boswell DJ, Ostergaard K, Philipson RS, Hodge RA, Blum D, Brown JC, et al. 
Evaluation of GW406381 for Treatment of Osteoarthritis of the Knee: Two 
Randomized, Controlled Studies. The Medscape Journal of Medicine. 2008 
11/12;10(11):259. 
163. Case JP, Baliunas AJ, Block JA. Lack of efficacy of acetaminophen in treating 
symptomatic knee osteoarthritis: A randomized, double-blind, placebo-controlled 
comparison trial with diclofenac sodium. Arch Intern Med. 2003 01/27;163(2):169-78. 
164. Ehrich E, Schnitzer T, McIlwain H, Levy R, Wolfe F, Weisman M, et al. Effect of 
specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo 
controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group. Journal 
of Rheumatology. 1999;26(11):2438-47. 
165. Essex M, O'Connell M, Brown PB. Response to Nonsteroidal Anti-Inflammatory 
Drugs in African Americans with Osteoarthritis of the Knee. Journal of International 
Medical Research. 2012 December 01;40(6):2251-66. 
166. Gibofsky A, Hochberg MC, Jaros MJ, Young CL. Efficacy and safety of low-dose 
submicron diclofenac for the treatment of osteoarthritis pain: A 12 week, phase 3 
study. Curr Med Res Opin. 2014;30(9):1883-93. 
167. Gineyts E, Mo JA, Ko A, Henriksen DB, Curtis SP, Gertz BJ, et al. Effects of 
ibuprofen on molecular markers of cartilage and synovium turnover in patients with 
knee osteoarthritis. Annals of the Rheumatic Diseases. 2004 July 01;63(7):857-61. 
168. Goldberg M, McIlwain H, Poiley J, Basch C. Controlled-release naproxen in the 
treatment of osteoarthritis. Current Therapeutic Research-Clinical and Experimental. 
1988;44(1):51-60. 
  
 
 
 
 
298 
169. Gottesdiener K, Schnitzer T, Fisher C, Bockow B, Markenson J, Ko A, et al. 
Results of a randomized, dose ranging trial of etoricoxib in patients with 
osteoarthritis. Rheumatology. 2002 September 01;41(9):1052-61. 
170. Katz N, Sun S, Johnson F, Stauffer J. ALO-01 (Morphine Sulfate and 
Naltrexone Hydrochloride) Extended-Release Capsules in the Treatment of Chronic 
Pain of Osteoarthritis of the Hip or Knee: Pharmacokinetics, Efficacy, and Safety. 
The Journal of Pain. 2010 4;11(4):303-11. 
171. Kivitz AJ, Makarowski WS, Fiechtner JJ, Recker DP. A Flexible Daily Dosage 
Regimen of Oxaprozin Potassium in Patients with Acute Knee Pain Associated with 
Osteoarthritis. Clinical Drug Investigation. 2001;21(11):745-53. 
172. Leung AT, Malmstrom K, Gallacher AE, Sarembock B, Poor G, Beaulieu A, et 
al. Efficacy and Tolerability Profile of Etoricoxib in Patients with Osteoarthritis: A 
Randomized, Double-blind, Placebo and Active-comparator Controlled 12-Week 
Efficacy Trial. Curr Med Res Opin. 2002 01/01;18(2):49-58. 
173. Luyten FP, Geusens P, Malaise M, De Clerck L, Westhovens R, Raeman F, et 
al. A prospective randomised multicentre study comparing continuous and 
intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip. 
Annals of the Rheumatic Diseases. 2007 January 01;66(1):99-106. 
174. Manicourt D, Bevilacqua M, Righini V, Famaey J, Devogelaer J. Comparative 
Effect of Nimesulide and Ibuprofen on the Urinary Levels of Collagen Type II C-
Telopeptide Degradation Products and on the Serum Levels of Hyaluronan and 
Matrix Metalloproteinases-3 and -13 in Patients with Flare-Up of Osteoarthritis. Drugs 
in R & D. 2005;6(5):261-71. 
175. McIlwain H, Silverfield JC, Cheatum DE, Poiley J, Taborn J, Ignaczak T, et al. 
Intra-articular orgotein in osteoarthritis of the knee: A placebo-controlled efficacy, 
safety, and dosage comparison. Am J Med. 1989 2016/11;87(3):295-300. 
176. Mendelsohn S. Clinical efficacy and tolerability of naproxen in osteoarthritis 
patients using twice-daily and once-daily regimens. Clinical therapeutics. 1991;13:8-
15. 
177. Moskowitz RW, Sunshine A, Hooper M, Olson NZ, Cawkwell GD. An analgesic 
model for assessment of acute pain response in osteoarthritis of the knee. 
Osteoarthritis and Cartilage. 2006 11;14(11):1111-8. 
178. Pareek A, Chandurkar N, Ambade R, Chandanwale A, Bartakke G. Efficacy and 
Safety of Etodolac-Paracetamol Fixed Dose Combination in Patients With Knee 
  
 
 
 
 
299 
Osteoarthritis Flare-up: A Randomized, Double-blind Comparative Evaluation. Clin J 
Pain. 2010;26(7):561-6. 
179. Schnitzer TJ, Fricke JR, Gitton X, Jayawardene S, Sloan VS. Lumiracoxib in the 
treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: 
results of three dose-response studies. Curr Med Res Opin. 2005 03/01;21(1):151-
61. 
180. Scott-Lennox JA, McLaughlin-Miley C, Lennox RD, Bohlig AM, Cutler BL, Yan 
C, et al. Stratification of flare intensity identifies placebo responders in a treatment 
efficacy trial of patients with osteoarthritis. Arthritis & Rheumatism. 2001;44(7):1599-
607. 
181. Silverfield JC, Kamin M, Wu S, Rosenthal N. Tramadol/acetaminophen 
combination tablets for the treatment of osteoarthritis flare pain: a multicenter, 
outpatient, randomized, double-blind, placebo-controlled, parallel-group, add-on 
study. Clin Ther. 2002 February 2002;24(2):282-97. 
182. Strand V, Simon LS, Dougados M, Sands GH, Bhadra P, Breazna A, et al. 
Treatment of osteoarthritis with continuous versus intermittent celecoxib. J 
Rheumatol. 2011;38(12):2625-34. 
183. Wiesenhutter CW, Boice JA, Ko A, Sheldon EA, Murphy FT, Wittmer BA, et al. 
Evaluation of the Comparative Efficacy of Etoricoxib and Ibuprofen for Treatment of 
Patients With Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial. 
Mayo Clin Proc. 2005 2016/11;80(4):470-9. 
184. Williams GW, Hubbard RC, Yu SS, Zhao W, Steven Geis G. Comparison of 
once-daily and twice-daily administration of celecoxib for the treatment of 
osteoarthritis of the knee. Clin Ther. 2001 February 2001;23(2):213-27. 
185. Wittenberg RH, Schell E, Krehan G, Maeumbaed R, Runge H, Schluter P, et al. 
First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in 
osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison 
with celecoxib [RCT00267215]. Arthritis Research & Therapy. 2006;8(2):R35. 
186. Yeasted R, McPherson J, Schnitzer T. Characterization of osteoarthritis pain 
variability (abstract). Osteoarthritis and Cartilage. 2014;22:S390-1. 
187. Young C, Parenti D, Hochberg M. Lower-dose diclofenac capsules developed 
using solumatrix fine particle technology result in clinically meaningful improvements 
in pain in a phase 3 study of patients with osteoarthritis (abstract). Osteoarthritis and 
Cartilage. 2014;22. 
  
 
 
 
 
300 
188. Zhao SZ, McMillen JI, Markenson JA, Dedhiya SD, Zhao WW, Osterhaus JT, et 
al. Evaluation of the Functional Status Aspects of Health-Related Quality of Life of 
Patients with Osteoarthritis Treated with Celecoxib. Pharmacotherapy: The Journal of 
Human Pharmacology and Drug Therapy. 1999;19(11):1269-78. 
189. Day R, Morrison B, Luza A, al e. A randomized trial of the efficacy and 
tolerability of the cox-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. 
Arch Intern Med. 2000 06/26;160(12):1781-7. 
190. Kivitz AJ, Greenwald MW, Cohen SB, Polis AB, Najarian DK, Dixon ME, et al. 
Efficacy and Safety of Rofecoxib 12.5 mg Versus Nabumetone 1,000 mg in Patients 
with Osteoarthritis of the Knee: A Randomized Controlled Trial. J Am Geriatr Soc. 
2004;52(5):666-74. 
191. Bingham CO, Smugar SS, Wang H, Peloso PM, Gammaitoni A. Predictors of 
Response to Cyclo-Oxygenase-2 Inhibitors in Osteoarthritis: Pooled Results from 
Two Identical Trials Comparing Etoricoxib, Celecoxib, and Placebo. Pain Medicine. 
2011;12(3):352-61. 
192. Essex MN, Behar R, O'Connell MA, Brown PB. Efficacy and tolerability of 
celecoxib and naproxen vs placebo in hispanic patients with knee osteoarthritis. 
Osteoarthritis and Cartilage. 2013;21. 
193. Yocum D, Fleischmann R, Dalgin P, al e. Safety and efficacy of meloxicam in 
the treatment of osteoarthritis: A 12-week, double-blind, multiple-dose, placebo-
controlled trial. Arch Intern Med. 2000 10/23;160(19):2947-54. 
194. Roth SH, Shainhouse JZ. Efficacy and safety of a topical diclofenac solution 
(pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, 
double-blind, vehicle-controlled clinical trial. Arch Intern Med. 2004;164(18):2017-23. 
195. Simon LS, Grierson LM, Naseer Z, Bookman AAM, Shainhouse JZ. Efficacy and 
safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with 
those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. 
Pain. 2009;143(3):238-45. 
196. Weaver A, Rubin B, Caldwell J, McMahon FG, Lee D, Makarowski W, et al. 
Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment 
of patients with osteoarthritis of the knee. Clin Ther. 1995;17(4):735-45. 
197. Rother M, Lavins BJ, Kneer W, Lehnhardt K, Seidel EJ, Mazgareanu S. Efficacy 
and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral 
celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled 
trial. Annals of the Rheumatic Diseases. 2007 September 01;66(9):1178-83. 
  
 
 
 
 
301 
198. Brandt KD, Mazzuca SA, Buckwalter KA. Acetaminophen, like conventional 
NSAIDs, may reduce synovitis in osteoarthritic knees. Rheumatology. 2006 
November 01;45(11):1389-94. 
199. Atukorala I, Pathmeswaran A, Makovey J, Metcalf B, March L, Bennell KL, et al. 
Is there a relationship between the intermittent and constant osteoarthritis pain score 
(ICOAP) and pain flares in knee osteoarthritis? (abstract). Osteoarthritis and 
Cartilage. 2016;24:S429-30. 
200. Erfani T, Zhang Y, Makovey J, Metcalf B, March L, Bennell K, et al. Intermittent 
analgesic use and risk of pain exacerbation in knee osteoarthritis: A web based case-
crossover study (abstract). Arthritis and Rheumatology. 2014;66. 
201. D’Agostino MA, Conaghan P, Le Bars M, Baron G, Grassi W, Martin-Mola E, et 
al. EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 1: 
Prevalence of inflammation in osteoarthritis. Annals of the Rheumatic Diseases. 2005 
December 01;64(12):1703-9. 
202. Zhang Y, Zhang B, Wise B, Niu J, Zhu Y. Statistical approaches to evaluating 
the effect of risk factors on the pain of knee osteoarthritis in longitudinal studies. Curr 
Opin Rheumatol. 2009;21(5):513-9. 
203. Zhang Y, Wheaton D, N, J., Wise B, Havey, W., Goggins, J., Hunter D. Recent 
heavy physical activities trigger knee pain exacerbation in persons with symptomatic 
knee osteoarthritis (abstract). Arthritis & Rheumatism. 2011;63(10). 
204. Atukorala I, Pathmeswaran A, Chang T, Zhang Y, Hunter DJ, (abstract). Do 
Traditional Risk Factors for Knee Osteoarthritis Predict Pain Flares in Knee 
Osteoarthritis? Ann Rheum Dis. 2016 07/15;75:835. 
205. Bassiouni H. Detection of changes in the serum and synovial fluid levels of 
resistin during flare ups and remissions in primary knee osteoarthritis. Arthritis and 
Rheumatology. 2015;67. 
206. Erfani T, Makovey J, Bennell K, Metcalf B, Chen J, March L, et al. Psychosocial 
Factors and Pain Exacerbation in Knee Osteoarthritis: a Web Based Case-Crossover 
Study. Intern Med J. 2014 MAY;44:16. 
207. Hunter DJ, Bennell K, Makovey J, Metcalf B, Chen J, March L, et al. 
Psychosocial Factors and Pain Exacerbation in Knee Osteoarthiritis: a Web Based 
Case-Crossover Study. Osteoarthritis and Cartilage. 2014 APR;22:S21-2. 
  
 
 
 
 
302 
208. Makovey J, Metcalf B, Zhang Y, Chen J,Sheng, Bennell K, March L, et al. Web-
Based Study of Risk Factors for Pain Exacerbation in Osteoarthritis of the Knee 
(SPARK-Web): Design and Rationale. JMIR research protocols. 2015;4(3). 
209. Parry E, Ogollah R, Peat G. Significant pain variability in persons with, or at high 
risk of, knee osteoarthritis: preliminary investigation based on secondary analysis of 
cohort data. BMC musculoskeletal disorders. 2017;18(1):80. 
210. Bartholdy C, Klokker L, Bandak E, Bliddal H, Henriksen M. A Standardized 
"Rescue" Exercise Program for Symptomatic Flare-up of Knee Osteoarthritis: 
Description and Safety Considerations. J Orthop Sports Phys Ther. 2016 11/01; 
2017/09;46(11):942-6. 
211. Cibere J, Kopec JA, Thorne A, Singer J, Canvin J, Robinson DB, et al. 
Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in 
knee osteoarthritis. Arthritis Care and Research. 2004;51(5):738-45. 
212. Cibere J, Kopec JA, Esdaile JM, Thorne A, Singer JD, Thorne A, et al. 
Glucosamine sulfate and cartilage type II collagen degradation in patients with knee 
osteoarthritis: randomized discontinuation trial results employing biomarkers. In: 
Journal of rheumatology. ; 2005. p. 896-902. 
213. Jawad ASM. Analgesics and osteoarthritis: are treatment guidelines reflected in 
clinical practice? Am J Ther. 2005;12(1):98-104. 
214. Zobel I, Erfani T, Bennell K, Makovey J, Metcalf B, Chen JS, et al. Relationship 
of buckling and knee injury to pain exacerbation in knee osteoarthritis: A web-based 
case-crossover stud. Interact J Med Res. 2014;66:S560-1. 
215. Woolacott NF, Corbett MS, Rice SJC. The use and reporting of WOMAC in the 
assessment of the benefit of physical therapies for the pain of osteoarthritis of the 
knee: findings from a systematic review of clinical trials. Rheumatology. 2012 August 
01;51(8):1440-6. 
216. Bellamy N, Sothern RB, Campbell J. Rhythmic variations in pain perception in 
osteoarthritis of the knee. J Rheumatol. 1990;17(3):364-72. 
217. Lewis JD, Aberra FN, Lichtenstein GR, Bilker WB, Brensinger C, Strom BL. 
Seasonal variation in flares of inflammatory bowel disease. Gastroenterology. 2004 
2016/11;126(3):665-73. 
218. Suri P, Saunders KW, Von Korff M. Prevalence and Characteristics of Flare-ups 
of Chronic Nonspecific Back Pain in Primary Care: A Telephone Survey. Clin J Pain. 
2012;28(7):573-80. 
  
 
 
 
 
303 
219. Bingham CO, Alten R, Bartlett SJ, Bykerk VP, Brooks PM, Choy E, et al. 
Identifying Preliminary Domains to Detect and Measure Rheumatoid Arthritis Flares: 
Report of the OMERACT 10 RA Flare Workshop. The Journal of Rheumatology. 
2011 August 01;38(8):1751-8. 
220. Bartlett SJ, Hewlett S, Bingham CO, Woodworth TG, Alten R, Pohl C, et al. 
Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT 
international patient and provider combined Delphi consensus. Annals of the 
Rheumatic Diseases. 2012 November 01;71(11):1855-60. 
221. Lie E, Woodworth TG, Christensen R, Kvien TK, Bykerk V, Furst DE, et al. 
Validation of OMERACT preliminary rheumatoid arthritis flare domains in the NOR-
DMARD study. Ann Rheum Dis. 2014 10/01;73(10):1781. 
222. Effing TW, Kerstjens HAM, Monninkhof EM, van der Valk PDLPM, Wouters 
EFM, Postma DS, et al. Definitions of Exacerbations: Does It Really Matter in Clinical 
Trials on COPD? Chest. 2009 9;136(3):918-23. 
223. Trappenburg JCA, van Deventer AC, Troosters T, Verheij TJM, Schrijvers AJP, 
Lammers JJ, et al. The impact of using different symptom-based exacerbation 
algorithms in patients with COPD. Eur Respir J. 2011 04/30;37(5):1260. 
224. O'Reilly JF, Williams AE, Holt K, Rice L. Defining COPD exacerbations: impact 
on estimation of incidence and burden in primary care. Primary Care Respiratory 
Journal. 2006 12/01;15:346. 
225. Sands GH, Brown PB, Essex MN. The Efficacy of Continuous Versus 
Intermittent Celecoxib Treatment in Osteoarthritis Patients with Body Mass Index ≥ 
30 and  
226. Skou S, Grønne DT, Roos EM. Prevalence, Severity, and Correlates of Pain 
Flares in Response to a Repeated Sit to Stand Activity: A Cross-Sectional Study of 
14,902 Patients With Knee and Hip Osteoarthritis in Primary Care. J Orthop Sports 
Phys Ther. 2019 09/06; 2019/10:1-26. 
227. Trouvin A, Marty M, Goupille P, Perrot S. Determinants of daily pain trajectories 
and relationship with pain acceptability in hip and knee osteoarthritis. A national 
prospective cohort study on 886 patients. Joint Bone Spine. 2018 Available online 17 
July 2018. 
228. Wesseling J, Bastick AN, ten Wolde S, Kloppenburg M, Lafeber FPJG, Bierma-
Zeinstra S, et al. Identifying Trajectories of Pain Severity in Early Symptomatic Knee 
Osteoarthritis: A 5-year Followup of the Cohort Hip and Cohort Knee (CHECK) 
Study. J Rheumatol. 2015 08/01;42(8):1470. 
  
 
 
 
 
304 
229. Soni A, Kiran A, Hart DJ, Leyland KM, Goulston L, Cooper C, et al. Prevalence 
of reported knee pain over twelve years in a community-based cohort. Arthritis & 
Rheumatism. 2012;64(4):1145-52. 
230. Schneider S, Junghaenel DU, Keefe FJ, Schwartz JE, Stone AA, Broderick JE. 
Individual differences in the day-to-day variability of pain, fatigue, and well-being in 
patients with rheumatic disease: Associations with psychological variables. Pain. 
2012;153(4):813-22. 
231. Schnitzer TJ, Popovich JM, Andersson GB, Andriacchi TP. Effect of piroxicam 
on gait in patients with osteoarthritis of the knee. Arthritis Rheum. 1993;36(9):1207. 
232. Murphy SL, Lyden AK, Gammaitoni A, Williams DA, Clauw DJ, Scott JR, et al. 
Characteristics of pain flares in knee osteoarthritis (abstract). Arthritis and 
Rheumatology. 2014;66. 
233. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation 
study of WOMAC: a health status instrument for measuring clinically important 
patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis 
of the hip or knee. J Rheumatol. 1988;15. 
234. Wood L, Peat G, Wilkie R, Hay E, Thomas E, Sim J. A study of the 
noninstrumented physical examination of the knee found high observer variability. J 
Clin Epidemiol. 2006 05/01; 2019/09;59(5):512-20. 
235. Peat G, , Lawton H, , Hay E, , et al. Development of the Knee Standardized 
Clinical Interview: a research tool for studying the primary care clinical epidemiology 
of knee problems in older adults. Rheumatology. 2002 10/01;41(10):1101-8. 
236. Peat G, Wood L, Wilkie R, Thomas E, for the KNE-SCI SG. How reliable is 
structured clinical history-takingin older adults with knee problems?: Inter- and 
intraobserver variability of the KNE-SCI. J Clin Epidemiol. 2003 11/01; 
2019/09;56(11):1030-7. 
237. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The 
American College of Rheumatology criteria for the classification and reporting of 
osteoarthritis of the hand. Arthritis & Rheumatism. 1990;33(11):1601-10. 
238. Buckland-Wright JC, Wolfe F, Ward RJ, Flowers N, Hayne C. Substantial 
superiority of semiflexed (MTP) views in knee osteoarthritis: a comparative 
radiographic study, without fluoroscopy, of standing extended, semiflexed (MTP), and 
schuss views. Journal of Rheumatology. 1999;26(12):2664-74. 
  
 
 
 
 
305 
239. Kellgren JH, Lawrence JS. Radiological Assessment of Osteo-Arthrosis. Ann 
Rheum Dis. 1957 12/01;16(4):494. 
240. Altman RD, Hochberg M, Murphy WAJ, Wolfe F, Lequesne M. Atlas of individual 
radiographic features in osteoarthritis. Osteoarthritis and Cartilage. 1995;Suppl A:3-
70. 
241. Burnett S, Hart DJ, Cooper C, Spector TD. A Radiographic Atlas of 
Osteoarthritis. London: Springer-Verlag; 1994. 
242. Duncan R. The association between symptoms and radiographic osteoarthritis 
in older persons with knee pain: population-based study. [Doctoral thesis]. Keele 
University. 2007. 
243. Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic 
pain. Pain. 1992;50:133-49. 
244. Peat G, Thomas E, Handy J, Wood L, Dziedzic K, Myers H, et al. The Knee 
Clinical Assessment Study-CAS(K). A prospective study of knee pain and knee 
osteoarthritis in the general population: baseline recruitment and retention at 18 
months. BMC Musculoskeletal Disorders. 2006;7(1):30. 
245. Cooper C, Snow S, McAlindon TE, Kellingray S, Stuart B, Coggon D, et al. Risk 
factors for the incidence and progression of radiographic knee osteoarthritis. Arthritis 
& Rheumatism. 2000;43(5):995-1000. 
246. Bastick AN, Verkleij S, Damen J, Wesseling J, Emans PJ, Bierma-Zeinstra SM. 
Predictors for the progression of knee pain in subjects with early symptomatic knee 
osteoarthritis - Five year results from the check study (abstract). Osteoarthritis and 
Cartilage. 2013;21. 
247. Daoust R, Sirois M, Lee JS, Perry JJ, Griffith LE, Worster A, et al. Painful 
Memories: Reliability of Pain Intensity Recall at 3 Months in Senior Patients. Pain 
research & management. 2017;2017:5983721-. 
248. Von Korff M, Jensen MP, Karoly P. Assessing Global Pain Severity by Self-
Report in Clinical and Health Services Research. Spine. 2000;25(24):3140-51. 
249. Tourangeau R, Rips LJ, Rasinski K. The Psychology of Survey Response. 
Cambridge: Cambridge University Press; 2000. 
250. Smith BH, Penny KI, Purves AM, Munro C, Wilson B, Grimshaw J, et al. The 
Chronic Pain Grade questionnaire: validation and reliability in postal research. Pain. 
1997;71(2):141-7. 
  
 
 
 
 
306 
251. Grotle M, Hagen KB, Natvig B, Dahl FA, Kvien TK. Obesity and osteoarthritis in 
knee, hip and/or hand: An epidemiological study in the general population with 10 
years follow-up. BMC Musculoskeletal Disorders. 2008;9(1):132. 
252. Felson DT, Naimark A, Anderson J, Kazis L, Castelli W, Meenan RF. The 
prevalence of knee osteoarthritis in the elderly. the framingham osteoarthritis study. 
Arthritis & Rheumatism. 1987;30(8):914-8. 
253. Chapple CM, Nicholson H, Baxter GD, Abbott JH. Patient characteristics that 
predict progression of knee osteoarthritis: A systematic review of prognostic studies. 
Arthritis Care & Research. 2011;63(8):1115-25. 
254. Conaghan PG, D'Agostino,M.A., Le Bars M, Baron G, Schmidely N, Wakefield 
R, et al. Clinical and ultrasonographic predictors of joint replacement for knee 
osteoarthritis: results from a large, 3-year, prospective EULAR study. Ann Rheum 
Dis. 2010 03/17;69(4):644. 
255. Cheung PP, Gossec L, Dougados M. What are the best markers for disease 
progression in osteoarthritis (OA)? Best Practice & Research Clinical Rheumatology. 
2010 2017/04;24(1):81-92. 
256. Rayahin JE, Chmiel JS, Almagor O, Belisle L, Chang AH, Moisio K, et al. 
Factors associated with two-year pain experience outcome in knee osteoarthritis. 
Arthritis Rheum. 2013;65:S906-7. 
257. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). 
I. Conceptual framework and item selection. Med Care. 1992;30:473-82. 
258. Bellamy N. WOMAC osteoarthritis index. A user's guide. London Health 
Services Centre, McMasters University: Ontario; 1996. 
259. Wood L. The physical examination of older people with knee pain : a study of 
reliability and relationship to self-reported function in primary care. Keele University. 
2004. 
260. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta 
Psychiatr Scand. 1983;67:361-70. 
261. Marshall M, Peat G, Nicholls E, van der Windt D, Myers H, Dziedzic K. Subsets 
of symptomatic hand osteoarthritis in community-dwelling older adults in the United 
Kingdom: prevalence, inter-relationships, risk factor profiles and clinical 
characteristics at baseline and 3-years. Osteoarthritis and Cartilage. 2013 
11;21(11):1674-84. 
  
 
 
 
 
307 
262. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. 
Randomised, double blind, placebo controlled study of fluticasone propionate in 
patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE 
trial. BMJ. 2000;320:1297. 
263. Allison PD. Discrete-Time Methods for the Analysis of Event Histories. In: 
Leinhardt S, editor. Sociological Methodology. San Francisco: Jossey-Bass; 1982. p. 
61-98. 
264. Willett JB, Singer JD. Investigating onset, cessation, relapse and recovery: Why 
you should, and how you can, use discreet-time survival analysis to examine event 
occurence. Journal of consulting and clinical pshychology. 1993;61 (6):952-65. 
265. Hougaard P. Multivariate frailty models. In: Hougaard P, editor. Analysis of 
Multivariate Survival Data. New York, NY: Springer New York; 2000. p. 345-84. 
266. Bouwmeester W, Zuithoff NPA, Mallett S, Geerlings MI, Vergouwe Y, 
Steyerberg EW, et al. Reporting and Methods in Clinical Prediction Research: A 
Systematic Review. PLoS One. 2012;9(5):e1001221. 
267. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: Wiley-
Interscience; 2000. 
268. O'Brien RM. A Caution Regarding Rules of Thumb for Variance Inflation 
Factors. Quality & Quantity. 2007;41(5):673-90. 
269. Kirkwood BR, Sterne JAC. Essential Medical Statistics. Oxford: Wiley-Blackwell; 
2010. 
270. Weisberg S. Applied linear regression. Toronto: John Wiley & Sons; 1985. 
271. Alten R, Pohl C, Choy EH, Christensen R, Furst D, Hewlett SE, et al. 
Developing a Construct to Evaluate Flares in Rheumatoid Arthritis: A Conceptual 
Report of the OMERACT RA Flare Definition Working Group. J Rheumatol. 2011 
08/01;38(8):1745. 
272. Gossec L, Dougados M. Do intra-articular therapies work and who will benefit 
most? Best Practice & Research in Clinical Rheumatology. 2006 FEB;20(1):131-44. 
273. de Miguel Mendieta E, Cobo Ibáñez T, Usón Jaeger J, Bonilla Hernán G, Martín 
Mola E. Clinical and ultrasonographic findings related to knee pain in osteoarthritis. 
Osteoarthritis and Cartilage. 2006 6;14(6):540-4. 
  
 
 
 
 
308 
274. Cohen G, Conway MA, editors. Memory in the real world. New York: 
Psychology Press; 2008. 
275. Dunn KM, Jordan KP, Croft PR. Recall of medication use, self-care activities 
and pain intensity: a comparison of daily diaries and self-report questionnaires 
among low back pain patients. Primary Health Care Research & Development. 
2010;11(1):93-102. 
276. Melzack R. The McGill Pain Questionnaire: Major properties and scoring 
methods. Pain. 1975;1(3):277-99. 
277. Melzack R. The short-form McGill pain questionnaire. Pain. 1987 August 
1987;30(2):191-7. 
278. Nicholls E, Thomas E, Van D,Windt, Peat G. The long-term course of knee pain 
severity in middle and old age: Distinct trajectories from latent class growth modelling 
in population cohort data (the cas-k study and the osteoarthritis initiative (OAI)). 
Osteoarthritis and Cartilage. 2013;21:S39-40. 
279. Ong BN, Jinks C. 'Walking like John Wayne': Open-format diaries of people with 
knee pain and disability. Chronic Illness. 2006;2(1):21-6. 
280. Fordyce WE. Behavioural methods in chronic pain and illness. St Louis: Mosby; 
1976. 
281. Birkholtz M, Aylwin L, Harman RM. Activity Pacing in Chronic Pain 
Management: One Aim, but Which Method? Part One: Introduction and Literature 
Review. British Journal of Occupational Therapy. 2004 10/01; 2017/06;67(10):447-
52. 
282. Burch P, Doran T, Kontopantelis E. Regional variation and predictors of over-
registration in English primary care in 2014: a spatial analysis. J Epidemiol 
Community Health. 2018 06/01;72(6):532. 
283. Davies AR, Chitnis X, Bardsley M. Hospital activity and cost incurred because of 
unregistered patients in England: considerations for current and new commissioners. 
jpubhealth. 2012 12/19; 10/7;35(4):590-7. 
284. OAI. The Osteoarthritis Initiative: A knee health study (http://oai.epi-ucsf.org/). 
OAI [Internet]. 2014:[Accessed 2017]. 
285. Turk DC, Dworkin RH, Burke LB, Gershon R, Rothman M, Scott J, et al. 
Developing patient-reported outcome measures for pain clinical trials: IMMPACT 
recommendations. Pain. 2006;125(3). 
  
 
 
 
 
309 
286. Smith BJ, Marshall AL, Huang N. Screening for Physical Activity in Family 
Practice. Am J Prev Med. 2005 2017/06;29(4):256-64. 
287. Kleinbaum DG, Klein M. Logistic Regression: A self learning text. New York: 
Springer Science and Business Media; 2010. 
288. Lunt M. Prediction of ordinal outcomes when the association between predictors 
and outcome differs between outcome levels. Stat Med. 2005;24(9):1357-69. 
289. Bagley SC, White H, Golomb BA. Logistic regression in the medical literature:: 
Standards for use and reporting, with particular attention to one medical domain. J 
Clin Epidemiol. 2001 10;54(10):979-85. 
290. Williams R. Generalized ordered logit/ partial proportional odds models for 
ordinal dependent variables. The Stata Journal. 2006;6 (1):58-82. 
291. Williams R. Understanding and interpreting generalized ordered logit models. 
The Journal of Mathematical Sociology. 2016 01/02;40(1):7-20. 
292. StataCorp. Stata Statistical Software: Release 13. College Station, TX: 
StataCorp LP. 2013. 
293. Ferreira-Valente M, Pais-Ribeiro J, Jensen MP. Validity of four pain intensity 
rating scales. Pain. 2011;152(10):2399-404. 
294. Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a 
comparison of six methods. Pain. 1986;27(1):117-26. 
295. Lavrakas P, editor. Encyclopedia of Survey Research Methods. London: Sage 
Publications; 2008. 
296. Althubaiti A. Information bias in health research: definition, pitfalls, and 
adjustment methods. Journal of multidisciplinary healthcare. 2016 05/04;9:211-7. 
297. Kramer M. Clinial Epidemiology and Biostatistics. Berlin: Springer-Verlag; 1988. 
298. Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, et al. 
Studies Comparing Numerical Rating Scales, Verbal Rating Scales, and Visual 
Analogue Scales for Assessment of Pain Intensity in Adults: A Systematic Literature 
Review. Journal of Pain and Symptom Management. 2011 June 2011;41(6):1073-93. 
299. Jensen MP, Karoly P, O'Riordan EF, Bland F, Burns RS. The Subjective 
Experience of Acute Pain An Assessment of the Utility of 10 Indices. Clin J Pain. 
1989;5(2):153-9. 
  
 
 
 
 
310 
300. Kremer E, Atkinson HJ, Ignelzi RJ. Measurement of pain: Patient preference 
does not confound pain measurement. Pain. 1981;10(2):241-8. 
301. Seymour RA. The use of pain scales in assessing the efficacy of analgesics in 
post-operative dental pain. Eur J Clin Pharmacol. 1982;23(5):441-4. 
302. Wilkie D, Lovejoy N, Dodd M, Tesler M. Cancer pain intensity measurement; 
Concurrent validity of three tools- finger dynamometer, pain intensity number scale, 
visual analogue scale. Hospice Journal. 1990;6:1-13. 
303. Amin S, Goggins J, Niu J, Guermai A, Grigoryan M, Hunter DJ, et al. 
Occupation-Related Squatting, Kneeling, and Heavy Lifting and the Knee Joint: A 
Magnetic Resonance Imaging-Based Study in Men. J Rheumatol. 2008 
08/01;35(8):1645. 
304. Palmer KT. Occupational activities and osteoarthritis of the knee. Br Med Bull. 
2012 06/01;102(1):147-70. 
305. Suri P, Rainville J, Fitzmaurice GM, Katz JN, Jamison RN, Martha J, et al. Acute 
low back pain is marked by variability: An internet-based pilot study. BMC 
Musculoskeletal Disorders. 2011;12(1):220. 
306. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur 
Respir J. 2003 06/01;21(41):46s. 
307. Glynn RJ, Buring JE. Ways of measuring rates of recurrent events. BMJ. 1996 
02/10;312(7027):364-7. 
308. Laird NM, Ware JH. Random-Effects Models for Longitudinal Data. Biometrics. 
1982;38(4):963-74. 
309. Harris RE, Williams DA, McLean SA, Sen A, Hufford M, Gendreau RM, et al. 
Characterization and consequences of pain variability in individuals with fibromyalgia. 
Arthritis & Rheumatism. 2005;52(11):3670-4. 
310. Maclure M. The Case-Crossover Design: A Method for Studying Transient 
Effects on the Risk of Acute Events. Am J Epidemiol. 1991 01/15;133(2):144-53. 
311. Maclure M, Mittleman MA. Should we use a case-crossover design? Annual 
Review of Public Health. 2000;21:193-221. 
312. Mittleman MA, Mostofsky E. Exchangeability in the case-crossover design. Int J 
Epidemiol. 2014 10/01;43(5):1645-55. 
  
 
 
 
 
311 
313. Parry E, Ogollah R, Peat G. ‘Acute flare-ups’ in patients with, or at high risk of, 
knee osteoarthritis: a daily diary study with case-crossover analysis. Osteoarthritis 
and Cartilage. 2019 August 2019;27(8):1124-8. 
314. Allen KD, Golightly YM, Olsen MK. Pilot Study of Pain and Coping Among 
Patients With Osteoarthritis: A Daily Diary Analysis. JCR: Journal of Clinical 
Rheumatology. 2006;12(3). 
315. Guest G, Bunce A, Johnson L. How Many Interviews Are Enough?: An 
Experiment with Data Saturation and Variability. Field Methods. 2006 02/01; 
2019/08;18(1):59-82. 
316. Ali F, Jinks C, Ong BN. "...Keep mobile, I think that's half the battle." A 
qualitative study of prevention of knee pain in symptomless older adults. BMC Public 
Health. 2012 09/07;12(1):753. 
317. Kolb SM. Grounded Theory and Constant Comparative Method: Valid research 
strategies for educators. JETERAPS. 2012;3 (1):83-6. 
318. Bazeley P. Qualitative Data Analysis with Nvivo, Second Edition. London: Sage 
Publications; 2007. 
319. Charmaz K. Constructing grounded theory. London: Sage Publications: Second 
edition; 2014. 
320. Braun V, Clarke V. Successful Qualitative Research; a practical guide for 
beginners. London: Sage; 2013. 
321. Barbour RS. Checklists for improving rigour in qualitative research: a case of the 
tail wagging the dog? BMJ. 2001 05/05;322(7294):1115. 
322. Richards L. Handling Qualitative Data: A practical guide. London: Sage 
Publications Ltd; 2015. 
323. Gidron Y. Explanatory Models of Illness. In: Gellman MD, Turner JR, editors. 
Encyclopedia of Behavioral Medicine. New York, NY: Springer New York; 2013. p. 
733-4. 
324. Leventhal H, Phillips LA, Burns EJ. The Common-Sense Model of Self-
Regulation (CSM): a dynamic framework for understanding illness self-management. 
J Behav Med. 2016;39 (6):935-46. 
  
 
 
 
 
312 
325. Jones CL, Jensen JD, Scherr CL, Brown NR, Christy K, Weaver J. The Health 
Belief Model as an explanatory framework in communication research: exploring 
parallel, serial, and moderated mediation. Health Commun. 2015;30(6):566-76. 
326. May CR, Eton DT, Boehmer K, Gallacher K, Hunt K, MacDonald S, et al. 
Rethinking the patient: using Burden of Treatment Theory to understand the 
changing dynamics of illness. BMC health services research. 2014 06/26;14:281-. 
327. Dixon-Woods M, Cavers D, Agarwal S, Annandale E, Arthur A, Harvey J, et al. 
Conducting a critical interpretive synthesis of the literature on access to healthcare 
by vulnerable groups. BMC medical research methodology. 2006 07/26;6:35-. 
328. Hale ED, Treharne GJ, Kitas GD. The Common-Sense Model of self-regulation 
of health and illness: how can we use it to understand and respond to our patients' 
needs? Rheumatology. 2007 04/19; 10/31;46(6):904-6. 
329. Leventhal H, Brissette I, Leventhal EA. The common-sense model of self-
regulation of health and illness. In: New York, NY, US: Routledge; 2003. p. 42-65. 
330. Hunter C, Chew-Graham C, Langer S, Stenhoff A, Drinkwater J, Guthrie E, et al. 
A qualitative study of patient choices in using emergency health care for long-term 
conditions: The importance of candidacy and recursivity. Patient Education and 
Counseling. 2013 November 2013;93(2):335-41. 
331. Paskins Z, Sanders T, Hassell AB. What influences patients with Osteoarthritis 
to consult their GP about their symptoms? A narrative review. BMC Family Practice. 
2013 12/20;14(1):195. 
332. Cameron L, Leventhal EA, Leventhal H. Seeking medical care in response to 
symptoms and life stress. J Pschosomatic Med. 1995;57 (1):37-47. 
333. Maly MR, Krupa T. Personal experience of living with knee osteoarthritis among 
older adults. Disabil Rehabil. 2007 01/01;29(18):1423-33. 
334. Halm EA, Mora P, Leventhal H. No Symptoms, No Asthma: The Acute Episodic 
Disease Belief Is Associated With Poor Self-Management Among Inner-City Adults 
With Persistent Asthma. Chest. 2006 03/01; 2019/11;129(3):573-80. 
335. Bunde J, Martin R. Depression and prehospital delay in the context of 
myocardial infarction. J Pschosomatic Med. 2006;68 (1):51-7. 
336. Ivankova N, Creswell J, Stick S. Using Mixed-Methods Sequential Explanatory 
Design: From Theory to Practice. Field Methods. 2006 02/01;18:3-20. 
  
 
 
 
 
313 
337. Skou ST, Koes BW, Grønne DT, Young J, Roos EM. Comparison of three sets 
of clinical classification criteria for knee osteoarthritis: a cross-sectional study of 
13,459 patients treated in primary care. Osteoarthritis and Cartilage. 2019 Epub 
ahead of print. 
338. Gatchel RJ, Neblett R, Kishino N, Ray CT. Fear-Avoidance Beliefs and Chronic 
Pain. J Orthop Sports Phys Ther. 2016 02/01; 2019/11;46(2):38-43. 
339. Lovell MR, Luckett T, Boyle FM, Phillips J, Agar M, Davidson PM. Patient 
Education, Coaching, and Self-Management for Cancer Pain. JCO. 2014 06/01; 
2019/11;32(16):1712-20. 
340. Superio-Cabuslay E, Ward MM, Lorig KR. Patient education interventions in 
osteoarthritis and rheumatoid arthritis: A meta-analytic comparison with nonsteroidal 
antiinflammatory drug treatment. Arthritis & Rheumatism. 1996 08/01; 
2019/11;9(4):292-301. 
341. Svege I, Fernandes L, Nordsletten L, Holm I, Risberg MA. Long-Term Effect of 
Exercise Therapy and Patient Education on Impairments and Activity Limitations in 
People With Hip Osteoarthritis: Secondary Outcome Analysis of a Randomized 
Clinical Trial. ptj. 2016 06/01; 11/16;96(6):818-27. 
342. Bykerk VP, Bingham CO, Choy EH, Lin D, Alten R, Christensen R, et al. 
Identifying flares in rheumatoid arthritis: reliability and construct validation of the 
OMERACT RA Flare Core Domain Set. RMD Open. 2016 05/01;2(1):e000225. 
343. Kim V, Aaron SD. What is a COPD exacerbation? Current definitions, pitfalls, 
challenges and opportunities for improvement. Eur Respir J. 2018 
11/01;52(5):1801261. 
344. Sidbury R, Tom WL, Bergman JN, Cooper KD, Silverman RA, Berger TG, et al. 
Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of 
disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 
2014 12;71(6):1218-33. 
345. Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a 
systematic review of the literature. Curr Opin Rheumatol. 2011 03;23(2):192-202. 
346. Squires SI, Boal AJ, Lamont S, Naismith GD. Implementing a self-management 
strategy in inflammatory bowel disease (IBD): patient perceptions, clinical outcomes 
and the impact on service. Frontline gastroenterology. 2017 10;8(4):272-8. 
  
 
 
 
 
314 
347. Gatheral TL, Rushton A, Evans DJ, Mulvaney CA, Halcovitch NR, Whiteley G, 
et al. Personalised asthma action plans for adults with asthma. The Cochrane 
database of systematic reviews. 2017 04/10;4(4):CD011859. 
348. Lenferink A, Brusse-Keizer M, van dV, Frith PA, Zwerink M, Monninkhof EM, et 
al. Self-management interventions including action plans for exacerbations versus 
usual care in patients with chronic obstructive pulmonary disease. The Cochrane 
database of systematic reviews. 2017 08/04;8(8):CD011682-. 
349. Mackay AJ, Donaldson GC, Patel ARC, Jones PW, Hurst JR, Wedzicha JA. 
Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to 
Evaluate Severity of COPD Exacerbations. Am J Respir Crit Care Med. 2012 06/01; 
2019/10;185(11):1218-24. 
  
  
  
 
 
 
 
315 
  
  
 
 
 
 
316 
11. Appendices  
 
Appendix A: Search strategies for systematic review of OA flare definitions 
 
Ageline/ASSIA/SportDiscus 
("KNEE OSTEOARTHRITIS" OR (knee N3 pain) OR (knee N3 arthrosis) OR (knee 
N3 joint) OR (knee N3 osteoarthritis)) AND (exacerbation OR flare OR (pain AND 
(diary OR diaries)) OR (pain N3 variab*) OR (pain N3 pattern$) OR (daily N3 pain)) 
 
Medline/PsychInfo/HMIC/EMBASE/CINAHL/AMED 
OSTEOARTHRITIS, KNEE/ 
OR (knee adj3 (pain OR painful)).ti,ab 
OR (knee adj3 (arthrosis)).ti,ab 
OR (knee adj3 (joint OR joints OR degenerative)).ti,ab 
OR (knee adj3 (osteoarthritis)).ti,ab 
AND 
OR exacerbation.ti,ab 
OR flare.ti,ab 
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OR daily adj3 (pain)).ti,ab 
(pain adj3 (variab$)).ti,ab 
OR (pain AND (diary OR diaries)).ti,ab 
 
Cochrane Library 
"knee osteoarthritis":ti,ab,kw or knee adj3 (pain or painful):ti,ab,kw or knee adj3 
(arthrosis):ti,ab,kw or knee adj3 (joint or joints or degenerative):ti,ab,kw or knee adj 3 
(osteoarthritis):ti,ab,kw 
AND 
exacerbation:ti,ab,kw or flare:ti,ab,kw or pain adj3 (variab or pattern$):ti,ab,kw or 
daily adj3 (pain):ti,ab,kw or pain and (diary or diaries):ti,ab,kw 
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Appendix B: Sample diary template presented to PPIE members 
Day 1: 
After evening dinner 
  Which of these activities have you done in the last 
 24 hours? 
Kneeling for 30 minutes or more  
Squatting for 30 minutes or more  
Climbing a total of 5 or more flights of stairs  
Lifting/moving objects weighing 25kg or 
more 
 
None of the above  
 
Have you used more pain medication 
than usual in the last 24 hours? 
Yes  No   
If yes, please give details 
Name:      Dose: 
  
 
 
Is your knee pain worse than a usual day for you? 
A little worse A lot worse  No     
If a little or a lot worse please answer questions below 
 
Circle the number that best describes your knee pain during the past 24 hours 
0 1 2 3 4 5 6 7 8 9 10 
No pain    Worst         
 possible pain 
            
 
Knee swelling     Yes   No     
 
Limping       Yes   No     
 
Knee stiffness for more      Yes   No     
than 20 minutes 
 
Woken at night by     Yes    No     
knee pain 
 
None of the above  
Has your knee pain stopped 
you from doing your normal 
activities?  Yes 
  No    
 
Can you identify any particular 
trigger for this increase in pain? 
    
    
Other comments: 
   
    
If you are experiencing pain circle all below that describe 
your pain: 
Dull   Throbbing    Numbness Sharp Aching 
Burning  Stabbing Pins & needles 
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Appendix C: Cross-sectional survey 
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Appendix D: Example diary 
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Appendix E: Patient information sheet for cross-sectional and daily diary study 
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Appendix F: Read codes for general practice electronic patient record search 
  
1M10 Knee pain 
 
N05z6 Knee osteoarthritis NOS 
 
N05zL Osteoarthritis NOS of knee 
 
N051B Primary gonarthrosis, bilateral 
 
N052A Post-traumatic gonarthrosis, bilateral 
 
N052C Post-traumatic gonarthrosis, unilateral  
 
N06z6 Knee arthritis NOS 
 
N094M Arthralgia of knee 
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Appendix G: Sample diary template 
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Appendix H: Cross-sectional survey cover letter 
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Appendix I: Reminder postcard 
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Appendix J: Reminder cover letter 
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Appendix K: Diary cover letters 
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Appendix L: Diary return reminder letters 
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Appendix M: Thank you letters 
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Appendix N: Favourable ethical opinion letter for observational diary study  
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APPENDIX O: Daily NRS graphs for each individual (Flare-ups indicated by blue line) 
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Appendix P. Worked example of case-cross over analysis with kneeling for ≥30 as 
the exposure in the 48 hours prior to a flare (NB. Participants with only unexposed 
concordant paired observations (Ca-Co-) are not displayed) 
Exposure = Kneeling for ≥30 min in the prior 48 hours (n=3 cases, 40 paired 
observations) 
ID of 
case 
Exposure status in 
case window 
Exposure status in 
control window 
Paired observation 
pattern 
148 + - +- 
148 + - +- 
148 + - +- 
148 + - +- 
315 + - +- 
315 + - +- 
315 + - +- 
315 + - +- 
315 - + -+ 
315 - - -- 
315 - - -- 
315 - - -- 
315 - + -+ 
315 - - -- 
315 - - -- 
315 - - -- 
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209 + - +- 
209 + - +- 
209 + - +- 
209 + - +- 
165 - + -+ 
165 - - -- 
165 - - -- 
165 - - -- 
298 - + -+ 
298 - - -- 
298 - - -- 
298 - - -- 
330 - + -+ 
330 - + -+ 
330 - - -- 
330 - + -+ 
191 - + -+ 
191 - - -- 
191 - - -- 
191 - - -- 
187 - + -+ 
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187 - - -- 
187 - - -- 
187 - - -- 
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Appendix Q: Initial mailing pack for qualitative study
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Appendix R: Information provided to general practices about the qualitative study 
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Appendix S: Consent form for qualitative study 
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Appendix T: Example pain graphs shown during interview
  
  
 
 
 
 
381 
  
  
 
 
 
 
382 
Appendix U: Topic guide 
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Appendix V: Favourable ethical opinion letter for qualitative study 
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Appendix W1: Example of coding in NVIVO 
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Appendix W2: Example coding frame 
Overarching 
theme 
Description of 
theme 
Codes Example of data for code 
Experiencing 
pain: 
Identifying 
flares 
This theme 
encompasses 
how patients 
describe their 
pain during a 
flare, the 
different 
components 
that 
participants 
used to 
understand 
their flares, for 
example, in 
terms of 
severity, 
duration, 
frequency and 
impact.  
Descriptions of 
pain flares 
“Well it’s just like.. like a pumping it’s like it’s like pumping in my knee. Like real sharp 
pain. It feels like someone is sticking like a hot pin inside and it’s it’s  phwoar.” P001 (M, 
51) 
 
“It’s got tonnes of knives [right] straight into it [right].” P003 (F, 66) 
 
 
Other 
associated 
symptoms 
“I just get like the slight swelling underneath the kneecap and at the side but not as 
much [okay] because at one time it really did swell…” P009 (M, 64) 
 
“Well at that time it was, erm, a matter of swelling [yeah].  Me knee sort of was like a big 
onion [right] [laughs].  Erm, but the, over the 12 months I got more discomfort when I 
was walking…” P015 (F, 85) 
 
Impact “Oh no there was a definite difference in that one last year because it stiffened it all. 
Really did I shouldn’t have walked on it really…No just the big one was a flare-up yeah. 
I think that’s fair to say…No, no. These minor ones I have had them for many years and 
I can live with it.” P002 (M, 78) 
 
Variability of 
pain intensity 
“Oh no there was a definite difference in that one last year because it stiffened it all. 
Really did I shouldn’t have walked on it really…No just the big one was a flare-up yeah. 
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I think that’s fair to say…No, no. These minor ones I have had them for many years and 
I can live with it.” P002 (M, 78) 
“Sometimes I have some good days and some days I get really bad days as I do totally 
have pain all from my leg all the way down and plus with my back as well.” P001 (M, 51) 
 
Duration “Well with me putting my cream on and my tablets it takes about two to three days…But 
er.. But sometimes I could be like one or two or three days I’m OK and then it starts 
flaring up..it starts playing up …and I suffer with it for about a week  or  a week and 
half.” P001 (M, 51) 
 
“It can last for weeks before it completely settles down. It eases off, but it doesn’t go 
[right]. It can take a couple of months really for it to really settle down [okay].” P006 (F, 
68) 
 
Magnitude of 
pain intensity 
“Er, well it’s stronger, it’s not an ache, it’s a definite pain and I want to sort of hold it sort  
of thing for comfort yes.” P004 (F, 81) 
 
Onset of pain “…well I think it is starting to do it sort of straight away now whereas when I used to go 
up the ceilings, it was the next day, it would show up the next day.” P012 (M, 81) 
Frequency “Ooh, about once a month, every couple of months, something like that.” P015 (F, 85) 
 
[On change in frequency over time]. “No, no they are more regular [yeah]. But as I say, I 
can honestly say they don’t really – I wouldn’t say bother me, but I know that they’re 
there and yes I have the pain, but they don’t stop me doing anything other than if I have 
to take it a bit steadier up the stairs or an incline.” P006 (F, 68) 
 
  
 
 
 
 
389 
Change over 
time 
“Erm, well last year I had a bad year with it and it was on and off all the time. But then it 
did clear up a little bit and I’d – I’d say a week on, a week off…” P010 (F, 69) 
 
“I would think there is very little difference over the years. In fact I feel I am in due to the 
type of living I mean these last 12, I mean I finished with alcohol a long long time ago I 
don’t have a drop at all 12 years ago. I have never smoked. I feel my health is in better 
condition now than when I was say 60. And I mean I’m nearly 80 so.” P002 (M, 78) 
 
Patient 
understanding 
of flares 
“To me it suggests something that erm it sort of comes out of the blue [yeah] and just 
sort of suddenly attacks the knee sort of thing you know [okay] yeah, yeah but I’ve 
never said I’ve had a flare-up of my knee, it’s not a term I would use truly you know.” 
P008 (M, 66) 
 
Beliefs on 
underlying 
disease 
process 
“In the knee. But I had never really looked on it as arthritis.  I thought it was maybe erm 
just bone on bone I suppose.” P002 (M, 78) 
 
First flare 
event 
“But, er, no I have no reason why it should happen at all, as I say I was just walking 
quite normally in [deleted name of town] down towards [deleted name of department  
store] and it just suddenly gave way….I had no premonition of it, no pain before, or  
aches or anything, it just happened totally out of the blue.” P004 (F, 81) 
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Appendix X: Peer reviewed publication: Defining acute flares in knee osteoarthritis: a 
systematic review
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Appendix Y: Peer reviewed publication: Significant pain variability in persons with, or 
at high risk of, knee osteoarthritis: preliminary investigation based on secondary 
analysis of cohort data. (No changes have been made to the article presented 
https://creativecommons.org/licenses/by/4.0/) 
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Appendix Z: Peer reviewed publication: ‘Acute flare-ups’ in patients with, or at high 
risk of, knee osteoarthritis: a daily diary study with case crossover analysis 
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